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Abstract
The crystalline lens, with its unique protein content and cellular architecture, provides
the refractive index required to focus light on the retina. Mammalian lens fibre cells
contain high concentrations of structural proteins known as α-, β- and γ-crystallins,
which account for approximately 90% of total protein mass in the lens. α-Crystallin
also functions as a molecular chaperone by maintaining structurally compromised
lens proteins in stable, soluble complexes. With age, crystallins undergo a multitude
of posttranslational modifications, which contribute to their destabilization. As a
result, the pool of soluble, uncomplexed α-crystallin in the lens is exhausted by age 40.
In the absence of a functional chaperone system, aggregation and association with the
cellular membrane/cytoskeleton increases significantly with age. These changes to
lenticular crystallins are believed to be the major contributors to lens opacification.
This thesis examines age-related modifications of crystallins and cytoskeletal
proteins in the lens. A large number of endogenous low molecular weight (LMW)
peptides, derived from the breakdown of crystallins, were characterized in the
human lens using mass spectrometry. LMW peptides originating from α-crystallin
were found to cover almost the entire amino acid sequence of the full length protein.
Peptides which originated from β-crystallin subunits and γS-crystallin were also
identified, but not from other γ-crystallin subunits. The large diversity of these LMW
peptides indicates that crystallins undergo extensive cleavage with age, and that the
lens is incapable of removing or completely degrading these products. Analysis of the
terminal residues of these LMW peptides suggested that the breakdown of lenticular
crystallins may arise from both trypsin-like proteolysis and non-enzymatic cleavages,
with subsequent cleavages accounting for the sequential loss of terminal residues of
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these peptides. Utilizing the powerful methodology of matrix-assisted laser
desorption/ionization-imaging mass spectrometry (MALDI-IMS), several LMW
peptides were spatially mapped in situ across thin cryosections of human lenses. It
was observed that four peptides, derived from αA-, αB- and γS-crystallins, appeared
predominantly in the nuclear fibre cells, and were only found in the cortical fibre
cells of older lenses. In contrast, another major peptide, derived from the C-terminal
breakdown of βA3-crystallin, was present in the cortical and nuclear regions of both
young and old lenses.
This thesis also reports on a mixture of cross-linked water-soluble complexes in the
lens. When digested, these protein complexes of 40-50 kDa were found to consist of
fragments from multiple crystallin subunits, with B1, A3 and S the dominant
species. Remarkably, these crystallin fragments were similar to the LMW crystallin
content present in the urea-soluble lens fraction. This suggests that there may be two
separate pathways operating in the aging lens; crystallin fragments either become
insoluble through interactions with cytoskeletal/membrane components, or form
cross-linked water-soluble complexes.
In a series of binding assays using fluorescently-labelled α-crystallin subunits, the
binding capacity of α-crystallin for both bovine and human lens membranes was
determined. It was found that the human lens nuclear membrane had the highest
binding capacity for both αA- and αB-crystallins, suggesting that the structural
components of the lens nuclear membrane may be significantly different from that of
the lens cortical membranes. Also, intact α-crystallin remain bound to the lens
membrane even after the membranes were vigorously stripped with alkaline solution,
demonstrating that α-crystallin may be an intrinsic component of the fibre cell
membrane. Moreover, in a series of pull-out studies using a recombinant
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maltose-binding protein-αB-crystallin (MBP-αB) fusion protein, α-crystallin was
found to associate with both the intact and breakdown products of lens cytoskeletal
proteins. The N-terminal region of filensin, in particular, appeared to be a major
region of this protein which α-crystallin associates with. These results demonstrate
that the interaction between α-crystallin and the lens membrane/cytoskeleton is
potentially a mechanism by which lenticular crystallins become insoluble with age.
Together, the findings of this thesis provide important insights into the major
age-related changes of proteins in the human lens.
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Preface

The chapters of this thesis were prepared as a series of manuscripts written for
publication. As a result, each chapter stands alone, accompanied by an introductory
section that addresses the materials in that chapter. Consequently, this introduction
aims to provide a general background to the thesis as a whole. Readers will find that
there are inevitable overlaps of certain materials between this chapter and the
introductory sections of subsequent chapters.
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1.1 General Introduction

The human lens is a unique structure of the human body as it consists almost
entirely of water and water-soluble (WS) proteins, with minimal other components
[1-2]. Of the proteins, crystallins are by far the most abundant, accounting for up to
90% of protein mass in the lens [3-4]. The high concentration and short range order
of the crystallins is crucial for the transparency of the lens. Among the crystallins,
α-crystallin also functions as a molecular chaperone [3, 5]. As there is negligible
protein turnover in mature lens fibre cells [6], the transparency of the lens is
dependent upon α-crystallin to maintain structurally-compromised proteins in
soluble chaperone-client complexes. With age, however, lens proteins undergo
extensive modifications, which eventually lead to denaturation that exceeds the
capacity of the α-crystallin chaperone system and gives rise to protein
insolubilization, precipitation and ultimately, lens opacity. This chapter briefly
introduces the protein constituents of the human lens and the age-related
modifications associated with these proteins.

1.2 The human lens

1.2.1 Anatomy of the lens
The human lens is an avascular cellular tissue with the primary function of focusing
light precisely onto the retina to create an image. The healthy lens is transparent, and
can adjust its shape to focus objects at various distances [1, 7-8]. The lens is
surrounded by various components in the eye including the iris, zonular fibres and
vitreous body (see Fig. 1.1 for a schematic cross-section of the lens), which maintain
3
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its position within the eye [1, 7]. There are three main parts of the human lens: the
capsule, the lens epithelium and the fibre cells (Fig. 1.1) [1-2, 9]. Lens fibre cells are
further differentiated by their distribution within the lens cortex or the nucleus (Fig.
1.1). Nomenclatures such as embryonic, fetal, juvenile and adult nuclei, as well as
the inner and outer cortex, have been used in the past to define sections where zones
of optical discontinuity have been observed [9-11]. However, the usage of these
terms has been questioned due to their inconsistency with the actual growth time
frame of the lens [9].

Fig. 1.1 Schematic cross-section of the eye showing the major components (left)
and a cross-section of the lens (right). (Figure reproduced from [12-13].)

1.2.2 Lens growth through cell differentiation
The induction of the human lens occurs at approximately 28 days’ gestation
(Carnegie stage 13) with the creation of lens placode through the thickening of
surface ectoderm close to the optical vesicle [9]. The lens vesicle, which consist of
the primary fibre cells, is complete by around day 56 (Carnegie stage 22) [9]. With
this establishment, the lens continues to expand through mitosis of epithelial cells in
4
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the lens germinative zone to form daughter cells, which migrate to the transitional
zone and form the secondary fibre cells. During this process, lens cells lose virtually
all intracellular organelles [1, 9, 14]. As a result, mature lens fibre cells consist
almost entirely of water and WS structural proteins [1-2]. The removal of
intracellular organelles is necessary as these cellular components would disrupt the
pathway of light and thus affect the optical clarity of the lens [9, 15]. This
mechanism of adding new fibre cells to pre-existing fibre cells continues throughout
life [14-15]. The formation of an adult nucleus is complete around 3 months after
birth, with newly formed fibre cells adding to the ever-expanding cortex [9].

1.3 Protein constituents of the lens

1.3.1 Protein isolation from the lens
Lens fibre cells contain a variety of structural proteins. As there is negligible protein
turnover in mature fibre cells [6], most of these proteins are surprisingly stable, and
remain in the lens for the duration of an individual’s lifespan [1, 16]. Methods have
been developed to isolate lens proteins, which normally involve sequential buffer
extractions from decapsulated lens tissues [1, 17]. Lens proteins extracted by diluted
aqueous buffer are termed the WS proteins, which account for up to 80-90% of total
proteins in normal lenses and consist almost entirely of structural proteins known as
the crystallins [1, 4]. Lens proteins that are solubilized in 7-8 M urea are termed the
urea-soluble (US) proteins, which consist of denatured crystallins and cytoskeletal
proteins [1, 18-19]. The remaining pellet that is insoluble even in 7-8 M urea is
termed the urea-insoluble (UI) fraction. This fraction consists mainly of components
from the lens fibre cell membrane, including the integral (intrinsic) proteins and
5
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lipids [1, 18, 20].

1.3.2 The crystallins
The transparency and high refractive index of the mammalian lens is mainly due to
the high concentrations of crystallins in the lens fibre cells [3-4]. Mammalian lenses
comprise three families of crystallins: α-, β- and γ-crystallin (see Table 1.1 for a
summary of crystallins in the human lens), which are differentiated by the order in
which they elute during size-exclusion chromatography of lens extracts [1, 21].
Specifically, α-crystallin appears in the first peak from a size-exclusion column,
followed by two β-crystallin peaks - βH (“heavy”) and βL (“light”), while the
monomeric γ-crystallins are the last to elute [1]. The β- and γ-crystallins share
similarities in structure and domain topology and are thus grouped as the
βγ-crystallins superfamily, while α-crystallin has been classified as an independent
protein family [22]. Both α- and β-crystallins form multi-subunit oligomeric
structures, whereas γ-crystallin exists as monomers [23].
The crystallin constituents in mammalian lenses can vary significantly between
species. For example, the lenses of some mammalian species also contain γE- [24],
γF- [24] and γN-crystallins [25], whereas these proteins are absent in human lenses.
In addition, δ-crystallin, a major crystallin family in avian and reptile lenses [26-27],
is absent in mammalian lenses.
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Table 1.1: A brief summary of human lenticular crystallins.

Crystallin

Molecular

Molecular

form

mass (kDa)

Subunit
Subunits

mass

Main function(s)

(kDa)
Structural protein

α

multimeric

αA, αB

300-900

20

and molecular
chaperone

β

multimeric

50-200

γ

monomeric

21

βA1-A4,
βB1-B3
γA-D, γS

20-30

Structural protein

21

Structural protein

1.3.2.1 α-Crystallin protein structure
α-Crystallin was first described in 1894 by Morner [28] as an important protein
related to the structural-stability of the lens. It accounts for approximately 30-40%
of the total soluble protein in the human lens, and is formed by two subunits - A
(αA-crystallin; acidic) and B (αB-crystallin; basic), in a ratio of approximately 3:1
(A:B) in the adult human lens [29-31]. These two subunits associate to form a
variety of polydisperse high molecular weight (HMW) oligomers with an average
mass of 600-800 kDa, containing a median number of 30-40 subunits [2, 32-34].
Human αA- and αB-crystallins are encoded by single copy genes on chromosomes
21 and 11 respectively [35-36], and their genomic sequences share approximately
58% homology [5]. The tendency of α-crystallin to form large polydisperse
assemblies makes structural characterization through protein crystallization difficult.
As such, limited information is available at present regarding the tertiary and
quaternary structures of α-crystallin.
Preliminary studies have established that the secondary structure of α-crystallin
consists approximately 40-50% of β-sheet and 5-10% of α-helix [37]. Information
regarding the tertiary structure of α-crystallin, however, has been largely limited due
7
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to the difficulties of obtaining crystallographic data of the protein. It is only recently
that some 3-D crystallographic data of truncated forms of α-crystallin were obtained
[38-39]. Bagneris et al. [38] demonstrated that excised α-crystallin domain from
human αB-crystallin (residues 67-157) form a homodimers through an antiparallel
β-sheet, with a shared groove at the interface. Building upon this result, Laganowsky
et al. [39] reported the crystal structures of truncated froms of bovine αA-crystallin
(residues 59-163) and human αB-crystallin (residues 68-162). Both structures
contained two dimeric interfaces; in the first interface, termed the “domain-swapped
interface”, the C-terminal tail was observed to swap into the neighbouring molecule
and interact with the hydrophobic groove positioned on top of the core [39]. A
second interface, termed the “antiparallel β-sheet interface”, involved an antiparallel
β-sheet which consists of three separate registration shifts [39].
Similarly, the quaternary structure of α-crystallin has been a subject to a wide debate
and interest amongst researchers, and over the years a number of models have been
proposed based on different properties of the protein [37, 40-43]. One model is a
GroEL-like structural model proposed by Carver et al. [43] (Fig. 1.2). This model
proposed that α-crystallin tends to form a hydrophobic core with the hydrophilic
regions of each subunit positioned at the surface of the assembly, and the
hydrophobic regions facing inside, forming the core [43]. In this model, the
hydrophilic C-terminal domains shield the hydrophobic core from direct contact
with aqueous solvents, leading to an increased stability of the quaternary assembly
[43]. A later model proposed by Horwitz et al. [37] suggested that αB-crystallin is an
extremely dynamic molecule with a hollow interior, and that the 3:1 ratio of αA and
αB is crucial in maintaining the thermal stability of α-crystallin.
In a recent study, Jehle et al. [44] presented an αB-crystallin structure which exists
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as a tetrahedrally symmetrical 24-mer with a hollow core, based on a combination of
small-angle X-ray scattering, solid-state nuclear magnetic resonance and electron
microscopy data. In this model, the authors argued that the homodimeric α-crystallin
domain acts as the building block of the αB-crystallin multimers, with a hexamer
being the result of interactions between three dimers via the C-terminal regions of
the αB-crystallin domains [44]. Building upon this pattern, interactions involving the
N-terminal region of αB-crystallin give rise to high-order multimers, with minimal
conformational changes. As the 24-mer variation represents only ~5% of the
multimeric species of αB-crystallin detected by mass spectrometry [45], the authors
also proposed that larger αB-crystallin multimers are formed via the incorporation of
additional αB-crystallin dimers in the shell of the 24-mer [44].

Fig. 1.2: The GroEL-like structure of α-crystallin proposed by Carver et al. [43]
in 1994. The model consists of a hole in the core region of the protein, which is
surrounded by the hydrophobic regions of the α-crystallin. The outer surface of the
aggregate consists of the hydrophilic C-terminal domains of α-crystallin. (Figure
reproduced from [43].)
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1.3.2.2 α-Crystallin as a molecular chaperone in the aging lens
Initially believed to function solely as a structural protein, it was not until the early
80’s that the property of α-crystallin to function as a molecular chaperone was
recognized [46]. Traditional molecular chaperones (ATP-dependent chaperones such
as GroEL and Hsp70) are proteins which directly or indirectly assist in the folding of
nascent or unfolded proteins into their native configuration [47]. These proteins do
not physically become a part of the target-proteins, but rather mediate their correct
folding/unfolding and assembly/disassembly through hydrophobic and ionic
interactions with the polypeptide chains [48]. As the chaperone function of these
proteins is often initiated by heat-shock (ie. an increase of temperature in the
chaperone’s surrounding environment), some are also referred to as heat-shock
proteins (Hsp) [49-50].
α-Crystallin is a member of the small heat-shock protein (sHsp) family [51-52].
Unlike ATP-dependent chaperones, α-crystallin does not actively refold partially
unfolded or degraded proteins, but rather incorporates these polypeptides into large,
soluble complexes [3, 5, 53] (see Fig. 1.3 for a graphic representation of the
chaperone function of α-crystallin). This interaction also minimizes undesirable
interactions between the partially unfolded proteins and other components in the
lens. As there is negligible protein turnover in mature lens fibre cells [6], the
transparency of the lens is heavily dependent upon α-crystallin to maintain partially
unfolded proteins in soluble chaperone-client complexes. Homogenous assemblies
of the individual A and B subunits of α-crystallin also possess chaperone activity
[51-52], with αB-crystallin a more effective chaperone under physiologically
relevant temperatures (37-40 C), while αA-crystallin performs better at elevated
temperatures [51]. Recent studies have shown that both αA- and αB-crystallins exist
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independently in tissues outside of the lens [51, 54-56]. αB-Crystallin, in particular,
has been found in heart, skeleton, muscle, kidney and brain tissues, and has been
associated with neurological disorders including Alzheimer’s, Parkinson’s and
Creutzfeld-Jacob diseases [55, 57].

Fig. 1.3: Graphical representation of the chaperone action by which sHsp (for
example α-crystallin) stabilizes and suppresses denatured proteins against
aggregation and precipitation. Native proteins (N) can become unfolded and enter
the molten globule (MG) state due to stress. If left unregulated, these denatured
proteins would aggregate along the off-folding pathway and eventually become
precipitated. Molecular chaperones such as sHsp can interact with these
unfolded/partially unfolded polypeptides (forming sHsp-I2 complexes) and maintain
them in soluble complexes until ATP-dependent chaperones (eg. Hsp70 or GroEL)
can refold them and convert the polypeptide back into its native state. (Figure
reproduced from [53, 58-59].)
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1.3.2.3 βγ-Crystallin family
The β- and γ-crystallins are important structural proteins which account for the
majority of crystallins present in the adult mammalian lens [1, 30] (see Table 1.2 for
the relative quantities of crystallins in a young human lens). The monomers of βand γ-crystallins are made up of two domains each consisting of two consecutive
Greek key motifs, which comprise four β-strands that assemble the domains in
anti-parallel β-sheet conformations. The two domains are then linked together
through a short peptide [26, 60-63].
At present, six different subunits of β-crystallin had been identified in adult
vertebrate lenses based on their primary gene products, which include three basic
(βB1-B3) and three acidic (βA1/A3, βA2-A4) subunits, ranging from 22 kDa (βA4)
to 28 kDa (βB1) in mass [1, 17]. In the mammalian lens, β-crystallins form complex,
polydisperse groups of heteropolymers ranging from 50 to 200 kDa [1-2, 17]. The
basic β-crystallins are structured so that N- and C-terminal peptides extend from the
four β-strand motif core of the protein, along with a small number of insertion
sequences [1, 26, 60-61, 63]. The acidic β-crystallins have a larger number of
insertions but lack the C-terminal extension [64].
The γ-crystallins present in the human lens consist of a group of four (γA-D) highly
homologous, 21 kDa monomeric proteins that have very similar symmetrical
structures [17, 65]. Of these proteins, γC- and γ-D-crystallins are by far the more
prominent species [30, 66-67]. They are expressed very early in lens development
and have one of the tightest molecular arrangements among the crystallins [68]. A
low molecular weight (LMW) crystallin species, γS-crystallin, was initially
classified with the β-crystallins, but subsequent cDNA sequencing revealed that this
crystallin species is more related to the γ-crystallins [26, 69-70].
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Table 1.2: Relative quantities of crystallin subunits present in the soluble
protein fraction of young human lenses. (Source from [30].)

Crystallin subunits

% of totala

αA

21.4 ± 1.0

γS/βA1

b

15.4 ± 1.2

βB2

14.3 ± 1.2

γC

14.3 ± 0.8

βB1

8.8 ± 2.4

αB
βA3/βB3

a.

b.
c.

6.3 ± 0.8
b

6.2 ± 0.8

βA4

4.7 ± 1.4

γD

2.5 ± 0.9

βA1 (16-251)

2.2 ± 0.8

βA3 (23-215)

1.6 ± 0.6

Total

97.7c

Percentages calculated based on 2-D electrophoretic gels of soluble proteins (mean ± 1.S.D.,
n = 4) extracted from a newborn human lens and lenses from 3, 4 and 7 day old human
donors.
Individual amounts of γS, βA1, βA3 and βB3 could not be accurately estimated from the
2-D gels.
The remaining 2.3% accounts for minor, unidentified proteins.

1.4 Lens cytoskeleton and membrane composition

1.4.1 Intermediate filaments
As with virtually all vertebrate cells, the cytoskeleton of lens epithelial cells
comprises three major components - microfilaments, microtubules and intermediate
filaments [71]. Amongst these filament systems, the intermediate filaments have
attracted the most interest as they are the most resilient filament network in the
cytoskeleton, and are the only cytoskeletal components retained in mature lens fibre
cells [71-72]. Mammalian lenses expresses a surprisingly large variety of
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intermediate filament proteins, which includes vimentin [73-76], glial fibrillary
acidic protein (GFAP) [77], keritins [77-78], nestin [79-80], synemin [81] and two
beaded filament proteins - filensin and phakinin [71, 82-84]. Of these proteins, only
the beaded filament proteins and vimentin are found in significant amounts in lens
fibre cells [71, 73, 76, 85-87].

1.4.1.1 The beaded filaments
The term beaded filaments was first used by Maisel and Perry [88] in 1972 to
describe a unique cytoskeletal structure in chicken lenses. This filament structure
was first seen in mammalian lenses in 1959 [89], and was later shown to be a
universal component found in the lens of all mammalian species, including humans
[71, 83, 89]. The structure of the beaded filaments consists of a filament backbone
(5-6 nm in width) “decorated” by beads of 15-20 nm in diameter [89] (Fig. 1.4B). It
is the only filament structure to survive all stages of cell differentiation and is
retained in the lens fibre cells for the entire lifespan [87, 89]. The beaded filaments
are believed to have important functions in the alignment and anchoring of cellular
components in lens cells [71, 90]. A residue deletion or mutation of these beaded
filament proteins can lead to lens opacity in mammals [91-95], with preliminary
studies suggesting that the same modifications could also compromise lens function
in humans [85-86, 96]. Despite their importance, limited information is currently
available on the structure and functions of the beaded filament proteins in the human
lens.
The beaded filaments are comprised of two lens-specific proteins - filensin (also
known as BFSP1 or CP115) and phakinin (also known as BFSP2 or CP49) [71, 87,
89, 97]. Similar to all intermediate filament proteins, the secondary structures of the
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beaded filament proteins are predicted to consist of an α-helical coiled-coil domain
(rod domain) flanked by non-helical N- and C-termini [71, 87] (Fig. 1.4C). The
structure of the beaded filament proteins, however, features two unusual motifs
positioned at the ends of the rod domain (Fig. 1.3C, yellow box), which consists of
the sequences LGER and RYHRIIEIE for mammalian filensin, and LGGC and
SYHALLDRE for mammalian phakinin, respectively, compared to the conventional
LNDR and TYRKLLEGE motifs found at the same region of other intermediate
filament proteins [71] (Fig. 1.4C).
Immuno-labeling studies have indicated that phakinin is localized in the core region
of the beaded filament backbone, with filensin occupying a more peripheral position
[98]. During lens fibre cell differentiation, both filensin and phakinin are extensively
cleaved in bovine lenses [73, 87]. While the purpose of this structural breakdown is
not known, it is speculated to be part of the maturation process where stable beaded
filament structures are formed in the lens [87].
α-Crystallin is also part of the beaded filament structure and appears to be the major
component of the “beaded particle” [76]. In the absence of α-crystallin, filensin and
phakinin form filament structures of 10 nm in diameter, similar to that of classic
intermediate filaments [76] (Fig. 1.4A). In contrast, while initially thought to be part
of the beaded filaments structure due to their in vivo proximity in the lens
cytoskeleton, vimentin forms a distinctive network in the lenticular intermediate
filaments that is separated from the beaded filaments [73, 83].
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Fig. 1.4: Assembly of beaded filaments in the lens cell and schematic
representation of the predicted secondary structures of vimentin, filensin
(BFSP1) and phakinin (BFSP2). (A) Micrograph showing that in the absence of
α-crystallin, filensin and phakinin form filaments (10 nm in width) resembling the
classic intermediate filaments structure when mixed in vitro in a 1:2 ratio. Scale bar:
500 nm. (B) Micrograph of the two native intermediate filaments systems in the lens:
Smooth filaments (10 nm in width) (arrowheads) decorated by α-crystallin particles
(small arrows) and the much more abundant beaded filaments (large arrows). Scale
bar: 500 nm. (C) Schematic diagram showing the predicted secondary structures of a
typical intermediate filaments protein (vimentin) and the unusual secondary
structures of the beaded filament proteins (phakinin and filensin). Conventional
intermediate filament proteins such as vimentin consist of an α-helical coiled-coil
domain (rod domain) flanked by non-helical N- and C-termini, with two highly
conserved LNDR and TYRKLLEGE motifs (yellow boxes) at each end of the rod
domain. Instead, mammalian phakinin (BFSP2) has LGGC and SYHALLDRE
motifs at the ends of the rod domain, and lacks the conventional C-terminal
characteristics of intermediate filament proteins. The LGGC domain (red box)
would actually disrupt the function of the protein and causes diseases if found in
other intermediate filament proteins such as GFAP. The structure of mammalian
filensin (BFSP1) also differs from other intermediate filament protein as it has
LGER and RYHRIIEIE motifs at the ends of the rod domain, a shorter rod domain
and an elongated C-terminus tail. (Figure reproduced from [71].)
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1.4.1.2 Vimentin intermediate filaments
Unlike the beaded filaments, the type III intermediate filament protein vimentin is
also expressed in many other tissues [99-100]. In the mammalian lens, vimentin
forms a distinctive filament network (10 nm in diameter) that is present in both the
epithelial and young fibre cells, but not in mature fibre cells [71, 73, 83]. Despite its
absence in mature lens fibre cells, studies using mammalian animal models have
shown that deletion or mutation of vimentin in the lens can lead to cataract and
blindness [86, 92, 94]. Cataract can also result from overexpression of vimentin in
the lens [101]. In addition, mouse studies have shown that filensin becomes
associated with the vimentin filament network in the absence of phakinin [102].

1.4.2 Lens fibre cell membrane components
Human lens fibre cell membranes consists of a similar proportion of proteins and
lipids [103]. Gel electrophoresis on the UI lens fraction revealed that human lens
membrane consist of a major 26 kDa protein known as aquaporin 0 (also known as
major intrinsic protein (MIP) 26), which functions as a water channel facilitating
water movement between cells [104]. Another important component in the lens fibre
cell membrane are gap junctions, which mediate the movement of small molecules
such as antioxidants between lens cells. Gap junctions are comprised of
transmembrane proteins known as the connexins [105-106].
The human lens fibre cell membrane is rich in cholesterol, accounting for ~50-60%
of the total lens lipids [107-110], although a cholesterol-phospholipid ratio as high
as 8:1 in membranes isolated from the lens centre has been reported [111-112]. Of
the phospholipid constituents of human lens fibre cell membranes, sphingomyelin is
by far the most abundant, and makes up approximately half (47-56%) of the total
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lens phospholipids [103, 110]. Dihydrosphingomyelins, in particular, exists in high
levels [113]. Other phospholipids from human lens fibre cell membranes include
phophatidylcholine (2-5% of total lens phospholipids), phosphatidylethanolamine
(9-18% of total lens phospholipids), phosphatidylserine (6-15% of total lens
phospholipids) and phosphatidylinositol (1-4% of total lens phospholipids) [103,
110], although the proportion of these phospholipids can change significantly with
age [114].
The high concentrations of cholesterol and sphingomyelin give rise to conditions
favouring raft formation [111, 115]. Lipid rafts, or detergent resistant membranes
(DRMs), are lipid/protein microdomains present in plasma membranes that are
believed to play a major role in a number of physiological processes, including
signal transduction [116-119], organization of the cytoskeleton [120-121] and
protein trafficking/recycling [122-123]. There is currently limited information
regarding the localization and function of lipid rafts in the human lens fibre cell
membrane. Preliminary studies have established that the cholesterol and lipid
contents of DRMs differ significantly between cataractous and non-cataractous
lenses [111]. In addition, aquaporin 0 was reported in the DRM fraction, whereas
connexins were not detected on the DRMs [124].

1.5 The aging lens

1.5.1 Insolubilization of lenticular crystallins
Crystallins present in young lenses are mostly WS. With age, as a consequence of
posttranslational modifications and other insults, crystallins undergo denaturation,
aggregation and cross-linking [17-19, 66, 125]. By age 40, the level of free,
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uncomplexed α-crystallin in the lens becomes negligible [126-128]. Together, these
events lead to crystallins becoming water-insoluble (WI) in old and cataractous
lenses (see Fig. 1.5 of a schematic representation of crystallin insolubilization in the
aging human lens). The accumulation of WI crystallin aggregates is a major
consequence of lens aging, possibly leading to the lens stiffening associated with
presbyopia, and may be a precursor to cataract.

Fig. 1.5: Schematic representation of crystallin insolubilization in the aging
human lens. Crystallins present in young lenses are mostly WS and are in their
native state. With age, crystallins undergo a variety of posttranslational
modifications, resulting in the denaturation and unfolding of proteins. Without the
chaperone function of α-crystallin, denatured crystallins undergo aggregation and
may become associated with lens fibre cell membranes. These changes all contribute
to the insolubilization of crystallins in the human lens.
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1.5.1.2 Posttranslational modifications of crystallins
Crystallins undergo a variety of posttranslational modifications during their lifelong
presence in the lens. Attempts to understand the mechanisms and functions of these
modifications have had only limited success. Certain modifications could be part of
the normal maturation process of the lens, while others, particularly those detected
in old and cataractous lenses, are associated with the impairment of normal
crystallin function [17, 125, 129].
Phosphorylation of α-crystallin has been reported to affect the chaperone function of
the protein, although the effects vary between the different target-proteins and buffer
systems employed [130-134]. Phosphorylation of αB-crystallin at residues Ser19,
Ser45 and Ser59 significantly reduced the ability of this protein to suppress the
aggregation of proteins such as α-lactalbumin, but has little or no affect on the
chaperone activity against other proteins such as βL-crystallin [130-131]. Crystallin
deamidation has also been associated with crystallin misfolding and aggregation in
the lens [135-138], and is one of the more common modifications of crystallins
present in the insoluble fraction of the lens and in cataractous lenses [129, 137].
Other notable modifications include truncation [18-19, 125, 139], disulfide bonding
[140], glycation [141-144] and racemization [145].

1.5.1.3 Crystallin breakdown
Truncation (cleavage) is a common age-related modification of crystallins within the
lens [17]. Crystallin cleavage occurs at an early stage of lens fibre cell development,
but increases significantly with age, particularly during and after middle-age and
with the onset of cataract [18-19, 125, 139, 146-147]. Some crystallin subunits, such
as αA- [66], αB- [66] and βB1-crystallins [148-149], are extensively fragmented
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even in young lenses [18, 66, 125, 139]. Many α- and β-crystallin subunits are
cleaved at multiple sites, generating a variety of breakdown products that are present
in both the WS and WI fractions of the lens [18-19, 66, 139, 150]. These crystallin
fragments become increasingly prevalent within the WI fractions with age [18, 66,
151-152]. In contrast, the monomeric γ-crystallins undergo very little cleavage over
time, with only one major cleavage event producing a 9 kDa fragment during early
lens development [153]. Recent studies have shown that a variety of endogenous,
LMW crystallin peptides exist in old and cataractous human lenses [139, 154]. The
accumulation of these peptides, as well as larger crystallin fragments, suggests that
mature lens fibre cells may be incapable of removing these crystallin breakdown
products through the normal degradation process [17, 139, 150, 154].
Crystallin cleavage has been proposed to be an important factor in the development
of lens opacity, as structural damage resulting from these cleavages could disrupt the
normal functions of crystallins [17-18, 139, 154]. In the case of α-crystallin,
cleavages at sequence regions reported to be responsible for the chaperone activity
of the protein (residues 70-88 of αA-crystallin [155] and residues 73-92 of
αB-crystallin [156]) could lead to the loss of its chaperone function. Additionally, a
number of LMW crystallin peptides were shown to inhibit the chaperone activity of
α-crystallin under in vitro conditions [139, 157]. These endogenous peptides could
facilitate protein aggregation in the lens, if their anti-chaperone activity is
maintained in the lens environment [139, 157].
Despite the abundance of crystallin fragments detected in the human lens, little is
known about the mechanism(s) responsible for the cleavages of the protein. While
the human lens contains several types of proteases and peptidases [158-161], there
appears to be negligible proteolytic activity in mature lens fibre cells [161-163]. The
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activity of calpains, the major proteases present in the lens, is largely inhibited by
high levels of endogenous calpain-inhibitor (calpastatin) in human lens fibre cells
[163-164]. Recent analysis on the breakdown of aquaporin 0 in old lenses indicates
that non-enzymatic cleavages may also contribute to protein cleavages in the human
lens [20, 165]. Overall, elucidation of the mechanism(s) underlying the cleavage of
crystallins in the aging lens awaits for more conclusive evidence.

1.5.1.4 Crystallin cross-linking
Investigations into the WI proteins in the lens have revealed a variety of crystallin
cross-linked complexes, with sizes varying between ~20 kDa to over 90 kDa when
separated on denaturing gels [18-19]. The mechanism(s) underlying this
cross-linking is not well understood, although posttranslational modifications
described in this chapter could play a major role [17-19, 129]. The number of
cross-linked complexes in the lens increases significantly with age and more so
during cataract, particularly in the WI fractions [18-19] Two notable types of
crystallin cross-linked complexes have been characterized in the lens WI fraction:
one which consists of fragments from eight different crystallins subunits (αA, αB,
βA1/A3, βA4, βB1, βB2, γS and γD), while the other derived from cross-linking
between α-, β- and γ-crystallins and the beaded filament proteins (filensin and
phakinin) [18]. The presence of these cross-linked complexes in the WI fraction, and
the tight association between crystallins and beaded filament proteins, suggests that
cross-linking may be a process by which crystallins become WI in the lens [18-19].

1.5.1.5 Crystallin aggregation
A variety of WS, HMW aggregates (molecular weight 50-300 × 106 Da), formed by
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denatured crystallins and their fragments, have been characterized in the lens [125,
151, 166-169]. These HMW aggregates may affect lens transparency, as crystallin
aggregates greater than 50 × 106 Da cause light scattering [170]. It has been
proposed that the constant exposure of hydrophobic regions between neighboring
molecules leads to the increasing size of the crystallin aggregates [171], and that the
continuous expansion of these macromolecules eventually exceeds their ability to
remain soluble [125, 151, 167]. Consequently, these soluble HMW crystallin
aggregates could be intermediate structures on a pathway to the formation of WI
crystallin aggregates present in old and cataractous lenses [151, 167].

1.5.1.6 Membrane-protein association
The amount of crystallin bound to lens fibre cell membranes increases significantly
with age and the onset of cataract [172-175]. This association with membrane is
believed to be a major factor in the insolubilization of crystallins in the lens [172,
174-177]. In fact, Chandrasekher and Cenedella [172] found that essentially all WI
crystallins in the lens are membrane-bound. Recently, large-scale binding of
crystallins to cellular membranes has been documented in the nucleus of the human
lens after middle-age [174-175].
Amongst the crystallins, α-crystallin has a particularly strong affinity towards lens
membranes, and this affinity appears to increase with age [173, 178-181]. It has
been suggested that the overall increase in crystallin binding to lens membrane is a
result of other crystallin species interacting with membrane-bound α-crystallin [180].
Attempts to replicate the membrane binding of α-crystallin under in vitro conditions
have produced variable outcomes. For example, Ifeanyi et al. [182] suggested that
the αA subunit of α-crystallin is mostly responsible for the membrane-association,
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while Cobb and Petrash [176] showed that both αA and αB subunits displayed
similar binding affinities to purified lens plasma membranes. The same group also
concluded that the only major limiting factor of the membrane binding of
α-crystallin is the surface area of the lipid bilayer, and that the increase in
membrane-bound crystallins arises from binding of larger crystallin aggregates to
the membrane [176-177].
Recent data suggests that phospholipids present in human lens membrane undergo
major changes with age [114]. For example, the level of glycerophospholipids in the
lens nucleus decline steadily with age, and are undetectable by age 40 [114]. In
contrast, the level of ceramides and dihydroceramides increases by approximately
100-fold in the lens nucleus during middle-age [114]. It is therefore possible that
changes to the membrane phospholipids may encourage the binding of α-crystallin.
In addition, α-crystallin may also become associated with the lens membrane via its
intimate association with the beaded filament proteins [183-184], as these
intermediate filament structures have been shown to interact with aquaporin 0
present on fibre cell membranes [185].

1.5.2 Oxidative core and lens barrier
The avascular nature of the lens means that the transport of metabolites within the
lens is dependent almost entirely on diffusion [9, 186]. In a healthy lens, metabolites
such as antioxidants and water are able to permeate through fibre cells across the
entire lens via diffusion through membrane-channels (eg. aquaporin 0 and gap
junctions) between cells [104, 186]. The movement of these metabolites is crucial to
the health of the lens. Glutathione (GSH), an antioxidant synthesized in the lens
cortex, is particularly important as it protects lens proteins from oxidative stress by
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neutralizing reactive oxygen species such as hydrogen peroxide and superoxide
[187].
As the lens ages, however, the amount of antioxidants able to reach the core region
of the lens steadily decreases [188-191]. Bova et al. [188] showed that the level of
GSH in the nucleus of the lens dropped from ~4.5 mM to ~1 mM between the age of
20 and 90 years. This reduction in GSH and other important antioxidants (eg.
ascorbate, NADPH) leads to the development of an oxidative environment within
the lens core [189-190].
The development of an oxidative core in the lens is the major precondition for
cataract [186-187, 192-193]. Lens proteins under oxidative stress are prone to
structural damage through the oxidation of Met and Cys residues and the loss of
sulfhydryl groups [162, 186, 194-195]. It has been reported that in the most
advanced stage of cataract, > 90% of Cys and almost half of the Met residues of lens
proteins are oxidized [194-195]. An important phenomenon associated with the
oxidative core of the lens is the development of a barrier to diffusion close to the
junction of the lens cortex and nucleus (approximate dimensions of 7.2 mm
(diameter) by 2.8 mm (axial)), which takes place at around middle-age [189] (see
Fig. 1.6 showing the impairment of metabolite diffusion to the centre of the lens past
middle-age). The formation of this barrier is believed to be the major factor which
impedes the movement of GSH and other metabolites into the centre of the lens [186,
189].
At present, the cause(s) underlying the formation of this barrier to diffusion in the
lens is not fully understood. It has been proposed that the binding of HMW crystallin
aggregates to lens membranes may result in obstruction of membrane-pores, thereby
hindering the movement of metabolites between fibre cells [174-175]. The timeline
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for the development of this diffusion barrier coincides with an increase in membrane
binding of crystallins in the lens centre [174-175, 189]. Additionally, cross-sectional
analysis of old human lenses showed that the barrier region consists of HMW
crystallin constituents similar to those present in the lens core regions, while these
HMW species were not found in the lens cortex [175]. These findings suggest that
membrane binding of HMW crystallin aggregates may be directly associated with
the formation of the barrier to diffusion in the lens.

Fig. 1.6: A barrier to diffusion which impedes the movement of metabolites is
present in the human lens past middle-age. Audioradiographs of axial sections of
a 19 year (left) and 56 year (right) lens after 48 h incubation with 35cysteine. Red
represents the background and blue is approximately a thousand disintegrations per
50 μm (10 × background). (Figure reproduced from [189].)

1.5.3 Development of cataract
Young human lenses are almost colourless, but with age they become more yellow
and fluorescent. With the onset of an age-related nuclear (ARN) oxidative
environment, the lens becomes opaque and “tanned” (dark-brown or black),
blocking the passage of light passing through the lens and onto the retina. This
phenomenon of sight-impairment due to the obstruction of the pathway of light is
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known as cataract. Cataract patients suffer from partial or complete loss of vision
[2].
Although cataracts can occur due to diseases, injury, congenital anomalies, or
exposure to certain toxic substances, the majority of cataracts in humans are
associated with the age-related biochemical changes in the lens [1-2]. Studies have
suggested that certain individuals, such as diabetics, are more at risk of cataract
development [1-2]. Other risk factors include prolonged UV-B exposure [196-197],
high corticosteroid levels [198], high alcohol intake [199-200], hypertension,
smoking [201], diarrhea and heatstroke [202]. Of all risk factors, however, age is by
far the most important [17, 90, 186].
There are three main types of age-related cataract: cortical, posterior subcapsular
and nuclear [1]. Cortical cataract is mainly associated with ionic imbalance [1, 203].
Nuclear cataract, which is much more common, is mainly associated with protein
insolubilization and oxidation in the lens with age [186, 191, 204].

1.5.3.1 ARN cataract
ARN cataract is the major cause of blindness in the world [205]. There is at present
no known way of preventing or treating ARN cataract other than surgical removal of
the lens, which is a significant financial burden worldwide [172, 206]. The onset of
ARN cataract can occur shortly past middle-age, with the transparency of the lens
deteriorating further with age [2]. In order to facilitate examination of the degree of
lens opacity, Antoinette Pirie proposed a classification system based on nuclear
colouration (Fig. 1.7) [207]. On this scale, Type I is predominantly cortical cataract.
Type II represents the onset of nuclear cataract. Type III and IV are classic examples
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of nuclear cataract [207], and in some cases, an advanced form of cataract (Type V)
is also included [208] (Fig. 1.7).

Fig. 1.7: Pirie’s classification of lens cataract based on nuclear colouration
(I-IV). Type V cataract was later added by Marcantonio and Duncan in 1987.
Photographs courtesy of George Duncan [208].

Although the exact mechanism(s) responsible for the development of ARN cataract
is not fully understood, it is widely accepted that ARN cataract formation is the
result of oxidation and insolubilization of crystallins in the lens [2]. Crystallin
modifications discussed in this chapter, as well as other age-related events such as
the formation of an oxidative core in the lens, are all important factors in ARN
cataract formation. Elucidation of these key events which lead to the development of
ARN cataract is the essential first step in the development of either a preventative
and/or therapeutic treatment for this disease.
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1.6 The aims of the current research

Age-related modifications to the protein constituents of the lens have a direct role in
the development of lens opacity. Although a number of these modifications, such as
those described in this chapter, have been investigated, many areas which may have
potential importance in lens development are yet to be examined. The aim of this
thesis is to investigate specific age-dependent changes to lenticular crystallin and
cytoskeletal components believed to have particular significance for the
development of lens opacity.

The specific aims of this project were to:

(i.)

Identify and characterize endogenous LMW crystallin breakdown
products (peptides) in the human lens. This aim also includes
determining the localization of specific crystallin peptides previously
shown to possess anti-chaperone activity against α-crystallin within the
lens tissue.

(ii.)

Examine the binding of α-crystallin to membranes derived from the
human lens cortical and nuclear tissues.

(iii.)

Investigate the breakdown of the intermediate filament proteins and
crystallins in the aging human lens, and examine the association between
α-crystallin and the intermediate filament proteins.

(iv.)

Characterize crystallin components of the WS 40-50 kDa protein
complexes in human lens extracts.
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Preface

Lenticular crystallins undergo extensive modifications with age, which include
truncation, cross-linking and aggregation. As these modifications are prominent in
aged and cataractous lenses, they have been associated with the development of lens
opacity. The breakdown of lenticular intermediate filament proteins in the lens has
also been associated with lens opacification, and the interaction between these
proteins with α-crystallin is thought to be an important mechanism by which
crystallins become insoluble in the lens. This work set out to investigate age-related
modifications to lenticular crystallins and the intermediate filament proteins. The
2-D SDS-PAGE analysis of crystallin complexes present in the lens was not part of
the original manuscript, but was later added to complement the IEF analysis of the
same group of crystallin complexes.

Publication:

Shih-Ping Su, Jason D. McArthur, Roger J.W. Truscott and J. Andrew Aquilina
(2011) “Truncation, cross-linking and interaction of crystallins and intermediate
filament proteins in the aging human lens.” Biochimica et Biophysica Acta: Proteins
and Proteomics, 1814(5): 647-656.
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2.1 Abstract

The optical properties of the lens are dependent upon the integrity of proteins within
the fibre cells. During aging, crystallins, the major intra-cellular structural proteins
of the lens, aggregate and become water-insoluble (WI). Modifications to crystallins
and the lens intermediate filaments have been implicated in this phenomenon. In this
study, we examined changes to, and interactions between, human lens crystallins and
intermediate filament proteins in lenses from a variety of age groups (0-86 years).
Amongst the lens-specific intermediate filament proteins, filensin was extensively
cleaved in all postnatal lenses, with truncated products of various sizes being found
in both the lens cortical and nuclear extracts. Phakinin was also truncated and was
not detected in the lens nucleus. The third major intermediate filament protein,
vimentin, remained intact in lens cortical fibre cells across the age range except for
an 86 year lens, where a single ~49 kDa breakdown product was observed. An
αB-crystallin fusion protein (maltose-binding protein-αB-crystallin) was found to
readily exchange subunits with endogenous α-crystallin, and following incubation at
37 °C, bind to filensin, phakinin and vimentin and to several of their truncated
products. Tryptic-digestion of a truncated form of filensin suggested that the binding
site for α-crystallin may be in the N-terminal region. The presence of significant
amounts of small peptides derived from S- and B1-crystallins in the WI fraction
of the lens indicates that these interact tightly with cytoskeletal or membrane
components. Interestingly, 40-50 kDa water-soluble (WS) complexes contained
predominantly S- and B1-crystallins, showing that modified - and -crystallins
may also be covalently associated in the lens.
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2.2 Introduction

Lens fibre cells contain high concentrations of structural proteins known as α-, βand γ-crystallins. α-Crystallin also functions as a molecular chaperone in the lens,
interacting with partially unfolded lens proteins and preventing them from
precipitating [3, 5, 209-210]. Due to the lack of protein turnover [6], the optical
properties of the lens are dependent upon the ability of α-crystallin to maintain
unfolding lens proteins in soluble chaperone-client complexes. However, in aged
human lenses, aggregation of proteins and protein fragments has been reported [125,
211], leading to a significant increase in the amount of WI [126, 212] and HMW
aggregates in older lenses [125, 213].
Crystallins undergo extensive posttranslational modifications with age, including
truncation, racemisation, glycation, deamidation and phosphorylation [17, 66, 129,
135, 186, 214-215]. While some posttranslational modifications, such as truncation
at the protein sequence termini, occur early in life [66, 148], the majority of
posttranslational modifications accrue over decades [17, 125, 129]. Several
crystallin subunits, including αA- [66], αB- [66] and βB1-crystallins [148-149], are
known to be extensively fragmented even in young human lenses, giving rise to a
pool of crystallin-derived fragments. These modifications contribute to the increase
of crystallin aggregation, cross-linking and insolubilization in the lens with age [160,
186, 214]. Furthermore, a variety of multimeric complexes, formed through the
cross-linking of crystallin fragments, have been reported in the human lens, with the
number of cross-linked crystallin complexes increasing with age [10, 18-19, 66, 125,
216]. It has been hypothesized that the development of cataract is due, in part, to the
aggregation of crystallin fragments generated by the breakdown of crystallins [160].
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α-Crystallin also associates with the intermediate filament proteins, filensin,
phakinin and vimentin, present in mammalian lenses [18-19, 76, 183-184]. The
intermediate filaments are structural components of the cytoskeleton of lens fibre
cells [72, 217]. During lens fibre cell differentiation, filensin and phakinin
copolymerize with α-crystallin to form beaded filaments [98] - important
intermediate filament structures which help align cellular components [71, 90].
Studies using bovine lenses found that filensin and phakinin are both extensively
processed during the formation of beaded filaments [73, 87]. Unlike other
components of the lenticular cytoskeleton, such as actin-based microfilaments and
microtubules, beaded filaments are also present in mature lens fibre cells [73, 87,
89]. In contrast, vimentin forms a distinct intermediate filament network that is
present in both epithelial and newly differentiated fibre cells, but not in mature fibre
cells [73]. These intermediate filament proteins are likely to have important roles in
maintaining the structural integrity of lens fibre cells. Mutations to the beaded
filament proteins [91, 93, 95] or vimentin [92, 94] can lead to lens opacity and
possibly cataract in humans [85-86, 96]. However, limited information is currently
available on the intermediate filament proteins present in human lenses.
In this study, we examined changes to, and interactions between, crystallins and
intermediate filament proteins in the aging human lens. Our results showed that
beaded filament proteins are extensively cleaved very early in life, with only
breakdown products from filensin being retained in mature lens fibre cells. Pull-out
studies using a recombinant αB-crystallin fusion protein showed that α-crystallin
interacts with filensin, phakinin, vimentin, and the majority of their breakdown
products at 37 °C. Using mass spectrometry (MS) techniques, we found evidence
that the breakdown products of other crystallins in the lens, such as B1 and S, may
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also bind to the intermediate filament structures and thus become insoluble. These and -crystallin fragments were also found in the WS fraction as covalently-linked
40-50 kDa cross-linked complexes.
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2.3 Material and methods

2.3.1 Protein extraction from human lenses and SDS-PAGE analysis
Human lenses were obtained from donors at the Lions New South Wales Eye Bank
(Sydney, Australia) and stored immediately at -80 °C. Except for the fetal lens,
which was homogenized whole, lenses were dissected into cortical and nuclear
regions using a 4.5 mm trephine. A cold scalpel was used to remove 1 mm of tissue
from each end of the resulting cylindrical center (nucleus). Lens tissues from both
regions were homogenized in buffer A (20 mM Tris-HCl, 20 mM NaCl, 1 mM
EDTA (ethylenediaminetetraacetic acid), pH 7.4) using a hand-held tissue
homogenizer, and incubated at room temperature for 15 min. The WS extracts were
collected after two centrifugation steps at 10000 × g for 30 min at 4 °C. Pellets were
resuspended in buffer B (8 M urea in buffer A), and incubated at room temperature
for 15 min. The urea-soluble (US) extracts were collected after centrifugation at
10000 × g for 30 min at 4 °C. The remaining pellets were then washed twice with
buffer B, followed by a wash with buffer A. The urea-insoluble (UI) extracts were
obtained by resuspending the pellets in buffer C (60 mM Tris-HCl, 1% SDS, 10%
glycerol, 1 mM β-mercaptoethanol, pH 6.8) and incubated at room temperature for 2
h. Protease inhibitor cocktail (P2714, Sigma-Aldrich, St. Louis, Missouri, USA) was
prepared as per the manufacturer’s specifications and used in all buffers. Protein
concentrations

were

determined

using

the

bicinchoninic

acid

assay

kit

(Sigma-Aldrich). Samples were analyzed on 12% SDS-PAGE denaturing gels
stained with Coomassie Blue R (Sigma-Aldrich). The intensity of gel bands were
measured using a GS-800 Calibrated Densitometer (Bio-Rad, Hercules, California,
USA) and calculated using Quantity One software (version 4.6.5).
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2.3.2 Protein isolation from SDS-PAGE gels and isoelectric focusing
Proteins from the cortex water-soluble (CWS) and nucleus water-soluble (NWS)
extracts of a 65 year lens were separated using SDS-PAGE and the gel was
negatively stained (Zinc Stain and Destain Kit, Bio-Rad). A broad 40-50 kDa band
was excised from the gels. Proteins contained within the excised polyacrylamide gel
pieces were eluted as described by Ueda et al. [218]. Eluted proteins were
precipitated using ReadyPrep 2-D Cleanup Kit (Bio-Rad) and resolubilized in SSS
buffer (8 M urea, 40 mM Tris-HCl, 100 mM dithiothreitol (DTT), 4% CHAPS, 0.8%
carrier ampholytes). The samples were then rehydrated overnight onto immobilized
pH gradient (IPG) strips (gradient, pH 3-10, 17 cm) (163-2009, Bio-Rad) with 2 l
of bromophenol blue solution (1% w/v) and mineral oil. The IPG strips were run on
a Protean Isoelectric Focusing Cell (Bio-Rad) at 100 V for 1 h; 300 V for 1 h; 600 V
for 1 h; 1000 V for 1 h; 2000 V for 1 h; 4000 V for approximately 10 h and 100 V
hold (12 h). The IPG strip was then stained for 1 h in Bio-Safe Coomassie
(161-0786, Bio-Rad), and destained in 20 mM Tris-HCl (pH 8.8) for 10 min.

2.3.3 Tryptic-digest of proteins separated by SDS-PAGE and isoelectric focusing
Polyacrylamide pieces containing individual bands from SDS-PAGE gels were
excised and placed in the wells of a 96-well plate. Coomassie Blue destain solution
(30 mM NH4HCO3 (pH 7.8) in 40% acetonitrile) was added to each well and then
allowed to destain for 1 h at room temperature under vigorous shaking. Gel pieces
were then vacuum-dried for 90 min before being incubated with 133 ng of
sequencing grade modified trypsin (Promega, Madison, Wisconsin, USA), made up
in 50 mM NH4HCO3 (pH 7.8), for 1 h at 4 °C under gentle shaking. Peptides were
eluted from the gel pieces by incubating overnight in 50 mM NH4HCO3 (pH 7.8) at
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37 °C under gentle shaking. Proteins in excised IPG strip bands were
tryptic-digested using methods described above without the Coomassie Blue
destaining step.

2.3.4 MALDI-MS and ESI-MS analysis of tryptic-digested lens proteins
For matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS)
analysis, samples were concentrated using C18 ZipTips (Millipore, Billerica,
Massachusetts, USA) and spotted directly onto a MALDI-plate by eluting the
peptides with α-cyano-4-hydroxycinnamic acid matrix. MALDI-MS analysis was
performed using a Shimadzu Axima TOF2 MALDI mass spectrometer. Peptide mass
fingerprinting (PMF) and MS/MS results were searched against theoretical spectra
on the SwissProt database (version 51.6, http://www.matrixscience.com), using the
Mascot version 2.2.1 software. Protein scores greater than 67 were considered
significant. MS/MS searches were set at a peptide tolerance of ± 0.5 Da and a
MS/MS tolerance of ± 0.8 Da, with individual ions scores greater than 35 considered
significant. Peptides greater than m/z 2000 were sequenced manually using
electrospray-ionization (ESI) tandem MS on a quadrupole-TOF Synapt mass
spectrometer (Waters, Milford, Massachusetts, USA).

2.3.5 2-D gel analysis of the 40-50 kDa WS crystallin cross-linked complexes
CWS and NWS extracts of a 45 year lens were resuspended in 20 mM Tris-HCl (pH
7.4) and acetone precipitated (1 in 10) at -20 °C overnight. After acetone
precipitation, proteins were resuspended in 2-D buffer (7 M urea, 2 M thiourea, 4%
CHAPS). CWS and NWS proteins (300 μg) were focused onto IPG strips (linear, pH
3-10, 17 cm) (163-2007, Bio-Rad) and separated on an 8-18% gradient SDS-PAGE
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gel. Gels were stained with SYPRO Ruby stain (S21900, Invitrogen, Carlsbad,
California, USA). Fifteen spots were excised from the resulting 2-D gel using the
EXQuest gel cutter (Bio-Rad). Gel pieces were destained with a 50% acetonitrile
solution containing 50 mM NH4HCO3, then tryptic-digested for 16 h at 37 ºC in 25
mM NH4HCO3 (10 µL). The digested peptides were separated by nanoflow liquid
chromatography (nanoLC) using a CapLC system (Agilent 1100 Series, Agilent
Technologies, Forest Hill, Australia). Samples were made up to 40 µL with solution
containing 2% acetonitrile and 0.1% trifluoroacetic acid and injected onto a peptide
trap (Michrom Bioresources, Auburn, California, USA) for pre-concentration, then
desalted with 2% acetonitrile and 0.1% trifluoroacetic acid at 10 µL/min. The
peptide trap was then switched into line with the analytical column containing C18
reverse phase silica (SGE ProteCol C18, 300 Å, 3µm, 150 µm x 10 cm). Peptides
were eluted from the column using a linear solvent gradient, with steps, from
H2O:CH3CN (9:1; + 0.1% formic acid) to H2O:CH3CN (0:100; + 0.1% formic acid)
at 500 nL/min over an 80 min period. The LC eluate was subjected to positive ion
nanoflow electrospray analysis on an Applied Biosystems QSTAR XL mass
spectrometer (Carlsbad, California, USA). The QSTAR was operated in an
information dependant acquisition (IDA) mode. In IDA mode, a TOF-MS survey
scan was acquired (m/z 380-1600, 0.5 seconds), with the three largest multiple
charged ions (counts > 25) in the survey scan sequentially subjected to MS/MS
analysis. MS/MS spectra were accumulated for 2 seconds (m/z 100-1600). The
LC-MS/MS data was searched using Mascot (Matrix Science, London, UK) against
entries for Homo sapiens in the SwissProt protein database. High scores in the
database searches indicated a likely match, confirmed or qualified by operator
inspection of the spectra and search results.
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2.3.6 Western immunoblot analysis of the lenticular intermediate filament proteins
Western immunoblotting was used to probe for the intermediate filament proteins in
lens extracts. Antibodies which recognize human filensin, phakinin and vimentin
were used and diluted to their working concentrations using PBS/T (137 mM NaCl,
2.7 mM KCl, 12.5 mM Na2HPO4, 1.8 mM KH2PO4, 0.05% (v/v) Tween 20, pH 7.4)
containing 0.5% (w/v) skim milk powder. Lens proteins separated by SDS-PAGE
were transferred onto polyvinylidene fluoride (PVDF) membranes at 30 V overnight
at 4 °C using the Mini Trans-Blot system (Bio-Rad). Membranes were blocked for 1
h at room temperature in PBS/T containing 5% (w/v) skim milk powder. After three
10 min washes with PBS/T, the membranes were incubated with either a 1:1500
dilution of monoclonal anti-filensin antibody (F1043, Sigma-Aldrich), a 1:5000
dilution of monoclonal anti-vimentin antibody (V6389, Sigma-Aldrich), or a 1:200
dilution of polyclonal anti-phakinin antibody (sc-67764, Santa Cruz Biotechnology,
Santa Cruz, California, USA) for 90 min at room temperature. Following another
three 10 min washes with PBS/T, the membranes were incubated for 1 h with a
1:2500 dilution of goat anti-mouse immunoglobulin G (IgG) horseradish peroxidase
(HRP) conjugate (SAB-100J, Stressgen, Ann Arbor, Michigan, USA) for
anti-filensin and anti-vimentin immunoblots, or a 1:2000 dilution of donkey
anti-goat IgG HRP conjugate (sc-2020, Santa Cruz Biotechnology) for anti-phakinin
immunoblots. Excess secondary antibodies were removed by three 10 min washes
with PBS/T, and the immunoblots were allowed to develop in a solution of 100 mM
Tris-HCl (pH 7.6) containing 1.4 mM diaminobenzidine and 0.015% (v/v) hydrogen
peroxide.
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2.3.7 Construction of pMAL-c2-αB
The pET24d(+) plasmid (Novagen, Madison, Wisconsin, USA), containing human
wild-type αB-crystallin gene, was a gift from Prof. W. de Jong (University of
Nijmegen, Nijmegen, The Netherlands). To facilitate the subcloning of the wild-type
αB-crystallin gene into pMAL-c2X (New England Biolabs, Ipswich, Massachusetts,
USA), the gene was amplified using polymerase chain reaction (PCR) with primers
5’-ACGAATTCATGGACATCGCCATC-3’

and

5’-CGAAGCTTCTATTTCTTGGGGGC-3’ (Sigma-Genosys), containing EcoRI and
HindIII restriction enzyme sites (underlined) respectively. PCR was performed in a
20 μL reaction mixture containing 1 μL of the pET24d(+)-αB-crystallin plasmid
template, 0.5 μM of each primer, 0.2 mM deoxyribonucleotide (Fermentas,
Burlington, Canada) and 1.25 U of PfuUltra HF DNA polymerase (Stratagene, Cedar
Creek, Texas, USA). Parameters for PCR amplification were 94 °C for 45 seconds, 55
°C for 45 seconds and 72 °C for 45 seconds for 30 cycles. The resulting amplicon was
cloned into pMAL-c2X using standard molecular techniques [219], producing the
expression plasmid pMAL-c2-αB.

2.3.8 Expression and purification of the fusion protein maltose-binding
protein-αB-crystallin
Escherichia coli TOP10/pMAL-c2-αB was grown in a 1 L rich broth culture (1%
tryptone, 0.5% yeast extract, 0.5% NaCl, 0.2% glucose) containing 100 µg/mL of
ampicillin with shaking at 37 °C. Recombinant protein production was induced with
the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) (0.5 mM final
concentration) after reaching an optical density of ~0.5 at 600 nm. After 6 h, cells
were harvested by centrifugation at 5620 × g for 15 min at 4 °C and stored at -80 °C.
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Bacterial cell lysates were prepared as described previously [220]. The recombinant
maltose-binding protein-αB-crystallin (MBP-αB) fusion protein was purified from
bacterial cell lysates using affinity chromatography with amylose resin (New
England Biolabs) as described by the manufacturer. The MBP-αB was further
purified by size-exclusion chromatography, using a HiPrep 26/60 Sephacryl S-300
High Resolution column (Amersham Biosciences, Uppsala, Sweden) in phosphate
buffer (50 mM phosphate, 100 mM NaCl, 1 mM EDTA, 0.1 mM DTT, 0.02% NaN3,
pH 7.2) (A detailed description of the cell lysis, affinity chromatography and
size-exclusion chromatography steps undertaken to purify MBP-αB is available in
Appendix I, section A1.1)

2.3.9 Interaction between MBP-αB and human lens intermediate filament
proteins at 37 °C
To examine the interaction between α-crystallin with the intermediate filament
proteins present in postnatal lenses, US extracts from a 13 years human lens were
used for this particular analysis. The urea concentrations in the extracts were diluted
to 0.6 M with buffer A prior to incubation. Lens proteins (100 μg) from the cortex
urea-soluble (CUS) and nucleus urea-soluble (NUS) lens extract were each
incubated with 100 μg of MBP-αB or MBP2* (E8044S, New England Biolabs) at 37
°C for 6 h to allow full subunit exchange between the proteins. The reaction
mixtures were added to centrifuge tubes each containing 200 μL of amylose resin
and allowed to incubate for 30 min at room temperature, followed by centrifugation
at 12000 × g for 5 min at room temperature. The supernatant was discarded and the
resin was washed twice with 1 mL of buffer A, followed by incubation in 100 μL of
buffer D (100 mM of D-(+)-maltose monohydrate in Buffer A) for 30 min at room
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temperature. The reaction mixture was then centrifuged again at 12000 × g for 5 min
at room temperature. The supernatant, which contained MBP-αB and associated lens
proteins, was aspirated and analyzed using SDS-PAGE and Western immunoblotting.
Western immunoblots were developed using the same techniques and antibody
specifications described above, with the exception of the monoclonal anti-filensin
antibody, which was diluted to 1:2000.
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2.4 Results
2.4.1 Age-related changes to human lens proteins
In order to examine protein changes associated with aging, WS, US and UI proteins
extracted from the cortical and nuclear regions of postnatal human lenses (16-86
years) and a whole fetal human lens (16.5 weeks) were separated using SDS-PAGE
(Fig. 2.1) (see Appendix I, Fig. A1.4 and Table A1.1 for a more comprehensive
presentation of proteins identified in Fig. 2.1 of this chapter; see Table A1.2 for the
breakdown of relative proportion of total lens protein found in each lens extract).
Protein bands were identified using in-gel digestion with trypsin followed by
MALDI-MS analysis. In the CWS extracts (Fig. 2.1A), an age-dependent
disappearance of the βB1-crystallin band at ~29 kDa (band 1) was observed. While
this band was dominant in fetal lens, it was present only at low abundance in the
CWS extracts of young postnatal lenses and absent from all NWS extracts. A
truncated form of βB1-crystallin at ~27 kDa (band 6) was detected in the CWS
extracts of postnatal lenses and also in the NWS extracts of young lenses, but not in
NWS extracts from lenses older than 35 years. This truncation of βB1-crystallin in
human lenses has been observed previously [148]. Non-crystallin proteins, such as
retinal dehydrogenase 1 (band 4) and glyceraldehyde-3-phosphate dehydrogenase
(band 5), were found exclusively in the cortex. Another major characteristic is the
presence of a broad 40-50 kDa band (band XC in CWS extracts; band XN in NWS
extracts) in WS extracts from lenses of all age groups. The broadness of this band
suggested that it could be a cross-linked complex of two or more lens proteins.
Characterization of the species responsible for this band is described in section
2.4.2.
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Fig. 2.1: SDS-PAGE analysis of age-related protein changes in the human lens.
Gels showing the (A) WS, (B) US and (C) UI protein extracts from a whole fetal
lens (16.5 weeks) and from the cortical or nuclear regions of lenses from individuals
aged 16, 20, 35, 43, 65 and 86 years (age indicated on the top of each lane). 50 μg of
protein was loaded onto each lane except for the fetal US extract and the CUI and
NUI extracts from postnatal lenses, which contained 25 μg of protein. The fetal UI
extract contained less than 25 μg of protein. Proteins were in-gel digested with
trypsin and identified using MALDI-MS, with the exception of MIP26 and MIP22,
which were identified based on comparison with results published by our group [20].
The position of major lens proteins are marked on the gel with circled numbers: 1,
βB1-crystallin (29 kDa product); 2, αB-crystallin (20 kDa); 3, αA-crystallin (20
kDa); 4, retinal dehydrogenase 1 (55 kDa); 5, glyceraldehyde-3-phosphate
dehydrogenase (36 kDa); 6, βB1-crystallin (27 kDa product); 7, spectrin (246 kDa);
8, filensin (115 kDa); 9, vimentin (58 kDa); 10, actin (42 kDa); 11, phakinin (49
kDa); 12, MIP26 (26 kDa); 13, MIP22 (22 kDa). A broad 40-50 kDa band,
consisting fragments of multiple crystallins, was found in both the CWS (band XC)
and NWS (band XN) extracts. Molecular weight markers are indicated on the right
of each gel.

Cytoskeletal proteins are typically insoluble in water, and de-aggregating agents
such as urea are required to dissolve them. In the US extracts (Fig. 2.1B), bands
derived from cytoskeletal proteins such as spectrin (band 7), filensin (115 kDa)
(band 8), vimentin (58 kDa) (band 9), actin (band 10) and phakinin (49 kDa) (band
11) all decreased in intensity with age in the cortex and were not detected in the
nucleus. In parallel with the age-dependent loss of cytoskeletal proteins and intact
αA- (Fig. 2.1B, band 3) and αB-crystallin (Fig. 2.1B, band 2), a distinct increase in
staining near the dye-front of the gel was observed. MALDI-MS analysis of this
band after digestion with trypsin indicated that it consisted mostly of fragments from
βB1- and γS-crystallins, with fewer peptides from αA-, αB-, βA1/A3-, βB2- and
γD-crystallins (Fig. 2.2). Densitometric measurements of band intensities (Fig. 2.1)
indicated that the proportion of these LMW fragments increased by five and
three-fold in the CUS and NUS lens extracts respectively, between ages 16 to 86
years.
In the UI extracts of adult lenses (Fig. 2.1C), two bands corresponding to masses of
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major intrinsic protein (MIP) 26 (aquaporin 0) (band 12) and MIP22 (band 13) were
detected. The increase of MIP22 proportionally with age has been described
previously [20]. Spectrin (band 7) and vimentin (band 9) bands were also observed
in the UI extract of the fetal lens, and the cortex urea-insoluble (CUI) extracts of
young postnatal lenses.
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Fig. 2.2: MALDI-MS PMF spectra of tryptic-digested crystallin fragments,
extracted from the SDS-PAGE gel (Fig. 2.1B) dye-front band of the (A) CUS
and (B) NUS extracts of a 65 year human lens. The identities of labelled peaks
were confirmed by MALDI-MS/MS.
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2.4.2 Characterization of WS 40-50 kDa crystallin cross-linked complexes in the
human lens

2.4.2.1 Isoelectric focusing/mass spectrometry characterization
In an effort to gain insight into the constituent proteins of a broad band at 40-50 kDa
in SDS-PAGE gels (Fig. 2.1A, bands XC and XN), we extracted the proteins from a
negatively stained gel (Fig. 2.3), and re-chromatographed them using isoelectric
focusing (IEF). Proteins originating from the CWS and NWS extracts of a 65 year
lens were focused on separate IPG strips, giving rise to similar banding patterns for
each (Fig. 2.4A). All IEF bands (I-X) were excised from the IPG strips, digested
with trypsin and analyzed using a combination of MALDI and ESI-MS.
MALDI-MS analysis was used to acquire PMFs of the proteins in the IEF bands,
and these spectra are presented for the cortical extract in Fig. 2.4B. A number of
peptides were observed in multiple IPG bands, suggesting that the protein
complexes had regions of sequence homology. In order to identify these tryptic
peptides, we used the peptide masses to search a database of in silico tryptic
fragments and peptide sequencing to confirm the identity of the peptides. The table
in Fig. 2.4C presents a summary of the peptides matching the mass spectral data in
this series of experiments. Peptides for which sequence data was obtained using
MS/MS and matched to a crystallin are indicated by shading, and these are also
aligned across the spectra by a dashed line (Fig. 2.4B). The dominant proteins
identified, based upon sequence match and ion intensity, were B1- and
S-crystallins, with four peptides each. The regions of primary sequence covered by
both sequence and mass matched peptides for B1- and S-crystallins are
highlighted in Fig. 2.4D. Overall, there was good coverage for B1 from residues

49

Chapter 2

Modifications to lenticular crystallins and cytoskeletal proteins

50-213 (or 51-214 including the N-terminal Met) (65%), whereas S peptides were
evident from the N-terminus, C-terminus and central regions of the primary
sequence. A3- and A4-crystallins were also positively matched from
collision-induced dissociation (CID) spectra, with A4 being matched to three
additional peptides, based on mass alone. Ions at m/z 1451.1, 1458.0, 1692.2 and
1730.2 were prominent in all IEF bands, demonstrating that B1-, A3- and
S-crystallins were consistent elements of the cross-linked species. This observation
suggests that there are more than two crystallin chains which constitute these higher
mass species, with B1 and S being the predominant species.

Fig. 2.3: Negatively stained SDS-PAGE gel of human lens CWS extract. Shown
here are the SDS-PAGE gels of the CWS extract from a 65 year lens stained with
Coomassie Blue (lane 1) and zinc stain via negative staining (lane 2). The 40-50 kDa
protein complexes from the negatively stained gel were extracted for IEF separation.
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Fig. 2.4: Separation and identification of WS crystallin protein complexes. WS
proteins of 40-50 kDa were extracted from a negatively stained SDS-PAGE gel and
re-chromatographed using IEF. (A) IPG strips showing bands for separated
components of the cortical (left) and nuclear (right) SDS-PAGE gel extracts. (B)
MALDI-MS spectra of protein bands I-V of the cortical extract after in-gel
tryptic-digestion. Ions for which sequence data was obtained (indicated on top of the
spectra) to verify the origins of the peptide are delineated by a dashed line, which
aligns peaks common to respective spectra. Ions arising from trypsin autolysis
products (T) and keratin (K) are indicated. (C) Table of ions matched to theoretical
digest fragments of respective lens crystallins. Peptides for which sequence level
verification was obtained are indicated by shading. The N-terminal Met of these
crystallins (with the exception of αA-crystallin) was ignored as this residue is
cleaved from the protein during translation (D) Linear representation of the primary
sequence coverage obtained for the two most abundant crystallin constituents (βB1
and γS) of the IEF separated proteins (indicated by shading).

2.4.2.2 2-D SDS-PAGE and nanoLC-ESI-MS/MS analysis
Building upon the information obtained using IEF separation, protein components of
the 40-50 kDa WS protein complexes were further investigated using 2-D PAGE and
nanoLC-ESI-MS/MS. CWS and NWS lens extracts of a 45 year human lens were
directly focused on IPG strips and separated by IEF, followed by SDS-PAGE as the
second dimension of separation. From the 2-D gels, it was found that the CWS (Fig.
2.5A) and NWS (Fig. 2.5B) extracts produced similar protein profiles. A total of 15
spots from the 40-50 kDa region of the CWS extract gel were excised (Fig. 2.6),
with

the

protein

components

present

in

these

spots

nanoLC-ESI-MS/MS after in-gel tryptic-digestion (Table 2.1).
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Fig. 2.5: 2-D SDS-PAGE gel of the (A) CWS and (B) NWS extracts of a 45 year
human lens. Proteins were focused onto IPG strips (pH 3-10) followed by SDS-PAGE
separation. Dashed box indicated regions where spots were excised for
nanoLC-ESI-MS/MS analysis (Fig. 2.6).

Fig. 2.6: Crystallin complexes of 40-50 kDa present in the CWS extract of a 45 year
human lens. A total of 15 spots (marked on the gel) were excised from the gel (Fig. 2.5A,
dashed box). Proteins present in these spots were identified using nanoLC-ESI-MS/MS
following in-gel tryptic-digestion. Crystallin fragments present in these complexes are
presented in Table 2.1.

Compared with section 2.4.2.1, where IEF was used as the second dimension of
separation, 2-D SDS-PAGE coupled with nanoLC-ESI-MS/MS produced similar but
significantly more sensitive results. βB1-crystallin was confirmed as the major
component of these 40-50 kDa protein complexes (Table 2.1), with all but one spot
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(spot no. 1) containing at least a peptide from this crystallin subunit. When
combining the sequence region of βB1 characterized from both IEF (section 2.4.2.1)
and 2-D gel (section 2.4.2.2) studies, it was found that almost the entire “body
region” (residues 51-214) could be accounted for (Fig. 2.7A). This region covered
almost all of the α-helix and β-sheet secondary structures of the protein (Fig. 2.7B).
Furthermore, peptides from 9 other crystallin subunits (αA, αB, βA3, βA4, βB2, γB,
γC, γD and γS) were present in these gel spots (Table 2.1). βA3- and γS-crystallins
were the second most abundant crystallin subunits behind βB1 (spot no. 4-15).
Complexes which gave rise to spots 13, 14 and 15 on the gel contained peptides
from 10 distinct crystallin subunits, while peptides derived from spots 9, 11 and 12
were mapped to 9 species of crystallins (Table 2.1) (see section A1.2.2 for the
Mascot search results of the peptides present in the 15 spots isolated from the gel
shown in Fig. 2.6 of this chapter). The abundance of crystallin fragments identified
in the 2-D PAGE analysis demonstrates the extraordinary heterogeneous nature of
these complexes, and judging by their masses, the formation of these complexes is
likely a result of cross-linking between multiple crystallin fragments, with βB1
acting as the major component.
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Table 2.1: Identification of crystallins present in the 40-50 kDa region of 2-D
SDS-PAGE analysis of the CWS extract from a 45 year lens. Protein scores from
Mascot searches are shown and colour coded (0-50: no colour; 50-100: yellow; 100-200:
orange; 200-300: pink; > 300: red). Scores over 50 were considered significant. Scores
in italics are based on a single peptide match only.
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Fig. 2.7: Sequence coverage of βB1-crystallin from the 40-50 kDa WS cross-linked
complexes. (A) Linear representation of the primary sequence coverage obtained for
βB1-crystallin of the IEF (in green) and 2-D gel (in red) protein identification. (B)
Structure of βB1-crystallin (as monomers) illustrating the protein sequence coverage (in
yellow) from the 40-50 kDa cross-linked complexes. Structures were generated using
Pymol (version 1.2.8) from PDBe files (1OKI for βB1) downloaded from Swissprot
(http://au.expasy.org/sprot/), and rendered in Pov-Ray (version 3.6).

2.4.3 Breakdown of lenticular intermediate filament proteins during aging
Western immunoblotting was used to examine the age-related truncation of filensin,
phakinin and vimentin in human lenses. Anti-filensin immunoblots (Fig. 2.8A)
revealed filensin to be extensively truncated as a function of age, with the majority
of breakdown products confined to the US extracts. In the fetal lens, the 115 kDa
form of filensin was present in all three extracts (WS, US and UI extracts), while 60
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kDa and 53 kDa forms of filensin were also present in the fetal US extract (Fig.
2.8A). In contrast, filensin displayed a broad range of breakdown products in
postnatal lenses (Fig. 2.8A). A similar filensin fragment pattern was observed in the
CUS and NUS extract of postnatal lenses, with the most prominent immunoreactive
bands seen at 40-50 kDa and 22-24 kDa. While the intensity of the filensin
fragments decreased slightly in the US extracts of older lenses, the general profiles
remained similar across ages. The 115 kDa, 60 kDa, 53 kDa, 43 kDa and 24 kDa
forms of filensin were also present at lower levels in the CUI extracts of young and
middle-age lenses (16-43 years), but absent in the CUI extracts of old lenses (65 and
86 years). Despite the presence of filensin in the WS fetal lens extract, the
anti-filensin antibody did not recognize it in the CWS and NWS extracts from
postnatal lenses (data not shown). Filensin was also not detected in the nucleus
urea-insoluble (NUI) lens extracts (data not shown).
Anti-phakinin immunoblots (Fig. 2.8B) of fetal lens extracts detected the 49 kDa
form of phakinin in the US and UI extracts, and a 45 kDa truncation product in the
WS extract. In postnatal lenses, multiple forms of phakinin appeared to be present
between 40 and 49 kDa. The major form of phakinin in CUS and CUI extracts was a
49 kDa product, with an additional group of minor truncated products down to ~40
kDa evident in the CUS lens extracts. The amount of phakinin in the CUS and CUI
lens extracts decreased progressively with age, and was essentially absent in CUI
extracts of older lenses (65 and 86 years). Phakinin was not detected in the lens
nucleus and the CWS extracts (data not shown).
The breakdown of filensin and phakinin was further investigated by MALDI-MS
(Fig. 2.9). Peptides were eluted from SDS-PAGE gel bands following in-gel
digestion with trypsin and samples were analyzed using MALDI-MS. All peptides
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derived from filensin and phakinin were characterized using MALDI-MS/MS (Fig.
2.10). From the broad 40-50 kDa band present in the CUS extract (Fig. 2.1B), we
characterized three filensin peptides derived from residues 5-11, 78-90 and 147-157
of the protein, as well as a phakinin peptide (residues 192-199) (Fig. 2.9A).
Interestingly, all three tryptic-peptides from filensin were also found in the 22-24
kDa filensin breakdown product (Fig. 2.9B). This finding suggests that both the
22-24 kDa and the 40-50 kDa immunoreactive bands contained the N-terminal
portion of filensin.
In marked contrast to the filensin and phakinin results, anti-vimentin immunoblots
(Fig. 2.8C) revealed that vimentin remained intact as a 58 kDa protein in the cortex
of all lenses across the age range, with the exception of the 86 year lens. Vimentin
was the only intermediate filament protein detected in the CWS extract of postnatal
lenses. Intact vimentin (58 kDa) was replaced by a 49 kDa truncation product in the
CWS extract of the 86 year lens. Vimentin was not detected in the nucleus extracts
(data not shown), indicating that vimentin was degraded in mature fibre cells.
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Fig. 2.8: Western immunoblotting analysis of the breakdown of intermediate
filament proteins in human lenses. Lens extracts identical to those shown in Fig. 2.1
were separated using SDS-PAGE and transferred onto PVDF membranes. Shown are (A)
anti-filensin, (B) anti-phakinin and (C) anti-vimentin immunoblots of human lens
extracts that resulted in positive detections. The ages (years) of the lenses are indicated
above each lane. Molecular weight markers are indicated on the right of each
immunoblot.
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Fig. 2.9: MALDI-MS analysis of the intermediate filament protein breakdown
products in human lens extracts. (A) PMF spectra showing filensin and phakinin
tryptic-peptides from the MALDI-MS analysis of the 40-50 kDa band excised from the
SDS-PAGE gel of the CUS extract (16 year lens, Fig. 2.1B). The corresponding blot
(taken from Fig. 2.8A) is presented on the left of the gel. (B) PMF spectra showing
filensin tryptic-peptides from the MALDI-MS analysis of the 22-24 kDa region of the
SDS-PAGE gel of the MBP-αB interacting proteins from the CUS extract (13 year lens,
Fig. 2.11A, lane 3). The corresponding blot (taken from Fig. 2.11B, lane 2) is presented
on the left of the gel. Identification of these filensin and phakinin peptides was achieved
using MALDI-MS/MS, as shown in Fig. 2.10. Due to the abundance of β-crystallin
subunits at 22-24 kDa, we were unable to obtain good PMF spectra from gels of the lens
extracts. Consequently, pull-out assays using MBP-αB were used to isolate the 22-24
kDa product of filensin. Molecular weight markers are indicated on the left of the
gels/blots.
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Fig. 2.10: MALDI-MS/MS spectra of the filensin and phakinin tryptic-peptides
present in the PMF spectra shown in Fig. 2.9. (A) MS/MS analysis of m/z 900.6,
corresponding to peptide SYVFQTR (residues 5-11 of filensin); (B) MS/MS analysis of
m/z 1082.6, corresponding to peptide YENEQPFR (residues 192-199 of phakinin); (C)
MS/MS analysis of m/z 1281.0, corresponding to peptide EADEALLHNLR (residues
147-157 of filensin); (D) MS/MS analysis of m/z 1311.8, corresponding to peptide
LGELAGPEDALAR (residues 78-90 of filensin). The major b, y and immonium (i)
ions are labelled on the spectra and indicated on the peptide sequences.
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2.4.4 α-Crystallin interacts with human lens intermediate filament proteins
As α-crystallin is a member of the sHsp family, we sought to examine what role, if
any, it plays in binding to lenticular intermediate filaments. Previous studies have
shown that a MBP-αB fusion protein (~64 kDa) displays chaperone activity similar
to that of wild-type αB-crystallin [221]. In our study, we incubated MBP-αB with
the CUS and NUS extracts of a young (13 years) human lens for 6 h at 37 °C to
mimic the interaction of α-crystallin over time with intermediate filament proteins in
older lenses. Proteins that associated with MBP-αB during incubation were isolated
by affinity chromatography using amylose resin and analyzed by SDS-PAGE and
Western immunoblotting. The αB-crystallin subunit was chosen as it is a more
potent chaperone at physiologically relevant temperatures compared to αA-crystallin
[51]. (See section A1.2.3 for the results of preliminary pull-out studies using extracts
from bovine lenses and human lenses of other ages)
SDS-PAGE analysis (Fig. 2.11A) showed that the major proteins in the US extracts
(Fig. 2.11A, lanes 2 and 4) that associate with MBP-αB (Fig. 2.11A, lane 1)
following incubation were αA- and αB-crystallins (Fig. 2.11A, lanes 3 and 5). This
finding is consistent with the fact that α-crystallin multimers are dynamic in nature
[222], and readily exchange subunits with MBP-αB. Western immunoblotting (Fig.
2.11B) was used to determine if the intermediate filament proteins in the extracts
(Fig. 2.11B, lanes 1, 3, 5 and 7) interacted with MBP-αB. It was found that MBP-αB
associated with most of the filensin fragments present in the CUS and NUS lens
extracts, ranging from 22 kDa to 115 kDa (Fig. 2.11B, lanes 2 and 4). Interestingly,
interactions between MBP-αB and filensin truncation products smaller than 20 kDa
were not observed (Fig. 2.11B, lanes 2 and 4). MBP-αB was also shown to bind to
various forms of phakinin (40-49 kDa) (Fig. 2.11B, lane 6), and vimentin (58 kDa)
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(Fig. 2.11B, lane 8). In control experiments, MBP2* (~42.5 kDa) alone did not
associate with any proteins in the lens extracts used in this study (data not shown),
confirming that the αB-crystallin region of the fusion protein was responsible for the
interactions observed.
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Fig. 2.11: Binding of MBP-αB to intermediate filament proteins in the US
extracts of a young (13 years) human lens. (A) SDS-PAGE gels of purified
MBP-αB (100 μg) (lane 1), CUS lens extract (100 μg) (lane 2), CUS proteins
associated with MBP-αB post-incubation (lane 3), NUS lens extract (100 μg) (lane 4)
and NUS proteins associated with MBP-αB post-incubation (lane 5). Molecular
weight markers are indicated on the right. (B) Western immunoblot analysis was
used to probe for intermediate filament proteins associated with MBP-αB
post-incubation. Immunoblots showing CUS lens extract (lanes 1, 5, 7), CUS
proteins associated with MBP-αB post-incubation (lanes 2, 6, 8), NUS lens extract
(lane 3) and NUS proteins associated with MBP-αB post-incubation (lane 4) were
developed using primary antibodies indicated on the top of each immunoblot. The
presence of large amounts of MBP-αB at ~64 kDa was responsible for the distortion
of immunoblots in this region for lanes 2, 4, 6 and 8. Filensin was the only
intermediate filament protein detected in the NUS extract. Molecular weight
markers are indicated on the left of the immunoblot.
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2.5 Discussion

In this study, we examined the age-related changes to crystallins and intermediate
filament proteins in the human lens. SDS-PAGE analysis (Fig. 2.1) of lens proteins
confirmed that major age-dependent changes take place in the WI fractions. In the
US extracts, the proportion of intact α-crystallin subunits (Fig. 2.1B, band 2 and 3)
declined steadily with age, particularly in the NUS extracts. This observation is
consistent with the finding of Grey and Schey [150], suggesting that there is little
intact α-crystallin in the lens nucleus past middle-age. Over this same period the
proportion of WI crystallin fragments migrating near the dye-front of the gel
increased significantly (Fig. 2.1B). Tryptic-digestion and MALDI-MS analysis
showed that this LMW protein band consisted of a mixture of crystallin fragments,
with the majority derived from B1- and S-crystallins (Fig. 2.2). Remarkably, these
B1- and S-crystallin fragments were similar to those present in the 40-50 kDa
cross-linked WS complexes (Fig. 2.4). This suggests that there may be two separate
pathways operating in the aging lens; B1- and S-crystallin fragments either
become insoluble through interactions with cytoskeletal/membrane components, or
form cross-linked WS complexes. Clearly, in the case of the 40-50 kDa cross-linked
WS complexes, this interaction involves covalent bonds. The detection of LMW
fragments of - and -crystallins in the US fraction indicates that these crystallins
bind tightly to components of the cytoskeleton in older human lenses, and this
interaction may be responsible in part for the progressive accumulation of insoluble
protein in older lenses. It is unclear if truncation and fragmentation of the crystallins
occurs before or after binding to cytoskeletal/membrane components.
Although 40-50 kDa cross-linked complexes consisting of - and -crystallins have
been reported [223], there is currently no sequence information regarding these
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crystallin cross-linked complexes (Fig. 2.1A, band XC and XN) present in the WS
lens extracts. We explored the heterogeneity of these complexes by further
separating the components using IEF, and mapping the major tryptic peptides
generated from these bands. Taking into account only those peptides for which
sequence data was obtained (Fig. 2.4C, shaded rows), all of the IEF protein bands
contained at least one S, B1 and A3 peptide. Bands I-V and VIII-IX also
contained a A4 peptide, and another twelve peptides matched the predicted masses
for tryptic peptides of αA, B1, B2, A4 C and D. Further investigations were
performed using 2-D SDS-PAGE and nanoLC-ESI-MS/MS, which demonstrated
that a total of 10 crystallin subunits (αA, αB, βA3, βA4, B1, βB2, γB, γC, γD and
γS) were involved in the assembly of these 40-50 kDa protein complexes (Table 2.1).
B1-crystallin, in particular, appears to be the common structural backbone of these
complexes (Fig. 2.7), while fragments of βA3- and S-crystallins were also
prominent. The heterogeneous nature of these protein complexes indicates that some
of the crystallin fragments involved in these complexes are of relatively low mass,
and are covalently linked in order to produce complexes of 40-50 kDa. Based on the
sequence coverage, it appears that B1 is present as a relatively complete protein
with truncations at both termini (Fig. 2.7), whereas S has quite distinct regions
identified at sequence level (Fig. 2.4). As expected, the N-terminal region of B1
was not identified, as this has been reported to be truncated in vivo [21, 66].
Covalent cross-links could be derived from several sources. For example,
lanthionine and histidinylalanine cross-links have been reported in aged human lens
proteins [224]. Evidence for covalent multimers composed of a multitude of
crystallin fragments has previously been reported in both the WS and WI fractions
of human lenses, with increasing prevalence in the WI fraction with age [18-19, 125].
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It is possible that the cross-linked WS species observed in this study are
intermediates on a pathway to forming HMW protein complexes that are WI. This
covalent interaction between -and S-crystallins may suggest that the two
crystallin species localize in close proximity in the lens cytosol and, alternatively,
that this association may help maintain the solubility of these crystallins.
In parallel with the age-related modifications of crystallins, structural and functional
changes of the lenticular intermediate filament proteins are also believed to be
important factors in lens development, as mutations in these proteins can lead to
cataract or blindness in mammalian species [91-95]. Despite their importance, there
is currently little information regarding these intermediate filament proteins in the
human lens. Our study showed that filensin and phakinin are extensively truncated
in the human lens from young ages (Fig. 2.8). A similar finding was reported for
bovine lenses [73, 87, 225]. The significant differences observed between prenatal
and postnatal lenses indicate that the extensive breakdown of filensin occurs either
prenatally, or shortly after birth, with truncated fragments retained in both the lens
nucleus and cortex for the entire lifespan. The fact that both filensin and phakinin
were present in the WS extract of the fetal lens, but not in any of the postnatal lens
WS extracts, suggest that structural modifications to the beaded filament proteins
may render them insoluble in postnatal lenses. The presence of both 115 kDa and 60
kDa forms of filensin in the fetal lens and the cortex of postnatal lenses, but not in
the nucleus (Fig. 2.8A), indicates that human filensin is processed into the shortened
forms during early stages of lens fibre cell differentiation. The major filensin
breakdown product(s) at 40-50 kDa may correspond to a 49 kDa filensin truncation
product that has been found in the bovine lens [225-226]. The absence of the 115
kDa form of filensin in the lens nucleus was also previously reported in bovine
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lenses [87, 227]. In contrast, phakinin was not detected in the nuclear region of the
postnatal human lens, despite the presence of low levels of phakinin breakdown
products in the lens nucleus of other mammalian animals [73, 228]. As our Western
immunoblot analyses were performed directly on lens extracts, it is also possible
that some breakdown products of intermediate filament proteins detected may be
cross-linked to crystallins or other lenticular proteins.
Using MALDI-MS/MS, we characterized three tryptic peptides of filensin
corresponding to residues 5-11, 78-90 and 147-157 of the protein (Fig. 2.9 and 2.10).
These peptides were found in both 40-50 kDa and the 22-24 kDa filensin bands that
were present across the age range (Fig. 2.8A). It is clear from the peptide sequences
that both the two major immunoreactive bands are from the N-terminal portion of
filensin. Since these two fragments were obtained via a pull-down experiment using
the fusion protein MBP-αB, these data suggest that the binding site for α-crystallin
lies within the first two hundred residues of filensin. When considering the
secondary structure of filensin [229], residues from these peptides are found within
the head region, and the linker 1 and coil 1B structures of the rod region (residues
1-184) respectively. Based on the apparent masses from SDS-PAGE of these filensin
breakdown products, it is possible that the 22-24 kDa product is a result of a
truncation at the end of coil 1B, which would give rise to a protein of ~23 kDa
(residues 1-201). The identity of cleavage site of the larger 40-50 kDa product is less
obvious but is presumably a result of truncation somewhere between residues
350-400. Posttranslational modifications may also affect the masses of these
breakdown products [225].
While previous studies have documented the breakdown of beaded filament proteins
in mammalian lenses [73, 87, 93, 230], the purpose of this breakdown, if any,
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remains unclear. As the beaded filaments are retained in lens fibre cells during cell
differentiation, it has been hypothesized that this cleavage facilitates the formation
of stable structures in the lenticular intermediate filaments [87]. This may explain
why the breakdown patterns of the beaded filament proteins, in particular filensin,
were remarkably similar in both the lens cortex and nucleus at all lens ages studied,
despite the long lifespan of humans. The presence of filensin and phakinin products
in the CUI lens extracts suggests a tight association between beaded filament
proteins with fibre cell membranes. Such interactions have been reported in
mammalian animal lenses [185, 227]. The absence of filensin and phakinin in the
NUI extract suggests that this interaction is lost in mature lens fibre cells. In the case
of filensin, the 115 kDa and 60 kDa products, which are present in both the CUS and
CUI extracts but absent in the lens nucleus, may contain binding sites to the
membrane components. In agreement with previous studies [18, 132], vimentin was
detected in all three extracts (WS, US and UI) of the lens cortex, but not in the lens
nucleus. The 49 kDa breakdown product of vimentin, detected in the CWS lens
extract of the 86 year lens, has been reported to result from calpain proteolysis
[231].
The binding of α-crystallin to intermediate filament proteins, or to crystallin
complexes associated with the intermediate filament proteins, may play an important
role in maintaining the structural integrity of the lens fibre cells [76, 183-184].
Muchowski et al. [183] showed that MBP-αB selectively associates with bovine
filensin, phakinin and vimentin after mild heat stress, but not with actin, α-tubulin
and spectrin. We found that under MBP-αB interacts with vimentin, filensin and
phakinin, and a variety of their truncated products when incubated at 37 °C (Fig.
2.11B). Interestingly, MBP-αB did not bind to truncated forms of filensin less than
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20 kDa (Fig. 2.11B), suggesting that if the truncation of intermediate filaments
becomes too extensive, the interaction of α-crystallin with the cytoskeleton may be
disrupted due to the loss of binding sites.
As lenticular intermediate filament proteins are typically WI, their interactions with
α-crystallin may contribute to the insolubilization of crystallins in the lens with age.
This interaction between crystallins and intermediate filament proteins may be
responsible for the accumulation of LMW fragments in the WI extracts (Fig. 2.1B),
as mentioned previously. Since intermediate filament proteins interact with
membrane channels such as aquaporin 0 [185], they may potentially provide a
means by which HMW α-crystallin aggregates associate with membrane channels. It
has been proposed on the basis of large-scale binding of crystallins to membranes
from older lenses [175] that occlusion of membrane pores could be responsible for
the development of a barrier to diffusion that becomes apparent at middle-age. This
barrier may be the pre-condition for subsequent ARN cataract by hindering the
transport of antioxidants into lens nucleus [189].
In conclusion, this study has documented the age-dependent truncation of crystallins
and intermediate filament proteins in human lenses. Several breakdown products of
filensin were detected, and these truncation products were found to be present in the
lens for the entire lifespan. Truncated forms of filensin larger than 20 kDa were
capable of binding to α-crystallin. Vimentin and phakinin were found only in
cortical fibre cells, suggesting that with age, or during cell differentiation, they are
degraded completely or to smaller fragments that were not detected by the specific
antibodies used in this study. The fact that crystallin fragments were observed in the
WI fraction of human lenses suggests they are tightly associated with cytoskeletal or
other membrane-bound structures in older human lenses. WS complexes of 40-50
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kDa were found to contain peptides from several crystallins, indicating that at least
10 different crystallin subunits are involved in the formation of these cross-linked
species. The polymerization pathway may allow crystallin breakdown products to
avoid binding to cytoskeleton and instead, remain WS in stable biopolymers.
Although it is not yet clear at which point these cross-links develop, the high
proportion of peptides fromB1- and S-crystallins may reflect the in vivo
proximity of these structural proteins in the human lens.
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Preface

The presence of endogenous crystallin peptides in the lens had eluded the attention
of researchers until recently, when preliminary studies suggested that these peptides
may contribute to the increase of WI crystallin aggregates in old and cataractous
lenses. This work set out to fully characterize the endogenous LMW peptides
present in both the WS and WI fractions of human lenses.

Publication:

Shih-Ping Su, Xiaomin Song, Dylan Xavier, Ardeshir Amirkhani, Jason D.
McArthur, J. Andrew Aquilina and Roger J.W. Truscott (2011) “Crystallins are
processed into a large variety of LMW peptides in the aging human lens.”
(Manuscript prepared).
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3.1 Abstract

Endogenous LMW crystallin peptides (< 4 kDa) present in the human lens have
been overlooked by researchers until recently, when preliminary studies indicated
that these peptides may have important roles in events leading up to protein
misfolding and aggregation in old and cataractous lenses. In this study, a total of 328
different endogenous LMW peptides were characterized in the water-soluble (WS)
and water-insoluble (WI) extracts of human lenses using nanoLC-ESI-MS/MS, with
316 peptides being cleavage products of crystallins. Peptides derived from
α-crystallin were the most abundant and covered almost the entire protein sequence,
while peptides originating from five other crystallin subunits (βA1/A13, βA4, βB1,
βB2 and γS) were also identified. Interestingly, with the exception of γS-crystallin,
we did not find any peptides from other γ-crystallin subunits, indicating that the
structures of the γ-crystallins may be intrinsically stable. Selected reaction
monitoring (SRM) quantification showed that the quantity of a prominent
α-crystallin peptide (αA57-65) in the human lens increased steadily with age. The
cleavage patterns of these peptides indicate that trypsin-like proteolysis may take
place in the lens, along with chemical cleavages at Ser, Gly, Thr and Asp residues.
Following these initial cleavages, progressive hydrolysis of the terminal residues
yields a series of peptides of diminishing chain length. The large number of
crystallin peptides discovered indicates that the cleavages of crystallins may have
significant effect on proteostasis within the aging lens.
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3.2 Introduction

The optical property of the human lens is dependent upon the integrity of the
proteins located within lens fibre cells. Lens fibre cells contain structural proteins
known as α-, β- and γ-crystallins, which by virtue of their unique interactions and
high concentrations, provide the lens with the refractive index required to focus light
onto the retina [30, 232]. α-Crystallin, which is composed of αA and αB subunits,
functions additionally as a molecular chaperone to mitigate protein unfolding in the
lens [3, 5, 209-210]. During aging, the lens undergoes negligible protein turnover [6]
and, consequently, lens proteins undergo extensive posttranslational modifications.
These modifications include truncation, phosphorylation, deamidation, acetylation
and glycation, amongst others [17-19, 125, 129, 152, 214, 233-234]. While certain
structural changes may be part of the normal maturation process of the lens,
improper or unregulated modifications have been associated with lens opacity [17,
186].
Protein cleavage (truncation) is a common age-related modification observed in
crystallins within the lens. Crystallin breakdown increases significantly during aging
and with the onset of cataract [18-19, 125, 139]. Crystallin fragments derived from
these truncations are present in both the WS and WI fractions of the lens, with
increasing prevalence in the WI fractions with age [18, 66, 151-152]. Recent studies
have shown that a variety of endogenous, LMW crystallin peptides exist in the lens
[139, 152]. Interestingly, the majority of these peptides were found in the nucleus of
the lens during the third and fourth decades of life, and only appeared in the cortical
regions of old-aged lenses [152] (Chapter 4). This progressive age-dependent
emergence pattern suggests that crystallin cleavages which give rise to these
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peptides are the result of specific changes in the lens environment which occur
around middle-age.
The emergence of these crystallin peptides may be a key event in lens aging and
could affect the normal functioning of lens cells. The large diversity of peptides
present in old lenses indicates that crystallins are increasingly cleaved with age [139,
152]. Such cleavages could compromise the structure and function of crystallin
proteins within the cellular environment of the lens. LMW peptides that interfere
with the chaperone activity of α-crystallin have also been identified in the lens [139,
157, 235]. The presence of such peptides in the lens may contribute to the protein
aggregation and misfolding observed in the aging lens [66, 125, 127].
In this study, endogenous LMW peptides present in the WS and WI fractions of
human lenses aged 16, 44, 75 and 83 years were characterized using
nanoLC-ESI-MS/MS. Our results showed that the majority of these LMW peptides
first appeared in the lens around middle-age and increase in abundance with age.
Sequence coverage of LMW peptides derived from αA- and αB-crystallins suggests
that α-crystallin contains a large number of cleavage sites. LMW peptides derived
from crystallin species of βA1/A3, βA4, βB1, βB2 and γS, and lenticular
cytoskeletal proteins phakinin and vimentin, were also identified. Interestingly, we
did not find peptides from γC- and γD-crystallins in the lens, suggesting that these
crystallins may be more structurally stable, and/or less susceptible to chemical or
proteolytic cleavages.
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3.3 Material and methods

3.3.1 Extraction and isolation of the endogenous LMW peptides in human lenses
Human lenses aged 16, 44, 75 and 83 years were obtained from the Lions New
South Wales Eye Bank (Sydney, Australia) and stored immediately at -80 °C. Lenses
were dissected into cortical and nuclear regions using a 4.5 mm trephine. A cold
scalpel was used to remove 1 mm of tissue from each end of the resulting cylindrical
center (nucleus). The WS and urea-soluble (US) lens extracts were obtained from
both cortical and nuclear tissues, and the LMW peptides present in these extracts
were isolated by filtration through 10 kDa molecular weight cut-off (MWCO)
membranes as described in Su et al. [152] (Chapter 4).

3.3.2 Identification of LMW peptides in human lens extracts using
nanoLC-ESI-MS/MS
Endogenous LMW peptides present in the lens extracts were identified using
nanoLC-ESI-MS/MS at the Australian Proteome Analysis Facility (Macquarie
University, Sydney, Australia) as described in Su et al. [152] (Chapter 4). MS/MS
results were searched against human protein sequences published on Swissprot using
the Mascot search engine. Searches were made to incorporate posttranslational
modifications commonly found on crystallins, which included acetylation at the
N-terminus and Lys residues; deamidation at Asp and Gln residues; methylation at
His, Lys and Cys residues; phosphorylation at Ser and Thr residues; and oxidation at
Met, Trp and Tyr residues.
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3.3.3 SRM measurements of the peptide αA57-65 in human lenses
For peptide quantification, SRM was performed using a QTRAP5500 triple
quadrupole linear ion trap mass spectrometer, coupled to a Waters NanoAcquity
UPLC system (Waters, Milford, Massachusetts, USA). Peptides were separated
using a 5 μm Symmetry C18 180 μm x 20 mm Trap column (Waters), coupled to a
1.7 μm BEH 130 C18 analytical column (100 μm x 100 mm) (Waters). Mobile phase
A: 0.1% formic acid, 99.9% water and mobile phase B: 0.1% formic acid, 99.9%
acetonitrile, were used to create a gradient run of 1% to 50% mobile phase B over
30 min at a flow-rate of 400 nL/min. 30 µL of each sample was mixed with 20 µL
(100 fmol) of internal standard, ESDTSYVS*LK (where *L stands for (Uniform 13C,
15

N isotope)-L-leucine, molecular weight 1135 Da) (Auspep, Tullamarine, Australia).

SRM ion intensities for peptide αA57-65 (LDSGISEVR) were normalized using the
internal standard. 5 μL (full loop) was injected for SRM and this procedure was
repeated twice. The normalized ion intensities from the repeated runs were averaged
and the ion intensities from all transitions were summed, giving the relative
concentrations of the peptide. The relative concentration was then multiplied by the
sample buffer volume to obtain relative quantities of the peptide in each lens sample.
The peptide quantities were then divided by the tissue wet weight for each cortical
and nuclear sample, giving the relative quantity of peptide αA57-65 per unit wet
tissue.
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3.4 Results

3.4.1 Identification of endogenous LMW peptides in human lenses
A total of 328 endogenous LMW peptides were identified from the WS and US
human lens extracts using nanoLC-ESI-MS/MS analysis (see Table A2.1 in
Appendix II for complete list of peptides in the lens extracts; Fig. A2.1 for examples
of the base peak chromatogram of the nanoLC-ESI-MS analysis). The majority (316
peptides) of these peptides were cleavage products of crystallins, with 109 derived
from

αA-crystallin,

103

derived

from

αB-crystallin,

19

derived

from

βA1/A3-crystallin, 2 derived from βA4-crystallin, 28 derived from βB1-crystallin,
39 derived from βB2-crystallin and 16 derived from γS-crystallin. To our knowledge,
only 26 of the 328 endogenous peptides we identified have been previously reported
[139, 152], including the 10 peptides first reported in our previous study [152]
(Chapter 4).
In the youngest lens (16 years) used in this study, a total of 38 distinct endogenous
LMW peptides were identified (Table 3.1). The number of distinct LMW peptides
identified in the middle-age lens (44 years) was 118, representing a 3-fold increase
when compared to the number found in the 16 year lens (Table 3.1). Both old lenses
(75 and 83 years) had approximately twice as many different LMW peptides than
that of the 44 years lens (Table 3.1). This increase in peptide variety and abundance
with age demonstrates that crystallin cleavage may be a progressive, age-dependent
process in the lens.
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Table 3.1: Number of endogenous LMW peptides identified in each human lens
(16, 44, 75 and 83 years) and protein sequence coverage.

Protein
Originsa

a.

Number of endogenous
LMW peptides identified in each lens

Protein
sequence
coverage

16 years

44 years

75 years

83 years

αA-crystallin

11

44

96

83

89%

αB-crystallin

14

38

79

64

98%

βA1/A3-crystallin

-

5

14

13

41%

βA4-crystallin

-

-

2

-

11%

βB1-crystallin

1

7

18

22

43%

βB2-crystallin

7

18

27

25

66%

γS-crystallin

1

4

15

9

53%

BFSP2

-

-

4

-

6%

VIME

2

-

-

-

4%

KPYM

1

-

-

-

2%

MATN2

1

2

-

-

1%

BHMT2

-

-

-

1

3%

CHSP1

-

-

-

1

10%

BASP1

-

-

-

1

6%

Total (per lens)

38

118

255

219

Abbreviations for lens proteins are: BFSP2 - phakinin; VIME - vimentin; MATN2 matrilin-2; KPYM - pyruvate kinase isozymes M1/M2; BHMT2 - betaine-homocysteine
S-methyltransferase 2; CHSP1 - calcium-regulated heat stable protein 1; BASP1 - brain acid
soluble protein 1.

Amongst the crystallins, α-crystallin gave rise to the largest pool of LMW peptides.
LMW peptides derived from αA- (Fig. 3.1) and αB-crystallins (Fig. 3.2) covered
almost the entire protein sequence of each crystallin subunit (89% and 98%
sequence coverage respectively) (Table 3.1). As can be seen in the αA-crystallin
sequence coverage map (Fig. 3.1), the region stretching from residues 115-133 was
not present in any of the αA peptides identified. Peptides originating from the
C-terminal region of αA-crystallin (residues 81-172) were found almost exclusively
in the WS extracts (Table A2.1). This is in contrast with αA peptides derived from
other sequence regions, which had a relatively even distribution between the WS and
US extracts (Table A2.1). In comparison with αA, αB-crystallin had only four
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Fig. 3.1: Endogenous LMW peptides present in
the lens derived from cleavages of αA-crystallin.
Shown here in colored boxes are the sequences of
the αA-crystallin peptide identified. The origin
within the full protein sequence is indicated by
matched shading. Posttranslational modifications
are indicated using the following symbols: ‡ for
deamidation; ✽ for acetylation and ※ for the
loss of water. Modified residues are underlined.
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Fig. 3.2: Endogenous LMW peptides present in the lens derived from cleavages of αB-crystallin. Shown here in colored boxes
are the sequences of the αB-crystallin peptides identified. The origin within the full protein sequence is indicated by matched shading.
Posttranslational modifications are indicated using the following symbols: ‡ for deamidation and ✽ for acetylation. Modified residues
are underlined. In the case where more than one modified residues are present on one peptide, symbols are listed so that the
modifications present on residues closer to the N-terminus of the peptide are listed first.
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residues (residues 71-72 and 119-120) that were not part of any LMW peptides (Fig.
3.2). A large number of αB peptides originated from residues 19-70, with 57 of the
total 103 αB-crystallin peptides derived from this region (Fig. 3.2).
Peptides derived from β-crystallins and γS-crystallin did not share the high protein
sequence coverage seen with the α-crystallin subunits. In the case of βA1/A3 (Fig.
3.3A), βB1 (Fig. 3.4A) and γS (Fig. 3.3B), a large number of the LMW peptides
originated from the terminal regions of these proteins. βB1-crystallin, in particular,
had 12 distinct peptides derived from the N-terminus of the protein (Fig. 3.4A). In
contrast, the majority of peptides originated from residues 14-30 and 169-185 in
βB2, with only two different peptides being derived from C-terminus, and no
peptides with sequences stretching beyond the Arg198 residue (Fig. 3.4B). On the
whole, peptides derived from β-crystallin species were more prevalent in the WS
extracts, with the exception being βA1/A3-crystallin (Table A2.1). Amongst these
proteins, the largest number of peptides (39 different peptides) originated from βB2,
which also had the highest protein sequence coverage (66%) (Table 3.1). βA4 had
the least sequence coverage (11%) (Table 3.1), with only 2 peptides originating from
this protein (Fig. 3.3C). Remarkably, despite the considerable quantities of γC- and
γD-crystallins present in the human lens [30], we did not identify any LMW
peptides from these proteins.
Several peptides were observed to differ by only one or two amino acid residues at
the terminal regions. For example, 16 different αB-crystallin peptides shared the
same N-terminus of Ser21, but differed slightly in their respective C-termini, which
included peptide sequences ending at Phe27, Phe28, Glu30, Asp36, Phe38, Pro39,
Thr40, Ser41, Thr42 and Leu44 (Fig. 3.2). This phenomenon of peptides with
“ragged ends” was also observed in peptides from other crystallin subunits (Fig.
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3.1-3.4), suggesting that it is a result of sequential truncation at the terminal region
of the longest peptide in each peptide group (peptides from the same sequence
region of the protein), which we termed the “parent” peptides (see Table 3.2 for the
list of “parent” peptides). When examining the truncation sites of “parent” peptides,
it was found that approximately half of these “parent” peptides were generated
through cleavage at Lys and/or Arg residues (Table 3.2, highlighted peptides). This
finding suggests that trypsin-like proteolytic activity may play an important role in
the cleavages of crystallin in the human lens.
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Fig. 3.3: Endogenous LMW peptides present in the lens derived from cleavages
of (A) βA1/A3-crystallin, (B) γS-crystallin and (C) βA4-crystallin. Shown here in
colored boxes are the sequences of the βA1/A3-, γS- and βA4-crystallin peptides
identified. The origin within the full protein sequence is indicated by matched
shading. Posttranslational modifications are indicated using the following symbols:
‡ for deamidation; ✽ for acetylation and # for oxidation. Modified residues are
underlined. In the case where more than one modified residues are present on one
peptide, symbols are listed so that the modifications present on residues closer to the
N-terminus of the peptide are listed first.
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Fig. 3.4: Endogenous LMW peptides present in the lens derived from cleavages
of (A) βB1-crystallin and (B) βB2-crystallin. Shown here in colored boxes are the
sequences of the βB1 and βB2-crystallin peptides identified. The origin within the
full protein sequence is indicated by matched shading. Posttranslational
modifications are indicated using the following symbols: ‡ for deamidation; ✽ for
acetylation and ¤ for phosphorylation. Modified residues are underlined. In the case
where more than one modified residues are present on one peptide, symbols are
listed so that the modifications present on residues closer to the N-terminus of the
peptide are listed first.
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Table 3.2: Endogenous LMW “parent” peptides present in human lens extracts.
Peptides generated through cleavages at Lys and/or Arg are highlighted.

Peptide
source

Peptide sequencea

CWSb

NWSb

CUSb

NUSb

Lens agec

Lens agec

Lens agec

Lens agec

16 44 75 83 16 44 75 83 16 44 75 83 16 44 75 83
αA
#1-16

MDVTIQHPWFKRTLGP-(F) ✽

#13-24

(R)-TLGPFYPSRLFD-(Q)

#15-30

(L)-GPFYPSRLFDQFFGEG-(L)

#20-34

(P)-SRLFDQFFGEGLFEY-(D)

#22-49

(R)-LFDQFFGEGLFEYDLLPFLSSTISPYYR-(Q)

#34-50

(E)-YDLLPFLSSTISPYYRQ-(S)

#38-56

(L)-PFLSSTISPYYRQSLFRTV-(L)

#42-65

(S)-STISPYYRQSLFRTVLDSGISEVR-(S)

#57-69

(V)-LDSGISEVRSDRD-(K)

#66-80

(R)-SDRDKFVIFLDVKHF-(S)

#79-88

(K)-HFSPEDLTVK-(V)

#81-91

(F)-SPEDLTVKVQD-(D)

#83-92

(P)-EDLTVKVQDD-(F)

#89-99

(K)-VQDDFVEIHGK-(H)

#91-101

(Q)-DDFVEIHGKHN-(E)

#100-112

(K)-HNERQDDHGYISR-(E) ‡

#105-114

(Q)-DDHGYISREF-(H)

#135-147

(S)-ADGMLTFCGPKIQ-(T)

#143-154

(C)-GPKIQTGLDATH-(A)

#146-157

(K)-IQTGLDATHAER-(A)

#148-160

(Q)-TGLDATHAERAIP-(V)

#155-172

(H)-AERAIPVSREEKPTSAPS-(S)

αB
#1-18

MDIAIHHPWIRRPFFPFH-(S) ✽

#12-22

(R)-RPFFPFHSPSR-(L)

#13-25

(R)-PFFPFHSPSRLFD-(Q)

#19-40

(H)-SPSRLFDQFFGEHLLESDLFPT-(S)

#20-42

(S)-PSRLFDQFFGEHLLESDLFPTST-(S)

#21-44

(P)-SRLFDQFFGEHLLESDLFPTSTSL-(S)

#23-56

(R)-LFDQFFGEHLLESDLFPTSTSLSPFYLRPPSFLR-(A)

#34-57

(L)-ESDLFPTSTSLSPFYLRPPSFLRA-(P)

#36-58

(S)-DLFPTSTSLSPFYLRPPSFLRAP-(S)

#43-65

(T)-SLSPFYLRPPSFLRAPSWFDTGL-(S)

#58-70

(A)-PSWFDTGLSEMRL-(E)

#73-81

(K)-DRFSVNLDV-(K) ‡

#75-82

(R)-FSVNLDVK-(H)

#77-84

(S)-VNLDVKHF-(S) ‡

#83-92

(K)-HFSPEELKVK-(V)

#93-103

(K)-VLGDVIEVHGK-(H)
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Table 3.2 (continued)
Peptide
source

CWSb
a

Peptide sequence

NWSb
c

Lens age

CUSb
c

Lens age

NUSb
c

Lens age

Lens agec

16 44 75 83 16 44 75 83 16 44 75 83 16 44 75 83
#95-109

(L)-GDVIEVHGKHEERQD-(E)

#109-118

(Q)-DEHGFISREF-(H)

#121-149

(R)-KYRIPADVDPLTITSSLSSDGVLTVNGPR-(K)

#134-151

(I)-TSSLSSDGVLTVNGPRKQ-(V) ‡

#138-152

(L)-SSDGVLTVNGPRKQV-(S) ‡

#152-175

(Q)-VSGPERTIPITREEKPAVTAAPKK

βA1/A3
#1-19

METQAEQQELETLPTTKMA-(Q) ✽

#27-36

(G)-SLGPWKITIY-(D)

#29-40

(L)-GPWKITIYDQEN-(F)

#33-45

(K)-ITIYDQENFQGKR-(M)

#54-64

(P)-NVSERSFDNVR-(S) ‡

#103-113

(S)-NAYHIERLMSF-(R) ‡

#126-137

(K)-MTIFEKENFIGR-(Q)

#142-150

(I)-SDDYPSLQA-(M)

#189-215

(H)-GGDYKHWREWGSHAQTSQIQSIRRIQQ

βA4
#107-118

(R)-LTIFEQENFLGK-(K)

#123-131

(L)-SDDYPSLQA-(M)

βB1
#2-16

(M)-SQAAKASASATVAVN-(P) ✽ ‡

#7-22

(K)-ASASATVAVNPGPDTK-(G)

#38-47

(T)-TLAPTTVPIT-(S)

#40-50

(L)-APTTVPITSAK-(A)

#51-60

(K)-AAELPPGNYR-(L)

#44-57

(T)-VPITSAKAAELPPG-(N)

#61-72

(R)-LVVFELENFQGR-(R)

#59-79

(N)-YRLVVFELENFQGRRAEFSGE-(C)

#151-160

(K)-ISLFEGANFK-(G)

#170-184

(D)-DAPSLWVYGFSDRVG-(S)

#203-214

(R)-GYQYLLEPGDFR-(H)

#233-252

(L)-RDKQWHLEGSFPVLATEPPK

βB2
#2-16

(M)-ASDHQTQAGKPQSLN-(P) ✽

#14-23

(Q)-SLNPKIIIFE-(Q)

#17-30

(N)-PKIIIFEQENFQGH-(S) ‡

#43-58

(K)-ETGVEKAGSVLVQAGP-(W)

#91-102

(R)-TDSLSSLRPIKV-(D)

#109-120

(K)-IILYENPNFTGK-(K)

#116-128

(P)-NFTGKKMEIIDDD-(V) ¤

#126-134

(I)-DDDVPSFHA-(H)

#135-147

(A)-HGYQEKVSSVRVQ-(S)
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Table 3.2 (continued)
Peptide
source

CWSb
a

Peptide sequence

NWSb
c

Lens age

CUSb
c

Lens age

NUSb
c

Lens age

Lens agec

16 44 75 83 16 44 75 83 16 44 75 83 16 44 75 83
#148-162

(Q)-SGTWVGYQYPGYRGL-(Q)

#169-180

(K)-GDYKDSSDFGAP-(H)

#174-185

(D)-SSDFGAPHPQVQ-(S)

#191-198

(I)-RDMQWHQR-(G)

γS
#2-22

(M)-SKTGTKITFYEDKNFQGRRYD-(C) ✽

#73-79

(R)-WMGLNDR-(L)

#85-95

(R)-AVHLPSGGQYK-(I)

#92-114

(G)-GQYKIQIFEKGDFSGQMYETTED-(C)

#132-146

(K)-VLEGVWIFYELPNYR-(G)

#159-166

(R)-KPIDWGAA-(S)

#160-178

(K)-PIDWGAASPAVQSFRRIVE

a.

b.

c.

Adjacent residues to the sequence of respective peptides are indicated in brackets. Peptides with
posttranslational modifications are highlighted. Posttranslational modifications are indicated
using the following symbols: ‡ for deamidation; ✽ for acelyation and ¤ for phosphorylation.
Modified residues are underlined. In the case where more than one modified residues are present
on one peptide, symbols are listed so that the modifications present on residues closer to the
N-terminus of the peptide are listed first.
Peptides with a positive detection (peptide score > peptide homology score) in the extract are
indicated by full-shading of the cell, whereas cells with diagonal-grids indicate that the peptides
were detected in the extract, but the Mascot analysis did not achieve peptide scores above the
peptide homology scores to confirm their identification. Peptides listed on this table are
positively identified in at least one lens extract.
Lenses aged 16, 44, 75 and 83 years.

As posttranslational modifications are important age-dependent changes of crystallin
proteins in the lens, we modified our Mascot database search to incorporate
crystallin posttranslational modifications reported in the literature [17, 125, 129, 137,
152, 234]. We identified peptides containing these modifications, and interestingly, a
number of peptides with novel residue-specific posttranslational modifications
(Table 3.3; the modified residues are indicated in Figs. 3.1-3.4). These previously
unreported posttranslational modifications included deamidation of Asn62 in
βA1/A3-crystallin; deamidation of Gln24, Asn26 and Gln28 in βB2-crystallin (see
Fig. A2.4 and Table A2.4 for the MS/MS analysis of peptide βB217-30, which consists
the deamidated Gln24, Asn26 and Gln28 residues); acetylation of Glu240 in
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βB1-crystallin and phosphorylation of Ser93 in βB2-crystallin (Table 3.3) (see Fig.
A2.5 and Table A2.5 for the MS/MS analysis of peptide βB292-99, which consists the
phosphorylated Ser93 residue). Although phosphorylation at Ser122 of αA-crystallin
[233-234, 236-237] and Ser19, Ser45 and Ser59 of αB-crystallin [233-234, 237] are
believed to be the major posttranslational modifications of lenticular α-crystallin,
our study did not detect phosphorylation at these serine residues. An unusual loss of
water at the Asp69 position in two αA peptides (αA66-75-H2O and αA66-80-H2O) was
also observed (see Fig. 3.5 and Table 3.4 for the MS/MS analysis of peptide
αA66-80-H2O; the MS/MS analysis of peptide αA66-75-H2O is also available in
Appendix II, Fig. A2.3 and Table A2.3). In addition, a phakinin peptide (residues
77-89) was found to consist a previously unreported deamidation at the Gln86
residue (see Fig. A2.6 and Table A2.6 for the MS/MS analysis of this peptide).
A number of endogenous LMW peptides derived from non-crystallin lens proteins
were also identified. These proteins included cytoskeletal proteins, phakinin and
vimentin, and other less known lens proteins matrillin II, pyruvate kinase isozymes
M1/M2,

calcium-regulated

heat

stable

protein

1,

betaine-homocysteine

S-methyltransferase 2 and brain acid soluble protein 1 (Table A2.1).
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Table 3.3: Posttranslational modified residues identified from the LMW
peptides.
Proteinsa
αA-crystallin
αB-crystallin
βA1/A3-crystallin
βB1-crystallin
βB2-crystallin

Posttranslational modified residuesb
Deamidation: Gln6, Gln25, Gln90, Asn101 and Gln104
Loss of water: Asp69c
Deamidation: Gln26, Asn78 and Asn146
Deamidation: Asn62
Oxidation: Met126
Acetylation: Lys6 and Glu240
Deamidation: Gln24, Asn26 and Gln28
Phosphorylation: Thr118, Ser93

γS-crystallin

a.
b.

c.

Deamidation: Asn15 and Gln107

BFSP2

Deamidation: Gln86

BASP1

Deamidation: Asn218

Abbreviation: BFSP2: phakinin; BASP1: brain acid soluble protein 1.
Residues containing posttranslational modifications that have not been reported previously
are indicated by bold letters. Acetylations at the N-termini residues of these proteins were
not listed in this table.
First reported in Su et al. [152] (Chapter 4).
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Fig. 3.5: The ESI-MS/MS of peptide αA66-80-H2O from analysis of the CUS
extract of a 65 year lens. CID spectrum of the isolated 462.744+ ion (M+H 1847.98),
showing the major b and y ions. See Table 3.4 for the complete list of matching ions.
The MS/MS analysis of peptide αA66-80 without the loss of water is also available in
chapter 4 (Fig. 4.2 and Table 4.1).
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Table 3.4: The predicted b and y ions of peptide αA66-80-H2O. The matching ions
observed from the CID spectrum (Fig. 3.5) are indicated in bold text (highlighted
cells).

#

b

b2+

b3+

Seq.

1

88.04

44.02

30.01

S

2

203.07

101.53

68.36

D

1760.95

880.47

587.65

14

3

359.17

179.58

120.39

R

1645.92

822.96

549.31

13

4

456.18

228.09

152.73

D*

1489.82

744.91

497.27

12

5

584.28

292.14

195.43

K

1392.80

696.40

464.93

11

6

731.35

365.67

244.45

F

1264.71

632.35

422.24

10

7

830.42

415.21

277.47

V

1117.64

558.82

373.21

9

8

943.50

471.75

315.17

I

1018.57

509.29

340.19

8

9

1090.57

545.28

364.19

F

905.49

452.74

302.50

7

10

1203.65

601.83

401.88

L

758.42

379.21

253.47

6

11

1318.68

659.34

440.23

D

645.34

322.67

215.78

5

12

1417.75

708.87

473.25

V

530.31

265.15

177.44

4

13

1545.84

772.92

515.95

K

431.24

215.62

144.41

3

14

1682.90

841.45

561.63

H

303.15

151.57

101.72

2

F

166.09

83.04

56.03

1

15

y

y3+

#
15

* loss of -18 Da at Asp69 due to the loss of water.
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3.4.2 Quantification of peptide αA57-65 in the aging human lens
Having established that the number of LMW peptides present in the lens increases
with age, we sought to determine if the quantity of a specific αA-crystallin peptide
(αA57-65), which was present in all lens extracts (Table A2.1), also increased with age
using SRM (see Fig. A2.2 and Table A2.2 for the MS/MS analysis of peptide
αA57-65). The relative quantity of peptide αA57-65 was measured in extracts of human
lenses aged 16, 44, 75 and 83 years. All samples were spiked with an internal
standard peptide (ESDTSYVS*LK). SRM data for peptide αA57-65 (LDSGISEVR,
molecular ion 488.32+)-y5, y7 and y8 ions and for the internal standard peptide
(ESDTSYVS*LK, molecular ion 568.42+)-y5, y6 and y8 ions were acquired (Fig.
3.6). SRM data acquisition was repeated twice. SRM ions for LDSGISEVR had
three chromatographically separated peaks eluting within one min. SRM triggered
MS/MS analysis confirmed that the three peaks had all originated from
LDSGISEVR, suggesting that this peptide may have three stereo-isomers (data not
shown). For quantification, the isomers were integrated together, and the peak areas
of the y8, y7 and y5 ions were normalized against the area of the y6 ion of the
internal standard.
SRM analysis indicated that peptide αA57-65 is predominantly WS (Fig. 3.7).
Between the ages of 16 and 44 years, the quantity of peptide αA57-65 per mg of tissue
increased by approximately 18-fold in the lens cortex, and approximately 22-fold in
the lens nucleus (Fig. 3.7). The quantity of peptide αA57-65 increased further between
the ages of 44 and 75 years, with a 2.4-fold increase per mg of tissue in the lens
cortex and a 1.8-fold increase per mg of tissue in the lens nucleus (Fig. 3.7). The 83
year lens had similar, but slightly lower amounts of peptide αA57-65 as compared to
the 75 year lens (Fig. 3.7). Interestingly, for all lenses, the amount of peptide αA57-65
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present in the nucleus was at least 3-fold higher than that seen in the lens cortex (Fig.
3.7). These results indicate that cleavage of α-crystallin occurs at an early age, and
that this process continues in the lens steadily throughout life.

Fig. 3.6: SRM extracted ion chromatogram of peptide αA57-65 and the internal
standard. Ions from peptide αA57-65 (LDSGISEVR-y5, light blue trace;
LDSGISEVR-y7, green trace; LDSGISEVR-y8, yellow trace) and the internal
standard (ESDTSYVS*LK-y5, red trace; ESDTSYVS*LK-y6, pink trace;
ESDTSYVS*LK-y8, dark blue trace) in the (A) CWS and (B) CUS extracts of a 44
year lens, and the (C) CWS and (D) CUS extracts of a 75 year lens are shown on the
chromatograms.
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Fig. 3.7: SRM analysis of the relative quantity of peptide αA57-65 in human
lenses. Bars showing the relative quantities of peptide αA57-65 in the WS (blue) and
US (red) extracts per mg of the cortical (C) and nuclear (N) lens tissues. Relative
quantity of peptide αA57-65 in extracts from human lenses aged 16, 44, 75 and 83
years are shown as percentages for each lens region as compared to the 75 year
nuclear extract. Relative quantities determined as intensities of peptide αA57-65
product ions (peak area) compared to the internal standard (ESDTSYVS*LK).
Values were adjusted for extract volume and lens tissue wet weight.
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3.5 Discussion

A remarkably large and diverse group of endogenous LMW peptides was identified
in human lenses. The majority of these peptides derived from crystallins, with most
being present only in the old lenses (75 and 83 years) (Table 3.1). Despite β- and
γ-crystallins accounting for approximately 60% of total soluble protein in the lens
[30, 238-239], more than two-thirds of the peptides originated from α-crystallin.
α-Crystallin peptides covered almost the entire sequence of the protein (Fig. 3.1 and
3.2), which was not the case for the β-crystallins and γS-crystallin (Fig. 3.3 and 3.4).
One possible explanation is that due to its role as a molecular chaperone in the lens,
the structure of α-crystallin may be more flexible, thereby more vulnerable to
proteolytic and chemical cleavages. Another possibility is that when α-crystallin is
bound to substrates, the protein’s “chaperone active” conformation reveals formerly
protected sequence regions to solvents, thus exposing the protein to proteolytic or
chemical assaults. However, as the tertiary and quaternary structures of α-crystallin
are not fully determined, it is difficult to correlate this cleavage pattern with protein
structure.
The appearance of significant levels of α-crystallin peptides coincides with the loss
of soluble α-crystallin in the WS fraction of the lens around middle-age [126-128,
150]. The only region of αA-crystallin that was not present in any LMW peptides
was between residues 115-133 (Fig. 3.1), a region that has a high number of basic
amino acid residues. LMW peptides derived from this region may readily associate
with the negatively charged phospholipids of the cellular membrane [240-242],
making the peptides insoluble even in 8 M urea. Another possibility is that this
region contains residues (130-133) of a β-sheet that forms a hydrophobic groove at
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the core of the protein [39], and therefore these residues may be protected within the
centre of the protein.
The broad variety of α-crystallin peptides (Fig. 3.1 and 3.2) suggests the protein
contains numerous cleavage sites. Such cleavages could seriously compromise the
structure of α-crystallin and affect the molecular chaperone function of the protein,
particularly as a number of these cleavages occur within regions reported to be
responsible for chaperone activity (residues 70-88 of αA-crystallin [155] and
residues 73-92 of αB-crystallin [156]) (Fig. 3.1 and 3.2). The presence of peptides
αA66-80 and αB1(2)-18 in old lenses (Table A2.1) could also affect the molecular
chaperone action of α-crystallin, as these peptide were shown previously to diminish
the chaperone function of α-crystallin in in vitro assays [139, 157, 235]. Another
interesting observation was that a large number of α-crystallin peptides in old lenses
were present in the US extracts. With age, these peptides may become part of the
HMW aggregates that are insoluble and/or associated with lenticular cytoskeleton
and membranes [174-175]. As the loss of α-crystallin’s molecular chaperone activity
and the increase in membrane-bound HMW crystallin aggregates in the lens are two
major events associated with aging, it is likely that the LMW α-crystallin peptides
identified in this study, and the cleavage event(s) responsible for the generation of
these peptides, have significant role(s) in the development of age-related lens
opacity.
Compared to α-crystallin, LMW peptides derived from β-crystallins and
γS-crystallin were less abundant and, with the exception of βA1/A3-crystallin, were
predominantly in the WS extracts of the lens (Table A2.1). βB2-crystallin, which is
an abundant β-crystallin species [30], gave rise to the largest variety of peptides
originating from β-crystallins. Remarkably, we did not find any peptides derived
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from γC- and γD-crystallins, despite the relatively high abundance of these proteins
in the human lens [30]. As γ-crystallins exist as monomers with multiple disulfide
bonds [68, 243], the compact nature of their molecular structures and their intrinsic
stability may prevent proteases or chemicals from accessing the protein. Compared
to α- and β-crystallins, truncations to γ-crystallins are rare, with the major truncation
producing a 9 kDa fragment during early lens development [153]. The domains of
γ-crystallins may be intrinsically stable and thus unaffected by the cleavage
mechanism(s) responsible for the generation of LMW peptides in the lens. In
comparison to γC- and γD-crystallins, the structure of γS-crystallin is more open and
has a flexible N-terminal extension [244-246]. This may explain why γS-crystallin is
more susceptible to proteolytic degradation, particularly at the N-terminal region of
the protein.
We also identified a number of LMW peptides containing posttranslationally
modified residues. Some of these posttranslational modifications, particularly those
present on β-crystallin peptides, have not been previously reported. As crystallin
deamidation has been associated with crystallin insolubilization in the lens with age
[129], and phosphorylation to α-crystallin is believed to affect the chaperone
functions of the protein [131, 247], these posttranslational modifications could
therefore affect the function of the proteins from which the peptides originated, if
the modifications were quantitatively significant. Two αA-crystallin peptides
(αA66-75-H2O and αA66-80-H2O) were found to contain an unusual loss of water at the
Asp69 position, a modification first reported in our previous study [152] (Chapter 4).
Based on similar modifications published for Asp residues [145, 248-251], it is
possible that this loss of water is due to cyclisation of the Asp residue, which results
in the formation of a succinimide structure. The fact that this Asp residue is flanked
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by two basic residues (Arg and Lys) could make it particularly prone to this reaction,
as studies have shown that residues adjacent to basic residues are more likely to be
deamidated [137] - a process linked to succinimide formation. It should be pointed
out that a natural variant residue substitution of Pro for Asp would also result in the
loss of 18 Da on this peptide. However, as the b ions of Asp69 and its adjacent
residues are clearly present on the CID spectrum (Fig. 3.5), and a Pro69
αA-crystallin mutant has never been reported in the literature, it is unlikely that the
loss of 18 Da on peptides αA66-75 and αA66-80 is a result of this residue substitution.
The relative quantity of α-crystallin peptide (αA57-65), which was present in all the
lens extracts, was measured using SRM (Fig. 3.7). The results showed that the
quantity of peptide αA57-65 in the lens increases steadily with age (Fig. 3.7),
suggesting that the accumulation of this peptide is a result of slow, progressive
cleavage of αA-crystallin in the lens. The accumulation of LMW peptides in the lens
indicates that lens cells may be incapable of efficiently removing these protein
breakdown products through the conventional degradation pathways. The higher
quantity of peptide αA57-65 in the lens nucleus when compared to the lens cortex is in
good agreement with the results of our previous MALDI-tissue imaging study [152]
(Chapter 4), which showed a nucleus-to-cortex emergence pattern of LMW peptides
in the lens from middle-age.
Despite establishing that a large variety of LMW peptides are present in the human
lens, the mechanism(s) responsible for these crystallin cleavages are not understood.
The large number of peptides with termini residues of Lys and Arg suggest that
trypsin-like cleavages may occur in the lens. In mature lens fibre cells, there appears
to be little or no proteolytic activity [161-163]. The activity of the major lenticular
proteases - the calpains, is largely contained by high levels of endogenous
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calpain-inhibitor, calpastatin [163-164]. However, as the lens contains a significant
variety of proteases and peptidases [158-161], unreported proteolytic activity could
potentially exist. Proteases with trypsin-like activity have been reported in bovine
lenses [252-254], and similar proteolytic activity could also be present in the human
lens.
The presence of a large number of peptides with “ragged ends” - peptides which
differ by one or two residues at their terminal regions, may offer an important
insight into the cleavage of crystallin. As proteases usually target specific residues or
sequences for cleavage, the apparently random nature of these cleavages suggests
that they may derive from non-enzymatic cleavage mechanism(s). For example, Asp
residues are known spontaneous cleavage sites [255] and are responsible for the
cleavage of lens membrane proteins (eg. aquaporin 0) [20, 165]. Interestingly, we
observed that many of these peptides are cleaved either directly before or after Ser,
Gly, Thr and Asp residues, which indicates that these residues may be favoured.
Protein intein-like cleavages, for example, would produce peptides with Ser, Thr or
Cys at the N-terminus [256-258], while spontaneous peptide bond cleavage via
imide formation at labile Asp/Asn residues has been previously reported in bovine
α-crystallins [255, 259]. Based on these findings, it is likely that many LMW
peptides are generated by one or more of these cleavage mechanism(s); Trypsin-like
activity and chemical cleavages being largely responsible for the generation of the
“parent” peptides, then over time, residues at the terminal regions of the peptides
become increasingly vulnerable to further cleavages, thus creating the “ragged ends”
of these peptides. Age-dependent changes to the chemical environment in the lens,
due to the formation of a barrier at the nucleo-cortical interface [189] and the acidic
environment in the lens nucleus [260], could all contribute to this process.
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In conclusion, a large diversity of LMW peptides derived from crystallins were
identified in the human lens, with many of these peptides appearing only in old
lenses. α-Crystallin was the most extensively cleaved crystallin, with LMW peptides
derived from this protein found to cover almost the entire protein sequence. SRM
analysis showed that the quantity of a prominent αA peptide (αA57-65) increased
steadily with age, suggesting that the cleavage of α-crystallin in the lens is an
age-dependent process. These cleavages, if quantitatively significant, could
compromise crystallin structures and lead to insolubilization and aggregation of
crystallins. Based on the peptide sequences identified in this study, trypsin-like
activity and chemical cleavages targeting Ser, Thr and Asp residues may be largely
responsible for the generation of the “parent” peptides, with subsequent
indeterminate cleavages creating the “ragged end” of other peptides. Interestingly,
we did not identify any peptides from γC- and γD-crystallins, suggesting that the
compact structures of these proteins are resistant to the cleavage mechanism(s)
occurring in the human lens.
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Preface

Having established that a large variety of crystallin peptides are present in human
lenses, MALDI-IMS was used to determine the localization of specific peptides
within the lens tissue. Peptides with anti-chaperone activity toward α-crystallin
and/or confined to the WI fraction of the lens were the subjects of this investigation.
This study was conducted in conjunction with the work presented in chapter 3;
however, it was published before the work in chapter 3 was completed. The reader
may therefore find some overlap in the results and discussion sections of these two
chapters.

Publication:

Shih-Ping Su, Jason D. McArthur, J. Andrew Aquilina (2010) “Localization of
LMW crystallin peptides in the aging human lens using a MALDI mass
spectrometry imaging approach.” Experimental Eye Research, 91(1): 97-103.
(Written permission has been obtained from Experimental Eye Research for the
inclusion of this journal article in this thesis)
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4.1 Abstract

LMW peptides, derived from the breakdown of the major eye lens proteins, the
crystallins, accumulate in the human lens with age. These LMW peptides are
associated with age-related lens opacity and cataract, with some shown to inhibit the
chaperone activity of α-crystallin. However, the mechanism(s) giving rise to the
production of these peptides, as well as their distribution within the lens, are not well
understood. In this study, we have mapped the distribution of these
crystallin-derived peptides present in human lenses of different ages using MALDIimaging mass spectrometry (MALDI-IMS). Our data showed that most of these
LMW peptides emerge in the lens at early middle-age, with peptides greater than
1778 Da in mass being confined to the water-insoluble (WI) fractions, and to a lesser
extent, the water-soluble (WS) fractions of older lenses. MALDI-IMS analyses
showed that four peptides, derived from αA-, αB- and γS-crystallins, were confined
to the lens nuclear fibre cells upon emergence during early middle-age, but were
present in both the cortex and nucleus of old lenses. In contrast, another major
peptide, derived from the C-terminal breakdown of βA3-crystallin, was present in
the cortical and nuclear regions of both young and old lenses. A comparison between
age-matched cataractous and non-cataractous lenses showed no distinct differences
in LMW peptide profiles, indicating that although cataract may be a potential
consequence caused by the emergence of these peptides, it does not contribute
directly to the peptide-generating process.
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4.2 Introduction

Human lens fibre cells contain high concentrations of structural proteins known as
α-, β- and γ-crystallins. α-Crystallin, which is composed of the subunits of αA- and
αB-crystallins, also acts as a molecular chaperone to suppress protein unfolding in
the lens [3, 5]. During aging, the lens undergoes negligible protein turnover [6] and,
consequently, the crystallins become increasingly modified. These age-related
modifications include truncation, glycation, deamidation and phosphorylation,
amongst others [18-19, 125, 129, 186, 214-215]. While certain structural changes
appear to be associated with the normal maturation process of the lens, improper or
unregulated modifications have been associated with lens opacity [186, 261].
Crystallin breakdown increases significantly in aged lenses and with the onset of
cataract [18-19, 125]. For example, crystallin fragments (peptides) have been found
in both WS and WI fractions of the lens, with the prevalence of these fragments in
the WI fraction increasing with age [18, 66, 151]. Recently, LMW peptides derived
from the breakdown of crystallins have been identified in young, old and cataractous
lenses [139]. Interestingly, a number of these endogenous LMW peptides appeared
to be confined to a certain age group (young or old lenses), while some were present
exclusively in cataractous lenses [139]. As there is very little protease activity in
older lenses [160], the mechanism(s) underlying this crystallin breakdown remain
unclear.
The emergence of LMW peptides is potentially a key event in lens aging and may be
responsible for the increase in protein aggregation and WI proteins in aged and
cataractous lenses. For example, the LMW peptides present in aged lenses, αB1-18
and βA3/A159-74, have been shown to diminish the chaperone activity of α-crystallin
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[139]. In the lens, this can lead to increased protein aggregation and light scattering key events in the development of ARN cataract [3, 18, 186]. Furthermore, the
cleavage mechanism(s) responsible for these LMW peptides are likely to
compromise crystallin structure, further contributing to protein aggregation and a
reduction in the chaperone efficacy of α-crystallin [155-156].
Despite recent reports on the presence of LMW peptides in the human lens [139,
154], the emergence and distribution of these peptides during the aging process have
not been investigated. MALDI-IMS has proven to be a reliable technique for
studying the distribution of proteins/peptides in tissue sections [262]. Recent studies
using MALDI-IMS on lens tissue have demonstrated that mapping and
quantification of native and modified crystallins in the lens is possible [150, 154,
263]. In the present study, we have examined the localization of LMW crystallin
peptides in the WS and WI fractions of both the cortical and nuclear regions of
human lenses of different ages. Furthermore, we have used MALDI-IMS to map the
emergence and distribution with age of the major LMW crystallin peptides in the
human lens.
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4.3 Material and methods

4.3.1 Lens protein extraction and isolation of LMW crystallin peptides
Human lenses were obtained from donors at the Lions New South Wales Eye Bank
(Sydney, Australia) and stored immediately at -80 °C. Lenses were dissected into
cortical and nuclear regions using a 4.5 mm trephine. A cold scalpel was used to
remove 1 mm of tissue from each end of the resulting cylindrical center (nucleus).
Tissue from respective regions was separately homogenized in buffer A (20 mM
Tris-HCl, 20 mM NaCl, 1 mM EDTA, pH 7.4) with a hand-held tissue homogenizer,
using 1 mL of buffer per 100 mg tissue (wet weight), and incubated at room
temperature for 15 min. The homogenates were centrifuged at 10000 × g for 30 min
at 4 °C, and the pellets were re-homogenized with buffer A and centrifuged at 10000
× g. The supernatants from both extraction steps were pooled together as WS protein
extracts. Remaining pellets were re-homogenized in buffer B (8 M urea in buffer A),
incubated at room temperature for 15 min, then centrifuged at 10000 × g for 30 min
at 4 °C. The supernatants were collected to give the urea-soluble (US) protein
extracts. The urea concentration in all samples was adjusted to 4 M using buffer B
for WS extracts and buffer A for US extracts. β-Mercaptoethanol (0.5% v/v final
concentration) was added and the samples were incubated at room temperature for
30 min, before being filtered through a 10 kDa MWCO YM-10 Microcon
centrifugal filter unit (Millipore, Billerica, Massachusetts, USA) by centrifugation at
8000 × g, 4 °C. Protease inhibitor cocktail (P2714, Sigma-Aldrich, St. Louis,
Missouri, USA) was prepared as per the manufacturers specifications and used in all
buffers.
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4.3.2 MALDI-MS and nanoLC-ESI-MS/MS peptide identification
Peptides present in the WS and US protein extracts were concentrated using C18
ZipTips (Millipore), and spotted directly onto a MALDI-plate by eluting the
peptides with α-cyano-4-hydroxycinnamic acid matrix. MALDI-MS analysis was
performed using a Shimadzu Axima TOF2 MALDI mass spectrometer (Save Sight
Institute, Sydney, Australia). The LMW peptides present in the lens extracts were
identified using nanoLC-ESI-MS/MS analysis at the Australian Proteome Analysis
Facility (Macquarie University, Sydney, Australia). Urea was removed from the
extracts using C4 ZipTips (Omix, Redwood City, California, USA) prior to
freeze-drying and loading onto an Agilent 1100 nanoLC system (Agilent
Technologies, Forest Hill, Australia) fitted with a peptide Captrap (Michrom
Bioresources, Auburn, California, USA) and a 150 μm × 100 mm, 300 Å C18
Protecol column (SGE Analytical Science, Ringwood, Australia), coupled to a Qstar
XL ESI mass spectrometer (AB Sciex, Mt Waverly, Australia). Peptides were
separated using gradient elution from 5% solvent B (90% acetonitrile, 0.1% formic
acid) to 40% solvent B in 40 min, at a flow-rate of 500 nL/min (solvent A: 0.1%
formic acid). Peptides eluting from the column were analyzed directly in
nanoLC-ESI-MS/MS IDA scan mode. MS/MS results were searched against protein
sequences published on Swissprot through the Mascot search engine (peptide scores
> 37 considered significant).

4.3.3 Tissue preparation and MALDI tissue imaging
Frozen lenses were sectioned equatorially into 20 μm thick tissue sections with
disposable blades at −20 °C, in a Shandon Cryotome E Cryostat (Thermo Electron
Corporation, Waltham, Massachusetts, USA). Lens sections were immediately
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thaw-mounted onto a Shimadzu MALDI-plate (TO-487, Shimadzu, Kyoto, Japan).
Lens sections were air-dried at room temperature, before being washed
consecutively with 30%, 50% and 70% ethanol for a period of 60 seconds each,
allowing air-drying in between washes. This method of ethanol-washing removes
physiological salts and lipids that would otherwise mask the ion signals of the
peptides of interest. Plates were then sprayed with a solution of 20 mg/mL sinapic
acid (Fluka, St. Louis, Missouri, USA) in 50% acetonitrile. Hand spraying was
performed in an open-faced box using a Preval Spray compressed gas device
(Precision Valve Corp., New York, USA). Sections were coated 8 times in a dual
pass process from a distance of 40 cm, and aiming the spray plume 15 cm above the
sample plates. A total volume of 30 mL of matrix solution was used in the coating
process. Air-drying between coats was allowed to occur for a period of 5 min.
MALDI-IMS was performed in linear mode on a Shimadzu Confidence
MALDI-TOF mass spectrometer (Australian Institute for Innovative Materials,
University of Wollongong). Effective laser power of 80 V was used for all imaging
with a TV raster function (50 shots per raster position) set at 200 μm intervals across
a 100 mm2 area, sufficient to cover entire sections. Total number of data points per
tissue section was 2601. Data was exported into BioMAP 3.7.5.5 functional image
analysis software (Novartis Institutes for Biomedical Research, Basel, Switzerland)
for processing and image optimization.
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4.4 Results

4.4.1 Distribution of LMW crystallin peptides in WS and US extracts of human
lenses of different ages
We have examined a broad age range of human lenses in an attempt to determine at
what stage of life, and in which lens regions, the crystallin-derived LMW peptides
are distributed. Fig. 4.1 illustrates the MALDI-MS spectra obtained for each of the
extracts from a 65 year lens. Peptides which gave rise to most of the major peaks
observed in Fig. 4.1 were separated, sequenced and identified using a
nanoLC-ESI-MS/MS approach in conjunction with Mascot database searching (for
examples of the MS/MS analysis, see Fig. 4.2-4.4, Table 4.1-4.3 for the analyses of
peptides αA66-80, αB93-103 and αB2-18, respectively). Species of primary interest in this
study were those that have previously been shown to possess anti-chaperone
properties [139], were found to increase in ion intensity with age, or were major
peptides in the US fractions. The WS fractions of a 65 year lens (Fig. 4.1A and 4.1B)
were found to have peptides derived predominantly from αA- and αB-crystallins,
along with an N-terminal peptide from γS-crystallin (residues 2-22), a βB1 peptide
(residues 238-247) and two βB2 peptides (residues 169-180 and 91-102). Peptides
extracted using urea included two N-terminal peptides of αB-crystallin (residues
1(2)-18) and a trio of βA3 peptides (Fig. 4.1C).
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Fig. 4.1: MALDI-TOF MS spectra of the LMW crystallin peptides present in
the (A) CWS, (B) NWS, (C) CUS and (D) NUS extracts of a 65 year human lens.
Peak ions and the peptide sequence origins of the major peaks are labelled.
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the major b and y ions. See Table 4.1 for the complete list of matching ions.
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Table 4.1: The predicted b and y ions of peptide αA66-80. The matching ions
observed from the CID spectrum (Fig. 4.2) are indicated in bold text (highlighted
cells).

#

b

b2+

b3+

Seq.

1

88.04

44.02

30.01

S

2

203.07

101.53

68.36

D

1778.96

889.98

593.65

14

3

359.17

179.58

120.39

R

1663.93

832.47

555.31

13

4

474.19

237.60

158.73

D

1507.83

754.42

503.28

12

5

602.29

301.65

201.43

K

1392.80

696.91

464.93

11

6

749.36

375.18

250.45

F

1264.71

632.86

422.24

10

7

848.43

424.72

283.48

V

1117.64

559.32

373.21

9

8

961.51

481.26

321.17

I

1018.57

509.79

340.19

8

9

1108.58

554.79

370.19

F

905.49

453.25

302.50

7

10

1221.66

611.34

407.89

L

758.42

379.71

253.47

6

11

1336.69

668.85

446.23

D

645.34

323.17

215.78

5

12

1435.76

718.38

479.25

V

530.31

265.66

177.44

4

13

1563.85

782.43

521.95

K

431.24

216.12

144.41

3

14

1700.91

850.96

567.64

H

303.15

152.08

101.72

2

F

166.09

83.55

56.03

1
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Fig. 4.3: The ESI-MS/MS of peptide αB93-103 from analysis of the CWS extract
of a 65 year lens. CID spectrum of the isolated 389.343+ ion (M+H 1166.02),
showing the major b and y ions. See Table 4.2 for the complete list of matching ions.
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Table 4.2: The predicted b and y ions of peptide αB93-103. The matching ions
observed from the CID spectrum (Fig. 4.3) are indicated in bold text and
(highlighted cells).

#

b

b2+

b3+

Seq.

1

100.08

50.54

34.03

V

2

213.16

107.08

71.72

L

1066.59

533.80

356.20

10

3

270.18

135.59

90.73

G

953.51

477.26

318.50

9

4

385.21

193.11

129.07

D

896.48

448.75

299.49

8

5

484.28

242.64

162.09

V

781.46

391.23

261.15

7

6

597.36

299.18

199.79

I

682.39

341.70

228.13

6

7

726.40

363.71

242.80

E

569.30

285.16

190.43

5

8

825.47

413.24

275.82

V

440.26

220.63

147.42

4

9

962.53

481.77

321.51

H

341.19

171.10

114.40

3

10

1019.55

510.28

340.52

G

204.13

102.57

68.71

2

K
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74.06

49.70

1

11
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y
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Fig. 4.4: The ESI-MS/MS of peptide αB2-18 from analysis of the NUS extract of
a 65 year lens. CID spectrum of the isolated 547.254+ ion (M+H 2186.01), showing
the major b and y ions. See Table 4.3 for the complete list of matching ions.
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Table 4.3: The predicted b and y ions of peptide αB2-18. The matching ions
observed from the CID spectrum (Fig. 4.4) are indicated in bold text (highlighted
cells).

#

b

b2+

b3+

Seq.

1

116.03

58.52

39.34

D

2

229.12

115.06

77.04

I

2071.13 1036.07 691.04

16

3

300.16

150.58

100.72

A

1958.04

979.53

653.35

15

4

413.24

207.12

138.41

I

1887.01

944.01

629.67

14

5

550.30

275.65

184.10

H

1773.92

887.47

591.97

13

6

687.36

344.18

229.79

H

1636.86

818.94

546.29

12

7

784.41

392.71

262.14

P

1499.81

750.41

500.60

11

8

970.49

485.75

324.16

W

1402.75

701.88

468.25

10

9

1083.57

542.29

361.86

I

1216.67

608.84

406.22

9

10

1239.67

620.34

413.89

R

1103.59

552.30

368.53

8

11

1395.78

698.39

465.93

R

947.49

474.25

316.50

7

12

1492.83

746.92

498.28

P

791.39

396.20

264.46

6

13

1639.90

820.45

547.30

F

694.33

347.67

232.11

5

14

1786.97

893.99

596.32

F

547.27

274.14

183.09

4

15

1884.02

942.51

628.67

P

400.20

200.60

134.07

3
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F
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2
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Table 4.4 presents a summary of the distribution of LMW crystallin peptides
detected in the WS and US extracts from the cortical and nuclear regions of lenses
ranging in age from 20 to 86 years. Peptides up to 1730 Da in mass were, on the
whole, found in both the WS and US extracts of a broad lens age range, with some
being confined exclusively to the WS extracts. Interestingly, peptides γS167-178 and
αA37-49 were found across a broad age range in the nucleus water-soluble (NWS) and
also in the cortex and nucleus US extracts of some age groups. The absence of these
peptides in the cortex water-soluble (CWS) fraction suggests that the molecular
environments of the cortex and nucleus are sufficiently distinct in the human lens
such that the nucleus renders this peptide more soluble than the cortex. Peptides
greater than 1778 Da in mass were confined predominantly to the US lens extracts
and, to a lesser extent, the WS of old lenses. The N-terminal peptides of
αB-crystallin (residues 1(2)-18) and C-terminal peptides of βA3-crystallin were
isolated exclusively from the US fractions. These peptides were found to be present
in the US fractions of lenses above 35 years, but not in the 20 year lens. Interestingly,
even though deamidation has been mapped to residues on peptides αA2-12(13), γS2-22,
and the βA3 C-terminus peptides [129], no such modification was observed.
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Table 4.4: Distribution of LMW crystallin peptides present in the CWS, NWS,
CUS and NUS extracts of human lenses aged between 20 and 86 years. Peptides
in the lens extracts were identified using MALDI-MS and nanoLC-ESI-MS/MS
analysis. Shaded cells indicate a positive detection (peptide ion intensity greater than
10% of base peak) of the specific peptide in the fraction. Peptides in bold text
indicate novel peptides identified in this study.

Peptide
mass
(M+H)

Peptide
source

1069.6

βB1-(238-247)

1152.6

αA-(67-75)

CWS extract

NWS extract

CUS extract

NUS extract

Lens age (years)

Lens age (years)

Lens age (years)

Lens age (years)

20 35 43 65 86 20 35 43 65 86 20 35 43 65 86 20 35 43 65 86

1165.7

αB-(93-103)

1193.6

αA-(150-160)

1210.6

αB-(45-54)

1239.7

αA-(66-75)

1258.5

βB2-(169-180)

1315.8

βB2-(91-102)

1388.8

γS-(167-178)

1403.7

αB-(28-39)

1426.8

αA-(2-12)

1448.7

αA-(57-69)

1507.8

αA-(69-80)

1527.8

αA-(2-13)

1543.8

αA-(37-49)

1550.8

αB-(45-57)

1731.0

αA-(43-56)

1778.9

αA-(67-80)

1848.0

αA-(66-80)a

1865.9

αA-(66-80)

2187.2

αB-(2-18)

2359.2

αB-(1-18)b

2598.4

γS-(2-22)c

3197.0

βA3-(190-215)

3252.7

βA3-(189-215)

3389.7

βA3-(188-215)

a. Peptide has a loss of H2O at the Asp69 residue.
b. Peptide has an acetylated-Met at the N-terminus.
c. Peptide has an acetylated-Ser at the N-terminus.
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4.4.2 MALDI-IMS mapping of LMW crystallin peptides across tissue sections of
human lenses of different ages
Having established that crystallin-derived peptides vary greatly in solubility and
gross distribution with age, we attempted to use MALDI-IMS to more accurately
map the distributions of anti-chaperone peptides, peptides that were found to
increase in ion intensity and/or area of distribution with age, and those present in the
US fractions. Lens sections were thoroughly washed in order to remove lipids and
salts, as well as the WS proteins and peptides, in an effort to identify peptides in the
WI fractions. Fig. 4.5 represents the summed mass spectra, acquired at 200 μm
intervals across lens tissue sections, for a 37 year (Fig. 4.5A) and an 80 year (Fig.
4.5B) lens. In the younger lens, the major species were the C-terminal βA3 peptides
at m/z 3197, m/z 3253 and m/z 3390, suggesting that these peptides are the first to
accumulate in the US component with age. This is in agreement with the detection
of these peptides in the cortex urea-soluble (CUS) and nucleus urea-soluble (NUS)
fractions of lenses older than 20 years (Table 4.4). In contrast to this, MALDI-IMS
analysis of an 80 year lens section revealed further significant peaks at m/z 2187,
m/z 2359 and m/z 2598, corresponding to N-terminal peptides of αB- and
γS-crystallins. A fourth, small peak, which matched our lens extract data
corresponding to peptide αA66-80-H2O, was noted at m/z 1848. Along with the major
βA3 peptide at m/z 3253, these ions, indicated by an asterisk (Fig. 4.5B), were
mapped in MALDI-IMS experiments performed across a broad lens age range (Fig.
4.6).
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Fig. 4.5: Summed mass spectra, acquired at 200 μm intervals across lens tissue
sections, for a (A) 37 year and an (B) 80 year lens. In the younger lens, the major
species were the C-terminal βA3 peptides at m/z 3197, m/z 3253 and m/z 3390. The
80 year lens section revealed further significant peaks at m/z 2187, m/z 2359 and m/z
2598, corresponding to N-terminal peptides of αB- and γS-crystallins. Along with
the major βA3 peptide at m/z 3253 and a smaller peak at m/z 1848 corresponding to
the peptide αA66-80-H2O, these ions have been indicated by an asterisk.
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(Years)

Fig. 4.6: MALDI-IMS spectra mapping the peptides indicated by an asterisk in
Fig. 4.5B. Lenses were sectioned equatorially and prepared for analysis by manual
spray deposition of sinapic acid. Ages (20-86 years) are noted in the x-axis whereas
peptide identities are labelled in the y-axis. Relative peptide intensities are illustrated
using a black-red-white scale, white being of highest relative intensity. Dashed oval
outlines indicate the edge of the tissue sections. Scale bars, 2 mm.
Images from a 37 year lens revealed that peptide βA3189-215 was the only significant
ion detected at this age (Fig. 4.6). At 42 years, this ion was equally abundant, and
additionally, signal arising from the αA, αB and γS peptides were shown to be
emergent in the nuclear region of the lens. By 58 years, a high abundance of the
αB2-18 peptide was evident in the nuclear region of the lens, with further less
dramatic increases of the other peptides. By age 80, all peptides were clearly
detected in both cortex and nucleus. The N-terminal αB peptides displayed a
dramatic expansion into the cortical region in this transition to old age, a pattern that
was also evident for peptides αA66-80 and γS2-22. Peptide βA3189-215 appeared to be
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distributed throughout the lens cross-section at ages 37 years and above. The oldest
lens analyzed was 86 years, which also was the only lens to display nuclear
opacification consistent with age-related cataract. This lens had a significant
increase in the prevalence of peptide αA66-80-H2O compared with the other peptides,
which showed only incremental expansion towards the periphery of this larger lens.
Another feature of this lens was the apparent bias in the distribution of all peptides
towards one hemisphere of the equatorial section, however, as the superior-inferior
orientation of lenses was not noted prior to sectioning, it is difficult to make any
assumptions regarding this bias.

4.4.3 Determining the effect of cataract on the genesis and abundance of LMW
crystallin peptides
In order to assess the impact of cataractogenesis upon the apparent abundance and
distribution of LMW peptides, spectra were acquired across the sections from a 69
year healthy lens (Fig. 4.7A) and a 62 year lens which displayed opacity consistent
with ARN cataract (Fig. 4.7B). The healthy lens contained each of the peptides
previously described and are labelled accordingly. Interestingly, there were no major
distinctions in the species of peptides present in the lenses. Taken together with the
imaging data (Fig. 4.6), we conclude that cataract per se is not symptomatic of
dramatic changes in the abundance of these LMW peptides.
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Fig. 4.7: Summed MALDI-MS spectra from imaging experiments performed
on sections from a (A) 69 year healthy lens and a (B) 62 year moderately
cataractous lens. No major distinctions in the species of peptides present were
observed, suggesting that cataract formation as such is not causative, nor
symptomatic, of the abundance of these LMW peptides.
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4.5 Discussion

In this study we have examined the LMW peptides in the WS and US extracts of
human lens cortices and nuclei. Our results complement those of a recent study by
Grey and Schey [150], who reported the distributions of α-crystallin subunits and
N-terminal peptides with m/z values greater than 4000 in human lenses over a broad
age range. In the present study, peptides greater than m/z 4000 were not detected,
indicating that our use of lower percentage ethanol solutions to wash the tissue
sections may have removed these larger peptides. The trend observed by Grey and
Schey [150] that crystallin truncation increases with age, in particular during the
middle-age, and that the products are degraded progressively to low mass peptides is
in good agreement with our findings.
Our results showed that peptides greater than 1778 Da were isolated predominantly
from the US extracts of lenses 35 years and older (Table 4.4). This implies that
either the solubility of these peptides in aqueous buffer is low, or that they are bound
to WI protein complexes, cytoskeleton or lens fibre cell membranes. These peptides
were found to originate from the chaperone binding region of αA-crystallin [155],
the N-terminus of αB- and γS-crystallins and the C-terminus of βA3-crystallin
(Table 4.4). The N-terminal peptides of αB-crystallin have been shown to
significantly reduce the molecular chaperone function of α-crystallin oligomers
[139]. In situ mapping of the αB peptides revealed that αB2-18 was densely localized
to the nucleus of a 58 year lens, with αB1-18 showing similar distribution but lower
ion density (Fig. 4.6). This dramatic increase of peptide αB1(2)-18 in the nucleus
during middle-age and their subsequent emergence in the cortex of old lenses may
well facilitate aggregation of crystallins in vivo, particularly if their in vitro
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demonstrated anti-chaperone properties apply to the crowded environment of the
lens.
It has been suggested that the interaction of lenticular α-crystallin with
anti-chaperone peptides could be a key event in protein aggregation and the
development of cataract during aging [139]. The extended periods that these LMW
peptides remain in the lens indicate that the lens may be unable to efficiently
degrade them, which can lead to unregulated accumulation of these peptides with
age. These peptides emerge in the lens (35-42 years in our study) during a period
which also sees a drastic increase in WI proteins and crystallin truncation [19, 125],
an increase in membrane associated lens proteins [174] and the onset of a barrier to
diffusion at the nucleo-cortical interface in the lens [189]. Taken together, the early
middle-age is potentially an important period in lens aging, during which crystallins
in the lens nucleus become extensively structurally modified and truncated. The
structural damage arising from the cleavage of these proteins may also result in the
loss of the proteins’ normal function, including the molecular chaperone function of
α-crystallin, particularly if the cleavages occur at the putative chaperone site
sequence (e.g. peptides αA66(67)-75, αA66-80 and αA69-80).
In addition, we have investigated the possibility that the production of these LMW
peptides in the lens may be a direct causative factor in cataractogenesis by
comparing age-matched healthy and cataractous lenses. Our data revealed no
significant differences in the abundance of LMW crystallin peptides (Fig. 4.7),
indicating that the changes to the lens environment caused by cataract formation do
not contribute directly to the peptide-generating process. This result corresponds to a
similar observation on the effect of cataract formation had on crystallin truncation
[150].
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Although we have clearly demonstrated that these LMW peptides are present in
human lenses, and that their distributions are dependent on age and solubility, the
mechanism(s) leading to peptide cleavage from the intact crystallins is not
understood. Interestingly, when examining the peptide sequences, we noticed that
the majority of these LMW peptides began with an Asp (αA67-75(80), αA69-80,
αA2-12(13), αB2-18), Ser (γS2-22), or even a Ser-Asp (αA66-75(80)), Ser-Pro (αB45-54(57),
γS167-178) combination. Moreover, the sequences of a number of peptides were
followed immediately by an Asp (αA66(67)-75) or a Asp-Ser (βB291-102), Ser-Pro
(αA66(67)(69)−80, αB1(2)-18) and Pro-Ser (αB45-57) combination. Also, the last residue of
peptide γS2-22 is an Asp, the last residue of peptides αA150-160, αB28-39 and βB2169-180
is a Pro, and peptide αA43-56 is preceded by a Ser. Spontaneous peptide bond
cleavage via imide ring formation at labile Asp/Asn residues has previously been
reported in bovine α-crystallins [255, 259]. Asp residues are known to be
intrinsically unstable, thus they are common sites of post-translational modifications
[255, 264]. This may explain the large number of LMW crystallin peptides cleaved
at Asp residues.
The frequency of Ser, Pro and their dipeptide combinations either at the beginning
of the observed peptide sequences, or immediately following in the corresponding
crystallin sequence, is also suggestive of a chemical or enzymatic cleavage
mechanism at these sites. While it is known that proline-directed kinases favour
phosphorylation of Ser-Pro [265] and similar cleavage patterns have been reported
from both bovine and human αA-crystallin [266-267], it is not known if this motif is
recognized by proteases. A sequence pattern also emerges when looking at the
penultimate two residues of peptides αA66(67)(69)−80 and αB1(2)-18 and the two residues
preceding peptide βA3189-215. The dipeptides are His-Phe, Phe-His, and His-His,
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respectively, each motif then contains consecutive aromatic residues. As calpains,
the primary proteases in the human lens, are known to cleave after consecutive
aromatic residues [268], this may suggest a role for lens-based calpains in these
particular instances. Furthermore, tertiary structural elements rather than primary
amino acid sequences are likely responsible for directing the cleavage of protein
substrates by calpains [268], which may explain the high degree of specificity that
we have observed for the αA, αB and βA3 peptides. However, the activity of calpain
in the primate lens has been reported to be largely inhibited by high levels of the
endogenous calpain inhibitor - calpastatin [163-164], indicating that other
mechanism(s) may be responsible for these cleavages.
At present, there appears to be no clear evidence linking calpains and other
lenticular proteases [158-161] with these crystallin cleavages. The absence of
significant proteolytic activity in adult lenses suggests that these LMW peptides may
be generated through non-enzymatic cleavage of crystallins. While the mechanism(s)
are not fully understood, lens proteins (such as aquaporins) have been shown to
undergo chemical cleavage with age [20, 165]. Age-dependent changes in the lens,
such as the formation of a barrier at the nucleo-cortical interface [189], may
encourage peptide cleavages, as they induce changes to the chemical environment of
the lens nucleus. In addition, lens nuclear fibre cells are older, have a slightly acidic
environment [260] and are more susceptible to oxidative-damage compared to
cortex fibre cells [186, 189] - characteristics that may all favour chemical cleavages.
In conclusion, the data presented in this study is the first to examine the distribution
and localization of LMW crystallin peptides in the aging human lens using
MALDI-IMS. The timing and the nucleus-to-cortex emergence pattern of these
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LMW peptides suggests that they may have a significant impact on the later
development of the human lens.
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Preface

Crystallins binding to the membranes of lens fibre cells increase significantly with
age. This membrane-crystallin interaction is proposed as a main cause of crystallin
insolubilization in the aging lens, as almost all WI crystallins present in
old/cataractous lenses are believed to be membrane-bound. To understand this
phenomenon, this work investigated the binding of α-crystallin to both bovine and
human lens fibre cell membranes, and the potential effect that endogenous LMW
crystallin peptides may have on this interaction.

Publication:

Shih-Ping Su, Jason D. McArthur, Roger J.W. Truscott and J. Andrew Aquilina
(2011) “Is α-crystallin an intrinsic membrane protein? Factors affecting the
association of α-crystallin with lens fibre cell membranes.” (Manuscript prepared)
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5.1 Abstract

α-Crystallin, an oligomeric structural protein of the lens, also functions as a
molecular chaperone. With age, large-scale binding of α-crystallin to fibre cell
membranes of the human lens has been documented. In the present study, we
examined the binding of the α-crystallin subunits, αA and αB, to membranes isolated
from bovine and human lenses. Remarkably, after stripping the membranes with 7 M
urea and 0.1 M NaOH, full length α-crystallin was found to remain associated with
both the bovine and human lens membranes. This suggests that a small proportion of
α-crystallin may be intrinsically incorporated into the fibre cell lipid bilayer. Assays
using fluorescently-labelled α-crystallin subunits showed that the binding capacity
of human lens membranes was higher than that of bovine lens membranes. For
human lenses, membranes isolated from the nucleus had consistently higher binding
capacities for α-crystallin compared to membranes from the cortical fibre cells.
Furthermore, urea-treated membranes from both the cortex and nucleus had
significantly higher binding capacities for αB subunits compared with αA,
suggesting that αB-crystallin interacts more strongly with residual membrane-bound
or intrinsic proteins. Binding studies incorporating known endogenous crystallin
peptides showed that peptide αB1-18 (Ace-MDIAIHHPWIRRPFFPFH) significantly
increased the binding of both αA- and αB-crystallins to human lens membranes,
suggesting that the presence of this peptide in older lenses could contribute to the
increased membrane binding of α-crystallin.
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5.2 Introduction

The human lens grows continuously throughout life through the addition of new
fibre cells on top of preexisting ones. This process leads to the formation of two lens
regions referred to as the nucleus, consisting of fibre cells formed in utero, and an
ever-expanding cortex which consists of fibre cells formed postnatally [10, 269].
Lens fibre cells contain a high concentration of structural proteins: α-, β- and
γ-crystallins. α-Crystallin, which is composed of subunits αA and αB, functions
additionally as a molecular chaperone [3, 5]. As there is little to no protein turnover
in mature lens fibre cells [6], the long-term transparency of the lens is dependent on
α-crystallin to sequester unfolded proteins and maintain them in soluble
chaperone-client complexes.
Lens proteins undergo a multitude of posttranslational modifications during aging,
which over time contribute to the unfolding and denaturation of crystallins [17, 125,
129, 214, 270]. With age, the level of unfolded proteins eventually exceeds the
chaperone capacity of α-crystallin in the lens, such that by age 40, all free
α-crystallin in the lens has been utilized [126-128]. Subsequently, the level of
water-insoluble (WI) crystallins and HMW crystallin aggregates in the lens
increases significantly [21, 66, 151, 166]. Large-scale binding of α-crystallin to lens
membranes has also been documented in the lens with age [173, 175, 178], and this
has been hypothesized to contribute to the development of nuclear cataract by
occluding membrane pores, thus leading to the formation of a barrier to diffusion
[174-175, 186].
The association between crystallins and lens fibre cell membranes is believed to be
an important process by which crystallin insolubilization occurs in the aging lens
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[115, 172, 175, 177]. Chandrasekher and Cenedella [172] showed that essentially all
WI crystallins in old human lenses are membrane-bound. α-Crystallin, in particular,
has a strong affinity towards lens membrane [173, 176, 178-181], leading to the
suggestion that the overall increase in the membrane binding of crystallins in the
lens is due to other crystallins associating with membrane-bound α-crystallin [180].
However, little is currently known about the mechanism(s) by which α-crystallin
associates with the cellular membrane, and how age-related changes to the
membrane compositions may affect crystallin-binding.
In this study, the binding of αA- and αB-crystallins to bovine and human lens
membranes was determined using Alexa350®-conjugated α-crystallin subunits. Our
results demonstrate that bovine cortical membrane preparations have less binding
capacity for α-crystallin than the equivalent human membranes. Furthermore, human
nuclear membranes have a significantly higher binding capacity for both αA- and
αB-crystallins compared to cortical membranes. A surprising result of the membrane
preparation was that α-crystallin remains bound to both the bovine and human lens
membrane even after alkali-treatment, suggesting that the protein is very strongly
associated with the membrane and may even be intrinsically incorporated into the
fibre cell lipid bilayer. Additionally, we determined the effect of two lenticular
endogenous LMW crystallin peptides [139, 152] on the membrane binding behavior
of α-crystallin. The addition of peptide αB1-18 (Ace-MDIAIHHPWIRRPFFPFH)
significantly increased the binding of α-crystallin subunits to membrane, whereas
the addition of peptide γS167-178 (SPAVQSFRRIVE) had little effect.
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5.3 Material and methods

5.3.1 Isolation of bovine and human lens fibre cell membranes
A total of 142 human lenses, aged between 54-84 years, were obtained from donors
at the Lions New South Wales Eye Bank (Sydney, Australia). Fresh bovine lenses
were obtained from a local abattoir. All lenses were stored at -80 °C prior to
dissection.
Lenses were separated into cortical and nuclear regions using a 4.5 mm diameter
trephine. A cold scalpel was used to remove 1 mm of tissue from each end of the
resulting cylindrical center (nucleus). The cortical and nuclear tissues from human
lenses and the cortical tissues from the bovine lenses were used in this study. Lens
membranes were obtained using methods published by Russell et al. [271] with
minor modifications. Briefly, lens tissues were homogenized in 7 times (w/w) of
Tris-membrane buffer (50 mM Tris-HCl, 5 mM EDTA, 10 mM β-mercaptoethanol,
0.2% NaN3, pH 7.4) and incubated at room temperature for 10 min. The homogenate
was centrifuged at 15000 × g for 20 min at 4 °C, and the supernatant was discarded.
The pellet was re-homogenized in Tris-membrane buffer and centrifuged at 15000 ×
g for another 20 min. The resulting pellet was washed with water (Milli-QTM) and
centrifuged to give the Tris-treated membrane. Another portion of the pellet was
re-homogenized in urea-membrane buffer (50 mM Tris-HCl, 7 M urea, pH 7.4). The
urea concentration in the homogenate was diluted to 3.5 M with water and the
homogenate was centrifuged at 15000 × g for 20 min. This extraction procedure
using urea-membrane buffer was repeated and the resulting pellet was washed three
times with water to give the urea-treated membrane. To obtain the alkali-treated
membrane, a portion of the urea-treated membrane pellet was re-homogenized in
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solution containing 0.1 M NaOH, 1 mM β-mercaptoethanol. The homogenate was
incubated on ice for 15 min and then centrifuged at 15000 × g for 20 min at 4 °C.
The pellet was further washed with 5 mM phosphate (pH 8.0), followed by two
washes with water.
Isolated membranes were resuspended in binding buffer (137 mM NaCl, 2.7 mM
KCl, 4.3 mM Na2HPO4, 1.4 mM K2HPO4, 5 mM MgCl2, pH 7.3). Quantification of
membrane samples was achieved by weighing freeze-dried aliquots of the
membrane suspension using an Excellence XS105 dual-range analytical balance
(Mettler Toledo, Greifensee, Switzerland). The concentration of membrane tissue
(mg/mL) in the suspension was calculated by averaging at least four separate
aliquots. Light absorbance of membrane samples at different wavelengths (220-850
nm) was measured using a POLARstar Omega multifunction microplate reader
(BMG Labtech, Offenburg, Germany).

5.3.2 SDS-PAGE and Western immunoblot analysis of bovine and human lens
membranes
Proteins in the bovine and human lens membrane preparations were examined using
SDS-PAGE and Western immunoblots. Samples were homogenized in SDS-PAGE
loading buffer (60 mM Tris-HCl, 1% SDS, 1% β-mercaptoethanol, 10% glycerol,
0.01% bromophenol blue, pH 6.8) and incubated at room temperature for 2 h prior
to loading onto 12% SDS-PAGE gels. Heating of the sample was avoided as
elevated temperatures can damage the structure of intrinsic membrane proteins (eg.
MIP26) [271]. All SDS-PAGE gels were stained with Coomassie Blue R
(Sigma-Aldrich, St. Louis, Missouri, USA). For Western immunoblot analysis,
antibodies which recognize proteins from both human and bovine lenses were used,
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and were diluted to their working concentrations using PBS/T (137 mM NaCl, 2.7
mM KCl, 12.5 mM Na2HPO4, 1.8 mM KH2PO4, 0.05% (v/v) Tween 20, pH 7.4)
containing 0.5% (w/v) skim milk powder. Proteins separated by SDS-PAGE were
transferred onto PVDF membranes at 30 V overnight at 4 °C using the Mini
Trans-Blot system (Bio-Rad, Hercules, California, USA). Membranes were blocked
for 1 h at room temperature in PBS/T containing 5% (w/v) skim milk powder. After
three 10 min washes with PBS/T, the membranes were incubated with either a
1:1000 dilution of polyclonal anti-αA-crystallin antibody (ab69552, Abcam,
Cambridge, Massachusetts, USA), a 1:1000 dilution of polyclonal anti-αB-crystallin
antibody (ab13497, Abcam), a 1:1500 dilution of monoclonal anti-filensin antibody
(F1043, Sigma-Aldrich), or a 1:5000 dilution of monoclonal anti-vimentin antibody
(V6389, Sigma-Aldrich) for 90 min at room temperature. Following another three
10 min washes with PBS/T, the membranes were incubated for 1 h with a 1:1500
dilution of anti-rabbit IgG HRP conjugate (65-6120, Invitrogen, Carlsbad, California,
USA) for anti-αA-crystallin and anti-αB-crystallin blots, or a 1:2500 dilution of goat
anti-mouse IgG HRP conjugate (SAB-100J, Stressgen, Ann Arbor, Michigan, USA)
for anti-filensin and anti-vimentin blots. Excess secondary antibodies were removed
by three 10 min washes with PBS/T, and the blots were developed in 100 mM
Tris-HCl (pH 7.6) containing 1.4 mM diaminobenzidine and 0.015% (v/v) hydrogen
peroxide.

5.3.3 Overexpression and purification of recombinant human αA- and
αB-crystallins
The pET23d(+) plasmid, containing human wild-type αA-crystallin gene, was a gift
from Prof. J. M. Petrash (Washington University, St. Louis, USA). The pET24d(+)
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plasmid (Novagen, Madison, Wisconsin, USA), containing human wild-type
αB-crystallin gene, was a gift from Prof. W. de Jong (University of Nijmegen,
Nijmegen, The Netherlands). Plasmids were transformed into electro-competent
Escherichia coli BL21 cells by electroporation using a GenePulser II system
(Bio-Rad). 900 mL of LB stocks (1% tryptone, 0.5% yeast extract, 1% NaCl) that
contained ampicillin (100 µg/mL) or kanamycin (50 µg/mL) were inoculated with
100 mL of overnight liquid cultures of BL21/pET23d-αA or BL21/pET24d-αB cells,
respectively, and grown at 37 °C under vigorous shaking. The culture was induced
with 10 mL of 50 mM IPTG after reaching an optical density of ~0.5 at 600 nm, and
further incubated for 3 h at 37 °C. Cells were harvested by centrifugation, and the
expressed proteins were isolated using methods by Horwitz et al. [220].
Recombinant human αA- and αB-crystallins were purified from the cell lysates
using anion-exchange chromatography (HiPrep 16/10 DEAE FF column; GE
Healthcare, Little Chalfont, UK), followed by size-exclusion chromatography
(HiPrep 26/60 Sephacryl S-300 column; Amersham Biosciences, Uppsala, Sweden)
(A detailed description of the cell lysis, anion-exchange chromatography and
size-exclusion chromatography steps undertaken to purify recombinant human αAand αB-crystallins is available in Appendix I, section A1.1).

5.3.4 Conjugation of Alexa350® to α-crystallin subunits
Alexa350® fluorescent tag (410 Da) was conjugated to recombinant αA- and
αB-crystallins using an Alexa fluor® 350 Protein Labeling Kit (A10170, Molecular
Probes, Carlsbad, California, USA), in accordance with the manufacturer’s
instructions. Purified Alexa350®-conjugated αA- and αB-crystallins were measured
using absorbance readings at 280 nm and 346 nm (A280 and A346) on a UVmini-1240
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UV-VIS spectrophotometer (Shimadzu, Kyoto, Japan). The protein concentration
and the degree of binding were determined using the following equations:

[protein] =

A280 ‐ (A346 × 0.19)

× dilution

protein

(Eq. 1)
mol of dye/mol of subunit =

A346 ‐ dilution
19000 × [protein]

(Eq. 2)

Where 0.19 is a correction factor to account for absorption of Alexa350® at 280 nm,
19000 is the molar extinction coefficient for Alexa350® and

protein

is the molar

extinction coefficient for α-crystallin.

5.3.5 Membrane binding measurements
Alexa350®-conjugated αA- and αB-crystallins were incubated with bovine and
human lens membranes in binding buffer at 37 °C. Control assays were set up by
replacing Alexa350®-α-crystallin subunits with unlabelled α-crystallin subunits. All
assays were performed in triplicate. After 6 h of incubation, samples were
centrifuged at 14000 × g for 30 min at 4 °C. The pellets were resuspended in 30 μL
of binding buffer and centrifuged again at 14000 × g for 30 min at 4 °C. The
supernatants from both centrifugations were pooled together. The resulting pellets,
which contained the membrane and bound Alexa350®-α-crystallin subunits, were
resuspended in a volume of binding buffer equivalent to that of the combined
supernatants. Both the supernatants and the resuspended pellets were transferred to
96-well polypropylene black microplates (Greiner Bio-One, Frickenhausen,
Germany), and the fluorescence reading (F) of the samples was measured using a
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FLUOstar Optima multifunction microplate reader (BMG Labtech). The excitation
and emission filters were set at 320-340 nm and 430-450 nm respectively. The
degree of binding ( ) was determined by the following formula, where background
fluorescence readings were obtained from control assays (using unlabelled
α-crystallin):

=

Fpellet ‐ Fpellet background
(Fpellet ‐ Fpellet background) + (Fsupernatant ‐ Fsuperntant background)

(Eq. 3)

The amount of α-crystallin subunits bound to the membranes was calculated by
multiplying the total mass of Alexa350®-α-crystallin subunits used in the assay by
the degree of binding ( ).

5.3.6 Effect of endogenous crystallin peptides on the membrane binding of
α-crystallin
Peptide αB1-18 (Ace-MDIAIHHPWIRRPFFPFH) was purchased from Biomatik
(Cambridge, Ontario, Canada) with sample purity ≥ 95%. Peptide γS167-178
(SPAVQSFRRIVE) was purchased from Peptide 2.0 (Chantilly, Virginia, USA) with
sample purity of ≥ 91%. Peptides were solubilised in binding buffer to give a 4
mg/mL stock solution. Peptides were drawn from the stock solution and incubated
with human lens membranes (80 μg) for 30 min at 37 °C. These were then incubated
for 6 h at 37 °C in the presence of 24 μg of Alexa350®-conjugated αA- or
αB-crystallin, or 24 μg of unlabelled αA- or αB-crystallin as negative controls.
Binding assays were carried out as described previously. Peptide interaction data
were analyzed using unpaired two-sample t-test.
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5.4 Results

5.4.1 Analysis of proteins associated with lens fibre cell membranes

5.4.1.1 Bovine lens membranes
SDS-PAGE and Western immunoblots were used to identify the proteins associated
with bovine and human lens membranes. SDS-PAGE analysis (Fig. 5.1) showed that
multiple proteins, ranging from 10 kDa to above 200 kDa, remain bound to the
bovine lens membrane after the Tris-buffer extraction. Full-length α-crystallin
subunits (~20 kDa) were the predominant protein species. A similar protein profile,
but with significantly less protein, was observed on SDS-PAGE analysis of the
urea-treated bovine (BU) membrane. In contrast, the alkali-treated bovine (BA) lens
membrane appeared to have negligible protein contents (Fig. 5.1).
Western immunoblots (Fig. 5.1) revealed that both αA- and αB-crystallins were
present in all bovine lens membrane preparations. In the Tris-treated bovine (BT)
lens membrane, reactivity towards both αA- and αB-crystallins antibodies was
observed across a broad mass range (~10 kDa to 130 kDa). As intact crystallin
subunits are ~20 kDa, this result suggests that several distinct truncation and
cross-linked products of α-crystallin are evident, and are also associated with the
lens membrane. Treatment with urea removed most of the small α-crystallin
fragments (< 20 kDa), but a significant amount of HMW immuno-reactive material
remained (Fig. 5.1). Remarkably, intact α-crystallin subunits and a ~43 kDa
cross-linked complex remain bound to membrane after alkali-treatment (Fig. 5.1).
Of the two major cytoskeletal proteins of lens fibre cells, intact filensin (115 kDa)
and multiple cleavage products were detected only in the BT and BU membrane,
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while vimentin (54 kDa) was present in all three bovine lens membrane preparations
(Fig. 5.1). Filensin products ranging from ~25 kDa to over 200 kDa were detected in
the BT membrane, but were mostly absent in BU membrane.

Fig. 5.1: SDS-PAGE and Western immunoblot analysis of bovine lens
membranes. Shown are the WI cell membrane pellets from bovine lens
homogenates washed with Tris-buffer (BT), 7 M urea (BU) and with 0.1 M NaOH
(BA). Samples were analyzed by SDS-PAGE (100 μg of membrane per lane) and
Western immunoblotting (20 μg of membrane per lane). Blots were probed using
anti-αA-crystallin, anti-αB-crystallin, anti-filensin and anti-vimentin antibodies, as
indicated. Molecular weight markers are on the left of the figure.

5.4.1.2 Human lens membranes
SDS-PAGE analysis (Fig. 5.2) revealed human lens membrane to be considerably
different from bovine lens membrane. Three proteins of ~20 kDa, 22 kDa and 26
kDa, which correspond to αA/αB-crystallin, MIP22 and MIP26 respectively, were
present in all human lens membrane preparations. The urea-treated membrane
preparations, particularly urea-treated nucleus (NU) membranes, showed noticeable
smearing down the length of the gel. In addition, an intense LMW band which
migrated along with the dye-front was observed in all membrane extracts. The
presence of this band indicates that a significant amount of LMW crystallin
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breakdown products [139, 150, 152] remain tightly associated with the lens
membranes even after extraction with urea.
Western immunoblots detected intact αA- and αB-crystallins (~20 kDa) in all human
lens membrane preparations (Fig. 5.2). A diffuse band at ~43 kDa was also present
in each of the αA-crystallin blots, with additional smearing between 70 kDa to 130
kDa, which is particularly noticeable in the alkali-treated nuclear (NA) preparation.
On the anti-αB-crystallin blots, extensive smearing was observed in the lanes of the
urea-treated membranes. Interestingly, a variety of smaller αB-crystallin products
less than 20 kDa remain bound to the lens membrane after urea-treatment (Fig. 5.2).
Most of these αB-crystallin fragments less than 40 kDa were removed upon
treatment with 0.1 M NaOH. Similar smearing was also present on the anti-filensin
blots of the urea-treated human lens membrane, while no filensin was detected in the
alkali-treated membranes (Fig. 5.2). Vimentin was only detected in the cortical
human lens membrane preparations (Fig. 5.2).
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Fig. 5.2: SDS-PAGE and Western immunoblot analysis of human lens
membranes. Isolated cortical and nuclear lens membranes were extracted with 7 M
urea in Tris-buffer (CU - cortex urea; NU - nucleus urea) and with 0.1 M NaOH (CA
- cortex alkali; NA - nucleus alkali). Samples were analyzed by SDS-PAGE (100 μg
of membrane per lane) and with Western immunobloting (20 μg of membrane per
lane). Blots were probed using anti-αA-crystallin, anti-αB-crystallin, anti-filensin
and anti-vimentin antibodies, as indicated. Molecular weight markers are on the left
of the figure.

5.4.2 Binding of α-crystallin subunits to bovine and human lens membranes

5.4.2.1 Purification of Alexa350®-α-crystallin subunits
Recombinant human αA- and αB-crystallins (Fig. 5.3, lane 1 and 2) were
overexpressed in E. coli and purified by anion-exchange and size-exclusion
chromatography. Conjugation of Alexa350® to αA- or αB-crystallin (Fig. 5.3, lane 3
and 4) was consistent for both α-crystallin subunits. On average, 0.56 ± 0.07 mol of
Alexa350® was attached per mol of αA-crystallin, and 0.44 ± 0.36 mol of Alexa350®
per mol of αB-crystallin.
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Fig. 5.3: SDS-PAGE of wild-type and Alexa350®-labelled αA- and
αB-crystallins. Gel showing recombinant wild-type αA- (5 μg, lane 1) and
αB-crystallin (5 μg, lane 2), and Alexa350-labelled αA- (5 μg, lane 3) and
αB-crystallin (5 μg, lane 4). Molecular weight markers are on the left of the figure.

5.4.2.2 Bovine lens membrane binding
In order to compare the binding properties of αA- and αB-crystallins to bovine and
human lens membranes, all binding assays were performed at 37 °C for 6 h. In
assays using bovine lens membranes (Fig. 5.4), 200 μg of membrane was used.
Binding assays using BU and BA membranes displayed saturable binding (Fig. 5.4),
which allowed us to calculate the binding capacity using the asymptote of each
curve (Table 5.1). The binding capacities for αA-crystallin were 28.1 ± 2.4 ng αA/μg
BU membrane and 19.5 ± 0.8 ng αA/μg BA membrane. The binding capacities of
αB-crystallin to both membrane preparations were lower, being 19.1 ± 1.1 ng αB/μg
BU membrane and 6.0 ± 0.6 ng αB/μg BA membrane. In contrast, both αA- and
αB-crystallins bound to BT membranes in a concentration dependent manner but did
not reach saturation under the conditions used in this study (Fig. 5.4). BT membrane
also displayed a lower overall binding for the α-crystallin subunits as compared to
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the BU membrane, and for BA membrane (in the case of αA-crystallin only) (Fig.
5.4).

Table 5.1: Binding capacity of bovine and human lens membranes for
Alexa350®-α-crystallin subunits.
Membrane
samples

αA binding
capacity (ng/μg
membrane)

αB binding
capacity (ng/μg
membrane)

BT

-

-

BU

28.1 ± 2.4

19.1 ± 1.1

BA

19.5 ± 0.8

6.0 ± 0.6

CU

31.5 ± 2.0

54.3 ± 4.2

CA

33.4 ± 2.8

31.6 ± 1.8

NU

95.4 ± 4.2

208.0 ± 13.1

NA

78.5 ± 2.0

67.0 ± 2.4

Fig. 5.4: Binding of α-crystallin to bovine lens membrane preparations. Binding
curves depicting the amount of bound Alexa350®-conjugated (A) αA- and (B)
αB-crystallin per ug of Tris-treated (○), urea-treated (●) or alkali-treated (▲) bovine
lens membrane as a function of the free α-crystallin concentration. Bovine lens
membranes (200 ug) were incubated with a mass range of Alexa350®-conjugated
αA- and αB-crystallins, for 6 h at 37 °C. Results are the mean ± SEM (n = 3).
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5.4.2.3 Human lens membrane binding
Overall, the binding of α-crystallin was greater to human than bovine lens
membranes for the cortical membrane preparations (Table 5.1). Human lens
membranes displayed no significant absorbance between 380-500 nm (Fig. 5.5),
indicating there would be minimal interference with the fluorescent signal emitted
by the Alexa350® dye. Due to sample limitations, Tris-treated human lens
membrane was not used in the binding studies.

Fig. 5.5: Relative absorbance of the human lens membrane. Graph showing the
relative absorbance of the urea-treated cortex (dark blue line) and nucleus (red line)
membrane, and the alkali-treated cortex (green line) and nucleus (violet line)
membrane between 380-500 nm. Binding buffer (light blue line) was used as
negative control.

Binding assays using human lens membranes were performed using 80 μg of
membrane and all assays displayed saturable binding (Fig. 5.6). Nuclear membranes
had a greater binding capacity for both αA- and αB-crystallins when compared to
cortical membranes (Table 5.1). In the case of αA-crystallin, binding to the urea- and
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alkali-treated membranes from the same lens regions showed similar behavior (Fig.
5.6A; Table 5.1). The binding capacities for αA-crystallin were 31.5 ± 2.0 ng αA/μg
urea-treated cortical (CU) membrane, 33.4 ± 2.8 ng αA/μg alkali-treated cortical
(CA) membrane, 95.4 ± 4.2 αA/μg NU membrane and 78.5 ± 2.0 αA/μg NA
membrane. By comparison, binding of αB-crystallin to the urea- and alkali-treated
membranes produced markedly different results, with the NU membrane exhibiting
a significantly greater binding capacity than the cortical membranes and also the NA
membrane (Fig. 5.6B). The binding capacities for αB-crystallin were 54.3 ± 4.2 ng
αB/μg CU membrane, 31.6 ± 1.8 ng αB/μg CA membrane, 208.0 ± 13.1 αB/μg NU
membrane and 67.0 ± 2.4 αB/μg NA membrane.

Fig. 5.6: Binding of α-crystallin to human lens membrane preparations. Binding
curves depicting the amount of bound Alexa350®-conjugated (A) αA- and (B)
αB-crystallin per ug of urea-treated cortical (●) and nuclear (▲) human lens
membrane, or alkali-treated cortical (○) and nuclear (∆) human lens membrane as a
function of the free α-crystallin concentration. Human lens membranes (80 ug) were
incubated with a mass range of Alexa350®-conjugated αA- and αB-crystallins, for 6
h at 37 °C. Results are the mean ± SEM (n = 3).
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5.4.3 Effect of crystallin peptides on the membrane binding of α-crystallin
subunits
In a recent study, we reported that crystallin peptides αB1-18 and γS167-178 were
present in human lenses across a broad age-range [152] (Chapter 4). Santhoshkumar
et al. [139] reported that peptide αB1-18 possessed anti-chaperone activity against
α-crystallin, while peptide γS167-178 had little effect. To determine if the membrane
binding of α-crystallin is affected by the presence of these endogenous peptides,
peptides αB1-18 and γS167-178 were incorporated into the membrane binding assays.
Binding assays were performed using 80 μg of human lens membranes and 24 μg of
Alexa350®-conjugated αA- or αB-crystallin, with or without the presence of peptide
αB1-18 or γS167-178 (48 μg). Peptide αB1-18 was found to significantly increase the
amount of membrane-bound α-crystallin subunits in all but the CU membranes (Fig.
5.7). In the case of αA-crystallin, the addition of peptide αB1-18 increased the binding
by 28.6 ± 4.3 (P < 0.05) ng αA/μg NU membrane (59% increase), 18.7 ± 3.3 (P <
0.01) ng αA/μg CA membrane (72% increase) and 38.3 ± 4.3 (P < 0.001) ng αA/μg
NA membrane (72% increase). Similar results were observed in binding assays
using αB-crystallin, with the amount of membrane-bound αB-crystallin increasing
by 13.3 ± 1.6 (P < 0.001) ng αB/μg CA membrane (61% increase) and 37.2 ± 2.5 (P
< 0.001) ng αB/μg NA membrane (69% increase). However, peptide αB1-18 did not
give rise to a significant increase in binding of αB-crystallin to the urea-treated
membranes (Fig. 5.7B). The addition of peptide γS167-178 had a negligible effect on
the binding of both αA- and αB-crystallins to all human lens membrane preparations
(Fig. 5.7).
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Fig. 5.7: Effect of crystallin peptides on the binding of α-crystallin to human
lens membranes. Graphs showing the amount (ng) of Alexa350®-conjugated (A)
αA- or (B) αB-crystallin bound per μg of human lens membrane in the presence of
crystallin peptides. Human lens membranes (80 μg) were mixed with either 48 μg of
peptide αB1-18 (solid bars), 48 μg of peptide γS167-178 (dotted bars), or with binding
buffer only (horizontal line bars), for 30 min at 37 °C. Alexa350®-conjugated αA or
αB-crystallin (24 μg) was then added and the mixtures were incubated for 6 h at 37
°C. Results are the mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001
compared with assays performed with binding buffer only (horizontal line bars).

To determine whether the increase in the membrane binding of α-crystallin subunits
was proportional to the concentration of peptide αB1-18, different quantities of
peptide αB1-18 were added to binding assays using the NU membrane (Fig. 5.8). A
significant increase (P < 0.001) in membrane-bound αA-crystallin was observed
when the amount of peptide αB1-18 (96 μg) in the assay was four times the amount of
αA-crystallin by mass. Binding assays using 24 μg (equivalent to the total mass of
αA-crystallin in the assay) and 2.83 μg (equivalent to the total molar ratio of
αA-crystallin in the assay) of peptide αB1-18 did not significantly change the amount
of membrane-bound αA-crystallin. Variations to the amount of peptide αB1-18 in the
binding assay failed to significantly impact the level of αB-crystallin binding to the
NU membrane (Fig. 5.8). Due to sample limitations, other membrane preparations
were not used in this particular experiment.
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Fig. 5.8: Binding of αA-crystallin to human lens membranes is affected by the
concentration of peptide αB1-18. NU lens membrane (80 μg) samples were mixed
with either 96 μg (solid bars), 24 μg (dotted bars), 2.83 μg (open bar) of peptide
αB1-18, or with binding buffer only (horizontal line bar), for 30 min at 37 °C.
Alexa350®-conjugated αA or αB-crystallin (24 μg) was then added and the mixtures
were incubated for 6 h at 37 °C. Results are the mean ± SEM (n = 3). Values for the
negative control were obtained from the previous assay (Fig. 5.7) but were
normalized to an internal control. ***P < 0.001 compared with assays performed
with binding buffer only (horizontal line bars).
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5.5 Discussion

There is growing evidence that association with fibre cell membranes is an
important process by which crystallins become WI in the lens [172, 175-176]. This
association may also contribute to the age-dependent loss of soluble α-crystallin
[126-128]. In addition, large-scale binding of crystallin aggregates [174-175] may
have functional consequences for the lens, since the appearance of large-scale
binding corresponds to the time of onset of the lens barrier [189]. Once a barrier
forms, the nucleus is no longer effectively linked to the cortex, where GSH is
synthesized and regenerated [187]. This predisposes the human lens nucleus to
oxidative stress and ultimately nuclear cataract [186]. Building upon previous
studies, where the membrane binding of α-crystallin was characterized using
non-human lens tissues [176-177, 182, 272-275], here we compared the binding of
α-crystallin to both bovine and human lens membranes. We also examined the
effects of endogenous membrane-bound proteins and crystallin peptides on the
membrane binding property of α-crystallin.
SDS-PAGE

and

Western

immunoblotting

were

used

to

examine

the

membrane-bound protein constituents of bovine (Fig. 5.1) and human lenses (Fig.
5.2). A number of truncated forms of αA- and αB-crystallin fragments remain bound
to bovine lens membranes after extraction with Tris-buffer (Fig. 5.1), and
αB-crystallin fragments of less than 20 kDa were also found attached to human lens
membranes after urea-treatment (Fig. 5.2). Intact αA- and αB-crystallins and
α-crystallin complex(es) of ~43 kDa remain tightly associated with both the bovine
and human lens membranes after extraction with 7 M urea, and remarkably, even
after the alkaline-wash. This strong association between α-crystallin and the lens
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membrane suggests that a portion of the protein may be intrinsically embedded
within the lipid bilayers of the fibre cell membrane. From the blots, we also
observed a range of HMW species that were bound to both the bovine (Fig. 5.1) and
human lens membranes (Fig. 5.2). In the human lens, HMW cross-linked complexes
of α-crystallin and other crystallins have been reported previously in the WI fraction
of the lens [18-19, 125]. It is possible that the membrane binding of α-crystallin, in
effect, renders these crystallin cross-linked complexes insoluble.
As there is dynamic exchange of subunits within α-crystallin assemblies, the
membrane binding capacities of Alexa350®-α-crystallin may be affected by residual
α-crystallin oligomers on the isolated membrane. In the case of the BT membrane,
Alexa350®-α-crystallin subunits could exchange with the abundant α-crystallin
oligomers on the membrane (Fig. 5.1), resulting in the quenching of fluorescent
signal,

thus

producing

low,

unsaturable

binding

(Fig.

5.4).

The

cytoskeletal/crystallin network present on the BT membrane could also hinder the
association of Alexa350®-α-crystallin subunits with the membrane, thus it is not
until this complex protein layer is removed via urea- and alkali-washes (Fig. 5.1),
that saturable binding of α-crystallin can take place. As the BU membrane retained
more membrane-bound proteins compared to the BA membrane (Fig. 5.2), and
displayed a higher binding capacity for both α-crystallin subunits (Fig. 5.4), it is
likely

that

these

membrane-bound

proteins

acted

as

conduits

for

Alexa350®-α-crystallin association. In contrast, the BA membrane displayed lower
levels of α-crystallin binding (Fig. 5.4). This may be due to the lower levels of
membrane associated proteins in this membrane preparation (Fig. 5.2), thereby
limiting the binding of Alexa350®-α-crystallin subunits to direct interactions with
the membrane phospholipids.
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Alkali-treatment of bovine membranes was found to have a greater effect on the
membrane binding of αB than αA (Fig. 5.4). A similar observation was found in the
binding assays using human nuclear membranes; binding of αA-crystallin to the NU
and NA membranes produced almost identical curves on the graph (Fig. 5.6A),
while the amount of αB-crystallin bound to the NA membrane was significantly
lower than that of the NU membrane (Fig. 5.6B). As αB-crystallin is a more potent
chaperone at physiological temperatures (37-40 °C) compared to αA-crystallin [51],
the higher binding capacity of the urea-treated membranes could be due to
αB-crystallin interacting with the membrane-bound crystallins. In contrast, the
alkali-treated membranes are largely stripped of these membrane-bound proteins
(Fig. 5.1 and 5.2), thereby reducing the interacting targets for αB-crystallin. The
greater exposed hydrophobic surfaces of αA-crystallin at physiological temperatures
[51] may allow it to more readily associate with membrane phospholipids,
suggesting that one mechanism for membrane binding of α-crystallin in the lens
involves the interaction between αA-crystallin and the membrane phospholipids.
We also examined the effects of crystallin peptides, αB1-18 and γS167-178, on the
membrane binding of α-crystallin (Fig. 5.7). Peptide αB1-18 significantly increased
the membrane binding of both αA- and αB-crystallins, while peptide γS167-178 had
little effect. It has previously been reported that when mixed with wild-type
αB-crystallin, peptide αB1-18 increased the oligomeric size of the protein [139]. Thus,
our results may reflect the fact that larger α-crystallin oligomers are binding to the
membrane. As the emergence of this peptide in the lens nucleus [152] corresponds to
the time when large-scale binding of α-crystallin to lens membrane is observed
[175], this and other endogenous peptides [139, 152] may be key elements in this
process.
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Previous studies into membrane binding of α-crystallin have produced conflicting
outcomes. For example, Ifeanyi et al. [182] found that the association of α-crystallin
to membranes is mainly due to the αA subunit. In contrast, Cobb and Petrash [176]
suggested that αA and αB subunits have similar binding capacities to lens
membranes. Typically, membrane binding studies were performed using non-human
lens membranes. As membrane binding of α-crystallin is affected by the presence of
membrane-bound proteins, and these differ between human lenses and other
mammalian species such as bovine lenses (Fig. 5.1 and 5.2), membrane binding
results using non-human lenses do not accurately reflect the association of
α-crystallin with human lens membranes.
Recent studies have also shown that the lipid composition of human lens membrane
differs considerably from that of other mammalian animals [113]. The levels of
dihydrosphingomyelin and cholesterol are much higher in human lenses [113], and
these hydrophobic components [276] could mimic the exposed hydrophobic residues
on substrate proteins, with which α-crystallin is known to interact [52, 277]. Another
characteristic of the human lens is that its phospholipids undergo major changes
with age [114]. The levels of glycerophospholipids in the nucleus of the lens decline
steadily, such that by age 40, their content is negligible [114]. In contrast, the levels
of ceramides and dihydroceramides in the lens nucleus increase approximately
100-fold during middle-age [114]. The breakdown of cytoskeletal meshwork is also
prevalent in the lens nuclear membranes (Fig. 5.2). If such changes affect membrane
binding of α-crystallin, we would expect cortical and nuclear membranes to produce
significantly different outcomes on the binding assays performed in this study. A
marked difference was indeed observed, with the binding capacity of α-crystallin
being significantly higher for the nuclear membranes (Fig. 5.6). It is therefore
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possible that age-related changes to membrane phospholipids favour the binding of
α-crystallin, particularly as the large-scale binding of α-crystallin occurs around
middle-age [175].
In conclusion, this study found that the membrane binding capacities of both αAand αB-crystallins was affected significantly by the quantity and nature of
endogenous proteins attached to the membranes. Nuclear membranes of the human
lens bound significantly more α-crystallin than cortical membranes. This may
suggest that properties of the nuclear membrane, such as the increased breakdown of
the cytoskeleton meshwork, as well as changes to the phospholipid composition,
promote the binding of α-crystallin to membranes. Interestingly, endogenous
α-crystallin remains associated with both the bovine and human lens membranes
even after the membranes were stripped with 0.1 M NaOH, suggesting that a
proportion of α-crystallin may be intrinsically incorporated into the fibre cell lipid
bilayer.
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Preface

This chapter aims to provide a general conclusion which summarizes the key
findings of this thesis and also discusses future directions. As this thesis was
prepared in a series of manuscripts for publication, the reader will find inevitable
overlaps between this chapter and the discussion sections of previous chapters.
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Aging of the human lens is a complex, dynamic process which incorporates a broad
spectrum of molecular, biochemical and structural changes. Despite the enormous
amount of research that has been invested into understanding the aging process of
the lens, only a percentage of this phenomenon has been elucidated. Lens aging is
intimately associated with the denaturation and insolubilization of crystallins events which are believed to be directly or indirectly involved in the development of
lens opacity. This thesis examined age-dependent modifications of lens proteins and
determined their potential effects.
Crystallin breakdown in the lens is a major age-dependent event which appears to
accelerate during middle-age and with the onset of cataract [19, 66, 125, 139, 278].
Surprisingly, the presence of LMW crystallin fragments (peptides) generated
through these cleavages had eluded the attention of researchers until recently, when
preliminary data suggested that these LMW peptides may be implicated in crystallin
insolubilization and aggregation [139]. A major finding of this thesis was the
characterization of 328 endogenous LMW peptides (including 316 crystallin
peptides) in the human lens using MS. This large number of endogenous peptides
suggests that the breakdown of crystallins in the lens is an extensive process, with
more than one cleavage mechanism being involved. Given the lack of available
information regarding the mechanism(s) of crystallin degradation, this finding
provides novel insight into the area. For example, the large number of “parent”
peptides with terminal residues of Lys and/or Arg indicates that a trypsin-like
proteolysis may be a major initial step in the breakdown of lenticular crystallins.
While proteases with trypsin-like activity have been documented in the mammalian
lens [253, 279], a conclusive study regarding the function and abundance of these
proteases has yet to emerge.
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The absence of enzymatic activity in mature lens fibre cells [280], however, suggests
that peptides which were found in lens nucleus extracts, or were shown to emerge
from the lens nucleus region using MALDI-IMS, may be generated through
chemical, rather than proteolytical, cleavages of crystallins. Chemical cleavages may
also be responsible for the generation of peptides with “ragged ends” - homologous
peptides which differ in length by single or a few successive terminal residues. It is
possible that age-dependent changes, such as the formation of a barrier to diffusion
at the nucleo-cortical interface [189] and the development of an acidic environment
in the lens core [260, 281], give rise to conditions in the lens centre that encourage
chemical cleavage. The future elucidation of these chemical cleavage mechanism(s)
will be an important step towards understanding the breakdown of lenticular
crystallins.
To appreciate the extent of crystallin cleavages in the lens, quantification of these
LMW peptides is necessary. High levels of LMW peptides in the lens may indicate
that these cleavages are, at least partially, responsible for the loss of structural
integrity and function of the crystallins with age [18-19, 125-128]. For example, the
chaperone function in α-crystallin may be affected if extensive cleavages occur in
the proposed target binding region of the protein [155-156]. Anti-chaperone peptides
(eg. αB1-18) may also affect the chaperone function of α-crystallin in high
concentrations [139, 157, 235]. Using SRM, we were able to quantify a major
α-crystallin peptide (αA57-65) in human lens extracts relative to a known standard.
Future studies utilizing synthetic isotopically-labelled analogues of target peptides
will be important in quantifying the LMW peptide content of the human lens with
age.
This thesis also focused on two other characteristics of crystallins which have been
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associated with lens opacity: the cross-linking of lens crystallins and the interaction
of α-crystallin with lenticular membrane/cytoskeleton. These two phenomena were
observed to be intimately associated, as a number of cross-linked complexes
involving α-crystallin were found to be bound to the lens membrane. Several 40-50
kDa WS cross-linked complexes were studied, and found to consist of multiple
crystallin subunit peptides, with fragments derived from βB1-crystallin being the
dominant species. Interestingly, these crystallin fragments were also found to be
associated with lens membranes, suggesting that two separate pathways may be
operating in the aging lens; crystallin fragments either become insoluble through
interactions with membrane components, or form cross-linked WS complexes.
In the human lens, cross-linked complexes consisting of fragments from multiple
crystallin subunits have also been reported in the WI fractions [18-19]. The
complexes observed in this study may therefore be intermediate products on the
pathway

to

become

WI

complexes

through

association

with

the

membrane/cytoskeletal components. As there is currently no conclusive sequence
information regarding the cross-linked regions of these crystallin complexes, further
studies are required to map these sites in order to understand the mechanism(s) of
cross-link formation and the potential role of these complexes in the formation of
HMW crystallin aggregates in the lens. Quantification of these complexes in the lens
is also important in determining the extent of crystallin cross-linking associated with
aging and the onset of cataract.
The interaction between α-crystallin and the membrane/cytoskeletal components of
lens fibre cells has been proposed as a major process leading to the insolubilization
of the crystallins [172, 175, 177], and is also believed to contribute to the formation
of a barrier to diffusion in the aging lens [174-175]. At a physiologically relevant
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temperature (37 C), we showed that the αB subunit of α-crystallin was able to
associate with the intermediate filament proteins (filensin, phakinin and vimentin)
and their respective breakdown products. The breakdown of filensin, in particular,
was found to be extensive, producing products ranging from ~15 kDa to over 115
kDa. Interestingly, the two major products (22-24 kDa and 40-50 kDa) shown to
interact with αB-crystallin both originated from the N-terminus of the protein, while
filensin products of less than 20 kDa did not share the same affinity towards
αB-crystallin. These findings provide novel insights into the interaction between
α-crystallin and lenticular intermediate filament structures, showing that specific
regions on the intermediate filament proteins may be targeted by α-crystallin. Future
studies should therefore aim to identify these regions at the sequence level. The
binding of the intermediate filament proteins to the αA subunit of α-crystallin should
also be examined, potentially through the creation of a MBP-αA-crystallin fusion
protein.
Experiments investigating the binding of α-crystallin subunits to bovine and human
lens membranes resulted in significantly different outcomes, with the human lens
membranes showing a higher binding capacity to both α-crystallin subunits. These
findings, along with recent data which highlighted the difference in the lipid
components of the human lens membranes compared to other mammalian lenses
[113], indicate that binding studies using non-human mammalian lens membranes
may not provide an accurate model for membrane binding studies of crystallins in
the human lens. The use of bovine or other mammalian lens membranes as a
replacement for human lens membranes should therefore be avoided in future
studies.
Perhaps the most surprising result was that α-crystallin remained tightly associated
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with both the bovine and human lens membranes, even after the membrane
preparations were vigorously stripped with 0.1 M NaOH. To our knowledge, this
finding is the first to suggest that α-crystallin may be an intrinsic component of the
fibre cell membrane. Within the human lens membrane isolates, the nuclear
membranes showed significantly higher binding capacity for α-crystallin subunits.
This is in agreement with recent findings, which showed that the level of
membrane-bound α-crystallins in the lens increases significantly with age [174-175].
This increase may be brought about by age-dependent changes to the membrane
phospholipids [114], particularly with αA-crystallin, as our findings suggested that
the αA subunit has a strong association with the membrane phospholipids. In
addition, this thesis showed that peptide αB1-18 significantly increased the membrane
binding of α-crystallin. Considering the plethora of intrinsic LMW peptides reported
in this thesis, there is a strong possibility that combinatorial effects are at play in
lens protein-protein and protein-membrane interactions. Further studies should
therefore aim to elucidate the underlying mechanism(s) of α-crystallin membrane
binding and the effects of various high abundance peptides on this interaction,
crystallin solubility and the permeability of lens membranes.
As the population ages, lens opacification and cataract threatens to become amongst
the most prevalent and costly diseases in the world [172, 206]. Since most optical
impairments develop over decades, understanding the underlying mechanism(s)
associated with disease progression could greatly assist the development of early
therapeutic intervention strategies. At present, only a small percentage of the
age-dependent changes in the human lenses have been documented. The tendency of
crystallins (particularly α-crystallin) to form large heterogeneous complexes has
compounded

the

difficulty

associated

164

with

examining

protein

Chapter 6

Conclusion

interactions/modifications in the lens. Therefore, additional research is required in
order to accurately map the changes occurring within the human lens during the
aging process, before any therapeutic approaches which target these changes can be
developed. This thesis examined a number of key changes to human lens proteins
with age that have been associated with lens opacification. Information gained from
these studies provides important insights into the mechanisms and changes in the
aging lens, and will act as a platform for future studies in this field.
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A1.1 Purification of MBP-αB, αA- and αB-crystallin

The purification of recombinant wildtype αA- and αB-crystallins was performed
using methods established by Horwitz [220], with minor modifications. The fusion
protein, MBP-αB, was purified according to the instructions provided by the
manufacturer of pMAL-c2X (New England Biolabs), in conjunction with methods
established by Muchowski et al. [221]. This appendix section details the purification
of these proteins which is otherwise omitted from the chapters.

A1.1.1 Cell lysis
Frozen bacterial pellets stored at -80 °C were resuspended in ice-cold Lysis buffer
(50 mM Tris-HCl, 100 mM NaCl, pH 8.0), using 3 mL Lysis buffer per g of pellet
(wet weight). The homogenate was incubated on ice until the pellets were
completely thawed. To 1 g of the starting pellet, 4 μL of freshly made
phenylmethanesulfonylfluoride solution (100 mM in 100% ethanol) and 80 μL of
1% lysozyme solution were added to the lysate, and the lysate were allowed to
incubate on ice for 20 min with occasional stirring. Deoxycholic acid (4 mg per g of
starting pellet) was then added to the lysate, followed by vigorous shaking at 37 °C.
At this stage, an additional purification step using a French Press Cell Disrupter (1
inch (diameter) cell, Thermo Electron Corporation) was performed according to
instructions provided by the manufacturer. Following the French Press step, DNase I
(10 μL of a 2% stock per g of starting pellet) was added to the lysate, and the lysate
was incubated at room temperature until the solution was no longer viscous. EDTA
was then added to the lysate to a final concentration of 1 mM. Proteins were
separated from the cell debris via centrifugation at 17000 × g for 15 min at 4 °C.
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A1.1.2 Anion-exchange chromatography
DTT (10 mM final concentration) and polyethyleneimine (0.12% v/v final
concentration) were added to the bacterial cell lysate that contained the recombinant
wild-type αA- and αB-crystallins. The mixture was incubated at room temperature
for 10 min, followed by centrifugation at 17000 × g for 15 min at 4 °C. Prior to
loading onto the anion-exchange column, the supernatant was filtered through a 0.22
μm Millex GP filter unit (Millipore).
Anion-exchange chromatography was performed using a HiPrepTM 16/10 DEAE FF
column (17-5090-01, GE Healthcare) on an AKTA Prime Plus System (po141810,
Amersham). Proteins were separated using a stepwise elution from 0%, 10%, 20%
to 100% AE buffer B (20 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.02% NaN3, pH
8.5), at a flow-rate of 2 mL/min (AE buffer A: 20 mM Tris-HCl, 1 mM EDTA,
0.02% NaN3, pH 8.5). αA-Crystallin eluted as the only peak at 0.2 M NaCl (20% AE
buffer B) (Fig. A1.1A), while αB-crystallin eluted as two peaks at 0.1 M NaCl (10%
AE buffer B) (Fig. A1.1B).

A1.1.3 Affinity chromatography
An affinity column was packed manually by pouring 10 mL of amylose resin (New
England Biolabs) gently into a 2.5 cm x 20 cm glass column. Once the resin settled,
the column was washed with 120 mL of buffer A (20 mM Tris-HCl, 20 mM NaCl, 1
mM EDTA, pH 7.4). Bacterial cell lysate that contained MBP-αB was diluted 5
times with buffer A before being loaded onto the column, and the bacterial
lysate-resin mixture was allowed to incubate for 1 h at 4 °C, under gentle shaking.
After flushing the column with 120 mL of buffer A, MBP-αB was eluted from the
column with 50 mL of buffer D (10 mM D-(+)-maltose monohydrate in buffer A).
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A1.1.4 Size-exclusion chromatography
Size-exclusion chromatography was employed as a final step to purify MBP-αB,
αA- and αB-crystallins. Fractions from previous chromatography purifications were
pooled together and concentrated using Vivaspin 20 Centrifugal Concentrators (10
kDa MWCO, GE Healthcare), followed by filtration through 0.22 μm Millex GP
filters. Size-exclusion chromatography was performed using a HiPrep 26/60
Sephacryl S-300 column (GE Healthcare) on an AKTA Prime Plus System.
Phosphate buffer (50 mM phosphate, 100 mM NaCl, 1 mM EDTA, 0.02% NaN3, 0.1
mM DTT, pH 7.2) was used at a flow-rate of 1 mL/min. The peak containing
αA-crystallin overlapped with a broad peak which contained E. coli proteins, so only
the initial two-thirds of the peak was collected (Fig. A1.2A). αB-Crystallin eluted as
a single peak (Fig. A1.2B), while MBP-αB eluted as two shouldered peaks (Fig.
A1.2C). SDS-PAGE analysis showed that the two peaks contained the same
MBP-αB species (Fig. A1.3), and fractions from both peaks were therefore pooled
together (see Fig. 2.11A, lane 1, for the SDS-PAGE analysis of the final MBP-αB
product; Fig. 5.3, lanes 1 and 2 respectively, for the SDS-PAGE analysis of αA- and
αB-crystallins). Size-exclusion chromatography removed the remaining E. coli
proteins from the samples, and also the maltose present in the MBP-αB samples.
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Fig. A1.1: Anion-exchange chromatograms of (A) wild-type αA-crystallin and
(B) wild-type αB-crystallin. αA-Crystallin eluted at the only peak at 0.2 M NaCl
(20% AE Buffer B), while αB-crystallin eluted at two peaks at 0.1 M NaCl (10% AE
buffer B). The concentration of AE buffer B during the column run is shown in red
bars.
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Fig. A1.2: Size-exclusion chromatograms of (A) wild-type αA-crystallin, (B)
wild-type αB-crystallin and (C) MBP-αB. Areas between dashed red bars indicate
regions where the final protein fractions were collected.
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Fig. A1.3: SDS-PAGE analysis showing that the MBP-αB species which eluted
in the first (lane 1) and second (lane 2) peaks of the size-exclusion
chromatography (Fig. A1.2C) consisted of the same ~64 kDa MBP-αB species.
The fractions were therefore pooled together (see chapter 2, Fig. 2.11A, lane 1).

A1.2 Age-related changes to lens proteins

A1.2.1 Isolation and identification of lens proteins
A more comprehensive presentation of proteins extracted from the human lenses is
presented in Fig. A1.4, as a complement to Fig. 2.1 in chapter 2. A total of 42 lens
proteins were identified using MALDI-MS and MALDI-MS/MS, with the identities of
these proteins assigned in Table A1.1. The breakdown of the relative proportion of total
lens protein found in each lens extract is presented in Table A1.2.
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Fig. A1.4: SDS-PAGE analysis of age-related protein changes in the human lens
(the same gel shown in Fig. 2.1). Gels showing the (A) WS, (B) US and (C) UI
protein extracts from a whole fetal lens (16.5 weeks) and from the cortical or nuclear
regions of lenses from individuals aged 16, 20, 35, 43, 65 and 86 years (age
indicated on the top of each lane). 50 μg of protein was loaded onto each lane except
for the fetal US extract and the CUI and NUI extracts from postnatal lenses, which
contained 25 μg of protein. The fetal UI extract contained less than 25 μg of protein.
Major protein components from 42 gel bands (band labels present on the left of the
gels) were identified using MALDI-MS (see Table A1.1). Molecular weight markers
are indicated on the right of each gel.
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Table A1.1: Major protein constituents of the SDS-PAGE gel bands from Fig.
A1.4. Proteins were identified using MALDI-MS and MALDI-MS/MS.

a.

Band no.

Major components

I
2
3
4
5
6
7
8
9
10
II
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

~B I ,yC

~BI

~B I

pBI , aA, yS
GAO PH
~BI
~A3
~B2

~A3 , ~A4

aA,yS
aA, aB
~B2 ,

aA, yC,yO
Reti nal dehydrogenase I
~B I , ~B2
~BI , ~B2 ,

yS

~BI

aA, ~B2
yO, yS
FilaminA
Spectrin
Filensin
GRP78
Vimentin
Acti n
GAOPH

~BI,

~BI
~A3, ~B3

~B2
~A3 , ~A4

aA, aB, yS

i

aA
yC,yO
Phak inin, ~B I
Filensin, Vimentin, ~B I
Filensin, Phak inin, Actin, ~B I
aA, ~B I
aA,aB
Spectrin
Vimentin
Aq uaporin 0 (MIP~"
Aq uaporin QJMl P22)'
aA, yS, yO, connexin-46

The identity of aquaporin 0 was assigned by comparing the masses of bands 40 and 41 with
data published by Korlimbinis et al. [20].
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Table A1.2: Breakdown of the relative proportion of total lens protein found in
each lens extract.

Lens
extract

Fetal WS
Fetal US
c

Fetal UI
Fetal TOTAL
16 CWS
16 NWS
16 CUS
16 NUS
16 CUI
16 NUI

Extract
volume
(ul)
383
150
-

Protein
concentration
(mg/mL)
11.78
1.00
-

2200
700
2000
1500
800
600

22.86
19.27
3.68
1.51
1.72
1.47

a

3000
400
1300
400
800
600

11.56
20.16
3.44
3.60
1.45
1.35

12.39
22.43
5.24
5.57
1.57
1.85
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%
of total
protein

b

96.79
3.21
0.12

100
66.47
17.83
9.73
2.99
1.81
1.17

0.32

34.67
8.06
4.47
1.44
1.16
0.81

100
68.50
15.93
8.83
2.85
2.29
1.60

0.24

42.12
22.43
10.48
8.35
1.26
1.11
85.75

30 TOTAL

(w/w)

50.29
13.49
7.36
2.26
1.37
0.88

50.62
3400
1000
2000
1500
800
600

Protein
/ tissue
wet
weight

4.51
0.15
-

75.66

20 TOTAL
35 CWS
35 NWS
35 CUS
35 NUS
35 CUI
35 NUI

(mg)

4.66

16 TOTAL
20 CWS
20 NWS
20 CUS
20 NUS
20 CUI
20 NUI

Total
protein
extracted

100
49.12
26.16
12.22
9.74
1.47
1.29

0.21

100
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Table A1.2 (continued)

Lens
extract

43 CWS
43 NWS
43 CUS
43 NUS
43 CUI
43 NUI

Extract
volume
(ul)
3200
700
2000
1500
800
600

Protein
concentration
(mg/mL)
10.84
18.33
4.31
4.05
1.47
1.43

(mg)

a

3200
1000
2000
1500
800
600

21.31
14.11
10.43
10.20
2.16
1.45

(w/w)

%
of total
protein

b

53.99
19.97
13.41
9.46
1.83
1.34
0.20

68.19
14.11
20.86
15.30
1.73
0.87
121.06

65 TOTAL

Protein
/ tissue
wet
weight

34.69
12.83
8.61
6.08
1.18
0.86
64.26

43 TOTAL
65 CWS
65 NWS
65 CUS
65 NUS
65 CUI
65 NUI

Total
protein
extracted

100
56.33
11.65
17.23
12.64
1.43
0.72

0.33

100

86 CWS
86 NWS
86 CUS
86 NUS

3600
1000
2700
1100

8.94
15.61
5.83
4.63

32.19
15.61
15.74
5.09

43.54
21.11
21.28
6.89

86 CUI
86 NUI

800
600

3.28
4.47

2.63
2.68

3.55
3.63

73.94

86 TOTAL
a.
b.

c.

0.15

100

Protein concentrations of each extract were measured using the bicinchoninic acid assay kit.
Tissue wet weight: fetal lens: 38.3 mg; 16 yr lens: 238 mg; 20 yr lens: 207 mg; 35 yr lens: 399 mg; 43
yr lens: 316 mg; 65 yr lens: 364 mg; 86 yr lens: 379 mg. Note that with the exception of the single fetal
lens, all other lenses used were in pairs.
Protein concentration of the fetal urea-insoluble extract was too low for detection using bicinchoninic
acid assay.
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A1.2.2 WS 40-50 kDa crystallin cross-linked complexes
A total of 15 spots were excised from the 2-D gel of the CWS extract from a 45 year
lens (Chapter 2, Fig. 2.6). Proteins from excised polyacrylamide gel pieces were in-gel
digested with trypsin and analyzed using nanoLC-ESI-MS/MS. Mascot (Matrix Science,
London, UK) was used to search the LC-MS/MS data against entries for Homo sapiens
in the SwissProt protein database. Presented here are the Mascot search results
(extracted from www.matrixscience.com) of the 15 different samples from the 2-D gel
(sections A1.2.2.1 to A1.2.2.15). Mascot search results included the names and masses
of matching proteins, protein scores (listed after the protein name and mass) and the
number of queries (peptides) matched. The higher the protein score, the more likely the
particular protein is in the sample. Protein scores derive from the individual peptide ion
scores, which are presented on the query list. Peptide ion score is -10*Log(P), where P
is the probability that the observed match is a random event. From these searches, a
particular peptide with an ion score of > 30 indicates identity or extensive homology (P
< 0.05). Peptides with ion scores > 30 were listed in red.
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A1.2.2.1 Mascot search result for spot 1
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R . VAJl:l'GIU'R . E

0 . 0028

K . ES~lAR . K

0 . 00016

Peptide

K . ~LSA'!'R . L+

MDHM HUHNI

Mass: 35481
Score: 64
Queries matched: 1
emPAl: 0 . 09
Malat ... d ... hydrog"en""e , mitochondri .. l OS~Homo ,,~pi .. n" GN~MDH2 P£oool SV_ J

[] Ch ... cl: to include thi" hit i n "rror tol .. r"nt "earch or "rchiv" report

fa

..

QueL)'
589

Observed
617 . 3112

~

Mr(exptl
1232 . 1 21 B

Ma ss:

62021

Mr(ca1c)
1.232 . 112t

ppm Mis s Score
Expect Rank
1.2 . 1
0
U
2 . 3 e-005

Score: 55

Quer:1e" matched : 1

emPAl : 0.05

Ker"tin , type I cyt =kel .. t"l 9 OS - Homo ""pian.. Q.I- h"RT9 PE- i SV- 3
Cl Ch .. ck to incl uda t hi" hit in .. rror

tole~ant

" .. "rch or archiv .. report

178

Peptide
JCU· GVTTLDIVR . ...

O:o.1d.au.on

,.,
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A1.2.2.2 Mascot search result for spot 2

f.~;r.."!fi

Mascot Search Results

u• • .,

Katt P

,0 r<;1 , a U

Eaail

.fit~b.n rye pro t._

s . .. r<:h title

sw...itted fr o. YON 15 spo t s l ro .. 2 D .,.,1 1I UMAJ1 by Ka"cot O. .... n o n APM · .... Z8

M6 da ta tile

, \Hu n peel \ HS_ DATA \0 . t u _Xl. \C.u ont "uple .\J une 2010 \ 'ROJ1 OJXX_ U01C10 WO',,-Z .lI9f

a . tab . . ..

s " t •• Prot 2 0 10 (517100 . ........ nee.: 1112.1<1 6551 ., •• i d .... . )
110-0 npia ne (b uaan ) (21lJ57 . .qu ene • • )

'I'axonoay

Ti • • • t:~
P", at .. h, hit.

IS .Jun 201Q _ " 2):10;42 I:It!T
, ~

Sochltol

d"lIyd[C~er'.:ille OS"I1~

lI apllR.8

~

~..Q7lU

,!4t

~V .. .

hTi 1'Iynth.........'oI,I "I. r- J>foC" , ..1C,,"Il OoW r ul IT'...-H... _ ... p.I."'" 'iII-""'P~li Pa.-l !'V~1
CRBB ! KUMA. lIey·C'~~uilln 1:1 oe .. tto..c. .lJilIJJ~r~'II
1't·1. 'S" . ~
~ H"l.l. d.IYydC'l'JIl.n .. ,.... ftJt<,>eh'OndtJ 11 ~
N"'1 U1t.;. pli'-l.;':"'J

",,",,-"'.1'Nf1

"'''f .'rIlI' ..

[m~lcoru 1•• 10- Lcg(P), whl'f'f P ,,-tlli! probability that till' olwe ~J mllldl is II rnndOI1l c!'Nnt .
Individual iOltJ ~"Qfel > 30 iridkal~ id~lItilY I>f ~xt("fU'I"e hQmoklgy tp<:O ,QS)

Protl!UI ~ IIr...hmwd from lOOt alCiM"t1I as II nOIl-probabdI111': bMlg fiM" tllnkW8 proteml1Ut.

i

•

I

III. I. - -I.
.

~Illt

...

~

_ _ ..

I' cplidt Summary Rtport
FQIIlliII.....

Pupfda Surml;;wy

Siplificanc(' th~.lloId ~ 0.05
---

MIlX. lIl1mbef (lfhiJ, IAUTO

Show pop-ups I! Suppress pop-ups 0
S9a,d"I S89dRd

SRl9d:AI
DHSO HUMJI.N

lio n : 36300

l

1(I".!Ia.."(lI~·llr ~"XI""cl",ul-.'fTl 32

MudPIT t.::anng

O&creasR1 Score

Sort un assigned

D Erro r loll'ranl

Score : 121

sh""'- o) lIh-",,~ '0-

Require bold red 8

AldWe R9fX!!1

Qu.e:d e.s .... tc.hed : 2

..,pAl : 0. _18

Sorbitol dehydrogenase OS-Homo sapien.!; GN-SORD PE-I SV-C
D Ch eck to i nclude this hi t in .. rror tolerant s;"L1Th or .archiv,," r"Por t
Qu e ry

Ob s erved

ill

455 . 2536

Hr ("xpt )
908 _4926

Hr (cai c )

iI
@I

2.2.§.

803 . 45ll

1604 . 8877

1604.8192

2.

908 . 5080

ppm MUs Scor.. Expect Ra nk
-16 . 93
41 0 . 0013
102

42 .7

Score: 11

PEptid ..
R _w.rEPGAPR . £

3 .. -009

Q-ue l' ie.s .... t cbed : 1

K _~VVVTDLSATR . L

emPAI : 0 . 06

AT P "ynthase "ubunit beta , mitochondrial OS-HoltD sapiens GN-ATP5B PE-I SV-3

o Ch <O'CK to include this hit in e tror t olerant ;;ean:h oe archive report

Ii'!

Que ry

Ob s e rved

Mr (exp t)

Y.r (calc)

ppm

126

71.8 . 4005

1434 .7865

1434 . 7467

27.7

ltiss Sc ore
11

Ex pect Ra nk
1.1.- 006

Ma n , 28006
Q-ueJ:ies ..... tched : 1
Scor e: 54
B", t a - crys u llin 81 OS-Homo sapien", GN><CRYBBl PE-I SV_2

Ii'!

..

Query

Ob s erved

Mr (eJlpt )

Hr (cal.c)

PP'"

2l.!

725.9085

1449.8025

1449 .7 616

28.2

~

Mu", 35491

Score: .31

archi~

Hi s. Score
0

54

report

EJl pect Ra nk

Peptid e

0 . 00021

Q-ue.rie.s ..... tched : i

Malate dehydroqena.se , mitochondrial. OS-Homo .sapieM

R . i""l"QAGSEVSALLGR . :l

OSIIPAl ; 0 . 12

CReBl HtIMAN

IJ Check to inciude this hit in error tolerant search or

I?o!!pUde

1

GlI~KDH2

R . LVVFEL£HFQGR . R

..,pAl: : 0 . 09

PE.o-l SV-.3

(] Ch eck to i ncl ude t.hi .. h i t in err",r tolerant search or archive repor t

fill

QUery

Ob s erved

Mr (expt )

Hr (calcl

ppm.

519

611 . 3181

1232 .7 4.16

1232.1129

2] . 3

liiss Score E xpect &ank
31

0 . 01.2
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i>ept:ide
K.J:FG'lTl'LOrvR.A

+
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A1.2.2.3 Mascot search result for spot 3

f.~"tf.:m Mascot Search Results
v.ar

: Matt

-"

r

.t.1t;:h. nryfi'p " o ~. _ ","g ....
: Subaitt .. d [tc-. vow 15 .pot.a: fr . . 2D gol ftllMAlf by "'...cot 0 ......" 0 11 APAr'_ ~2 11
: \\" . . . .pec.1 \ MB D.II.TA\ ootar x t. \C: lhnt l u.pl •• ' "una 2 010 \ I'ROJl OJ XX vow U \ UOW 3 ."9t
, Qwl . . "" o t 201 0 - , 51"'1100 • .quone •• : 1112146551 r . . ldu. . ,
, K_
..p~.n. (,",-nl ! 20:Jn . "qu"nC1l',
: U .run 2010 at 23:11 : 2 2 <MI'

~

SOl. reh t.ltl.

NI'J ~ta

tn.

D.tM> • • •

TaXon- r
!~.tup

."o toin h i t.

, aliI! IfUI.UJI a.. g -cryllullin at ~ • .Qca.:I U:pl "ruo GtI.oO!.'CIlIl p:&-I
~ An- "Ynthll" .. :rubunlt: boh , llUu,<:!hDndrlU os-e....,.
~

X4r .. U.ro , tVf>t> 11

cytQ$~.hl ... l

I OSlo.ll<:;lrlCi S"J#h' l1r

av,,?

"'"pu"""

~1

tiIfooATf!dl Va-I .....••.
Ps-1 ,,>,0«

1'-'115 !k:O!e H· l D"'l.0f{P). ""ll(:re P Ii 11\1: p t,ba bilil)l lhllllhl: obwrvM mate)1iJ II I'llIldNJI ~'eili.
InJivi dililllOIl:l ~rtll ~ 30 lIldh;al e ldl,:ntlf)' o r e";\: hmiiv.; JItJl111J1..,gy ~O,O!i)
pn:lIcin 1CQte1 1l1i! de nwll f[\lIll l"n$!OCI'>'es a!I II TlOI'I-I',<lbllbW.__ ic balri~ fOl milking plll ld ll bib .

P ... plid l' Summ:II')' R epol1

."""""'

FOOlJlltAs

Significance thredt.,IJ ,..:: 0.0$
SlamlaJd !K'QI'UI,!!;
Show p.1 (l-tlpS

MH,'(. TIluTllicx l'f ltitIJ AUTO

.o\lud l'r'rS<:Onn&

Saarch SeIocS8d

,.

CRBB 1

~

uTla~iglled 0I!aHsInp Sme

Son

SUpprei.i I~llll~

D Erro r to lera nt

Score: 129

Ma ss : 28006

Rcqu ir& bold f C11

AretINa Report
_AI : 0 . 76

QuerJ. e s .... tched: 5

Beu - crys t allin Bt OS-Hcmo sapi e .... GN-CRYBBl PE-l SV-2
Cl Olack t o include this hit in .. ~~or I:ol .. ~an (; " .. a~ch

.,,"""
• '"
• .lli
•
• '"
• m
503

Observed

Mr(expt)

Mr(ca1c)

491 . 7t58

981 . t77 1

981.48t1

-7 . 17

5 U . 2715

1086.5325

1086.5t58

- 12 . 23

553 . 31.27

11.24 . 6108

11.2t . 58titi

U .S

725 .9013

Un . 78U

Un . 7U6

18 . 3

729 . 3728

USti . 73l.l.

U56 . 6987

22 . 3

,.

""" ,

Score: 74
AlP "ynt tuosa "ubunit b .. ca ,

o~ a~chiv .. ~"'P0rt

...
.

H1.ss Score

"
"

QUe>:y

Obs erved

Mr(expt)

Mr (ca1c )

PPI*

745

718 .403 3

U3t . UU

U3t . 74ti7

31.7

,

O. OOU

1t . ISLn:GItoNI"It.G

cytosl<~letal

R . Lvvn:IZJl!"QOIl . II.

0 . 0038

R . GTQTLLEl'GOl1I. .tI

_AI :

0 . 06

~rchiv ..

trtss score
7t

r'"POrt

I!:llpect Rank
2 . 2.-005

1

Peptidia
R . f"T(lAGSJN"SAl.I.Gl . t

I OS-Homo sapi ..n.s GN-KR"!"l P E-l SV- 6

IJ Chack t o include "this hi t in ",reor t ol .. rant s"arch or archiv"" report

!i!I

Que>:y

Observed

Mr(expt)

Mr(calc)

435

51 7 . 2'63

1032 . 5181

1032 . 5087

OJ<1d&tiOD. (H)

0 . 00018

score: 33
Kera t in , type II

+

1t.AAEI.PPQlYR . L

05-HolllO "apian:! Ql-A"fPSB PE-l SV-J

IJ Check to include thi" hi t in .. no~ tol .. t a nt " .. arch or

!i!I

P"P tide
R . ~ILI3( . G

O. OOlli

Quer:1es .... tched : 1

aitochond~lal

,

E.Kpect Rank

0 . 0008t

PP"
9 . 11

trt s s Score Eq>eet Rank
0

33

0 . 03t

181

I

Peptide
R . TI.U:GEZSR . "
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A1.2.2.4 Mascot search result for spot 4
MaSCO t Searc h R es ults

I,AlA1'IUX
' el ncr!I

IUU. ,

U.er

... n

..ri t."h.nry ~ prot ._ .0" '01. au

S •• rch title

Sw...ittad

f,,_

VOW l!; spGt. h -... 2D ."..1 HUHAI by w..e coct 0 ........ on JUlAF - WS- 2B
\ \1otI ••• pacl \ HS_DAT"\ Q.U,,_XL\Cli ent 'upl •• V Ila. ZOlO\PROJlOJXX_UO"'_15\UOW_4 .....t
SWiliPTot. 2010 ($ lU OO .e-quence. : 182:146551 "' . . i ....... )
110_ ..pie '" (huaan ) (20367 .equlnc:e.'

data tn.

NS

OatAbe ••

"exono.y
nup

T, ••

15 .llln 2010 It 23 : 11:515 rom
e .. U-orylll.llln 81 OS_H_ up.l. .. n~ GK..cJI;YJlBI Pf>l iPf-:;!

Pr otei n hit s

!;orbl tv1

d.r.ydroll<jJ.n.~

" .. plo1n~ GoN-:oao E... I SV-4

0$-11_

ATP ::JynLlu.:re .ubl.ln1\. hta . IrJ,lcn::hol\d:n..,d OS","",,,,,, upi.llI:I

B.. t.-ery_ullin

~

0$-11_

(m·J\TP~1!

p~:a

!IY-]

crn"'''''IlIA1 f'f·t SV -A

.s'pl~nlf

.......... -c:rystdll/l [I (IS-H_ upt,nll GH .....I\Y!;D 1',-1 SV-)

Ga"'... ·cryn.l hn jI. OS-HIJIIIl

If~pll;rl:t

GII-I:1\YGA

'£a~ ~V·j

8t!ta"c!:),BuU.lh S OS-Ho.a '''pUII'' GlI-CRYGS. I'E-l 511- '

8eta-ctyllulun 82 OS-H...c> Bapnn3 G!/aCRYlB<: l'!:-l ~V- .l
:FLuClO. . . b.upha:!lphate aldol.lle A O!"IfOIllO Up.l..o!.iU uW .... I.!luA PEal :S'I.~
AIph" ·cl"Y.~Uin A eha.In OS-l:L::=o 8i1p.1"n" GH....::JttM li-1 !v-:!
)I.oIl...Ile di!ttyd r 09l!'n.. ~"' . eJ.loclland ri .iI1 OS-KOIIII ~~'1e.n!l CN-MUH:! PEal SV-}
Iiily.: .. 'o:)l-1-p ....",',.1.. ~ d.~ydloq.,"U" t-U~. ptot<t~n ')!.o-Il~ capu",1 GH ..1r1l1 1. FS-1 S'/ ..1

Prob:lbilily Based Mows(" Scort"
[ t\II~ .core i!- IO"LcSO'), where P II the probability that tile ol/re",ed motdl lr a random evl:n t.
[lId1\1dualt;,»1J ~rc, :> .' 0 mdicare idl1rtity or \""'leJ\~"~ h'tnloJI'g)' (p--=tI .OS).
Protein KOI\.'1 >11'01 denved INm iollt iCo)re. at II non.probabilirtic batiI for fankul{t protein hit,.

P('rtidl~

Summnry R('pIlI'l

Format As

Peptde Surrmary

Significance threshold pc: ~
Standard scorin g 0 MudPIT .'!Coring

1\ lax. numberorhiu: AUTO

e

Ions score

Show pop- ups ., Suppress pop-ups 0

01'

Show sub-sets 0

expe ct cul·ofT 30

Sort un assigned Oecreasfig Score

Require bold red ta

.-A.
1.

CREBl HIJM1o.N

Ma .... :

Beta- crysullin III

2B006

OS~HO<110

Score: 181
Qu...,ie .. .... tched : 5
Siipiens GN-CRYB81 PEO-l sV_2

....,pAl : 0 . 16

Cl Check to include this hit. i.n error tolerant sear<::h or archive report

•
•
•
•
•
,.

Q""'Y

Ob .....,ved

Hr (expt l

Hr (calc)

p"",

ill
lli

544.2759

1086.5~13

1086.5U8

-1 . 11

56) . 2931

1124 . 5116

11.24 . 5866

·1] . )0

ill
21!.

125.89)9

1449.11)2

1449 . 1616

1 . 98

129.)546

1456.6941

1456 . 6981

-2 . 14

ill

860.4206

In8.8261

1118 . 805)

DHSQ H1JWo,N
Sotbi tol
a

).

Mu s: 38300

d"hyd~ogen .. se

"

SCONl : 119

.

er~or

"

Ob .. eJ:ved

Kr (expt )

Hr (calc)

ill

455 . 2540

908 . 49)4

908 . 5080

- 16 . 01

€I

221

80).4224

"1604.B)02

1604.8192

6.81

56525

0 . 00091

1(.

2 . 4 . -006

ISInGAKFK . G

R. LVVFEIDl'FQGR .11.

1.6e-005

R. GYQYLlLPGOFR . H

0.000)9

_

Peptide
K. AAELPPGNm . L

K . VSSGl'JI'VGYQYPG'IR . G

AI : 0 . 19

SV~4

tolerant search or archive report

Qllery

Ma .... :

"

Expect. Rank
0 . 0011

Quru: ie5 matched: .2

€I

ATPB HUMAtl

• "
,."

OS-Homo sapiens GN_SORD PE- l

Che-ck to include this hit i.n

,

Kis .. Score

Score : 94

ppm

Kis .. Scol:e

0

60

Expect Ra n k
6 . 1 .-005

1

Peptide
1I . VU£PGAPR . £
K.~WVl'DLS.A'DI. . L

Quru:ies matched : 1

fDPAI: 0 . 06

A1'P synthase subunit be t a , mitochondrial OS-Horro sapiens GN·,."TPSB PE-I SV-3
Cl Check to inClude this hi t in enOr tolerant :o!earch o r archiV'e report

182

+ Os.idation

(H)
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QUeIj'

eI

..

ill

Qb"e>:ved
118 . 3682

Mr(ellpt)
1.43 4 .1218

MJ:{ca~c)

ppm Kia" SCOI:e
E"pect Roonk
- 11 .31
0
9 4 2 . le-008
1

1 43 4 . 1 461

CRB,>,l HlJl'o!.W
Mus: 2~l34
Seo>:e: 85
Que:r.ies _ tched : Z
Se t a - nystallin A3 OS-Homo sapiens GtI-cRYBAl PF.o-l SV-4

Pepti.de
R . P'I"QAGSEVSALLGR . I

....,pAl , 0 . 29

CJ Check to include this hit in enol: toletant "e<ltch oc acchive report
Que ry

Qb se>:ved

Mr(e. pt)

Mr(calc)

E1!

l!

392 . 6910

183 . 3614

183 . 3831

eI

.!1.§:

728 . 3629

1454 . 1113

145 4 . 70U

CRGO HillW'l

Mu,, : 20725

ppm Kia s Score
- 20 . 81
31
4 . 95

GN~CRYGD

1

0 . 042
5.2 ..-007

Que..:ie.s _tched : 4

ScoJ:e.: 82

Gall1!la - crystallin 0 OS-HoIlIo 3apien.5

80

E.pect RIonk

Peptide

K.!:!l'lEEK ...

+

Ollidation (K)

K . rr:r~ . 1l

eaPAl: 0 . 8::

PEo--l SV-)

[] Check to include this hit in error tolerant search or IlIchive report

•
•
•
•
6.

p,..

Qbse>:ved

Mr(e.pt)

Mr(ca~ c)

m

455 . 2140

908 . 4134

1108 . 4603

ill

547 . 71130

1093 . 5115

10113 . 5168

- 4 . 81

50.

591 . 26114

1180 . 5242

1180 . 5261

-1.61

ill

636 . 31311

1210 . 6132

1210 . 6016

• .U

Q""'Y

~

Ma s.: 20863

Kias Score

.."

- 51 . 61

SCONt : 13

" .pect R.ank

Peptide

0 . 0059

K. ITL YEDR . G

0 . 00091

"
"

H . GKITLl'D>1l • G

0 . 009

R . YQDIIGA'lHAR . V

0 . 024

R . Q~'!1I. . R

+

_Al: 0 . 35

Que..:ie.s _tched : 2

Ganrna - crYlltallin ,>, OS_Homo sapiens GN-cRYGA P&-Z SV-3

o

!ia

8

Check ta include this hit in error t olerant search or archive r'3port
Query

Obse>:ved

Mr (e.pt)

MJ:(calc )

ppm

ill
ill

47 2.2 2711

1142 . 4413

1142 . "'41

-] . 62

564 . 7829

1121 . 5513

1127 . 5611

-8 . 1]

li.is . Sco>:e
46
51

E.pect Rank
0 . 0014
0 . 00011

Peptide
K. I'I'FYEDR . D
H . GIaTFD:mI. . D

Proteins matching the same set of peptide.:
eRGB HUMAN
Ma ",, : 20894
SeoNt : 13
Que..:ie . ..... tched. : 2

Gdmma- crystallin B OS - Homo sapiens GN-CRYGB PEo--l SV- 2
I~RGC HUMAN
Ma ",,: 20865
Seol:e; 13
Querie" matched: 2
Gamma - crysta llin C OSEHoroo sapiens GN_CRYGC PEa l SV_2

~

1.

Score: 59

Mass: 2(l993

emPAl: 0 . 56

Queries matched: 3

ee t a - crystallin S Os - Homo ""pi en" GN-CRYGS PEo--l SV- 4

o

Check to include this hit in
Query

• m"
• ill
B

8.

e~~o~

toleran~ sea~ch o~

Observed

Mr (e.pt)

Mr(ca~c)

381l . 2180

116 . 4 2 1 5

176. 4U 2

386 . 1 959

1155 . 5658

1 155 . 6037

- 32 . 18

506 . 516]

1 516 . 1012

1.516 . 7310

-15 . 14

p".

a~chiye

~~port

Miss Score Expect Rank

-28 . n

"
.,"

K . ~ QI FEK.G

0 . 02 2

R . AVlILPSGGQYK . I

I?l

,.

er ~ or

K . ITFYEDIQiIl'OGR . R

0 . 0026

CRBB2 HUM.>.N
Ma",, : 23365
Scol:e : 53
Querie " matched: I
Beta - crys t allin 52 OS- Homo .!!apiens GN-CRY5B2 PF.o-l SV-2

C Check to include this hit in

Peptide

0 . 021

emPAl: 0 .1 4

tolerant search or archive r<:'pol:t

Query

Observed

Mr(e.pt)

Mr(ca~c)

ill

104 . 8866

1407 . 1586

H 01 . 73g8

Ppm
13 . 3

Mi ss Score
0

53

Expect Rank
0 . 00026

1

Peptide
K . IILYENPNFl'GK . K

ALOO,>, HUMAN

Score; 44
Ma ",, : 39395
Que..:ie " matched: 1
emPAl: 0 . 08
'ructose-bisphosphat.e aldolase A OS~ Horro sapier", GN~ALOOA PEa l SV .. 2

o Check to inClude tilis h i l in error toleu.nt searcY! or archive report.
Query

Ii!!

1.

Ob"e>:ved
382. 2253

Mr(e"pt)
762 . 4361

Mr(ea~c)

762 . 46 4 0

ppm Mi "" Score E"pect Rank
- 36 . 57
0
44
0 . 0035
1

Peptide
K . VLAAVYK . A

Proteins matching the same set of peptides,
ALOOB HUMAN
Mass, 39 4 48
score: 44
Querie s ma.tched.: 1
Fructese-b1sph"sphate aldolase B OS- Herro ;>apiens GN-ALOOB FE-! 5'1.. 2
AUXX; HUMAN
Mass : 39431
Scor.. : U
Qllerie" matched: 1
E'rucLose-b isphosphate aldola.se C OS-HOlOCl "apiens GN- ,>,UO:: PE-l SV-2
10.

CRYM HUMAN

Ma " ,,: 19897

Score: 42

Que..:ie s matched: 1

183

emPAI : 0 .1 7

Olli..wtion

fH'

Appendix I

184
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A1.2.2.5 Mascot search result for spot 5

(fc,;"";.'!,Jf) Mascot Search Results

..."

: Matt

U'Clt"

:

O" ...,:::h U tl .

r

.fi t ' h.nry@p,,<>~_.

'''''!l .•''

: Dllhmltt.d f r<;110 \lOW 15 spo ts h -_;2D 9 ,, 1 KIINAJI b y MUo=t D. ....n li n Af'1II'- WS - 28
: \\1I4."p-c:: l \ ND DA'lA' Oster lCL \ C:Uen t . .... h . 'Jun .. 2010\ PRQ.J l03X); vow U \ UOW S . a.gf
: o..i . . l'rot. 20 10-( 5 1710 0 •
e • • : 182 14555L r esi due.)
K..... '.pi.ft. l h .... n ) (20361 ......." .... ,
IS ,Jun 20 10 at 23: 12: 3 2 <JH!'

HZI' droItA f i le

.qu. ..

o.t..ob . . ..

or. xona.y
'I'~_t~

:a~t.I .C'~y.t;o.llJ-n

,,,,, l ai n hit &

:ana

111 OS·a.:.o "ilPunli mI--ol'lloBl 1'];,-1

1J'v-~

~~tallll1
s OS-lJomg ,,;ap1ellll G1looClll'OS ~l __
.... U".l dellydtoy.""". 1 ~-u ..... :r1lf,1+n$ ~ALJ)81A1 Prol SV<i

E,t.-ery:rt.1L,n A) OSelJg;aQ ",,,,,1.n, QI""'=R';ll1tl P"''1 QV....
• "t.II-et:-yIlUIUn -.2 O$"a-o J",I'"~ Gl'~ r.t-J i'b.;.
AD' SYlltbaae rulhiDlt lieu, IlUHICbCndrlill DS4a.G :saJ\l."f GW-An.!lB
t.lIlC UlIg!!l protl!tn 114 M..g1Jol(! ....,.1.J:I". Cltoo[NJl'lH PI["1 £"'''1

10_ cry/ltatllll ... OS~ ''''pi!!n, ~YGA p~~ 'iv.. ,
Ank;yf~n "PUt dQlO1e1.l'I-o::'OIluiltln, prot-Un 1"7 OSOOS_ ~-.>~.n'

~~~~ ~:~!~c~r!~~:I1:~~~~~r~::~::,:\!~ ::~"~~,,~~DIU
!:

Prub;l hilit)'

l'~l ~!

GJl·~1"I ~I

Dol 5V·~

1.1.13 !1OIU.ll> ,ltd BEAI npaal _ccOldil,l.ng procain JU.All.HUI Oo5-B011O I!..lIp..Iell! GH~JOAAH~'! PP.l 9'0'

naJ(w ~ lowJ(e SroN!

- \ O"Ulg(P). ",herd P is OIl! {I'OO'olbib ty thai UU.l obM'ved mll1Cl1i. a randOru eVt;: ul.
Individ,w i~'J!j !IC,1re:i > 30 indicaTe iden tlly ,'r e.'(I l'fl~...e h(\l11Oiogy (JKOOS)
Protein ~,~ ml d eri~ from ions ~COfClll ~ II non.probabilistic basil! fnrmnlrill&protein hil~
InlU lI\!Or~ 1i

I~rplide

Su ummry Rrport

~ I Pepldes urlTl\afy
Sign ifica nce th reshold p< ,0.05

Show pop-ups I!J Suppress pop·ups 0

Sort una ssigned DeCl'easing ScotS

Ma SS : 28006

Mr (E! "p t )

- 5 . lt

5 . 55

563 . 310S

ll.2" . 6065

.11..2 .. . S8U

17 . 1

~

"725 . 8983

10149 . 1821.

1 .... 9 . 1616

101 . 1

m

72' . 38101

10156 . 7 4 82

10156.6987

H .O

~ .."rch

0"

a~chive

..

=~

~

..,.
"

Require bold red ii!t

eml?AI ;

0.76

rep<>rt

E>tp<:!Ct Rank
0 . 0038

R. . ~ILEK . G

0 . 0016

It. AAt:I.l'PGlftll . L

0 . 006

It. ISLFEGANFX.G

PeptidE!
+ O.l<id.ation

1e-00S

R . LVVFELEMFOGR. . R

0 . 00024

R. . GYQT:r.LEPGDFR . H

Querie s matched; 6

S core; 97
~"pi"n"

SVE2

.. ,.. • .,

Mr I=1c)
981. .. S.. 1
10S6 .!i"!i1

Mass: 20993

P~l

"

'111 . "791
i086 . !i!HS

CRBS HUMAN

,.

Queries matched : 5

GNECRYBBI

491 . 7468

Obs erved

SE!t,,- cry"tllllln S OS- HolllO

•
•
•
•
•

score; 140

OS~HOOlO ~"p; .. n'"

!i .... . 2S32

OU"""

•

I

O>..ck to illc l u::l .. thi", hi t in .,,-.-or tol .. ,,"nt

• ill
• .!!!
• '"
•
o

30"1 Show sub- sets :O-

Ions $COn.: or expect c ut-ofT

Beta - cry"'tall in Bl

•

/l,t1 X. num ber of hils ,AUT O ,

!

Standard scorin g 0 /I,'ludPIT sco ring

CRBBI \-l\Jl>!AN

o

_AI , ! . 4 4

~ .. "

.. ch 0 .. ",chive

..

~"P0, t

OU"'"

Observed

Mr( e xpt )

11

389 . 2057

71ti . n68

Mr (= lc)
776 ..... 32

- 5' . 82

liQ.

45" . 2 078

906 . "011

906 . "018

-0 . 7"

0 . 033

R. ~ . L

ill
ill

45 " . 2!i9!i

906 . 5045

906 . 517 4

-101 . 27

0 . 0014

R . 0YLLDKIt. E

451 . 2246

9101 . 01346

9l.4 . "38!i

- 4 . 30

O. OOU

Il . IT!Tl:DICN

no

386 . 20n

ll55 . 51n

11!i!i.6037

-17.08

O. OOll

fl . AVHl.PSGGOTK . l

ill

!i06.!i88"

.1516 . 7435

13l1i . 7UO

1.20

0.0047

K . ITF'fEOIQIYOGR·R

Reti n d

Mass: 54827

dehyd~og .. n ""e

1

""

rn-CRYGS PE·! SV-4

Ch..ck to include thi'" hi t in .. ~ .. o~ toler"n t

ALI;"! HUMAN

ilV""

""" , "
"
"
"
"
~

,

Score E>tp<:!Ct Rank
0 . 021

U

Quer:1es matched ; 2
Sc=E!' 54
""pie"", CN - ALPHIAI PEs ! SV· 2

OS~Homo

185

Peptide
It . IQIn:K . G

_AI ;

0 . 12

+ O.x1<iation

(H'

Appendix I
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u_

"''' r ~_~,
1.1 ... _

.... 0:

•• ~ ., ..

" "..

tn'. nl<

•

11"" .......

l!l

>6 .......

O«>u:

~ ............ '·""" . .

e.,,,,,,. '" '-""'''''''

J.

'n'.,. """.In .IA... $<

Ib ." ....... j . . . . , _,<b ,.

1.1..-_••"

......... _

•• .•

,

_ _ .... '....,

• .....,.. aaa>.

..

",·x""" ••• "_j

.,o>~_ ~_._

0,0"

187

•
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~ , lCI_. '
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A1.2.2.6 Mascot search result for spot 6

ttt:;;Xg
' j Mascot Search Results
u.~

: tu t t l'

1tIu.i1

: .f;it:thon ~F rOb"" . or<J . . ..
: s ubo i t.hd. b _ UO'H' 15 .pot " (¥'OJO 2D ~1 KUKA!I by It. .cot. D• ...,n on APAF- WiS- 2 8
! \\Ka'''IOp''''''' \ MS DJ,T.Io \ O_t.ar XL\Cl:i ent " ..-p I . . \ JUn .. 201D\ PROJl (l3XX UOH lS\UDW 6 . •
: S>th.Prot 20 10-1~ 171 00 ••
18 2 U 6 551 r u i ,*,,,.)
: NO- ..p i." " 1h_ 1 (203 61 ..quaI\c .. '
15
2 0 10 & 1' 13: 13 : 08 CKr

s . .....:.. Li tl.
ItS'dab U1 ..
D.ub ....

Taxo nc.y
T1_" t.a"'P

q., ....,.. ;

8.u-... y~t ...lh.n u ~ ,../~al" GIf<RYE81 '1:-1 5\.....
sal.lO<>fyudl.lln Al O!i-tlo., rllJl.lE!11:t GIf'oC~T,I;Al PE-l $V...
F\uj.l\al d.hydr(>~.n •
1 I'ri~"t...o fI~'Hof!ItI ('::1~""[Olt l"l ~I SV...

Prot.40in hiu

.t.

Btlu t'rystd~ .. 1:1 ='5-1:10.. aaplela <JM-Cf>YMi:: f:E~.1 sv-::
Btlt.I eiy"tillhll ! 05"'~ .... p~>!I'" GN<flroS
1 !'1.~

Alpha- cl"f'!'wllJ.n

~

c:l'\uII

,)!~OIIO

'E..

lIapi'H,1I OUo<lIYM l,t..l

"a-.a_cryst.;oll1" tI

OS~

.r...pJ.e ....

O~GD

!,tJ·t'I"'pu:ll1ll ,..

~.a/)lol;i

3"f1,l"~:1 Glt-fYfBA~

peal.

~ .. .l

5V·~

n:.. l <;Vol,

G.-il--<cry.1ull1l1 0: ~-H(t.:l "af1l'!~ GIfOoCRYGC n ..1. SII"-.i.
H.Lot.. d.~.tr"'aUl"", QW.\olo:II•.:oncid.•u IJS-H_
'ilf--M1lII2 PKo-l J ....... ~

."p'"''''

Probab ili1y Based !\Iol\ow Srol""
lonll to:ore W- IO· I...ot!:(P). where P ia the probabilil)' Il.al the. ob~~ 0I31cllIJ "randO/u " tIll
Individlllli ionr ~"COr~ > 30 indiCllte iden6ty or extt'fIJ'iV6 hOlllolug)' (p<:O.05).
Proteill llOOte. al\.' d•.nwt! from ion. ""'Oft',

iii II.

IIOfl-prubaliJiJ:lic ~ rot rdloong proteill hilll_

tJ"ptit.lc S UnllIIUry R"port

~p1ickI SUJlITl3ry

Format As

Significance threshold p< ~

~1ax. number of hits lAUTO

Standard scoring 0 rvludPlT scoring

Ions score or expect cut-off ~ Show sub-sets

Show pop-ups
SaI9d".

,.

I SaI9d Nooe

Suppress pop-ups 0
Seardl Selected

Sort un:J.ssigned Deaeashg Score

I:l Err or to lera nt

i ArdlNe RepoIt

Mas .. : 28006
Score: 2 55
Queries matched: 7
Be t ,, - cry ... tall in B1 OS . Hama ... apien ... GN .. CRYBBl PE~l SV.2

o

OJ

Require bold red iI

I
emPAl: 1 . 20

Cheek to indude thi ... hit in .. rror t o ler"nt " .."reh or a ..ehive report

• "'=
'"
• .ill
• '"

•
• '"
• l'"l i
•
7~3

Observed
Ul .7581

Mrtexpt)
981 . 5028

Mr(calc )
981. 4841

p","
19 . 0

5 44. 293 1

1086.5716

1086.5458

23 . 8

563 . 3122

1.124 . 6098

1124 . 5866

20 . 7

725.90'4

UU . 8042

1 .... '.7616

29. 4

729 . 37!'>2

U!'>6 . 7359

U !'>6.6997

25 . 6

735.3457

1468 . 6769

lt68 .6252

35 . 2

860 . elBD

:L71B . B61!\

1718 . 8053

32 . 7

..

"',

~O~

U

"

"
"
"
"
"

,

pe ptide

E:cpect Rank
0 . 0049

}l .~IL£K . G

0.0011

IC . AAELPPGNYR .L

0 . 00027

+ olllid ation

IC . ISLf1!:GNIn: . G

5 . 5.-006

}l . Lvvn:LI:tJl'O(III..}l
}l . GYQYLU:PGDFR . H

0 . 00012

+ Prcpion.am1de

1 . 2.-007

}l.1oEFSGE£SNIADR.9

1 . 4 .. -DO!'>

K . VSSGTfIVGYOYPGTR . G

C"RBA.! llUMAN
MaU: 2S 1J4
Score: 132
QUe.r.i .. .!I matched : J
Beta - cry ... tall in A3 OS - Homo "".p ie n ... GN-CRYBA1 PE- 1 SV- 4

(M'

eml?AI: 0 . 46

I:l Check to include thi ... h it i n enor t o lera nt ..... arch or archive rBport
QUery

observed

744

728 . 182!,>

HIO(ellpt)
1454.7505

iii

750

500 . 9228

Ii!!

804

537 . 9500

Ii!!

Mr(calc)
145 4 .7041

ppm Mi .!! s Seo,,"
EXP"Ct Rank
31.8
0
6!'> 1.8G-00!'>
1

1499 . 7466

lU9 . 7442

1. 60

1610 .8281

1610 . 8053

14 .2

4 .. -006

50

0.00049

Ka!ls: S4B27
Score: 128
Queries matched: 6
Retinal dehydrogen .. " .. 1 OS - HOJI\o ... apien ... GN- ALDHIA1 PE- 1 5V-2

188

Peptide
K.ITIYDQENFOGK . }l
K . ~r n: ICDI FIGR.Q

+ OIldat.1on (N)

K.ITIYl,)Ql&NFQGfIlt.1ol

emPAI : 0 . 42

(e)

Appendix I

[J Check to incl u de thi .. h i t in eHor tolerant " " arch or archive repor t

Query

Observed

Mr"(expt)

Mr(calc)

395 . 2125

788 . 4104

788.4280

iii

12
E

408 . 7468

81.5 . 4790

815 . 475 3

4 .55

EI

322

473 .2 731

9U .531/i

9U .5291

2. 66

Ia

ppm

Mi s s Score

- 22 . 23

iii

530

595 . ]08 2

1188 . /iOU

1188 . 5040

-1 . 75

Ia

730

698.8557

1395 . 5969

1395.5738

16 . 5

iii

782

772 . 9095

1543 . 80U

1543 . 7571

24 .2

..

0

Expect Rank

35

0 . 031
0.0012

R . VTLELGGK . S

,."

K . SIJ>DV:lKR. A

"76

0 . 026

R.LllA~~GGIt.L

1 . 4. -006

R . nPlOONFl"TTTR . H

0 . 051

Mass: 23365
Scor.. : 113
Queries matched: 4
Bete - cry"t.al li n B2 OS_Homo s apiens GN_CRYBB2 PE_1 s-J_ 2

Query

Observed

Mr"(expt.)

Nr(calc)

ppm

.!Ql

512.7334

10 23 . tS22

10 23. 4410

11 . 0

Ii!!

ill
2!!.1..
lli

Ii!!

Ii'!

,.

archiv~

Check to include thi .. hi t in error tolerant " "arch or

if!

Mi s s Score

0

R . QAFOIGSPWR . T

repoet

Expect Rank

35

0.018
1 . 5_005

70 4 . 8961

1407 . 7776

1407 . 7398

26 . 9

66

512.9661

lS35 . 876 4

1535.8347

27.1

40

0 . 0047

880 . 9581

1759 . 9016

1759 . 8318

39 . 6

51

0 . 00038

Peptide

1

R . RDSWTSSR . R
K . llLYENl'NrI'GX . K
Jt . lILYENl'N1!"TGJ(I( . N

R . VQSGTWVGYQYPGYR .G

emPAl: 1 . 44

Check to incl u de thi ", h i t in errOl" tol erant " .. a rch or archive repo r t
Query

Obs erved

Mr"(expt)

Mr(e ... l.c)

ppm

Ii!!

1.Q

389 . 2280

776 . 4414

776 . 443 2

- 2.31

Mi s s Score Expect Rank

0

32

0.046

1

Pept1de
K .IOln::lt.G

if!

ill

454 . 2099

906 . 405 3

906 . 4019

3 . 81

R . ~. L

2)3

459 . 2257

914 . 4]69

914 . U85

-1. 83

"

0 . 01

!ill

47

0 . 001/i

ICITFYmK . M

Ia

ill

U6 . 790 4

991 . 5463

991 . 5 451

1 . 27

46

0 . 0018

R . GRQYLLDK . K

iii

~

386.2090

1155 . 6052

ll55 . 6037

1 .35

47

O.OOll

R.AVHLPSGOQYK. I

III

176

506.5923

151/i. 7552

151/i. 7310

15 . 9

]8

0 . 0089

lI;.lT~KtU"QGI. . R

..

+ 2 Oxidation

emPAl: 0 . 71

CRBS HlJ1oWoI
Maas: 20993
Score: 113
Queries matched: 6
Be t a - cry"tall i n S OS - Homo .. api an .. GI-CRYGS PE- l SV- 4

o

Peptide
K.SXDlWIK.R

0 . 0036

"

CRBB? HUt-'.AH

o

1

Mass: 19897

CRYAA HlWAN

102

Score:

Queries matched : 2

+ Ox.tdat1<m

(M)

emPAl: 0 . 37

SV~ 2

Alpha - crY"tdlin A chain OS·Ho:n" .. apien", GN·CI\YAA PE· l

[J O1,.cI: to include thi,. hit ln er~or tolenmt " .. ~rc h or archive eepot"t

Qllery

Obs erved

Mr (expt)

Mr (ca1.c)

ppm

!;'I

ill

588 . 3285

1174 . 6425

ll14 . 6194

19 . 1

III

084

437 . 9005

131.0 . 679/i

1310 . 6579

l /i . 6"

,.

Score: 61

Mis s Score

0

Expect Rank

84

2 . 8e-001

"

0 . 001.4

Querie. matched : 3

Peptide
R . TVIDSGISEVR.S

emPAI : 0 . 57

Gamma - cry"'t.a1 1 i n DOS - Homo sapie"" GN- CRYGD PE- I SV-3

o

Check t o inc l ude thi ,. hit in "rro. tol,." .. nt ""a rch or archive report
Qllery

Obs erved

Mr (expt)

Mr (calc)

ppm

fill

ill

541 . 8051

1093 . 5957

10U . 5769

11 . 3

III

1l1.

591 . 279 4

1190 . 5 44 3

1180 . 5261

15 . 4

34

0 . 024

R . YQIlI'I'GATNAR.V

iii

6 00

6]6 . 32]8

1.270 . 6]30

1.270 . 6016

24 . 1

39

0 . 0073

R.O~YR . R

,.

Mass: 22360

Mi s s Score Exp ec t Rank
1.

0 . 0017

39

Queries matched: 1

Score: Hi

1

Peptide
K.GlUTLYEr.!. . G

+ Oxidation (N)

emPAl : 0 . 15

Be t a - cry"tallin A4 OS - Ho:no .. apien .. Q I·CRYBA4 PE- 1 SV- 3

o
fill

..

Check to include thi ", hit in "r.or tolera nt " .. a rch or
Query

Ob s erved

Nr (expt)

Mr (cal c)

ppm

140

119 . 9018

1437 . 7890

14.31.150 4

2/i . 9

~

Ma ss : 20865

~rchive

0

0 . 001.4

46

Queries matched: 3

Se<Jr1O: 45

repoet

Miss Score Expect Rank
1

Peptide
R . LTlFEQEMFLGK . K

emPAl : 0 . 56

Gamma - c"Y"'ta11i" COS_Homo "apie"" GN_CRYGC PE_l SV_ Z

o

O;eck t o incl ude thi " hit in ....ror t o le,. .. nt " .... rch or archive report

Hi .ss Score. Expect Rank

Qllery

Observed

Mr"(expt)

Mr(eal.c )

PPII

451. 2519

900 . 4991

900 . 4811

9 . 12

eJ

ill
ill

47 2 .2141

"'2 . tS37

94 2. 4404 7

9 . /i1

34

0 . 027

K . lTP'lEDR . A

.Ell

488

564 . 9011

ll21 . S899

1121 . 5611

24 . 6

35

0 . 02 2

N . GXlTfT!:DR . A

Ii!!

~

10 .

M.... : !HI!U

K!o_~te .l...hy<uooen~a •

0

Quuy

Ob-..rve<1

Mr (e." t)

.E

' I'1. S""!lo

U .S 1 . " 4 0!lo

0 . 011

1

Peptide
R . nlLSEIR .S

s core: .(

• llitochonddal

:-S-JlI)~ ..JQ~l.ao!l" ~~

OIe"k to indu.de v.I. hi" in e"I:"O" t·,,1 .. ,... n:: .......u··~lI

RI

38

~

(_Ie;:)

1232 . "UJt

p~

22 . 4

(l,.

Mi.ss Scon
0
16

..

tt41 !tV"".

cd,iv.. r .. port.
Itxpect P.anlr.

0 . 014

189

1

hpttd.
LI F09Tr:LD..I:VlI. . A

(M)
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A1.2.2.7 Mascot search result for spot 7

(tt,'i:tfJ Mascot Search Results

_.

•• w

S ....",h

tiu ..

HS ct..uo fUe
Dat:ab •••

T..""n-y
'fi_ ~ t.II~

Prot..ill hit.

;
,
:
,

IMtt ,
.. Ut : hen ~pr ote. . . _o"9 .• u
suJ:.it.t.d r~ UOW 15 apab £..,., 20 9"l IftnUJl by w... •...,t O._n an AJ'AF- WS -28
\ \ H.a u-r>ecl\MS_ DAT" \ Qat:.r_XL\C l i e nl: ••
2010 \PAOJiOJXl<_ UOM_1 5\UOM_"l.~
, St/i . . P ..... t 20 10 1.$17100 •• quan"",. ; 112146551 .,•• i.""•• ,
Homo .... 1. n. (huaan) 12036"1 ..qua.,,;,• • ,
15 .:run 2010 .It 23:13:415 GMt'
Bau,-.::yse.dbn 110!:_1f0\0lCl' lI..pJa ,,,, G!K"~Yt\Sl 1'£-1 ~.;

"'Pl"' ''''n.

UU-C"l"1"'tdlln A;. '~H~ :o1pUn: G:t-CR'(1!Al PE-1 S~~
0 O::-HOI'IO •• op.I .. ns GIfooCJtY"<30 I'E_1 5V·-'
!le.U ..ery.!t.;tllin 92 ~ U¢I!- ~.YBBl Pf)ol 5';";
Alpht-<:rylIt..dUn 1>. c:1\a:1l ¢6-iJ"""O !t"pUlla Gli"'-"'YoU, J-"(>-! S'J'a
G._"~c: r.,... Ull'n

a.,t..I ·c:ryaul1HI

~

os·a.:.a..:;,

aaplllDII GN<AYQS

!'~.!

SV-4

G. . ..,..c (y"uillo C o:!IoflOlki IIIf.IHI!I.iI GW-Cf;YOC P~l SV·J
ATP 3YfILh.,,- Mlbufl,lt: bet • • mtochondrial cs-41o!110 :tdJ!Le-r,. aH ......fFSB i£:..l ,;v'"
JIooul'kll afhy<i[ogln""''' 1 ~"HOIIoD NpinM ..:;:r!.-Al.1!H1Al I'c:.l 5\'.. 2
~lut1n , typ. Jt .ytQllhhu 1 OSKf:!~o ll1l fllllllO .. N·~'1'l U;u.! "$V-.)
Pyruvate IUIlUII

1.Ol[Y.~

Hl,K:! Ds-H" • .:. :rapl"illI

a.u-<:, ...... ~ .. Uill

A4 b9-00H.:JbIO

'rnc:l'lu~c:lnlr-.J

prDt.ln P'.IMl1S17

GK~rr.MZ

P£·I SY-t

~.opJ"lW m.'<ItV!A~ ~~1 ~V..;;>

,:er.aun , tyJ:I~ 1 cytOllkel"yl 10 os&tla.o Silp.1.ell •

.;w ..)'JIt10 P&ot SV""fi

~-~ U.p~""T

r;","",JAAl1'97 ""1

5'V..o

flrobAbilily R!tst'd 'Iowllf' Soon'
101\11 "()ft' 1I. I O~LO{I(P),. who!1'\' P Ii 111" probability th:11 111eobi:el'Yj!(j nl:1lch if a rnOOo:lm l'venl
Indi\<idna,l iOlls IOI)m ;> 30 indicate idenilty or eXI...,lBivll hOnJol!'g)' (p<:O (5).
Protein jCOre, are-dellvrd fronr iOll' IWret a' a n~ ·probabffinil,: b~~ IhrTllru.3n& protetD ltibl~

PC'ptidc Summm)' RC'p0l1
~s

I Peptide Surrmary

Significa nce thres hold p< ~

Require bold red iii

Suppress pop- ups 0

Sort unassigned Docreasng Scorn

C Error to lera nt

A.chive Raport

Queries matched : 9
Scor .. : 295
BoI t .. - c,.y",t"Uin 81 OS - Homo ", ..pi en", GN- CRYBBI PEE l SV~2

CRBBI HUMAN

(J Ch .. ck

• "'-=
m
• .!i2.
•
m

•
•
•
•
•
•
,.

-1

Show sub-sets 0

Show pop-ups •

S9>\'ch Sek;>cted

,.

1\,lax. num ber ofhits !AUTO

Standard scorin g 0 MudPIT scorin g ® Ions score or expec t cut-off l30

Ma ... ,, : 28006

to include thi,. hit in .......... 0 .... tol erant ..... a rch
Mr(expt)

Mr(Ciil.C )

ppm

981 . 4848

981 .4841

0.66

5 U .U08

108/i . 5610

108/i.5458

19 . 6

563 . 3011

1124 . 5881

11.24 . 5866

1 .U

Ob s erv ed
491.7491

'"
""
ill

5U . 7801

ll8 5 . 5469

1185 . 5203

7Z5.897/i

1449 . 780/i

1449.7/i1/i

729 . 3/i13

145/i . 7081

145 /i.6987

'"
'"
.!!11.

135 . 3404

14/i8 . "/i2

14/i8./i252.

5 4 2..5973

1/i2.4 . 7101

1/i2 4 .72 /i3

2. /i . 9

8/i0 . 4364

1718 . 8583

171 8 . 8053

30 . 9

CRBAI HUt'oAN

No,,", s :

lS 1 34

Mh.

"
"
"
"

2.2. . 5

.."

13 . 1

Scor e : 142

Expect Rank
0.01/i

tc. AAt.:LPl'GtIYR . L

0 . 00033

ICI SLf'EGMI!'X .G
R . WN'l"II'SSSYR . S

5 . /i .. - 00/i

R.LVVl"ELENFQGR.R

0 . 0001

R . GYQYLLEPGDP'R . H

3 . /i .. -007

"
"n

Peptide
R.GE!!FlLEK .G + Oxidation 'N)

0.00077

0 . 03'

"
"

21 . 9

emPAl : 1 . 75

0 ..........chi" ........ port

~O~

0

1

R.AEFSGE£SNLAml . G + Proplon-=l.de 'C)
R . RAEFStZ!:;SNLADR . G + Pn>pionamid.. 'C)

0 . 00035
, .. - OO/i

Querle .. ma tched : 3

K . VSSOTWVGYQ'iPOYR . G

emPAI : 0 . 46

BGt,, -cry ... tal lin A3 OS- Homo "apien" GN-CRYBAl PE- l SV-4
[J Gh.-ck t o include thi " hi t

Query

in .. ""o~ tol er"nt " .. ,, ~ch

Ob s erved

Mr(expt)

Mr( cal c )

p,,"

Ii!!

700

7Z8.3800

1454 . 1454

1454 .7041

28.3

€I

707

500.9233

1499 . 7481

1499 .7 442

2 . 55

III

ill

537 . 9509

l/i10 . 8309

lUO .80S]

15 . 9

m ..

0 ...... rchi""

~ O~

"
"
"

[epoct

Expect Rank
8 . /i .. -00/i

K . ITI'fDQEIfFQGK. Po

5 . /ie-005

tC!!l'lfllK£\Q'lGll. . Q + Oxict.tion

4 .. -005

190

P"ptide

tc . ITI'fDQEHFQGI\R . M

'M>
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,.

CPGD HlJ?d.AN

Ma as : 2 0725

Score:

Queries ma.tched: 4

114

Gamma - c,¥"ta ll in 0 O$KHomo ""phon" c;N..CRYGD

PE~I

_AI: 0 . 82

SV~3

r:l Check t o i nclude thl " hit in .. .... ror 1Oo l " rll.nt ..... arch or archi ..... report

'"'=

• ill
• '"
•• ."

~

..

Observed

Mr(expt)

Mr{cal.c)

p..,.

.55 . 2381

909 . 4628

908 . 4603

2: . "13

541 . 80U

1093 . 581"1

1093 . 5768

10 . 0

5n . 21U

llBO . 5U 2

1160 . 5261

" .,

636.3215

12'10 . 6284

1.210.6016

21 . 1

MaU : 23365

CRS82 WMAN

,

..

Ni ... s Score

score: 100

"
"
"

,

Peptide

Expect RanI::

0 . 015

K. lnn:OR . G

0 . 0007 4

IIl . GIOTLTEDR . G

0 . 0001..1

R . YQDWGATNAP. . V

0 . 000u.

R . Q~.R

Que.r.ie.s matched: 2

+ Ox.1dAtion (N)

emPAI: 0 . 3\

Be t a - cry"tallin B2 OS - Moato sap ien" GN- CRYBB2 PE-l SV- 2

o

Check t o include thi " hit i n ere or toleu.nt " "arch o r archive report
QUery

Observ...:1

(""pt)

Mr (calc)

Ii'!

§.11

104 . 9016

1401 . 7886

1401 . 1398

'311 . 6

III

833

880 . 9625

11!59 . n04

l1!'1 9 . 8318

44 . 1

,.

CRYAA HUMAN

Mr

19897

Mass:

Alpha - e ~~t.allin

ppm

Mis" Sc","", Expect Rank

0

57

0 . 0001

/i4

2 .. -00 !5

Queries matched : 3

Score: 12

Pept.ide

1

It . lILYI!':NPNFTGK . lt

R . VQSGTWVGYQYPGYR . G

emPAI: 0 . 37

A chai n OS_Homo ""pien" GN_CRYAA PE" l SV_ 2

o Ch .." k t o include thi" hit i n .. rror t.olerant. "earch or archive report

"''=

..

• .!!i
• ."
• '"

Kr(expt)

Kr(cal.c)

!588 . 322o

1.114 . 6294

1114 . 61901

588 . 321>4

ll.14 . /i382

l.l1t . tiUt

4037.9045

1.310.691.8

1310.6579

.."

,

lIi . 0

(30)

'"'=

,.

ill

Observed

Kr(expt)

Kr(cal.c)

389 . 2 247

77/i . 4349

17/i.4432

-10 . 12

•

•

458 . 2280

914 . 4414

91.4 . 4385

3 . 18

386.2083

1.155 . 60 2 9

1155.6037

-0 . 53

!l0/i . 5 91.2

15l1i . 1518

151/i . 131o

13 . 1

,

"''=

Ob served

Kr(expt)

Kr(calc)

'"

451. 2 429

900 . 4712

900 . 4811

-11 . 13

no

472 . 2 329

942 . 4513

94 2 . 4447

1 . 05

ill

564 . 7981

l.l27 . 5811

1127.5611

18 . 3

ATPa HUMAN
ATP

,.

~yntha"e

"
"
"
"

Peptide
K. lQIFEJIt . G

0 . 015

K. ITPYEOK . "
R.AVHI.PSGG(lYK . I

0 . 001.3

K. ITFYEI»QI!"QGR . R

0 . 023

WlPAl: 0 . 56

MaSS : 56525

,

Peptide

U

0 . 0061

"

0 . 01.3

K. ITFYEDR . A

0 . 018

N . GKITE"TEDR . A

"

Queries lDatched: 1

score: 52

,

Miss Score Expect Rant;

p,",

R . !"HLSEIR . S

emPAl: 0 . 06

QUexy

Observed

695

718 . 3965

hit: 1 n error tolerant !!earch or archive report

("xpt)

Mr (calc)

ppm.

1434 . 7784

1434 . 1461

22 .1

Idr

Ma s,, : 54827

Score: 48

Retinal deh ydr og"na !! .. 1 OS KHocno ::!apien::!

Ii!!

,

0 . 05 9

!! ubunit b"ta , mit och ondrial OS - Homo !!api"'n!! GN-ATP5B PE-l SV- .3

ALIAl HUMAN

o

emPAl: 0.56

Ch .. c k to include thi !! hit: i n .. r ro ... tole ... a nt !!ea ... ch or archive report

[J Check t o include thl "

iI

JIt.IQTGLIlATHAER . A

Mi ss Score [xpect Ran'"

p,",

Ma ss: 20865
Score: 57
Queries ..... tched: 3
Ga!tllna - ery!!t.aLl i n C OS_HoItlo ""pi"n'" GN_CRYGC PE_ l SV_ 2

•

R . TVLDSGISI':VR . S

0 . 026

~

o

peptide
R . TVLDSGIst:VR . I;

4 .. -005

"

"

25 . 9

0 . 06

Chec k t o include th i " hit i n .. rcor to lerant !!earch or archive report

• l!.
• i'"'l l
•
•

,

p..,. Miss SCore Expect Rant;

Quaries lDatched: 4
eRes HUMM'
Ma SS: 20993
score: 66
Beta - cryat.allin S OS - Homo " api .. , .., GN-<:RYGS PE- l SV- 4

o

..

Observed

Miss scon
0

Observed

Mr(expt)

Mr(CHC)

lQ.

408 . 1396

8l.5 . 4646

815 . 415 3

F.:xpect Ran'"
o . 00037

Querle" matched : I
Gtl~ALOHIAl

Che", k t o inc l ud .. thi " hit 1n .. "cor t o l " ' '' tlt " .."re h
Query

52

PE~l

o~

Peptide
R . f'T(pIGSEVSA1.LQt . I

emPAI: 0 . 0 6

SVK2

archive C"pOr t

ppm Mis" Score Expect Rank
- 13 . 08
0
48 O. OOll
1

Proteins matchinq the same "et of peptide .. :
ALIA2 HUMAN
Ma " ,,: 56688
Score: 48
Querle" matched : 1
R.. t i mll d"hyd"ogen"" .. 2 OS - HOIOo ::!"pien::! Gtl- ALDK1A2 PE~l SV- .3
AL IA:) HtWAN
Ma.9s: 56073
Sco.,...: 48
Queri"s matched : 1

191

Peptide
R . VTLELGGK . S

Appendix I

Aldehyde d"hydn,q .. m." .. folldly t ",,,,,,b<>r 1'<3 OS-Ho.o "~Pl""'" GI~I'<I.DH ! A3 Pt- ! SV~Z
AL ! SI HW»:
Ma.:'I9: '57202
score: 48
Queries matched: !
Ald ..hyd.e d"hyd r oq"na"" X, mitoChonc\ria.l OS_Hemo " .. pi"n" GN_A LClllBI PE-l SV~2
ALDH2 HUMAN
~s: ~6J46
Scor.. : 48
Queries matched: 1
Ald"hyd .. d"hydroi!"na"", , mitochondri .. l OSaHexao "apiana GN-ALDHZ rE-I SV-Z
~

10.

Score: 3~
Quari"" matched: 1
_AI: 0.05
1 OS_ Heno "api .. n ... GN-KRT I PE_ l SV- 6

Ma .... : 65999

I(.. r .. t.in , type II <:yto"k" l eta l

Cl 01.. ",,- to inc.lud" thi .. hit in "rro< t o l arant .!!"arch oc arc ld ..... report

!i'I

11.

QUery

Observed

Mr(expt)

Mr(ca1c)

ppm

:n~

5 11 . 21 1 0

1032 . ~21!5

1032 . 508 1

1 11 . 2

)''P'fM HUMAN

Ma as:

Score: 33

~1~OO

Miss Score Expact Rank
0

35

0 . 0 24

Queries matched:!

Pyru ... a t e kin"sa i"ozym.as H1/HZ OSaHOIflO ""pia"",

GI~rKM2

PEal

Query

Observed

Mr(expt)

Mr(ca1c)

4 69

511 . 3099

1.UO . 6052

U 4 0 . S02S

~ote.1ns

KPYR

12.

ppm Ml.ss Score Expect Rank
2 . 26
33
0 _031

Peptide
R . WLOIE I PJU:tCV

...a.tching the s ame set oOf peptide.:
Ha .... : 61191
Queries matched: 1
Scar<>: 33

Mao",,: 22360

t'RBA4 IlWAN

iI

H'po~t

H\J}<.AN

a..ta - c~y"t:"ll in

o

emPAI: 0 . 06

SV~4

Cl Che<:k toO include. thia hit in erro r t o lerant .!!"ar.::h or lirchi ... e

iii

Peptide
R . TLIEGEESR . M

1

A4

OS~Homo

Score: 32
"api'm~

QU""ies matched: 1

emPAI: 0 . \5

GN- CRYBA4 PE - l SV- 3

C"h<>ek t " includ .. thi" hit In .. rrOI"" tolera nt " .. arch
Query

Observed

Mr (expt)

Mr (ca1c)

ppm

ill

119. 89 9 0

1431 . 1835

1431 . 150 4

23 . 1

o~

arcoi ..... repor t

Mis" Score Expect Rank
0

32

0 . 03 4

Peptide
R . LT r FEQEHFLGIC . K

1

K1 C10 HUMAN
Maos s : 56792
Score: } I
Querie .. matched : 1
emPAI: 0 . 06
](&,-at:in , t:ype 1 cyt=k .. l .. t:al 1 a OS_l1omo ""'plen" GN_KRT10 PE_ 1 SV_6

13.

Cl Check t o include this hit in .. rror tol ,Hant "earch cr ,,!'Chive reporL

QUery
!a

&

Observed

Mr(expt)

Mr(ca1c)

ppn

404 . 2003

806 . 3861

806 . 392 3

- 1 . 64

~ote.lns

Mi. a" Score Expect Rank
0

0 . 05

Jl

1

Peptide
R . LAADDn t . L

matching the same aet of peptidea:
Mass : 4~~'>7
Score: 31
QU""ies matched: 1

K1C13 HtJIo'J\I1

KeI:at:in , t:ype I cyt c"kaletal 13 OS- H<Xrlo ""pien " GN- KRT13 PE- l SV-'l
K1C14 HUMAN
Mas s : 5 1529
Score: 3 1
Queries matched: 1
Karat:i" , tYP" t cyto,,);elet.al l4 OS~Hcno ""pioon" GNzKR'14 P&<l SV- 4
KleiS IiI1MAN
MaSs : 4~ 1 67
score: 31
QUerie" matched: 1
KoI r"tin , rypo;o I cyt os k .. l _t.a l IS OS- Herno ""p:i'm ~ GN_KRTl~ PEs ] SV_2
I':lCl6 HUMAH
Mass: '51236
Score: 31
Queries matched: !
Ka~ at: in , t:ype ! cyt.o"kelet"l 16 OS- Herao sap ian" GN-KRTl6 PE-l SV- 4
K1 C !1 HUI-'.'IN'
Maos s : 411076
Score: 3 1
QU""ies matched : 1

K.. ,-.. t:in , t:ypo> 1 cytolok .. l .. t ~l 17 OSoH=o ""pi .."" GN~"Rn1 PE-1 sv" Z
/GelS HUMAU
Mass: 48029
Score: 31
QU""ies matched: I

K&,-,.tin , t:yp .. I cyt.oak .. l .. t"l 18 OS=oHC<no "api .. n" GN_KRT1El PF... 1 SV• .2
IClC19 HUMAN
Malls: 44065
Score: 31
Queries matched : 1
K... at-i n , t:yp<i- I <;:ytook .. l .. taJ 19 OSoH<XrlO "api.m" GN- KRTl9 PEal SV~3
K1C24 HUMAN
Maos s : ~~O!iJ
Soore: 3 1
Queries matched: 1
K•.,. .. t:in , t:YP'" r cyto"k.l~t:al 24 OS=!leno ""pl .. '1" GN"KFT24 PE- 1 SV-1
HUt-'JIN
Mass: 50536
Score: 31
QU""ies matched: 1
fuorat.in , ~ype 1 ,"yt""ke l eta l 28 OS .. H"...o "apl .. n~ al~KRT2B PRo-I SV~2
KlH ! HUM1IN
Ma s s: 412Q7
Score: ~ l
Queries matched : 1

Incze

K.. ~ .. tin , t:ypo;o

r

~

Ma ",, :

cuticul",- H,,1 OS"'li<.>m.o "apien" GN"I(RT31 Pl;'"l SVE]
~0286
Score: 31
Querie .. matched: 1
Ken""i n , :cyp.. ] cutic:ur" ,- Ha2 OS--Holo.o ,,"p Lom" GN~KRT32 PE - I SVE2
MaSI: 46 185
Score: 3 1
Queries ..... tched : 1
KT33E HlJIo'"AN
K.. r .. t.i n , type 1 cutic:ular ~,,3 - 11 OS_H"IOO ~ap ien!'l GN~ KP.T33E PE~l SV~3

KRT35 HUMAN
~s: 50329
K.. ,-.. tin , t:YP'" 1 <;:ut.i~ul~r HaS
)'1'T36 HUMAN
Mass: 522 14
Keratin , t:yp .. I cut i c:ular Ha 6
KRTJ1 WIMAN
Man: 49715
Kflcatin , t.ype 1 ,"uti<:ular Ha1
Mas s : 50447
KRT38 HUM.'IN
Ii.. r .. t-in , t:l'P" 1 cuticula,- HaS

tlnct."u<::t.;.rl~ ... ~

C Check

. ~

Score: 3 1

Queries matche d: 1

OS-HoIoO ,, ~pl .. n" GN" KRTJ5 Pt;*'2 SV- 5

Score: 31

Querie .. matched : !

OS~Ho!oo

""p i ",n" GN~KRTJ6 PE_I SV~1
scot:e: 31
Querie" matched: 1
OS- HOIOo .!!apiene GN_ KRT31 PE~2 SV_ 3
Score: 3 1
Queries matched: I
OS-Ik:<oo

,,~pi<m"

(;)"14:RT38 P£z2 sv-.3

proteI" 1I:IMI"'97 OO-Mccc .ii!'.ple,,,, 2,",I':!MI791 P!.-l !IVo-l

Inuude thJe hit In

e=~l

t.:lAc",n" 3&e,;::II'f .r::hlve r"P'ct

Query

Observed

Mr (expL)

Nr 1....1<;: )

PIB

!!..

~ n . nn

17" . 010t

n93 . 0 ....

- 4.1 . U

Mi . . Score IIIpec.t a.D.t.

JO

0 . 048

192

Pept.1d1t
(l . ~PQVLCtlk..D
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A1.2.2.8 Mascot search result for spot 8
(~W(/A'~

Mascot Search Results

u . ....

: H.-tt ,

_u

:

cat_ ...
T."on....y
'I'1 ....

.fttln.nry ~pr o e-e .or9 · ·\1

: 9L1t1aitteo:l frc. DOW l!i ,pot. tr<:a 2D 9"1 "UNAII ~ ....eot O.l._n on Al'M'- W!l -28
: \ \ tu, •• pK l \ MO_ DAI'A\ Q.u,r_X L\ CU . llt .uph.\ .JI,IlI. 2 0 10\ PJllo..nOJ:lOr_UON_ U \ I.IOW_ B • ...,r
: liNt •• PrOt 20 10 ( 511100 "'quln c . , ; 11 2 146551 ... . 1dUI' )
M'-> ' .ph .. , ( h ...... ! 12036' • • qu ....... . ,
15 "un 2 0 10 . t 23 : 14:26 can-

ae.f'CII Utl.
IW ","u tit.

t..,..,

"ii~~~[ !:::::;:~:~;hn
.5:
l1n

81

nll

PJ>II"l !W_'

05·B~ "'iIPl .. QI~nutl
.Ii"..'::
A) (:.:;-.!J.c!IiO ..... ,." .. !;lI-:':.1\"!l1Jll l'£)oj
suOOlIl.t DeUl, "l.ltOCbondr.L41. Cii"'IIOIIC "ap.1Ant

proUln IHt.

Gl'I'~T"~B l'Pl $vo<l

6:::,,:~~~~~~' tI OS-&al "1IfIl-1!11" Gj(~D Fbol SV")
!l OSooBo/110 "'''1».01' GfI.. '=I':tG& VDol $V"~
»~t..J.

lItt.-C'ry"t.ll!n».l

CROA HUIIA.

1'l"Obllbili1y

1J~I $ed

(IS....a..:;.o '!.lIhit ~,o;tta: ~"'1

SV-l

H"t.t ... tl",lIydragaD""., ...It;=lro,,ch:..lai 0_....:; .... p1-en:J ~1l!iI.<:"Ptt>-l ev<o l
Alp1\ .. - o ryeU.t.II;n A en/Hn OS91l<itoo(j dpl.r~ (;N<1\YAA r-.. , $VY..
•• ~·C'ry.t.dL1n .... OS'"&;ft) ~~n! GJi~~ Pi>l S'iIJ
r.lycr,.,l-J-rt)OPl'b,U d"lYtdt .. q.",,,~r I-Hb> proUill OS-S- ..,.tlpJ,.o-N' r.tloQ'OII ,."..1 """"1
G_"'-Cl"putl.J.u" ()!I:~~ tlilP.l.e:fI~ GH-<:/It:GA 1"!:.'0<': ~')

MO"·,t Scun

Itlns SOJi'1: II -IO"Lug{l». Yfhl:N f> i.! lh~ probability lhill tho ~ ~'1Y...d match J:I iI randQm io'VCIIL
Inilivnhlll i i.,n., s.::1lru!I > 30 irtt.fu;au: idllJ11J1Y »/ t'l}(h:l ~tl ~"'n.'\I"t;Y (1,.::0.05).
ProIem $COm! a~ den ved Itom i01l1 K O!l.:1!l II~ II oon- pmtrd billstl.:: basis t'i.'f rankill& protein hin.

·

'"

I

.I.

I'tplid t SUDlllmry R .. port

FOIiTlatAs I I Peptde SunTnafy
Significance th reshold p< 0.05

/I.'lax. n umber ofhits lAUT O ,

Standard scoring 0 MudPIT scoring FI Ions $core or expect cut-ofT

L

Ma SS: 28006
Bl OS~HOOlO

c"RBBl \-IlJl>!AN

BelO,, - cry"'lO~llin

score; 241
~~pien'"

GNECRYBBI

"""",,
~

,

ObslE>rVed;

Mr( " xpt)

Mr (ca.lc)

Queries matched: 7
P~l SVE2
~ .."rch

o O>..ck to incl'Jd .. thi", hi t in 'Hror tol .. "ant

• '"
• lli
• '"
• no
• no
•
• ""

.. ,..

"

~

0"

!ilL 01830

981.4,84,1

-1.15

1086 . 5618

1086 . 54,58

14. . 7

50

563 . 3094,

1l.24, . 6043

11.2 4, . 5866

>S .'

725 . 9100

1 U 9 . 805 4,

~4,"" .

7616

30 . 2

72' . 3751

14.56 . 7356

U56.6987

25 . 4,

735 . 3391

1468 . 6636

14.58 . U52

26 . 1

860.4398

1718 . 8651

1718 . 8053

3 4, . 8

"
"
"
"
"

~u - cry"'lOdl

a~chive

<=~

4 91 . 7488
5U . 2882

CRBllI HUHAN

p""

ObslE>rVed

Mr("xpt)

Mr(calc)

726

728 . 3806

14.54, . 7466

1454, .70 4 1

29 . 2

Ii!l

737

500 . 92.U

1499 . 74, 70

1499 . 74.4 2

1.82

iI

803

537 . 94,81

1610 . 82 24.

1610.8053

10 . 7

AiPS HUMAN

MaSS:

56525

score: 80

,

GO . .

Query

..

<==

"
"

1.20

""po~t

,

EXpE!ct Rank

P"ptide
R . ~IL£K . G

K . AAEI.PPQfYIl . L

0 . 00032

K . lSLRGANrK . G

6 . 3e -006

R . Lvvn:I.E:NFQ(R . R

O . OOOH

R . GYQn.u;pGl)fR . H
R . AO""SGl:£$NlJ\l)R . G" Pmplonalllld.

6 . 8e-005

11; . VSSmwYGYQYPGrR . G

en>PlU:

0 . 46

r"po~t

EXpE!ct

2 . 2. -005

Rant:

,

6 . 8e- OOS

P<!ptide
11; .

lTlTOQENFQGII: . R

1I; . !p"U·EIIDQ·lGR . Q ..

0 . 00013

QIler.l.. s matched; 1
~"arch

(W,

J . 2 . - 007

K . ITlYOQF.;Nf'QGKR . 1oI

_AI ; 0 . 06

.'liP ",ynt h"~" ",ubunit oota , ",i t ochooori"l OS-Homo ~apien'" GN~ATP5B PE- I SV- 3

IJ Q,eck to in cl udE> thi", hit in "",,0. to l ""'lDt

.. Oxidation

0 . 0007

MalIS: 25134
Queri .. s matched: 3
SC<ll"'" 131
in A3 OS-HOOlO "apien", GNaCRtBAI P~l SV- 4

il

Require bold red ii!t

emPAI:

0 . 0084,

"

o Check t.o inClude t.his hit in .. rro~ tol .. r~nt "" .. rch or archiv"

,.

30"1 Sho w sub- sets ~

I

Sort unassigned Decreasing ScotS

Suppress pop-ups 0

Show pop-ups

0" a rchiv ..
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Query
e

..

721

Observed
718 . 4043

Mr(expt)
1434 . 1940

ppm Miss score E.pect Rank
33 . 0
0
80 5 ..-007
1

score: 7B

o

Gamma - cry~tll. ll in

D OS_Hcmo

Check to includ."

thi~

~apie""

Queries "",tched: 3
~ es rch

hi t in error tolerant

Obs erved

Mr(expt)

Mr(ca1c)

PlU

iii

236

455.2390

909 . 4634

908. 4603

3.41

i!I

4 86

591 . 2911

1.180 . 5 4 89

1.190 . 5261

iJ

513

636 . 3236

.1270 . 6321

.1270 . 6016

CRES HlJI>'.AN

MaSS: 20993
OS~ Hoao

Beta - cry"tallin S

o

..

19 . 2

55

0 . 0002

Il. . TC!DWGI'LI'NAR. . V

24.5

46

0 . 0016

Il. .Q~rn . R.

Queries _tched: 4

Score: 67

,... ,

Mr(ca1c)

776 . 4398

116 . 443 2

- 4 . l9

906 . 5120

906 . 511 4

-5 . 95

386 . 2066

1.155 . 5980

1.155 . 6037

-4 . 86

506 . 590 1

.1516 . 1 48 4

1516 . 1310

11.5

score; 66

MaSS; 23365

Query

Observed

713

704 . 0934

OS~Hemo

Mr(expt)
1401 . 1722

"~pi .. ",,

K . ITLYEDP. . G

_AI:

,

Mi. s s Score Expect Rank
0 . 037

"

+ Ollidation

0 . 81

"
"
"
PE--l

Peptide
K .IQI FEK .(j

0 . 02

P. . QTI.I:DKK . E

0 . 01

Il. . AVHIRSOOQTlt . [

0 . 0071

K . I=DKNf'QGIP. . R.

Queries matched; 1

GN~CRYBB2

Mr(ealc)

PlU

1407 . 1398

23 . 0

MaSs : 35 4 81

dehydrogena~e ,

eml?AI: 0 . 14

SV~2

Mi.ss Score

eno~

Obs erved

Mr(expt)

Mr(calc)

PlU

611 , 3821

1232 . 1496

1232 . 1.129

29 . 1

463

Obs erved
588 . 3301

,.

P<!ptlde
K . IILYEHPNFT~ .K

emPAI: 0 . 09

GN-MDH2 PE- I SV-3

Miss score

score: 47

60

Expect Il.anl:.
6 . 5.-005

1.

Queries ..... tched: 1

~eptlde

It . l¥G'l1'TIDlVIl. . A

emPAI: 0.17

A "hain OS_H01tlo s"-pi ..",, GN-CRYAA PE_l SoIs'L
~" ... rch

C Chack to include thil! hit in error tolarant
Query

1

toleran t "" ... ~ch or ... rchive !:&por t

ill

Mass: 19697

Expect Rank
1 . 5 .. -005

66

~apien8

Query

A1pha - cr~ta l lin

0

Queries ma.tched: 1

score: 60

mitochondrial OS-Hemo

Check t o includa thi" hi t in

CRYAA HUM1\I,

Ii'!

1

"api""" m-:::R"lGS PE--l SV-4

Mr(expt)

MDHM HIJMAN

Ii!

Peptide

0.026

0

Check to includ .. thi" hit in e.ror tol .. rant " .... rch or .. rchive ... port

Malate

o

or archive report

34

454 . 2633

B<ot .. - cry"t .. llin B2

,.

_AI: 0 . 51

Mi. ss Score Expect Rank

Observed
389 . 221.1

CRBB2 Hl.lMAN

il

R. . I"TQAGst:VSAJ.LGR . l

Check to include thi" hit in error tolera n t "e... rch or .. rchive .eport

• """'"!d
•• '"
m
• '"
o

Peptide

GN_CRYGD PE_I SV_3

Query

,.

..

Mr(ealc)
1434 , 1461

Mr(expt)

Mrlca1c)

PlU

1.114 . 64 57

1174 . ti1 94

22 . 4

Mas s : 22360

of archive report

Mi. s" Score Expect Rank

SCor.. : 34

0

41

0 . 0013

Peptide

1

R .TVI.DSGISEVR .S

eml?AI: 0 . 1 ~

Queries matched: 1

Bat.3 - crY8tallin A4 OS-Heme "apie"" GN-CRYBA4 PE>-l SV- 3

o
o

Check to includ e t hi" hit in en or !;olerant searr;,h
Query

Observed

Mr(ou:pt)

Me(ca1c)

PlU

722

719 . 0955

1431 . 176~

1437 . 750 4

18 . 2

GPDIL l{UHAN

10.

Mass: 38394

score: 32

O~

archive report

Mi.ss score expect Rank
0

34

iii

i1.

Check to inc l ude

thi~

hi t in error tolerant

Query

Observed

Mr (expt)

Mr (calc)

ppm

ill

453 . 7211

It05 . 4216

905 . 4 217

- 0 . 05

eRG.>. HUBAl!

Mas ,,: 20863

S=re: 32

R .LT lfEO£NFLGIt . K

Queries matched: 1

Glycero l- 3 - pho"ph ltt" d .. hydroga n a"e I - l i k e pro t "in OS_Homo

o

~e" r"h

emPAI: 0.09

"api"n~

GN~GPD I L P£~l

or "rchive report

Hi"s Score Expact Rank
0

Peptide.

0 . 024

32

0.042

Querie s matched: 1

1

Peptide
P. . IC>EUGII. . V

_AI: D. 16

Gallllrta - c'ystallin A OS-Hemo ""pi .."" GN-CRYGA H>2 SV-3
o

II

Check to include thi" hi t

in "nor toleran t " .. arrh or .. "chlv.. r .. port

Query

Observed

Mr(el<pt)

lU(ealc)

ppm

289

412 . 2323

942 . 4501-

9 42 . 44 41

5.78

!Un s=re Expect RanI:.

32

0 . 036

<I"

'7'-' IflJH1l:;
" .... a ! ZO,t
Score : ) ; '
Q\lAr1.a .... t.cbed : l
GaaMa-::ryat&.llia B ::.!i-)t.-., u(:l<i .... 2""OYGl> 1'£-1 sv-:.
~
""aa , ;:.nB'~
Score ; 12
Qa&d..a _ tched , I
~.-

rysulUn c ns-\f

upt.._ '2/,<OYGC n-l lN _
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e

Il>

l!1
ill
...ll

~1 . U6l

1583 . ,.71

t.5"' . 7~,)

,U . "I

542 . 5""

1'24 . 1'25

U24 , 12&3

22 . S

"
15

0 . 0002'1
1.1.- OK

R..lWltsOI!!:£SlWUlfI..G + Proploumldl> Ie )

UCI . U01

1118 . '6'1

111.8,8053

3' . 1

11

3 . 1.-00'

K. VSSmwvoT(l'l'PGB. . G

kLl"l fI'IJMAN
Ha.... : ~482·p
~ : 'l!.9
Ollert... . . tCII-.d :
R..t.in.l d .. hyarOVi<I\AM I OS~I~ .upl..,. o;;r;.AWHIAI n·1 5V~2

2.

o

Ch...::k t..,

~

9

hlt In .rr ... tol .. r .. nt .s..... eh or .....:hiVt'

Obl4rVtIG

ME(.XPt)

.H lo95 . nOa
.!f 408 . 1U9
!! .1.5 2 U.,

'88 . Un

I)vtory

Ie

l"",l~ ~hi.s

l~

ppa MiU Scor.

ME(e.I.le)
"l8S . U80

-2 . 32

8 15 . 4172:

81!5 . "'53

2 • .12

828 . • "48

82' . "'05

5 . 18

40

"

rolPC'~~

IU:poet. IUnk

PtlpUdto

O. OON

fl. lttDD"nJ( . a

1

It . vn.m.OGK . S

0 . 0033
0 .05 1

1l . LADLCER . D

IiJ

:711

413 , 2182

,U .5 2U

13 .5

60

8 . 8.·005

1l . SlllOY"l fIR . A

£...

541 , U11

1014 . ' 7 K

1094 . 5608

.1l . 1

65

l . h-O~

It. VArroST'fiVGIt . L

iii

"i'

5!>0 , ana

10" . 62 02

lO" .5 t85

1' . 1

]1

0 . 051

M8 . Un

.11.14 . ..,11

UU . 6' 1I1

1.£ .5

4.

0 . 002!1

m

+ Od.doIUou ( M)

_AI : 1 . 40

I!

9

U4 . 5U'

.

0

R . ~tl.£IU1ICTPR . "

1t. LADl.l£ROR . t.
fl. fU)LIESOI(K . t:

ill

595 . 1.181

U81 . 6229

1.188 . 60 40

l.5.'

60

6 . "-005

R. QAf'OlGSPMR . "

Ie

§.£

U8 . MS.

Ut!5 . "1' 2

13'5 . 6718

lO . •

iii

• _2 .. -oD!l

1I. . ~~OOIt. L + 2 ou.s..Uon

e

!!1!

111 . a'lK

14 ] 3 . 1'"

10133. 1224

' 0.1

"

O. OU

"

9.-G01

lit

..:£

7"12 . " "

.15&.1 . 82'3

lS 43 . 1nl

36 . 4

Ii!!

ill
1....::.

"'!I . U IK

1588 . 85&5

1588.'18'6

. 9.1

549 . 2166

16 "

lii U . 1896

ll . 2

4.l

0 . 0021

82] . 4280

lIi U . 8U.

16014 . 8035

2' . 0

lil

• . 1.·005

5 &1 . 1i098

llin . 8076

16" . 1"12 9

20 ••

"

•

t

. 8081

It . r:I!tF'QoYQQI~ • •

(W)

+ Ox..lcl.touon (M)

11. . TIPl.DGM"fTTTIl. "

R . AIIln'P'laLSAaVPTK . D
K . lnIOfEllllDSVSQt . 1t
R . II'V1!ZSInEl'VlI. . R

0 . 01.9

R . ~~ . T

,.
Illph. - "ryato.lli .. '" ct,dn :>Soo1\QK> ... "pi ..... r.;r-; .. Cf<YM ,.Dol S'i"'2
[I

'::tl..,k

t

.i.no::l<7.M th1.

I" .cco;... tol ...... t __ .. ch or .n,hl . . . . ~[.

ctu&Q'

ObMC¥<14

ME(.:w;pU

~"6

51t . 1890

103' . " 3.

10310 .534%

- .1" .'15

ill

586 . 8129

U11.U.u

U1J. 5 813

20. "

hi~

1((" ..... lC)

pp"

ill 588 . 3289 U1 t . t U3 u n . li1t4
if!. ' ' ' . l U S 1114 . 5444 U1 • • UH

20 . 4

Irl
Ii!!

463

!l88 . ]lO'

ll1 t . U 13

ll 1 t . li1t4

23 . 8

III

603

t 3 1 . 9003

ill-O . ' ' ' l

U10 . U H

16 . 2

Ii!!

..

~

Ii'!

0

..,3

b~t.

0 .015

36

R . TVlDSGI SEV'R . I

• • 2e -00'

K . IQ'lGUlAl'KU:R .A

~

0.61

to include this hit in error tolerant a .... rch 0 ..... rchive report
_U~

Query

OI>.MlrYed

141:(e.q>t)

141:(<;.II1c)

PI:-

696

128 . 3858

14!1t . l!I11

14!1t . 10U

3I . t

1.,9 . 1 44 2

1"'.15"

IfiU

0

S~

lit

i!:JlptI<:.t ll,ank

2 . 3e-005

eI

1.Ql

500 . 9252

6 . 21

1i 5

1 . 8.-005

111

111
ill

!l31 . 9!lU

lilO . U,.,

1110 . 805]

1"1 . 1

!I'

1i . 2e-00!!

I!I

!I"' _1i 321

U2Ii . " ••

uu . un

20 . '

!l8

1.-0D!l

iii

ill "' • . 100'

2291 . 0810

2210 . " 41

]1 . 1

!l1

&. 1.-005

..

R . TVLOSGlSEVR . 1

' , !>rOO'
(!l2)
0 . 000.11

2~134
SCon. : IB6
QUar1 ...... t.ch..,, '
OS-HOIDo "'ph"", GN-CRYBA.I FE-I S1I-G

Peptld.
R . TwpnpsR . L

R . TVlJ)SG 1SEVR. 1

"

11

Roo>'l'"
I

0 . 0062

IU) 1 . 6.-006

n .3

Ma . . ,

Bate.- c .. yst.Uin
[I O\ec:k

..

Mha Sco.n

1

K. I 'l'l YDQDfI'QQK . II.
K . ~IrEItt:II'naR . O

+ OJli.s..Uoa 011)

K . I T r~ . 1f

R . I!:WGSHAQTSQIQSIR . R
R . ~ftSS£PNVS£IU;FDNVIl . '

~

Na. . , 23365
a..to - c .. y",~ ... llin 92 OS-Hcooo ""pie"" GMo-CIIY9B2 FE-I 511-2

IJ Ol,.."k too include th i .. hit in .. nOr tol .. ran t .... nch Or ... rchiv.. report

8

OI>.MlrYe<I

Mr(."Pt)

Mr (e.l1c)

ppm

324

U2 . 2!11.1

982 . t811

"2.4110

12 . 0

Mi . . Score

12 15 . 1 82)

1i . 18

0

Expect IUnlt

40

O. DO!I'

"

O. ODOU

Ii')

ill

401 . 2]12

12U . IiU8

Ii!!
Ii'!

ill

"10 • . 8189

140' . » 33

14 0" . 1"8

10 . '

740

512 . 94O!ll

l!il!l . t'JS!I

15S!1 . U 41

25 . ]

U

0.0019

il

lli
!!!

!l16 . 2811

1125 . 145 4

1125. 8011

22 . 1

5'

0 . 00012

880 . 15!11

l1!11 . 19!1&

l1!1' . "18

lI . 2

11

I!l

6.

Quezy

~

[I O\eC'k to

""' . . : 20993

Score: 122

!I'

1

0 . 05 3

R. . TllBLliIil.lUo'Ul . V

K . IILTt:IfPt(ft!lll: . Jt

1t. IILrDlPNrTClKIl . ...
K . OSSDf'OAPHPQVOSVR . R

1.3.-006

Quarl .." . . tched, '7

R . VQSGTWVGTQTPGfR.G

_AI: 1 . 44

includ .. thh hit in .r.. or tol .... ant " .... rch or ... rchlv .. report
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~

389 . 2298

716 . .... 50

116 . ""'32

2 .3"

iI

201

458 . 2269

914 . 4392

914.4385

0.11

"

0 . 0 45

K . IQIFEK . G

0 . 023

ILITrrEDll.N

€I

332

496 . 1818

991 . .5" 90

lIlI1.5 451

4 . 00

"

0 . 016

I!1l

lli

386 . 20'6

1155.60n

1155.6031

2 . 82

U

0 . 0025

36

i!l

727

506 . 5926

.I.51 6. 1559

1516.1310

16 . "

52

ill

129

!,)06 . 5983

1!'>U . 1131

1!'>16 . 7310

27 . 8

(35)

i!l

e33

511.3110

1728 . 9112

1728.8941

9.50

54

,.

eRGD HUMAN

Mas s: 20725
D OS-HOOIO

~"pien::<

Query

i!l

ill
ill

Ii!!

~40

,.

CRB.>.~

Observed
547 . 8064

Il . ITFTl'XIKNFQGR . R

0 . 016

K . I TFYEDKNFQGR . R

0 . 0002

R . KPIIl'IJGAASPAVQSFR . R

_AI : 0 . 57

GN-<:RYGD PE -l SV- 3

Cl Ch<i>Ck to includ .. thi ::< hi t in .. ~~o~ tol .. ~an t

iI

0 . 00036

Querle s matched: 3

Score : 1 1 6

Gamrn,, - c r y~tallin

R . GRQTLLD K . ~

R . AvtILl'SGOOTK . I

~ .. "~ch

o. archiv..

~epoI" t

Ran~

Mr( e xpt)

Mr( calc)

1093 . 5982

1093 . 5768

PP" "I1u score
!!I . Ii
'51

591. 2903

llBO . 5li60

.1.180.521i.1

33 . 8

50

0 . 0005'5

R . Y(pIfGATNAR. v

li36 . 33U

1210 . 65!,)3

1270 . 6016

42 . 2

65

1 . 7e- 005

R . Q~m . R

HUMAN

_a s: 22360

Score: 11 3

E Xpect
0 . 00011

Peptide

1

Qner.1ea matched: 3

N . GIllTLn:oR.G

+ Oxi d ation

(M)

emPAI: 0 . 52

Beta - cI"Ylltallin A4 OS - HOOIO Mp i""", GN-CRYBA4 PE-I SV- 3

a

O\&ck to inc l ude thi::< hi t in enOI" tol"I"an t "eaI"ch or aI"chivG I"epo.t
Query

Observed

Mr( e xpt)

Nr( calc)

pp"

Ii!!

679

119 . 9012

1437 . 7819

1431 . 750 4

26 . 1

10

6 . 1e- 006

!i!I

685

121 . 8510

1 " !,)3 . 681!')

145] . 62!!6

]9 . 8

50

0 . 0005

eI

75~

522 . 96 14

1!'>65 . 8624

1565 . 84\53

10 . 9

40

0 . 00008

,.

Miss score

Expect Rank

_ u: 20865
Score: 79
Querles matched: 4
Garnma - cI"y"ta l lin C OS_HOOlO "apie"" GN_CRYGC PE -l SV_2
in

~~ror

tol eran t. " ..... rch or ... ~chive

Query

Observed

Mr( e.Xpt)

Kr(calc)

pp"

Ii!!

lE

" 51 . 2530

900.4914

'00 .• 811

10 . 1

Ii!!

267

412 . 2340

"'2 . 4550

942 . .... 41

i!I

lli
lli

5 64 . 8009

112 7 . 5812

606 . 2612

J.Zl0 . 5H1

!i!I

CRYMl HlJMAN

10.

11 . 0

36

0 . 011

1121 . 5611

23.1

U

0 . 0049

N.GKITra:DR . A

1210 . 41 41

31 . 2

41

0 . 0011

1I..£QIIiI"~ . A

1

K . ITf'Y!!DR.A

Querle" matched: 2
PE>-l SV~2

Query

Observed

Mr ("xpt)

Mr (calc )

PP"

329

4 93 . 158B

905 . 50]0

'8!i . 4 069

16 . ]

e!

449

389.2250

1164 . 6532

1164.6503

2.5]

0 .. ~"chive

1i!I

toleI"ant

Query

Ob9erved

Nr( e xp t)

Nr (calc)

PID

370

514 . 1'41

1027 . 5136

1021 . 5&6 2

1 .2 4

'!'HOIO HUMAN
!>$a u: 68253
IQ motif ano a nkydn I"epeat

12.

e~~or

Query

ill

Observed
436 . 7659

on ;

emPAl: 0 . 3 6

"I1 s" Score
0

Expec t Rank

Peptide

46

0 . 0016

K . HFSPED.K . V

50

0 . 00058

1

Score: 35

~",aI"C:h

oc ... cchive

_Al:

~epo.rt.

Miss score J;; xpect Rank
0

42

0 . 06

0 . 00"]

"Peptide

1

R .AlOiJll.I.AR . N

Querl .." matched: 1
ernI?AI: 0 . 05
pI"ot .. in LOC642574 OS·Holllo ,,~ pi .. n" PE·4

dom~in- cont~ininq

(] Ch"",): to indud .. thi" hi t in 0" .. 0I" tol .... " nt

!a

+ Oxida tion

I"eport

QuerIe s matc hed: 1
GSHB HUMAN
Mass: 523~2
Score : 42
Glutathion .. .'Syntheta" e OS.HOOIo 9apie"" GN·GSS P .... l SV. l
(] Q1ack to im::lude thi" hit in

R . I"HLSEIR . S

GN~CR YA.B

thi" hi t in "I"I"OI" tolo","'nt .'SeaI"ch

e!

11 .

Oddatlon (M)

"Peptide

0.0012

Score: 10
_ " .. : 20U6
a chain OS~Homo "api .. n~

includ~

+

~eport

.. 0

Alpha - cI"y"t~llin

(] Q1""k to

K . ~FQG'I. . R

R. LTI R QENE"LIJI(k . G

Miss Score E xpec t Rank

0

R . L Tl RQ~ . K

_AI : 0 . 82

~

Q Ch"",k. to inc l ooe thi" hi t

"Peptide

1

NI::(e xpt )

Mr(calc)

ppm

811.511]

811.4875

3" . 1

~ .. a .. ch

SV~ 2

Or a I"chiv .. I" epOI"t

Nisa Score Expect
1
35
0.026

Ran~

1

Peptide
R.LRQEAQK.A

OrO! Ii1..IMAN
_ as: 116599
Score: 34
QUerIes ma tched : 1
_AI : 0 . 03
O.al - fac i al - diqit a l syndrome 1 pI"otein OS- Hol!lO sapien .. Ci"l-0F DI PE- l SV- l

13.

o

Ch~k

Query

Ii!

ill

to im:lOOe thi " hit in .. nOI"
Obaerved
553 . 0213

tol"I"~n t

Mr( e. xpt)

Nr( calc)

.110 5 . 6280

.1105 . 6053

~ .. aI"ch

OI" ... "chive

r epo~ t

PP" Miss score E xpec t Rank
20 . 5
1
34
0 . 024
1

197

Peptide
K . !:~lI'XSuaK. I

+ Oxidation

(N;)

PrOpionilllldde

(e)
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A1.2.2.10 Mascot search result for spot 10
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,.

ALIAl HIJ}'.All

MaS,.: 54827

Re tinal deh yd'ogen .. "" 1

o
ia

Score:

O S ~HOI!lo

Quer:1es matched: 7

151

emPAl: 0 . 50

""p ian ... GN2ALDHIAl PE·l SV-2

Check t o indude thi" h it .in 'nco,- to l enmt " .... reh or an:hiv .. repo,-t

ppn

Qu ery

Observed

Mr (expt)

Mr (ca1c)

22

395.21.35

188.4..125

188.4280

-U . til

Mis s Score

0

Expect Rank

31

0 . 017

Ii!)

~

408 . 7415

815 . • 684

8.15 . 4.753

-8 . 48

21

415 .2 420

8 2 8 . 46941

820.4105

- 1. 35

"

0.0012

Ii'l

eJ

334

fo1l . 2 16 J

9U . 53 81

9440 . 5291

9 . 56

!l1

a . GOGH

iI

468

548. 2 983

109 • . 5820

1094.5508

19 .3

62

3.Be-OOS

Ii!)

ill

595 . 3030

1188 . 5915

1188 . 6040

-10 . 5 )

35

0 . 02

iI

826

112 . 9141

1543 . B148

15403.1671

30 . 9

51

0 . 00044

,.

Mass:

eRa"l HUMAN

25134

Score: 14 7

Peptide

1

K . SUlDVI:K . R

R . VTU:UJOIC S

0.0056

U

Queries matched: 3

K. LADLI£R . D
K . SIDDVIKR . A
K . VAt'TGSTIWGlC L

R . QAFOIGSPWfLT

R . TIPIDGNFFTYTR.H

emPAI: 0 . 4 6

e.. t ,, - c::yst .. llin A3 OS - Homo ""pie"" GN-CR'tBAl PE-l $'1- 4
o

iii

Ch<tc k t o inc:lud" t hi " hit in "rror to1"r"nt " .. ar"h or a,,,hi,, ,, r"port
Query

Observed

Kr(expt)

Kr(calc)

ppm

122.

128 . 3119

1454 . 1413

1454 .1 041

25.6

iii

189

500.'238

1499 . 1495

1499.14 4 2

3 . 49

eI

ill

531 . '5 31

1610.8392

1610.8053

21 . 1

..

EJ:pect Rank

Miss Score
0

86

1 . 6e- 001

61

' . ' .. -006

fa

+ OJ:idat.1on n4)

K . ITITD(lENI"QGl(R . III

emPAl: 0 . 6 0

Check to include thi!! hit i n error to1er"nt " " "rch or archive report
Query

Observed

Ia (expt)

Mr (ca1c)

.!!Q.

.519. 1833

1036 .35 2.1

1036 . .5342

PP<'I

Mi ss scor..

ia

529

588.3304

1114 . 6463

1114 . 6194

iii

703

431 . 8948

1310 . 6626

1310.6519

3.H

E:o:pect Rank

Peptide

U

0 . 00085

R . TL<Wf'TPSR . I.

54

0.00022

K . IQTGUlATHAER . A

-115 . 67
22. ,

,.

Peptide
It . ITIYDQENl"OGJ(.R
K.~lFEICEN!"IGR . Q

0 . 0011

CRy;,;.. HlJIoW,j
MaSS: 19891
score: 131
Queries matched: 3
Al p ha - crY8t.allin A chai n OS_Hom" sap iens GN_CRYAA PE ~ l 5'1_2
[l

1

R . TVLDSGISEVIt . S

CRBA4 HUMAN
wa.s ... : 22360
Scor.. : 130
Queri ..... matched: 2
Be t " - c,y" t.ft llin .114 OS ~ Homo ""p ian" GN_CRYBA4 PE- ] 5'1- 3

emPAI: 0 . 32

[J Check to include thi " hi t in "Hor tol"nmt " " a rch or archiv" repor t

Query

Observed

ldI::(expt )

la(ca1c)

ppm

iii

lli

119 . 9006

1431. 1861

1431.1504

25 .2

iii

778

121 . Bn4

1453 . 6B03

145 3 . tiZ96

34 . '

..

Hi ... s

0

Sco,,",

El<pect Rank

' 3

2 . 0 .. - 00B

63

2 . 1e-005

MaSS: 2336~
Score: 1 0 1
Queries matched: 3
82 OS _ Homo "ap i e ns GN_CRYBB2 PE_ ] 5'1_2

CRBB2 HUMAN

1

Peptid e
R.LTIF!:(J!:NFLGK.K
K . ~EDGFQGR . R

+ OJ:idat.1.on

amPAI: 0.50

~t,, - crystallin

o Ch""k to include t hi!! h it i n error tolerant ....... rch or "rchive report

score

Expect Rank

Peptide

Ii'!

421

512 . 7321

10 23.4.509

10 23 . . ..10

9.69

42

0 . 00. 3

R . WDSWTSSR . R.

Ii!)

76~

104.8940

1401 . 7135

1401 . 1390

2• .0

51

0 . 0001

fa

l!.iL

880 . "'41

1159 . 9136

.1159.8318

46 . 4

51

0 . 00036

Query

,.

Observed

Mr(e:.pt)

Kr(calc)

ppm

Hi ss

Querie ... matched: 7
~
NUS: 20993
score: 99
Bet8 - cryet"llin S OS- HCClO "ap i"n .. Gti-CRYGS PE - ] SV- 4

1

K . IILTENmFTG1LK

R . VOSGl1fVGTQY(>G"fR.G

anPAI ; 1.44

I::J Check to include thi s hit in error t ole L"n t .. e "rch or "rchive report
Observed

Mr-

~

389. 2 180

116 . 4215

716 . 4432

- 21 . 95

iii

264

• .5 • . 2 135

906 . H Z.

906 . 4018

11. 1

39

0 . 01

R.~. L

iii

212

458 . 2281

914 . . . 28

914 . 4385

' . 62

3.5

0.025

K.ITnEI:.t . N

496 . 7181

991 .5.U

991 . .5451

-2 . 16

43

0 . 0037

386.2085

1155.6036

1155.6031

- 0 . 01

31

0.013

R. AVULPSGGQYK. I

Ii!!

ill
ill
2l.l

518.8143

.1155 . 614 .1

ll55 . 6037

9 . 08

(34 )

0 . 029

R • .AVHLPSOOQYK . I

iii

820

506.5928

1..516 . 1564

1516 . 1310

16 . 8

52

Ii!)
Ii!)

,.

CRG(" HUMAN

Ma liS :

("l<pt)

20 B6~

Mr-

(calc)

Mi ... s score

QUery

iii

Score : 78

G<>mma-cry:ot."llin C OS- HOItlo ""pi"n"
[l

ppm.

0

31

El<pect Rank
0 . 058

~E~l

Pflpl1d e
K . IQlPEK . G

K . ITnEDIQil"OGR. . R

emPAl : 0 . 56

SV- 2

Check to include thi" hit in error tol",."nt "e" rch or "rchive r"port
QUery

Observed

Kr (e:.pt)

Kr (calc)

ppm

Hiss Score

El<pect Rank

200

+ OIid.ati o n

R . GltQYI,UlK . K

0 . 00035

Queries matched: J

GN~CRYGC

1

Peptide

(M)

(M)

Appendix I

iI

237

451 . 2U4

900 . 4842

900 . 4811

2 . 15

51

0 . 00015

III

332

472 . 2l51

942. 4556

H 2. U4 1

11 . 6

0 . 011

iI

ill

564.8011

1121 . 5816

1121 . 5611

2l . 5

"

..
!i1I

~

Observed
59:1 . 2181

III

.§£2.

6l6 . 1310

Query

10.

GSHB HIJM./IN

K. ITrYEOR.A

0 . 0011

4Ii

CRGD flIJl"'JIN
Ma as : 20125
Score : 71
Queries matched: 2
Go.mllla - c.y:nallin 0 OSKHoJoo "apiens (;NKCRYGD PE~1 SV- 3
[J Check to includ .. thi "

R . FHLSEIR . S

M.GlOTFYmR . A

emPAl : 0 . 35

h it in .. ,," "" tol .. rant " .. arch Or archiv .. ""port

Mr(expt)
ll80.5428

Nr(calc)
1180.5261

ppm His" Score
14 . 1
0
45

1.270.641 5

1.210 . 6016

l6 . 1

Mas.!!: 52352

Score:

54

Expect Ranlo
0 . 0021
1

R . Q~.R

0 . 00023

Queries matched: 2

6~

Peptide
R.TQDftGATltAR.V

emPAI : 0 . 1.1

Glutathion .. "ynth.. ta"e OS-Homo ""pian s Gi-GSS PE-l SV- I
[J Check to include thi .. hit in e'Tor tole""nt. " e ~"ch o. archive .epoet.

Query
~

330

III

ill

Ob " erved
411.l122
514 . 7981

Mr (expt)

Mr (calc)

940 . 6098

940 . 5105

1021 . 5811

ppm Miss Score
41.1
0
36

1021.5'62

59

15 . 1

Expect Rank
0 . 015
1
1 . 2e-OOS

Peptide
R . ALAEGVLLR . T

R.JUD/El.J..AR.N

K2Cl HtJIo'.AN
Ma s.!!: 65999
Score: 52
Querie" matched: 1
emPAl : 0 . 05
Keratin , type I I cy t osk... l ... tal 1 OS_Horno sapi ... n~ GN_ KRTl PE_ I SV_6

11.

o
III

Check to includa thi .. hit in ... 1:""" tol .. nmt '....',ch
Que ry

Observed

Mr (expt)

Mr (ca1.e)

ppm

4.17

51.7 . 2693

1032 . 5240

1032.5081

14 . 1

01:"

archiv .. report

Mi s s Score
0

52

Expect Ranlo

o. OOOU

1

Peptide
R . TI.LEGlEESR . W

Queries matched : I
emPAI: 0 . 06
!GGIO HUMAN
MaSS: 58792
Score: 36
K.. raUn , t~ 1 cyto"kaletal 10 OS~ HC<Ilo ""pian" GN-KRllO PE--l SV-6

12.

o

~

Check to include this hit in .. rror tolerant !!ea rch or archive report
QUery

Observed

Mr(ElXpt)

Mr(caJ.e)

ppo

~

404 . 2042

806 . 3'3'

806 . 3923

1. 97

W .... score EXpect Ranlo

J6

0 . 01"1

Peptide

R . lAADDFR . L

Protein s match:l.nq the S8llle set of pept.1de s :
KICU HUMAN
Mass: 49557
Score: 3 6
Queries matched: 1
Ka,"tin , t.ype 1 cyto"k" l .. tal 13 OS'-HC<D.O "6pi"n!! GN- KRTl3 PEal SV- 4
MaS S: !;1529
score : 36
Queries matched : 1
h"lC14 IllJl<W'I
Keratin , tY"P" I cytOl!kel"tal 14 OS-Homo " ... piens GN-KRTI~ PE_ I Sv- q
I(IC1~ HUMAN
M...... : 49167
Scor.. : 36
Queri .. s matched: 1
Keratin , t.ype I cyt:oske letal 15 OSo-HC<Ilo " "' pian" GN-KRTI5 PE_l SV- 2
KlC16 HUMAN
Mass: 5123:6
Score: 36
Quer ies matched : 1
"a ~at:in , t.'/P" 1 cywsk"latal 16 OSooH<;fIlo ""p.i.an" GN-IIRil6 PEal SV-4
nCt1 HUMAN
MaS S: 48076
score: 36
Quexi .. s ..... tched : 1
Kerat:in , t~ I eyt08kelet:61 17 OS-HcrJlO sapiens GN-KRT17 PEa l SV_2
IU.CH.I H"UMAN
Mass: 48029
Scor.. : 36
Queries matched: 1
Karatin , type I cytoskeletal 18 OS- HCfllO s"'pian" GN- KRTI8 PE_ I SV-2
"ICI!! H\.IW\N
Mas s : 44065
Score: 36
Queries matched: 1
Karatin , ""YP'" 1 cyt.o,.k"l .. tal 1 q OS~H<;XlIo ""p1o.lruo GtI"'''~TI9 Pg..l SVK3
KlC24 H\.II1J\}l

Ma SS:

55053

score : 36

Queries matched: 1

Karatin , type I cy t ollkeletal 24 OS-Hano s"'pien" GN-KRT24 PE_ I SV- I
KielB Hl.1I-tII.N
Mas s: ~0536
Score: 36
Queries matched: 1
K.. ~ ... tin , t.yp<> I cyto"k"I .. ta.1 28 OS-Hccco ""'pian" GN-KRT2E1 Pg..l SV- 2
KIHl HU?-'.AN
Ma .... : 47207
Score : 36
Queries matched: 1
t~ 1 cu ti cula~ Hal OS-HoI;.o ""plan" GN"'KRT.3 1 PE "l Sy..3
Ma ss : 50286
scor .. : 36
Queries matched : 1
Keratin , type 1 cuticular H62. OS-Homo .'!apian!! GN-KRT32 PEa l SV- 2
KT33B HIJM.I\N
Mass: 46185
Score: 3 6
Queries matched: 1

Kerat.in .

~

K.. r .. t:in , ~ r cu t icula,. H,,3-Ll OSmHomo " ... pi..,n" ~K~T33B PEsI SV-3
KRTJ5 HUMAN
Mas . : 50129
Score: 36
Queries matched : 1
" ... ati n . rype J cutL<=ul",. HaS oSaHolO.o ""pi.an " GN=K~TJ5 PE~2 SVKS
KRT31.i HlJHAll
MaSS: '52214
Scor.. : 3 6
Queri .. s matched : 1
KAratin , typ .. 1 cuticul .. r Ha6 OS.Ho",~ s8.pi ...... " GN_ KRT.16 PE~l SVool
KRTl1 Hl.JK>.N
Mas s : 49'115
Score: 36
Queries matched: I
"'... "tin , t:yp6 1 cuticul .... 11,,1 OS"Homo ""pi.en,. GN'=KRTJ1 1;'£*2 Sy..3

1.3.

HllHM HUMAN

Ma as : 35481

Score : 36

Queries matched: I

201

emPAl : 0 . 09

+ Oxid.iltion

(M)

Appendix I

"e~reh

r:J ctJ.eck to include thi" hi t in error wlenl.nt

iI

14.

[J

Ii!I

15.

Query

Observed

Mr ("xpt)

Mr (calc)

ppm

.lli.

611 . ]881

U3l'.7616

12]2 . 7129

.] g . 5

Score: 35

ENOl'. HUMAN

Ma as : 47139

Alph" - .mol",,~

OS- l!= " .. pi~"" GN-ENOI

or archive ""po,t

Miss SCOr<!! Expect Rank
~6

0

0 . 016

Queries matched: 1
~E - l

Peptid..

1

K . IF<.VTTLDIVR . A

emPAl: 0 . 07

SV~2

<::11 .. c k t o include t hi" hi t 1n .. rror tol .. r"nt "e ... rch or ",,,hive report
Query

Observed

Mr-(expt)

.!l

40] . 7310

805 . H75

~

Mu ... : S6S25

Mr-(calcl
805 . H46

PP'"

Mi. .... Score Expect Rank

] . 57

0

score: 33

]5

0 . 02]

Peptide
K . TNOLlR . r

1

Queri ..... matched: 1

emPAl : 0.06

ATP "yn t hllse "ubunit beta , mitochondrial OS-Homo ""pien" GN-ATP5B FE- l SV-3

o
iii

(beck t o include thi" hit in erro .. toler .. nt " .... ,eh or ... ,chive cepo, t
Query

Observed

Mr (expt)

Mr (calc)

ill

718 . 4000

143 4 . 7855

14:14 . 1467

Mas ,, : 57069

ppm

Miss Score Expect Rank

27 . 1

Score: 32

0

33

0 . 027

Peptid..

1

Queries matched : 1

R . F'1'Q'-GSEVSALLGR . I

emPAI: 0 . 06

ho"tacyclin "yntha" .. OS- Homo "api .."" GN - PTG1S PE - \ SVz l
[:J (h .."k to include thi "

iii

hit in .. rror toler"nl: '''''arch or a rchive .. eport

Query

Observed

Mr-(expt)

Mr(calc)

ppn

1i

40.5 . 8073

809 . 6000

809 . 5487

61 . 4

Mi"s Score Expect Rank

1

12

0 . 03 ]

202

1

Peptide
R . l.U'lU.AP. . G
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A1.2.2.11 Mascot search result for spot 11

llt11Xt#J Mascot Searcb Results

....

-"
...."""..

-

. . .. ok . . . . .

..

~

. . . . . .. . . . _ 0

.n " ....... , •

..IO\.oo.n ..:o:_.o._,,\..._. .... ,

•• • • u •

~

.,.....
.......

~" .

.;,, __

,"-~, .. "

~_ "''''''' if .'O"L<WP ~ whon P io tho prOOilility LboI.lIoo - . - J -.;:h if . -.10m "" ... .
_"illta1 ;o"..",","" • JO .. "".,.. idtruIy o...
~ ~ 11'0:0.05,.
1'1" ..... "" .... .., """,,<d ...... ""'" ...... '" •
tiI&IIi< _

".noiI..

""'"r", ...

1,11
· ,11.1
,.
f_~ ,

-

R~ p<>r1

".,.&0.." '1nsId.! poe

M",."""...,..or". A\lTO

n~

0.'_ .
... ,,......"" .,.........." .-.... .......... .....,...........,
--......... '"
........,,"
. . .. .... .. ..."
" .. ......... ,,.,.......,.,
'"
"
...
.
..
""
...
,.
.
",..""
......,......". .....
...... .............
.
" ...,.".,.. ...
"".""
.,,. .....
.... ... .........
' .""""''*''_0_·'
. . ... 2101.

L

I,

_5_

P'1'lid. S ommo ,,'

r... ,.,....."',,"'" '""

" .'"

101

"""""H' ..

" " _o<yoto.1h. "
p ••••
_I .v·'
C Ch,,' to ,n".'" co... "," C ,n '''0' ro'.cont .... "" 0'

•
•
•
•
•
••

90"~

ill
ill
ill
ill
ill

Pop".'

• . -¥,.a.. .• •
•. '!.. . .......

. . . . 1 ...

, • • • . ~Tl.

n .•

...... n

~

!f;!

» . .. ...

.... . no>

ill

. ....00.
•••• O/.l'

.....,..", .......,
'" "...... .....,... .......
• '" ,....... ......,.. ......." >0.'
•

"cr.,_ "po"

)

.... ........
.....
" ........,
"

203

0 ........

. . un'",,".~

~."",--"

• . •••• LIa . .. . . .

. . . . . .LID . . . . . .

......_go"'"""•.• •••• p, .........

'"

no, . y_ :

Appendix I

•

2.!:.

~ZS . 1353

L!)83 • ..,IU

l.583 . ..,153

U .8

....,

O.OOll

Ii!

.!l!

5 4 2 . 5U-I

UiU . 1S5'

1124 . ",z63

.ll . :t

"15

.1...,...006

1l . 1U\D~ . O

e

...!!

860 . 4 41 4

1..,.18 . 8183

1111 , 1 053

4:2 . ~

84

2 . 1.-001

k . 9S8OnWGTQTPGnI. . G

II

~

8U . OSlI

Z 43' . 2288

un . uu

.sa . 8

"

o . oon

2.

"1\YMHI'MAI1

M;,.. . :

Al~"""ryn.llin

1989"

A "haln

Qt>oariou....,tcbed : 6

269

~:

C\!-~

upieNi GN-CR'lM

o Cheek. t.o lnelu:l" ".hL.!! hit in .. ncr

~

oo-rv.d
!lU . ZZl1

Kr(.xpt)

lCr (CAlc )

- ...

10)6 . U8e

1036 . 5342

-LOLU

~

JL !la' .aus

U1.l .U2S

ll11.58·))

21 . 5

U'J4 . 6U"

20 • •

N1...

n
'0

R . T'lUlSG1 SEVIl. 1

588 . 3315

U'J4 . US4

u n _ltlt.

2 1 . '"

84

~..

t.2J . S531

1285 . 6375-

12.15.nO)

~ . 63

U

U10 . '57'

U .,

I!i

c'1':tA,l

M.a • • , 25134

~'MAII

u,..·b-~ry.t.dUn

awe);.

~

Sco:IrOI : 2:"lf.

It . llFSftDUVJI; . V

2. 5.-00'"

IT.

o

R . n.Gl'rTl'SR L

5 .1.-005

R . ~II!lYR . S

iii

3.

1'0000tida

nl) , . t_oo..,

19

1310 . n u

_AI : I . n

0 000"'5

588 . 32tO

437 .89"

It . GNTll!l~Gll'SDIl . Y

Expect Rank
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0
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1t . ~ . H
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ppm MI. •• Scar..

iii
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.,2 . Z528
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"2 . 4110

384

51.2 . "'lCO

102l . 4574

1023 . 40410

1f . 0

"3.

0 . 041

ill

IlL

~Q4

41Ni . U""

U.15 . nl1

1.2.15 . I8U

"' . 11

I..,

0 . 0014

iI

ill
.ll!!

..,01 . to31

140"' . ..,,22

1.40"' . 7398
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5'

' . _005
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411 . 2551

1425 . 11"
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m
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~
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31 . 4
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1 . .... 00fi
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ill

512 . '''2
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1.1 . 3

U
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~

6.

E .~t
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0 . 00041
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Score: HI
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1
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_AI, 1.44
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QUery

!!l
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3" . 230.
451 . 2295

Mrtft:q>t)
116 . 4411.
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PI"" N1 a. Scar..
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0
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&iI

no

• ProplOltUUde te )
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I!

1.1..,4 . 64'.

.. o"",,",UOQ

, ••ud\ 't .. n;:ht"". r<lQo)1't.

t..~I"r'\nt

/01

QYU7

1l . ~ll%IQZ'tl'R . 1II

bpect bilk

Peptide

0 . 03'

1t . 10IFP:It. 1i

1t. lTrYEDIt . 1I

ill

4~ . "'850

Ul . 5554

Ul. 5 451

1 0. 4

l5
U

0 . 021
0 . 011

Ii!!

4~e
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ll55 . 603..,

1 . 41

4'

0 . 0014

IIiIl

]J..!

51Ni . 5"".

1.51.1 • ..,116

1.511 . ..,310

21 . '"

51

0 . 0001.2

iii

lli

571 . 31.50

1121 . J232

1121 . .,....,

1.1 . '

"'1

" . a-olNi

204
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Appendix I

,.

Mas s : 46344
Score: 139
Queries matched: J
FumarylacetoacBtase OS-HOIDO ""pi ens ~-FAH PE - l SV-2

FAA!< HUMAN

mlPAl:

0 . 23

o Checl< to include this hit in error tolerant search or archive report

Ii'!

Query

Observed

wr(expt)

I.rr (calC)

ppm

~

417 . 2906

952 . 566'

~2.5Sn

1.U

Miss score

0

R . ASSVVVSGTl'IR . P.

1 . 5ft-DO!)

R . Vn.QHLLSVSQAR . L

!ill

469

586.8 481

1111 . 6816

1.111 . 6561

21.1

676

131 . 9505

U13 . B865

141] . 8304

18. 1

66

Cl\YAB HUI-W'I

MaSS : 20146

1

_AI:: 0 . 86

Queries IlIatched: 4
score: 13B
"" pi.",,, GNsCRYAB PE-l SV-2

OS~ HOOlO

Alpm. - c"""tallin B ch" in

Chack to include thi .. hi t in error tol",rant s"arch or archive repo:n;
Query

Observed

ppm

Expect Rank

Peptide

!i'l

334

409] . 1586

Sl85 . 5021

985 . 4869

Hi . O

42

0.0042

K .HFSPEELX.V

e
e

43 4

544 . U18

10B7 . 5211

1087 .5 041

15 . J.

51

0 . 00015

i§2

389.226]

11.64 . 6572

ll64 . 650]

5. 90

16

1.1e-006

!i'l

709

156 . 8169

1511 . 'J393

1511 . 611.5

"

..

PGl(l HUW\N

Mt:'(expt)

: 44566

Man

Pho"Phcqly" .. rat ..

kin~" ..

1

!orr (calc)

Mtu Score

0

Queries ma.tched: 4

sccu:e: 123
OS~HOlOO "~ pi .. ",,

Query

Observed

Mr(expt)

Mr (cal.e)

GN~PGKI

ppm

0, .. ~chiv..

Min Score

Expect Rani<

4 34.2t59

866 . 4772

866.4604

10 . 1

527

62t . 3460

1246 . 6791

1246 . 6809

-1 . 41

757

5 45 . 6101

16]3 . 8102

1633 . 1049

15 . 5

54

0 . 00023

ill

860

992 . 0241

1902 . 0]31

1901 . 9303

52 . 2

66

1e-005

1

38

0.011

MaJla : 20665
Score: 94
Querle" ma.tehed: 4
Gamma - crystallin C OS- HOOIO sapien.!! GoI-CRYGC PE- 1 SV-2

Query

Observed

Mr(expt)

Mr (ca1e)

ppm

.ill

4 51.2529

900 . 4912

900 . 4011

10 . 5

iii

276

472 .2]41

942 . 4536

942 . "47

9 . 49

e

447

564 . 0019

1121.5893

1121 .5 61.1

!ill

4q7

606 .2 661

1210 . 5117

1210 . 4747

~

Ma.!lS:

Gamrnll - cr~tallin D

. Oz1dation (M)

K . l"SUPVAV£lK . S
K . LG:DVYVNnAFG'I'AHR . A
K . ~JGTSLn:a:GI\K . I

• Ox.1.d.iltion (III)

_AI: 0 . 82

20725

Score:

OSg Harno ""pi"""

Mi ll" Score

0

Expect Rank

51

0 . 00064

25.0

"

45

0 . 0022

35.5

51

0 . 00049

0.01.3

Querl"", ma.tched: 3
PE_1 SV_J

91

1

Peptlde

R . nn.sEUt..S
K . ITrtEDR . A
N . GlUTTYl:DR . A
R. ~. A

•

Oxidati.on

(KI ; Prop.1onamide (e)

emPAI: 0.57

(N~CI1YGD

Ol<>ek t o include thi" hi t in "HOr tol""ant "eareh o. ,,," chiv .. r<lpOrt
Query

Observed

Nr(expt)

Nr (ca1e)

ppn

435

541 . 8013

1093 . 6000

1093 . 5168

21.3

B

47i

591.2870

1100 . 5595

1.100 . 5261

20.2

46

0.0016

R. YQDIfGA.TNAR . V

B

5 42

636 . 3331

1210 . 6511

1210.6016

39.4

51

0 . 00051

R.Q~Ylt . R

Mi ll s Score

1

50

Expect Rank

0 . 00054

1

Peptide

N.G1UTLY!XfI..G

• Illl1datlon

1M)

Querlea matched: 2
_AI: O. Li
Mas s: 39395
Score: 50
Fruct.08e - bl s phosph"te ... ldol ... ".., A OS - Homo ""'pien" Gl- AlJX)A PE- 1 SV- 2

12.

ALOOA HUMMl

o

(hac:k

to include

Query

Observed

Mr(expt)

Mr (cal.c)

il

~

382 . 23]8

162 . 4530

162 . 4640

B

759

549. 6l!il

1645 . 0235

1645 . 8019

thi~

hit in error 1OO1.,ran1O ""al:"ch or a,chive ,"port

ppn Mi.as score Expect Rank
-14 .3 6
0
50 0 . 00096
1

U .,

0.04

Peptide
l CVLAAVYK.lI,
R . LQSI~.F

Queries matched: 1
_AI: O. Oi
Masa: 44906
Score: J8
4- hyd,OKyphenylpyruv"te diol<ygena"a OS - Homo ,,~pien" Gl- HPD PE- l SV- 2

~

13.

o Ol<>ek t o inc1ud .. this hit in enor 1Oo1",r ... nt "ea.ch o r

Ii!

(M)

a,,,,,k t o include thi" hit in erl:"Ol:" tolerant " ..",·ch 01:" archiv .. report

8

9

+ Oltid.iltion

Peptide
K .~.E

0.0009

CRGC HlJl-Wl

o

R . APSWFD'l"GLS~ . L

raport

ill

11.

K . VLGDVlEVltGK . H

_AI : 0 . 33

E1'I

o

R .QOf:I«.>FlSR.£

PEsl SVs 3

e
e

10.

1

0.0032

.9

C a,,,,,k to inchld .. thi" hi t in "rIcOr tol .. .,ont " .. ~rch

14.

ft .~ H'ISK . ~

2 . 6a-006

i!

o

Peptide

~nk

1.1e-005

74

,.

Eapect

59

QUery

Ob" erved

Mr(expt)

Nr (ca1e)

ppm

436

550.2761

1098 . 5316

1090 . 5168

1' . 0

~rchive

rapo.1O

Miss Score Expect Rank

0

38

0 . 0094

1

Peptide
K . ~1.'.LAYR .1>

t

Ozldat.1.00 (M)

Queriea matched: 1
_AI: 0 . 01
eAClI HUMI\.'!
Haas: .244945
Soor<!: 12
Voltage- dependent T- typa calcium channal subuni t ... lpha- lI OS-Harno "apians GN-<:AOlAll PE- 1 $V- l
C (he<:k t o includ e

thi~

hi t in error tolerant ""a,ch or "rchlve '''POl:"t
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A1.2.2.12 Mascot search result for spot 12
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c:

!>a1Nll1i t.:'n'.UllIJl

nat

05·1[0100 lIi1PlelU. GlI·Cl\fGC

,v-.l

"..I S~

..2

Ga_ii"cryuillll.l1 • QS-II..o lIap lilnit Glloo<:lI\o ... ilt.. , eV-i
torbltol IP.l'lyQ~ nOl'. 03-801lI0 lIilJHtna 1iM~lffJlUI fP'1 '~4
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Upb" ·C ~.li1lllJl I

., .... ""110 ".p.i.n, GH"'IIJI

t:h.u.n

C.II""~

P~l ~\I·2

s.puu eM-aU.II a-I I:V..z

IJrobllb ilily n U,I\«I.J\1owse Soon-

Ions score ii ·In''lOJlP~

~'herr

P is [/Ie probalJility Unit die romer\'N mau:h iJ . rllnda)nt eVil,", .

Individual toos ~ores> 30 wdiellll! idelltily orulelUivt hOflV)l~' (JKtl .OS)
Protein k"Ol'tB are derived from tans!lNn'S as 111 IKlfl-probMbllislk baN lOr ranLillg Ilmtrin hill.

P("ptilie Summary Report
Foonat As

Pep1ide Sunrnary

Significance thfl.'shokl p< 0.05

M ax. number of hits IAUTO

Stand.:!rd scoring 0 /... lud PIT scoring

Ions score or cxp.:ct cut.olT ~ Show sub -sc ts ro-'

®

Sort unassigne d IDeaeaslng SCOfIl

Show pop-ups e Suppress pop-ups 0
I Select AI

,.

Search Selectad

Select None

CREEl HUMAN

Mass : 2800 6

e...t~ - "'-Y"t~llLn

o

",~p L ..n'"

'"'=

2QQ

m

Ob"erved

Mr(expt)

Mr(calc)

491 . 1551

981.4969

981 . 4841

50t . 2 1149

1006 . 5153

1006 . 5634

544.21136

1086 . 512 6

1086 . 5 4 58

553 . 3140

1l.2 t . 5134

1.12 4 . 5866

511l . 1803

1 1 85 . 5460

1.185 . 5203

125.9038

lUIl.11130

lU9 . 1616

1211 . 3128

1456 . n09

1456 . 6991

135 . 3449

1468 . 6153

1468 . 6252

528 . 9336

L583 . n81l

1583 . 1653

542.5952

1624 . 1636

1624 . 1263

860 . 4426

1118 . 8106

lUS . 805l

C!<8B2 f!UM./IN
Mass: 23365
Beta - c.y", t a ll i n B2 OS-Homo

' ArchMt Report

Quer:1ea matched: 11

emPAl:

2 . ~~

GN- ClWBBI PE-l SV-2

Che<::k to i n cl ude thi'" hi t in e.-ICor to lenmt

• m00'
• .ill
• .!!l
• m
•
• '"'
• m
•
•
• nl
• '"
,.

Bl OSmHOJOO

[] E rr or IO lcr anl

Score: 340

RC(juirc bold red ii'I

"e~ ," ch

"IC arch i ve '""P"ICt

"'" • .,
"
"
"
"
"
"
"
,."

W .. " Scare

13 . 0

..

ll. . 8

24 . 1

2l . 8

,

Expec t Rank
0 . 0011
O. OU

Peptide
R . ~u:tt . G ...
R . ~nu'IICM

O. OOll

II: . AABLFP"GNYR . L

0 . 00046

"' . I SL.n:GNI"nC G

(H'
(H'

21.6

0 . 008

21 .1

3 . 4.-001

R . Lvvn:LE:KFQGR. R

22. 2

• . 3e-005

R . GYQTLLEPGOf"R . K

3t . l

3 . 1e-001

R . AEI"SGII!:!:SIIlJIDR . G ... Proplon am.1de

8.55

0 . 01.3

23 . 0

2 . 5 ... 001

l8 . 0

5 ... 006

score: 195
Querie s matched: 8
GN-CRYBBl PE- l SV- l

R . WNnfSSSYR . S

R . ~u:KGETPR.W

R . RAEr~SlIIAIlR.G

emPAl : 1 . 93

",~p i .. n'"

QUery

Observed

Mr(expt)

Nr(calc)

ppm

ill

482.2852

962 . 55511

1162 . 5 t 37

12 . 7

Wn Score
0

33

Expect Rank
0 . 035

207

... Oa.1dation

1

Peptide
R . GLQYl.Lf.lCG

(H'

... propiolUlJllide

II: . VSSG"l""iWGYQ'!PGYR . G

o ChQC k to i nc lude !:hi" h i L in "r r or to l erant ",,,arch or a"ch ive ""Port

Ii!!

Oxidation

... Oxldation

'C,
'C,

Appendix I

iii

1.li

492 . 2498

982 . 485 1

982 . 4160

9 .2 5

I!'I

386

512.1320

1023.4494

1023 . 4410

8.22

iii

ill

406.2359

1215 . 6860

1.215 . 6823

3. 0 2

iii

689

104 . 8989

1401 . 1833

1401 . 7398

30 . 9

I!'I

2l§.

512.9616

1535.8630

1535.8341

18. 4

"
"
"

"

0 . 038

K . GEQEVFEK . G

0 . 025

R . WOSlfTSSR . R
R . TDSISSllU'IK. V

O . Oll

K. I

49

0 . 00061

iii

828

516 . 2852

1125 . 8331

1125 . 8011

15.4

50

0 . 00041

Ii'J

ill

880 . 9601

1159 . 9069

17M . 8318

42 . 6

80

5 . 5e-001

K. DSSDFGAl'HI.>QVQSVR . R

_AI ; 0 .8 7

Ch&<O k to include thi", hit in ... ror coler" n t "".,•• ch or arch iv," r epo.t
QUery

Observed

Mr(expt)

I!lr(cal.c)

ppm.

I!'I

.§2.2.

128 . 3832

1454 . 1518

1454 . 1041

32 . 8

I!'I

106

500 . 9253

1499 . 1540

1499 . 1442

6 . 54

iii

ill

531.9516

1610.8329

1610 . 8053

11 . 2

I!'I

.ill

564 .5 985

1690 . 1131

J.li90 . 1488

14 . 1

53

0 . 00021

iii

529

516 . 6281

1126 . 8644

1126 . 8351

14 . 9

51

8 . 3e-005

..

Miu Scar«

0

Peptide

Expect Rank

64

2 . 2 _ 005

65

1 . 1e-005

1

K . lTI 'lDQENFQGK . R
rt.!!l I ff.:I<ENYI!:R . Q

R . wnMfSGSNA'lHIER . L
R . f."W(ISlQ'oQTSQIQ8IR . R

emPJU : 0 . 60

Chooc k to includ .. thi" hit in .. ,,:or tol .. r" n t " .. " r ch 0" "rchi ..... rlilPo .. t

MI.""

Query

Ob"erved

Mr(expt)

Nr(cal.c)

I!'I

lli

519.1182

1036 . 3418

1036 . 5342

-185 . .59

Ii'!

467

588 . 3254

1114 . 6362

1114 . 6194

14 . 3

Ii'!

46B

588 . 3 2 14

1114 . 6403

1114 . 6194

11 . 8

8 .5

2 e-001

R . TVWSGISEViI. . S

I!'I

625

437 . 8919

1310 . 6719

131 0 . 6519

10 . 1

61

.58-005

K . IQTGLIlII\.TlIAER . A

,.

ALooA HUMAN

Mass,

39395

ppa.

Score: 1 30

Score

0

Expec t Rank;

31

0 . 0.13

Queries ItIatctt.erd:

Ob a erved

Mr(expt)

Nr(cal.c)

382. 2 333

162 . 4521

162 . 4640

I!I

2.
.il

401. 2492

800.4838

800.4156

10 . 3

iii

280

470 . 1546

939 . 4947

939 . 4114

iii

633

666.8685

1331.1231

1331 . 6932

..

Peptide

R . l"LGPf"YPSR . L
R . TVWSGlSt:VR . 8

emPJU: 0 . 38

4

SV~ 2

Chec k to includ" thi'" hit in error tole .. ant ",earch or arch ive report

QUery

I!'I

1

(55) 0 . 00022

Fructo.se-bi"pho.sph"te a ldo l a"e A OS-Homo ",api""" GN-A.UXlA PE - l
o

+ Olddiltion

K . ITI YDQENFQGKIt . N

CRYAA HUMAN
MaSS: 19897
score: 159
Querie s ItIatched: 4
A.1pha- c.y",tallin A chain OS~Homo ",,,pi.m,,, GN'"I:RYAA FE-I SV~2

o

K

R . VQSGl'IfVGlQYPG"I'R . G

Querie s ItIatched: 5
CReAl HUMAN
MaU: 25134
score : 186
Beta - crY.5u.llin A3 OS-Homo "api<>n.5 GN- CRYBAI PE- I SV-4

o

[L YENPNFl'GK .

K . I I LYENPNFTGRK . M

CRas HlJMI\N

WI .... : 20993

Score:

W a s Score

ppm
- 15.52

Expect Rank

49

0 . 00098

18 . 5

"

48

0 . 00091

22 . 5

18

1.1e- 006

107

Peptide

K . VIAAVYK . A

0 . 01

7

QUeries _t.ched:

R.AL~.A

K . E:I.SOIAHR . I
K. GlIAADESTGSIAK. R

_./\.I'

1 . 44

Be.t.. - cry"ta l lin S OSEHomo ""pi .. n ", GN-CRtGS PE-l SV-4
o

Ch"c k t.o .i.nclud.. t.hi", hi t. .i.n error to l "r.. nt ",,,a rch or arch.i. ..... report
QUery

Observed

Mr(expt)

Nr(cal.c)

ppD.

I!'I

l2.

389 . 2218

116 . 4410

116 . 44 32

-2 . 85

Mi ss Scar«

~

390.2179

118.4213

118.4225

-1.51

iii

228

458 . 2 2 68

914 . 4391

9 14 . 4385

0 . 60

iii

49 6.1819

991 . 5492

991 . 5451

4 . 16

iii

ill
ill

386.2093

1155. 6060

1155 .6031

1 . 99

"
"

41

0 . 0013

I!I

721

506 . 591.5

1516 . 1528

1516 . 1310

14 .3

50

0 . 00051

K . ITFYEDIOIFQGR . R

iii

830

577 . 3111

1128 . 9 1 34

1128 . 8947

iO . 8

52

0 . 00029

R . KPIDWGAASPAVQSH'l . R

0

34

"

Expect Rank

0 . 034

K . n!"Y~ . N

0 . 02 9

R . GRQYLIDK . K
R . AVHLI'SGGQYK . I

emI'./\.I: 0 . 33

Check to include this hi t in error toler .. nt ""arch or archive report
QUery

Observed

Mr(expt)

I!lr(cal.c)

ppm.

ill

434 .2 470

866 . 4794

866 . 4684

12 . 1

I!I

.!1.:l

442 . 1323

883.4500

883 . 4439

6 . 81

iii

40 3

522 . 8295

1043.6445

1043 . 62 2 7

20 . 9

58

9 . 3 ... 005

iii

ill

566. 32 31

1UO . 6329

1130 . 6084

21 .1

49

0 . 00085

CRGD HUMAN

Ma a,,: 20125

Garnll".- cry",tallin 0
o

R.QYI.LI»(.K

0.072

iii

..

Pepti de

K . IQln:K . G

0 . 024

Score: 106
Querie. _tched: 4
PGRI HUMAN
Maa ", 44 586
Ph""pooqlycerat.e kina",e 1 OS-Homo .. ap i e"" GN-PGKI PE-l SV_3

o

1

OS~Homo

Miss Scar<!!

1

44

Expect Rank

0 . 00 41

Score: 106
Querie" "",tched: 3
"api ""'" GN_CRYGD PEo-I SV~3

+ Ol<1di1 t1. on

K.ELNY"FAK . A
K . Ln.aQ.INK. G

K . AEPAKIEAH'l . A

eml'AI: 0 . 57

Ch&<Ok t.o Includ .. t.hi" hit in .. ,,:or tolar .. nt. "earch or archi ..... r"Port.

208

P"Pt1.de
K . AOO~ . E

0 . 002

(It)

(M)

Appendix I

Ii!!

QUery

Ob s erved

Mr(expt)

Mr(ca1.c)

ppm

4 33

541 . 8066

10'3.5'86

10113.51611

20.0

Mi ss Score

@I

.!1Q 5'1. 2 8 14

1 1 80 . 5483

1180 . 5261

18 . 8

I!'I

ill

1210 .6191

1210 . 6016

13 . 8

..

636 . 3168

1

Expect Rank

51

0 . 00045

54

0 . 00022

R . YQDWGA.TNAR . V
R . Q~YR . 1l

CRBA4 HUI>!N<
Man: 22360
score: 93
Querie.s Ulatche.d: .2
B<l.t ,, - c<"Y" t .. llin M OS ~ Ho",o " "pian" lJN- CRYBA4 Pg.. l SV~ 3

Cl Chec k t o inc Iud .. thi " h i t in en'or toler a nt " .. arch

1"1

~

Observed
llll . !w23

@I

698

121 . BSU

QUery

10.

HPPD!l\JWUoI

Mr(expt)
1&31 . 11100

Mr(calc)
1431 . 150.

ppm Hi 58
21 . 6
0

1453 . 6936

1453 . 6296

U .O

Mass :

0 ..

+ D.tldation c:K}

eml?JU : 0 . 32

" rchive rep o .. t
E><pe<::t Rank

~

10

6 . 1e-006

U

~eptide

1

R . LTlFEQENl"LGK . K
t('~EllGf"QG1R . 1l

0 . 00014

Queries matched: 4

Score: 92

44 906

Peptide
K .GICITLTEDR.G

+ oudation

(M)

_AI: 0 . 33

4-hydroxyphenyl py"uv .. t .. dioxygan" " .. OS " Homo " "pian" GN-HPD PE-I SV- 2

Cl Oleck to include thi" hit in e.r .. or tolerant " ... arch or archive report
QUery

Observed

Mr(expt)

Mr(ca1.c)

ppm

I!!I

22 5

455.11111

901l . 5 UII

1109 . 5284

18.2

Miss Score

Ii'!

ill

516.3012

1030 .581'

1030.565'

21. 4

47

O. OOll

I!!I

43 6

550 .2140

10'8 .5 335

10'8 . 5168

l!i . 2

53

0 . 0002'

K . ~n:PI.AYR . G

eI

ill

568.2861

1134 .5511

1134 . 5305

24 . 0

40

0 . 0061

K .Al!"EEEQtIUI..G

0

Expect PalIk

30

Score: 8 1
Queries matched: 4
Masa : 20865
cry" t ... llin COS _ Homo " "'pi..." " Gtt-CRYGC PEEl SV~2

Garru:l ... -

o

R . EVVSHVIK.Q

K . TEDIlTAIIl.H

ill

Observed
451 .25 02

Mr(expt)
1100 . 4858

Mr(calc}
1100 . 4811

ppm Mi ss Score Expect Rank
4 .51
0
U
0 . 0035
1

1l . flU.SElll.S

eI

282

4 12 .2 3 U

1142 . 45 42

' 42. 4441

10 . 1

41

0 . 0014

k.ITFTEM.A

Ii'!!

445

564 . 8001

1121 .5868

1121 . 5 6 1.1

22 . 8

n

0 . 0031

N . GKI TFYEDR . A

III

ill

606 .2584

1210 . 5023

1210 . 4141

22.8

33

QUery

o Check

t o include thi " hit in er .. or tolerant " e ... rch or at-chive report

ppn Mi .... Score. E.peet Rank
111.1
n
41 0.0014
I

Observed
472 . 22H

Mr(e>tpt)
942 . 4~42

"4~ . 4447

Ill1 .5810

U~1 . 5555

22.1

31

0.055

ill

ll~7 . 5868

1121 . 5611

22 . 8

4.3

0.0 Jl

282

564 . 80(\;

Mr(ca1.c)

QUeries matched: I
Ma .... : 38300
Score: 51
Sorbit o l d<>hydrogena"e as - Homo "apie rl.!! CN- SO"lW PE-I SV- 4

222

Observed
455 .2608

Mr(expt)
1108 . 5010

Mr(calc)
1108 . 5080

ppm

- 1.06

Hiss Score Expeet Rank
5 1 0 . 00054
1

°

Queries matched: 1
Ma SlO: 46344
Scw::e: 38
Flunacyl acetoacBt .."" OS- Herno " "piarus IJN-FAH P&-l SV- 2

o Check to inolude thi" nit in ....
QUery

I!!I

l!i.

2~8

Observed
411 .2512

CRYA.B H1.IM./IN

Mr(expt)
952 . 499'

0,..

Mr(calc)
952 . 55'3

_58: 2 0 146

r"P0~t

tol ...." nt " .. arch o r .. rchi" ..

ppm Hi .... score J;;.pect Rank
-62 . 39
0
38 0 . 00112

score: 32

1

QUel'les matched :

Peptide
R . VAIEPGAPII. . E

_AI: 0 . 01

~

14.

R . ~AK . V

H. GKITFYEDR . A

Che c k t o in"lud ... thi" h.i t in e.rOr tol " r " nt ,,""rch Or ... rchive report
QUery

8

J?eptide
lI . lTFY £l)fLA

_AI : 0 .09

~

o

R . ~ .A

_AI: 0 . 56

.i:lll. 5511 . 11118

QUery

13.

~eptide

Il . LGBPIPlSK . A

emPAl: 0 . 17

Alpha- cry" t"llin B cha in OS-Ho:l\o s api ... ns Gl - CRYAB PE- i SV- 2
o Ch""k t o in" l ude tht" hit in error tol e rant " .."rch or archiv .. report
QUery

!II

338

Observed
493 . 1510

Mr(expt)
98 5 . 4\194

Mr(cal.c)
118!ii . 4869

ppm

12 .1

Peptide matches not assigned to protein hits:

~

+ Oxida tion

(H) ;

Peptide

0 . 025

Queries matched: 3
CRGB HUMAN
""'s s: 208~4
Score: 64
Gamm"- <lI'"yst"llin B OS - Ho",o "api.,.ns GN- CRYG8 P<:>-l SV- :>

I!'l

(N)

Oleck to include thi " hiL in error tolerant s ..... rch o r archive ".-port

e!

12.

+ Oxidation

_AI: 0 . 82

~

11.

Peptlde

0.058

Hiss Score Expect Rank
0
32
0 . 046
I

Peptide
K. HFSPEELIC . V

In Q d .. tllil" ",.." rus no ,. a t c h )

QUery

Observed

Mr(e><pt)

Mr(calc)

ppm

£.1

19D . 2179

17" . 1213

""S . 422S

-L S"?

Hi ... s Score E.peet Rank

33

0 . 044

209

1

Peptide
?~"tEVK

JJropioll~de

(e)

Appendix I

A1.2.2.13 Mascot search result for spot 13

aPllxlft} Mascot Search Results
Us e "
Elllail
Se ..:t:ch tit1 "
ItS data £ i1"
Databa se
T axonomy
TilIlest .....p
P"ot e in hit s

111£1 tzhe m:y@p"ot e Olne .o'"''1.au
SubJRitted £"Olll UOW 15 s pot s b:om 2D 'l e l HIIMAH by Masc ot Daemon on APAI'-WS-29
\\Massspecl\MS DATA\Qstu: XL\C1ient s amp1es \Jun e 2010\PROJIOJXX UOW 15\UOW 13.m<J:E
SwissP:o:ot 2010-(511100 sequ e nces; 182146551 l:e s idu es )
Homo sapiens (human) (20361 sequences)

15 Jun 2010 at 23:11:21 GMT
HUMIIH
HIIMA1I

B e t a -c r y ~ tallin

Et 05=Homo
11.3 05=Homo

~ a p i en ~

GII=CR YBBI

Pf = l

SV=2

B e ta -cry ~ tallin

~api en ~

GII=CRYBA I

PE = l

SV=4

CRBB2 HUllAH

Bet,, - c~y ~ t a l l i n

E2 05=Homo

~ a pien~

GII=CRYBB 2 PE=l 5V= 2

D 05=H omo

~ a pien~

GII=CRYG D PE=l SV=3

CRBO l

eRDAl

.£B..!iIl.J!!!!

G annn", - cry~talli n

CRYAA HIIMA1I

Alpha-cry ~ tallin

~

B e ta-cry~tallin

~

Gamma- c~ y~t allin

Jl.L DOJl. HIIMAlf

rructo~~-bi~pho~phat~

~

G amma -cry ~tallin

CRBM

HIIMAH

CRYJI.B HIIMAH
~

A lph a -cry ~tallin

I\B CB6 HHHIU! ATP -b i nding
Glycoprot~in

GP 1 55 HIIMAH

I n t~gra l

JI.IIR 1 1 HIIMAH Ankyrin

r ~ p~at

4 -hyd ro xyph ~ nylpyruvat ~

ST AP? Hl!UAN

5ignal-tr an ~ duc i ng

p ro t~ in

~

NAD

AR I P4 HIIMAlf

H ~ lica~~

~ "'p i ~n~

05=Homo

4- lik ~

~api~ n ~

r ~c ~ pt o~

~ a pi ~ n ~

~ ap i~n ~

GII=AIIKRD17 PE= l

SV=3

GIFHPD PE=l 5V=2
GII=S TAP2 PE=l SV= 2

~ ap i~ n ~

2 QS=Homo

GN= rMNL2 PE= l

~ ubun it

GIFAE CE6 PE=l 5V= 1

SV= l

GN=ATP13Al PE=l 5V=2

~a p i~ n~

~ a p i~ n ~

p~ot ~ i n

~a p i~ n ~

GIF MAIIEA PE= l

GIFG PR155 P E=l SV=2

1 7 OS=Homo

13Al Og=Homo
2 QS=Horoo

prot ~i n

f a cto r

mitochondrial 0 5 =Homo

QS=Horoo

p~ot~in

A TPa~ ~

2 05=Homo

GBRAJ HIIMAH Gamma- a minobutyr i c a c id

6,

ru ~ mb ~r

dioxyg-~na~ ~

adapto~

CUL4- M ~ oc ia t ~d

r ormin- lik~

E

GlFg ORD PE=l 5V=4

GP R155 OS=Ho roo

domain-containing

~

GIFC RYAE P!=l 5V=2

~a p i~ n ~

~ a p i~ n ~

~ ub- fa ru il y

cation-tran~porting

a nd

GII=CRYG B PE= l SV=2
GII=C RYE A4 PE = l 5V=3

~ a pi~n~

QS=Horoo

p ~ot ~ i n

Pr obabl~

m N!2 Hl !Ui1.H

~ap i ~n ~

~ndo- a lpha- l, 2- ma nno ~id a ~~

m ~nb ran~

Jl.Il 31 HI/1:!l\H
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A1.2.2.14 Mascot search result for spot 14
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Appendix I

E!I

2.!1.

'135 . H09

H68 . 66'13

if68 . 6252

28.6

Ii!!

??4

528.9328

1583 . '1'166

l.583 . '1653

'1.08

Ii!!

7S9

5 4 2.5920

1624 . '1542

1624 . '1263

1'1.2

E!I

ill

860 . 4403

1'118 . 8661

1'118 . 8053

35.4

Mas s: 198n

CRY.V. HUf'.AN

o

OIlery

Observed

Ml: (expt)

406

5111. 1954

1036 . 3163

1/1

i11
ill

586 . 8114

E'l

5 88 . 3268

Ii!!

486

588 . 3219

1/1

481

III
Ii'!

0.002

83

R.~I~YPR . 1f

2.3e- 00'1

_

(calc)

( ~)

+ PJ::oplon.omide

(C)

K . VSSI3TlfVGYQYPGYR . (I

_AI: 1 . 19

PPlll

Miss score

!;:xpec:t Rank

- 152 . 31

11'11 . 6083

1111 . 58'13

17. ,

5e-005

1114 . 6391

1 11 4 .619 4

16.8

(65) 2 . 1e-005

U'14 . U12

1114 . 6194

18.6

588 . 3282

1114 . 6419

1114 . Iil!14

ill

429 . 5000

1285 . 4782

lli

431 . 8919

1310 . 6720

Mass: 23365

49

86

0.00083

1

Peptide
R . TLGPF'lPSR.L
ICKFSPEDLTVX . V
R . TVl.DSGISEVR.S

1. . 7e-00'1

R . TVLDSGISEVR . S

19.2

(84) 2. 7e - 00'1

R . T'VLDSGlSEVR..!I

1285 . 6303

- 118 .31

0 . 0026

K . VQDDf"VEIHGK.H

1310 . 6579

10 . 8

.

14

2 . 4e-006

Queries matched: S

Score: 252

K . t QTm.DATHAER . A

_AI: 1 . 56

Check to include thi '" hit in error tolerant ", earch or archive report
OIlery

Observed

M:r (expt)

Mr (caJ.c)

E'l

ill.

51.2 . 712'1

1023 . 4509

1023 . 4410

9 . 68

.'E2

406 . 2370

121.5 . 6891

1.215 . 6823

5 . 59

ppm

Mi ss Score

E!I

697

104 . 8975

1401 . 7804

1407 . 7398

28.8

E'l

ill

476.2646

H25 .7719

1425 .75 04

15.1

E!I

153

51.2.9633

1535 . 8680

1535 . 8341

2 1 .1

E!I

ill

516 .2 820

1'125 . 8242

1'125 . 80'11

9 . 92

Ii!!

866

880.9631

1159 . 9121

1759 . 8318

46.0

E!I

867

881.1812

1160 .3 478

1'159 .8318

293

0

Expect Rank

34

0 . 025

..

0 . 0069

59

1

6 . 4e-005

U

K . IIl.YENPNFTGK . K

0.002

R . GLOYLLEItGDYK.D

0 . 004

K . IIl.YEMPII'F'lGIG< .N

le-005

"

78

Peptide
R . WOSIifTSSR . R
R . TDSLSSI.P.PIK .V

K . DSSD!'GAPHPQVQSVR . R

1 .3e-00 7

R . VQSGTWGYQYPGYR. G
R . VQSI3TlfVGYQYPGTR . (I

Queries matched: 5
CREAl H\JMI\N
Mas s: 25134
Score: 184
Beta-crystallin A3 OS- Homo sapien.!! Gi/- CRYBAI PE - I SV- 4
(I

+ oxld.l.tton

R . RAE!,SGE~SNLADR.(I

Queries matched: 7

Score: 298

Ii!!

..

R . AE!"S(3££SNlJIDR . G + P.roplol\alIl1.de (C)

3 _ge-008

1036 . 5342

CRBB2 HUMAN

o

91

Check to include thi", hit in error tolerant ",earch or archive report

Ii!!

,.

..

Ch.",k to include thi" hit in .n·cor tolerant ", ea,ch

0.

emE'At: 0 . 87

archiv" repo,t

Query

Observed

M:r(expt)

MI::(calc)

ppn

E'l

22l!.

128.3832

145 4 . 7519

1454 . 7041

32.8

I!I

717

500 . 9252:

1499 . 7538

1499 . 7442:

6.38

62:

3.3a-005

I!:.~IFE KENFI~.Q

E!I

783

531 . 952:2:

1610 . 8348

1610 . 8053

18 .3

60

5 . 6e-005

K . ITlYDQ£II'FQGKR . M

~

.§.Q1

564 6018

1690 .7835

1690 .7 488

20.5

54

0.00022

III

856

516 . 6213

1'126 . 8600

1'126 . 838'1

12.4

59

6 .3 e-005

Miss Score
a

64

Expect Rank
2.2e-005

score; 160
Queries matched: 4
PGKI H'JMAN
Ma sa: 44586
Pho5phog1ycer"-te kina"e 1 OS-Holllo ",,-pi ens GN- PGKI PE- l. SV- 3

1

Peptide
K . ITlYDQEII'!'QGK.R
+ OIld.l.tion (M)

R . WJ)AJiISG/)KAYHIER.I..
R . EWGSHAQTSQtQStR. R

emPAI: 0 . 33

D Check t o lnclud .. thi " hit in ",rror t olecan t ",_ rch Or archiv", , "port
QUery

I!I
I!I
Ii'.!
E!I

..

ill
ill
ill
.2!lli

M:r(expt)
866 . 4744

M:r(calc)
866 . 4684

1043 . 6466

1041 . 622'1

545.6095

1633 . 806'1

1633.7849

13.4

992 . 0257

1982 . 0368

1981. 9303

53.8

ALC(lJI. HUMAN

Ma ... .,:

3S'395

ppm Miss score
6 . 90
48

..

23 . 0

Scor.. : 150

!;;xpect llank
0 . 00088
0 . 0011

peptide
K . AOO~ . E

+ O:tldlltion Ol)

K . LTLDKIDVK . G

60

4 . .ge-005

K .LGDVYVNllAFGTAHR. A

88

6 . 5e-008

K . VI.lm!:!EIGTSLFDEEGAK . 1 + Oxidation (M)

Querie" matched: 4

_AI: 0 . 38

Fr u cto",, - bi"'phospha t e aldola", ,, A OS-Homo ""-p i"n,,, QiI-ALOOA PE-I SV- 2

o

Che"k to include thi ", hit in eccor tolecant ", .. a,ch 0" archive repon:
OIlery

E!I

,.

Observed
434 . 2445
522 . 8306

.!.Q

Observed.
382 . 2:329

M:r (expt)

Mr(calc)

'162 . 4 512

762 . U40

ppm Miss Score
- 16 . '13
50

Expect Rank
0.00091
1

Peptide
K . VLAAVYlt.A

I!I

g

401 .2472

800 . 4798

800 . 4756

5.32

68

1.1a-005

R . ALQASALK.A

E'l

645

666.8698

1331.7250

1.3.n . 6932

23.8

88

1.1a-007

K . GtIJIJW!:STGSIJIK . R

E!I

ill

549.6143

1645 . 8211

1645 . 8019

11 .6

0 . 036

R . LQSIGrENTI:ENRR. F

CRBS HUMAN

MaSS: 20993

SCore: 123

Queries ..... tched: 7

215

emPAl: 1 . 44

Appendix I

B.. t~-c.y"t ~llin S

OS~Ho",o

""pi en" GN-CIWGS PE-l SVa4

CJ Check to include thi" hit in erro. tole.ant "ea.ch o. archive rapo.t

!if

QUery

Observed

Ml:(expt)

t>ft:( c alc )

11

389.2284

116 . 44 22

176 . U 32

- 1 . 26

ppm!di ,.,. s c ore
0

!;;Xpec t Rank
0 . 034
0.016

R . QnI.DK . K

33

0.038

K.ITFn:IlK . N

II

390.2198

118.4250

178.4225

3.21

458.2288

914 . 4430

914 . 4185

4.93

Ii!)

ill.
ill

496 . 1811

991 . 5416

991 . 54!H

2.52

35

0 . 022

!if

~

386.2091

1155 . 6012

1155 . 6031

3 . 05

41

0 . 0013

iI

140

506 . 5932

1516 .1511

1516 .1310

11 . 6

52

0.00031

e

851

511 . 3U1

1128 . 9133

1128 . 8941

10 .1

65

1 .1.-005

Ii!)

,.

CRBM

Ma"s : 22360

~

B"t .. - c~y"t"lJin ... 4

OS~HolllO

Score:

Querles matched: 2

1 15

1

~ptide

34

K . IQIFEK .G

R.GRQYI.IDK.K
1I. . II.VIU.1?8GGQYK . I
P\ . ITFY£DKNFQGR. II.

R . lCPIDWQJUU:PII.VQSrR. II.

emPAI : 0 . 32

""pi""" GN-CRYB ... 4 Pll:- l SV-3

CJ Check t o includ" t hi" hit in ".ror t ol ... ant " .."rch or a r chive r epo.t

!i!I

QUery
705

Obs e.r:ved
719.9018

Ml: (expt)
1U1 .18 90

t>ft:(calc)
1431.75041

ppm Miss score
!;;xpect Rank
26.9
0
69 6.9 .. - 006

R . t.TlFEQE:NFLGK."

III

707

127 . 8482

1453 . 6819

1453 . 6296

36.0

,e !:!VVWDEDGFQGR. II.

,.

HPPD H\JMAN

Ma ,.,. :

~ 4 906

Score: 114

4 - hyd.oxyph"nylpy,.uv"t .. dioxY9' .. n~" ..
[J Ch .. ",k

11

4 . 6a-006

Querles matched: 4

OS~Ho",o

Peptide

emPAI : 0 . 33

""pi .. "" GN-HPD PEEl SV-2
".~r",h

t o includ .. thi" hit in .. rror tol .. " .. nt

o. ",,,,hiv.. r "po"t

Ml: (e xpt)
909 .533 0

r.n: (calc )

e

ill
ill

Observed
4155.1738
516.2916

1030 . 5806

1030 . 5659

U .3

55

0 . 0002 4

!if

.ill

550.2146

1098 .53 41

1090 . 5168

16.3

65

2.2e-005

K . ~n:PLAYR.G

B

456

568 . 2855

11341 . 5565

1134 . 5305

22.9

48

0 . 000941

K . AEEEEQtILR . G

QUery

Ii!J

10.

~

Mass: 20725

ppm Mi,.,. s c ore
5.08
0
35

909 . 52841

Score: '019

+ Odda tion UiI)

!;;Xpect Rank
0 . 02

Querles matched: 3

Peptide
R . EVVSIiVtP\ . Q
K . TEDIITAIR.H

+ OXIdation (N)

emPAI : 0 . 51

Gamma - ""Y"tallin D OS-Homo ""pie"" GN-CRYGD PE-l S'I-3

CJ Check to inClude thi" hit in .. rror t ol .. ran t " .. arch or "rchiv.. ""po"t
Query

Ob served

Ml:( ex pt)

Mr( c aic)

ppm

6!1

ill

!5417 . 8048

10U . !US1

1093 . 5168

16.1

!di .... Score

III

!2.Q.

591.2808

1180 . 54111

1 180.5261

iii

ill

636.3285

1270 . 6424

1210 . 6016

1

£ xpec t Rallk
0 . 00011

17 . 8

411

0.00l.]

• • YQaI'GATMAR . V

32. 1

51

0 . 000410

R . Q~R . R

tu .... : 20865
Score: 93
Querl e .. ma tch ed: 4
GamlQa - cr}'3tallin C OS-Horlo sapieTUI GN-CR'fOC PE-l SV-2

~

11.

o

N . G1aTLTEDR . S

Observed

HJ:: (e xpt)

Mr (calc)

ppm

III

~

451. 2S0'

900.4812

'00 . 48 11

6.08

U

III

290

412 . 2 333

9412 . 41!520

942 . U41

1.13

31

0 . 011

Ii!!

lli

564 . 79 96

1121.5U7

1127 . 5611

20 . 9

411

0 . 0011

III

~09

606 . 2531

1210 . 5 1 16

12 10 . 41741

30.5

52

0 . 00033

amPAI : 0 . 82

CRYAB HUMAN

Ma..... : 20146

Mi .... Score

E xpe ct Rallk

Peptl de

0.0032

R.na.sEIR . S

Querles matc hed : 3

score : 92

K. ITFYEOR . A
M. GKlTFYEDR . 1I.
R . ~.II.

emPAI : 0 . 59

Alph-o - cry::<t<lUi n B chain OS- Hoao ""piGn" Q-I-CRYAB PE- l SV- 2
[J

Ch .. ck to includ .. thi " hit in .. ".or tol .. "ant """reh o. archive report

!i!I

Query

ill.

Ob served.
49J. 7544

Ml: (e xp t )
985 . 4942

Mr (cal c )
985 . 418n

III

ill
.!2!

5414 . 7662

1087 . 51'18

1081 . 50417

12 . 0

389.2211

1164 . 6U2

1164 . 6503

-5 . 05

iii

~

13 .

Ma .... :

Ga!!Ulh" - C.y"t<lllin

o

Ii!!

+ OXldatioll (N)

Check t o inel"de this hit 1n errO r tolerant search or archive r .. port
Query

12.

1

Peptlde

!51

e

20894

ppm Mi ss s core
1 . 38
0
34

..:xpect Rank
0.024

K . HP'SP£JO:U: . V

410

0.0071

R . QDI!:HGf'lSR . £

76

1 . 1e- 006

Quar le. ma tc hed. : J

Scor e: 92

peptide

amPAt: 0 . 56

OS-HolltO ".pi<>TUI GN-CR'tGS Pt-l sY-2

Check to incluct" this hit in error tolerant ""arch Or ".chive report

ouery
290

Ob served
412.2333

Ml:( e xptJ
942.452~

Mr( c alc )
942 . 4H1

ppm
7.1

ill

559.8032

1117 . 5918

1 117 . 5556

32 . 41

!di ss score
0
31
55

Expec t Rallk
0 . 011
1
0 . 00022
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Peptlda
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A1.2.2.15 Mascot search result for spot 15

a/!..i}~fj

Mascot Search Results

Use"
Entail.
Se ..:t:ch tit1e
MS dat a file
Databas e
Taxonomy
Timestmnp
P"otein hit s

nd'i tzhem:y@p"oteoJRe.o"g.au
Subndtted :hOl" liD" 15 spot s h:.- 2D gel HIIMAH by Mas cot DaelO.on on APAf'-IfS-28
\\Mas ss p ec l\MS DATA\Qstu: XL\Cli e nt samples\June 2010\PROJI03XX lIOW 15\UOW 15.mg:f
Swi u P"ot 2010-(511100 sequences; 182146551 " u idu es )
Homo s api e n . (hlDllan) (20361 s e qu e nces)
15 Jun 2010 at 23:09:28 GMT
CRBBl H!!lIAIl 8et a -ery ~ t a llin B l 05=80mo ~apien~ GII=CRYBBI PE = l 5V=Z
e RDAl H\P1AH 8eta-cry~tallin A3 05=Homo ~a p i e n ~ GII=CR YEAl PE = l SV= 4
CRBB 2 HIIMA1I

8 et a -cry ~tallin

CRI BII. Hl !H!U!

Alph a -c r y ~tall.1 n

A ch" i n

OS=HOlID

~"pien~

GIF C RYAA PE= l

SV= 2

CRY AII HIIMA1I

Alpha-cry~tallin

8 chai n 03'=Ho roo

~apien ~

GIFCRYAB

5Y=2

CR8U H\!!:!A1l

E~ta-cry~tallin

A4 OS=Homo

CR8 S IIIIMAil

E~t a -c ry~tallin

5

CRGD IIIIMAN

Gamma-cry~tall i n

D 05= Hom o

~ a pi~n ~

GII=C RYGD Pl= l

CR GC IIIIMAil

Gamma- cr y~ ta llin

C 05=Homo

~api~n ~

GII=CR YGC PE=l SV=2

K2 C1 IIIIMAN

K~ratin,

typ~

II

Gyto~k ~ l~t a l

K~r a tin ,

typ~

I

K1 C9 IIIIMAil

~ a p i e n~

B2 05=80'"0

05=Horoo

Gam ma - cry~ t allin

Sorbitol

d~byd rog- ~na ~ ~

9

K22E IIIIMAil

QS = Homo

5Y= 3
SV=3

GII=KRTl P E=l SY= 6
GIFKRT9 PE = l

~ap i ~ n~

5Y= 3

GII=C RYGB PE=l SV=2

~api~n~

~a pi ~ n~

GIF S ORD PE=l SV=4

K~ratin,

typ~

K1 c 15 HIIHA1I

K~ratin ,

typ ~

I

cyto~k~l~t a l

15 OS=Homo

~ a pi ~ n ~

GII=K I!T15 PE= l

KIC19 HIIHA1I

K ~rati n,

typ ~

I

cyto ~ k ~l~t a l

19 05=Homo

~ api ~n~

GII=K RT19 PE=l SV= 3

typ ~

I

cy t o~k~l~t a l

16 05=Homo

~api~n ~

GII=K RT16 Pl= l

K1 C1 6 H!!HA!!

K~ratin,

JlL 11ll HIlMAII'

R~tinal

lQI T 36 HUll'"'

K~r a tin,

cyto~k ~ l~t " l

PE = l

P!= l

~api ~ n ~

1 OS=Homo

OS = Horoo

SV= 2

GIF CRYGS PE=l 5Y=4

~api ~ n ~

B OS=Homo

PE = l

GII=C RYE A4

~ api~ n~

cyto ~ k~l ~ t a l

CRG8 IIIIMAil
~

GII=CRYB82

II

d~hydrog-~na~ ~

typ~

I

~ pid~rrnal

2

1 05 = Homo

cu ticular

~ a pi~ n ~

Ha6 OS= Horoo

~ ap';"'n ~

OS=Homo

GII= ALDH1Al PE = l

~a p i~ n ~

GII=KRT2 PE = l

K1C28 HUlIAH

K ~ r ati n,

typ ~

I

cyt o~k~l~t al

K ~ratin ,

typ ~

I

cuticul ar

K~ratin,

typ ~

I

cyto~k~l~t a l

a

OS=Homo

~ a pi ~ n ~

GII=K RT18

'[J q o

H IIHIIM

K ~ ra ti n,

typ ~

1

cyto~k~l ~ tal

1 0 05=Homo

~a pi ~ n ~

GII=KRT10 PE= l

typ ~

I

cuticular Ha5 05=Homo

KR T 35 HIIHA1I

K~ra ti n,

MllliEII H\U1!U!

Glycoprot~ in

!!!!..!:!!:!...

Mal a t~

q U!!SV H\U111 11' CaM

~a p i ~n~

~ api ~ n ~

~nd o-alpha-1 ,2- manno ~ ida ~ ~

d~hydrog-~n a ~~,

kin a ~~ - lik ~

~ap i ~n ~

5Y=1

KlelO HUlIAH

2 8 0 5=Homo

prot~in

Pl=l 5V= 2
5Y=3

Pl=l SV=2

GII=K RT35 PE = 2

05=Homo

SV= 6

SY=5

GIF MAIIEA PE = l

~ api ~ n ~

~ap"-~ n ~

mi t ochon drial 05=Homo

v~ ~i cl ~ - ,,~~oci a t~d

GII=KR T2 8

GII= KRT31 Pl = l

OS=Homo

SV= 4

SY=2

GII=KRT36 PE = l

.!U.!I.L!!!!!:1

Hal OS= HOlOO

GIF MDH2 PE = l
~ api ~ n~

PDS58 HUlIAH

Si~t~r

chromatid

coh ~~i on

prot ~ in

PD S5 homolog- B 05=Homo

~a pi~n~

GII=PD S 5E PE= l

SV=l

PDS51!. H\!!:!A1l

S~t~r

cho matid

coh~~i on

prot~in

P DS5 homolog A 05= Homo

~api~n~

GII= PDS5A PE= l

S V= 1

4 -h ydrox yph ~ nylpyruv a t~

N pOll HUlIAH

rructo ~ ~ - bi ~ p ho ~ph a t~

MIlP 3 IIIIMAN

Ca nalic ular

~

Mult idru g

IIXJl.4 IIIIMAil

Ho m ~ obox

dio xy g ~ na~ ~

" ld ola ~ ~

multi~p~c ifi c

OS=Homo

~a pi~n ~

A OS=Homo

organie ani o n

~ ap i ~n ~

GIFHPD Pl=l SV=2

GIFALDOA Pl = l

tra=por t ~r

2 OS= Hom o

r ~~i ~tanc ~ -a ~ ~o ciat~d

prot~in

9 05 = Ho mo

Hox-A4 05= lI omo

~ a pi~ n ~

GII=HOXA4 PE=l SV=3

prot~in

P TG IS IIUl11!.l1

Pr o ~ tacyclin

PE8Pl HUlIAH

Pho~phat id y l~tha nolam in~-bindi ng

prat~ in

1 OS= Hcrm o

Pr ot ~ in

~ubunit

12B OS=Ho roo

.IllL.t!!!!:!a!

~ynth M ~

ph o ~p hat M~
r~p~at

and

~ up pr ~~ ~ o~

1

05=Homo

~ api ~n ~

HYP T2 H\!!:!A1l

TP 538 HUlII!.1I Tumor

~ap"- ~ n ~

r~gul ato r y

SOC ~

bo x

prot ~ i n

p53-binding

prot~in

~Y=2
~ a pi~n~

5Y= 2

GIFPE EP 1 Pl = l

5 Y= 3

~ "pi~n~

~api ~ n~

GII= PPP1 R1 2B PE= l

11 OS=Homo

~ap i ~n~

GII= A5Bll PE= 2 SV=l

1 OS=Homo

~ apien ~

GII= TP 53BP l

I l pe pUde Summary
Significance threshold p< 0.05

Max. numb er of hits AUTO

Standard scrring .: MudPIT scorin g I~ Ions serre or expect cut-off10

o

I

Select No ne

HUMILIl

B ~ t,,-cry ~ tallin

Ch ~ ck to

f! . Suppress pop-ups

II

H ass :

PE= l

SV=2

S V=2

Activat~d RIIA poly""' r M ~ II tr a n~ "riptional co a ct i vator p15 05=Homo ~a pi~n~ GII=3UB1 PE= i

Peptide Summary Report

CRBE l

PE= 2 S V= 3

GII= PT GI5 P E=l SV=l

Ims sc ore is -l O*Lo g(P), wh ere P is the probability that th e oo served match is a random ~ent
Individua l ictu scores :;' 30 indicate identity or extensive homology (p<0.05)
Protein scores are deriv ed frem ions scores as a nm-prooabildic basis for ranking protein hits

Show pop-ups

GII=ABCC3

GII=ABCC12 PE = l

Mascot Score Histogram

~

SY=l

SY=3

GIFCAMKV PE = 2 5 Y=2

~

Jl.SB ll HUlIAH Ankyrin

FO'matAs

5 Y= 2

S V= 2

Search Selected

28 006

B1 05=Homo

'~

I

D Error tolerant

Sco:t: e : 3 28
~ a pi ~ n~

i nelud ~ thi ~ hit i n

~ rro r

Show sub -s ets 0

Sort unassi gned Decreasing Score

H a tche s:

91 9 1

I

Arc h ve Report
Sequenc e s:

GII=CRYBB1 PE=l SY=2
t ol ~rant

~ ~a rch o r

Re quire bold red

ar Ghiv~ r ~ port

218

9191

e mPJl.I:

1.75

0

SV=3
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A1.3 MBP-αB pull-out studies
Pull-out studies using MBP-αB were optimized with bovine lens extracts prior to the
use of human lens extracts (Chapter 2, section 2.4.4). WS and US extracts from the
cortical and nuclear tissues of bovine lenses were obtained using the same methods
detailed in section 2.3.1 (Chapter 2) for human lens protein extractions. The urea
concentration in the US extracts was diluted to 0.6 M with buffer A prior to incubation
with MBP-αB. MBP-αB (50 μg) was incubated with 50 μg of the CWS, NWS, CUS and
NUS extracts from bovine lenses at three different temperatures (23 °C, 37 °C and 45
°C), followed by purification with amylose resin, using the same methods detailed in
section 2.3.9 (Chapter 2). Additionally, in order to determine whether heating is a
necessary element for the interaction between MBP-αB and lens extracts, 50 μg of CWS
and NWS extracts were pre-heated in 45 °C for 20 min prior to the addition of MBP-αB,
and the mixture was immediately purified using amylose resin.
The result of these binding assays showed that incubation at 23 °C resulted in negligible
interaction between MBP-αB and lens proteins (Fig. A1.5A, lanes 2, 7 and Fig. A1.5B,
lanes 11, 16). Similarly, pre-heating of the lens extract prior to the addition of MBP-αB
led to minimal interaction (Fig. A1.5A, lane 5 and Fig. A1.5B, lane 14). When MBP-αB
was co-incubated with lens extract at physiological (37 °C) and heat stress (45 °C)
temperatures, αA- and αB-crystallins appeared to be the major interacting partners of
MBP-αB, as evidenced by the two ~20 kDa bands present on the gel (Fig. A1.5A, lane 3,
4, 8 , 9 and Fig. A1.5B, lane 12, 13, 17, 18). These findings were consistent with the
results published by Muchowski et al. [183].
Building upon these results, pull-out studies using human lens extracts were performed
(Chapter 2, section 2.4.4). The quantities of both MBP-αB and lens extracts were
increased to 100 μg in order to produce clearer bands on the SDS-PAGE gels and
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Western immunoblots. It was found that pull-out studies performed at 45 °C resulted in
the precipitation of lens proteins and MBP-αB. As such, subsequent incubations were
performed at 37 °C only. The incubation time was increased to 6 h to allow full subunit
exchange between MBP-αB and lens proteins.
Pull-out studies were performed using MBP-αB and the CUS and NUS extracts of
human lenses aged 13, 28, 41, 61 and 80 years. Western immunobloting was used to
probe for the presence of filensin, phakinin and vimentin in the pull-out samples using
the same methods detailed in section 2.3.6 (with the exception of the monoclonal
anti-filensin antibody, which was diluted to 1:2000). As intermediate filament proteins
in postnatal lenses did not display significant age-related changes (Chapter 2, Fig. 2.8),
MBP-αB was found to interact with similar proteins across all age groups (Fig. A1.6).
Consequently, only the blot of the pull-out study using extracts from a 13 year lens was
presented in the manuscript (Chapter 2, Fig. 2.11).
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Fig. A1.5: MBP-αB pull-out studies using bovine lens extracts. (A) Purified
MBP-αB (50 μg) was incubated with 50 μg of bovine lens CWS extract (lane 1) at
23 °C (lane 2), 37 °C (lane 3) and 45 °C (lane 4) for 20 min, and also with bovine
lens CUS extract (lane 6) at 23 °C (lane 7), 37 °C (lane 8) and 45 °C (lane 9) for 20
min, followed by purification using amylose resin. Alternatively, 50 μg of MBP-αB
was added to 50 μg of CWS extract that was pre-heated at 45 °C for 20 min, and
immediately undergo purification using amylose resin (lane 5). (B) Purified
MBP-αB (50 μg) was incubated with 50 μg of bovine lens NWS extract (lane 10) at
23 °C (lane 11), 37 °C (lane 12) and 45 °C (lane 13) for 20 min, and also with
bovine lens NUS extract (lane 15) at 23 °C (lane 16), 37 °C (lane 17) and 45 °C
(lane 18) for 20 min, followed by purification using amylose resin. Alternatively, 50
μg of MBP-αB was added to 50 μg of NWS extract that was pre-heated at 45 °C for
20 min, and immediately undergo purification using amylose resin (lane 14).
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Fig. A1.6: Western immunoblots showing the interaction of MBP-αB with
filensin, phakinin and vimentin from US extracts of human lenses aged 13-80
years, upon incubation at 37 °C for 6 h. The age of the lenses are indicated above
each lane. The presence of large amounts of MBP-αB at ~64 kDa was responsible
for the distortion of immunoblots in this region. Molecular weight markers are
shown on the right of the blot.
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Table A2.1: Endogenous LMW peptides present in human lens extracts.
Peptides were isolated and characterized from the CWS, NWS, CUS and NUS
extracts of human lenses aged 16, 44, 75 and 83 years, using nanoLC-ESI-MS/MS
in conjunction with online Mascot database searching. Peptides with a positive
detection (peptide score > peptide homology score) in the extract are indicated by
full-shading of the cell, whereas cells with diagonal-grids indicate that the peptides
were detected in the extract, but the Mascot analysis did not achieve peptide scores
above the peptide homology scores to confirm their identification. Peptides listed on
this table are positively identified in at least one lens extract.

Peptide
sourcea

b

Peptide sequence

Peptide
mass
(Da)

CWS

NWS
c

Lens age

CUS
c

Lens age

NUS
c

Lens age

Lens agec

16 44 75 83 16 44 75 83 16 44 75 83 16 44 75 83
αA
#2-9

(M)-DVTIQHPW-(F)

994.49

#2-9

(M)-DVTIQHPW-(F) ‡

995.47

#2-10

(M)-DVTIQHPWF-(K)

1141.56

#1-9

MDVTIQHPW-(F) ✽

1167.54

#2-12

(M)-DVTIQHPWFKR-(T)

1425.75

#1-11

MDVTIQHPWFK-(R) ✽

1442.70

#2-13

(M)-DVTIQHPWFKRT-(L)

1526.80

#1-12

MDVTIQHPWFKR-(T) ✽

1598.80

#2-14

(M)-DVTIQHPWFKRTL-(G)

1639.88

#2-15

(M)-DVTIQHPWFKRTLG-(P)

1696.91

#2-16

(M)-DVTIQHPWFKRTLGP-(F)

1793.96

#1-14

MDVTIQHPWFKRTL-(G) ✽

1812.94

#1-15

MDVTIQHPWFKRTLG-(P) ✽

1869.96

#1-16

MDVTIQHPWFKRTLGP-(F) ✽

1967.01

#13-21

(R)-TLGPFYPSR-(L)

1036.53

#14-22

(T)-LGPFYPSRL-(F)

1048.57

#15-24

(L)-GPFYPSRLFD-(Q)

1197.58

#14-24

(T)-LGPFYPSRLFD-(Q)

1310.67

#15-25

(L)-GPFYPSRLFDQ-(F)

1325.64

#13-24

(R)-TLGPFYPSRLFD-(Q)

1411.71

#15-26

(L)-GPFYPSRLFDQF-(F)

1472.71

#15-28

(L)-GPFYPSRLFDQFFG-(E)

1676.80

#15-30

(L)-GPFYPSRLFDQFFGEG-(L)

1862.86

#20-26

(P)-SRLFDQF-(F)

911.45

#20-27

(P)-SRLFDQFF-(G)

1058.52

#20-27

(P)-SRLFDQFF-(G) ‡

1059.50

#25-33

(D)-QFFGEGLFE-(Y)

1072.49

#24-33

(F)-DQFFGEGLFE-(Y)

1187.51

#20-29

(P)-SRLFDQFFGE-(G)

1244.58

#28-38

(F)-GEGLFEYDLLP-(F)

1251.60

#23-33

(L)-FDQFFGEGLFE-(Y)

1334.58
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Table A2.1 (continued)
#20-33

(P)-SRLFDQFFGEGLFE-(Y)

1690.80

#20-34

(P)-SRLFDQFFGEGLFEY-(D)

1853.86

#22-49

(R)-LFDQFFGEGLFEYDLLPFLSSTISPYYR-(Q)

3363.64

#22-49

(R)-LFDQFFGEGLFEYDLLPFLSSTISPYYR-(Q) ‡

3364.62

#43-49

(S)-TISPYYR-(Q)

898.45

#43-50

(S)-TISPYYRQ-(S)

1026.51

#34-42

(E)-YDLLPFLSS-(T)

1053.54

#37-46

(L)-LPFLSSTISP-(Y)

1060.58

#43-51

(S)-TISPYYRQS-(L)

1113.55

#43-52

(S)-TISPYYRQSL-(F)

1226.63

#43-53

(S)-TISPYYRQSLF-(R)

1373.70

#37-49

(L)-LPFLSSTISPYYR-(Q)

1542.81

#37-50

(L)-LPFLSSTISPYYRQ-(S)

1670.87

#43-56

(S)-TISPYYRQSLFRTV-(L)

1730.00

#35-49

(Y)-DLLPFLSSTISPYYR-(Q)

1770.92

#35-50

(Y)-DLLPFLSSTISPYYRQ-(S)

1898.98

#34-49

(E)-YDLLPFLSSTISPYYR-(Q)

1933.98

#34-50

(E)-YDLLPFLSSTISPYYRQ-(S)

2062.04

#38-56

(L)-PFLSSTISPYYRQSLFRTV-(L)

2261.18

#42-65

(S)-STISPYYRQSLFRTVLDSGISEVR-(S)

2773.44

#57-65

(V)-LDSGISEVR-(S)

974.50

#57-66

(V)-LDSGISEVRS-(D)

1061.54

#56-65

(T)-VLDSGISEVR-(S)

1073.57

#55-65

(R)-TVLDSGISEVR-(S)

1174.62

#57-67

(V)-LDSGISEVRSD-(R)

1176.56

#57-69

(V)-LDSGISEVRSDRD-(K)

1447.69

#51-65

(Q)-SLFRTVLDSGISEVR-(S)

1677.91

#69-75

(R)-DKFVIFL-(D)

880.51

#71-78

(K)-FVIFLDVK-(H)

979.57

#67-75

(S)-DRDKFVIFL-(D)

1151.63

#66-75

(R)-SDRDKFVIFL-(D) ※

1220.67

#66-75

(R)-SDRDKFVIFL-(D)

1238.67

#67-76

(S)-DRDKFVIFLD-(V)

1266.66

#70-80

(D)-KFVIFLDVKHF-(S)

1391.80

#69-80

(R)-DKFVIFLDVKHF-(S)

1506.82

#66-78

(R)-SDRDKFVIFLDVK-(H)

1580.86

#67-80

(S)-DRDKFVIFLDVKHF-(S)

1777.95

#66-80

(R)-SDRDKFVIFLDVKHF-(S) ※

1847.00

#66-80

(R)-SDRDKFVIFLDVKHF-(S)

1864.98

#83-89

(P)-EDLTVKV-(Q)

802.44

#82-89

(S)-PEDLTVKV-(Q)

899.50

#81-89

(F)-SPEDLTVKV-(Q)

986.53

#83-91

(P)-EDLTVKVQD-(D)

1045.53

#82-91

(S)-PEDLTVKVQD-(D)

1142.58

#82-91

(S)-PEDLTVKVQD-(D) ‡

1143.57
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TableA 2.1 (continued)
#83-92

(P)-EDLTVKVQDD-(F)

1160.56

#79-88

(K)-HFSPEDLTVK-(V)

1171.59

#81-91

(F)-SPEDLTVKVQD-(D)

1229.61

#81-91

(F)-SPEDLTVKVQD-(D) ‡

1230.60

#92-97

(D)-DFVEIH-(G)

758.36

#92-98

(D)-DFVEIHG-(K)

815.38

#91-97

(Q)-DDFVEIH-(G)

873.39

#91-98

(Q)-DDFVEIHG-(K)

930.41

#92-99

(D)-DFVEIHGK-(H)

943.48

#90-97

(V)-QDDFVEIH-(G) ‡

1002.43

#89-97

(K)-VQDDFVEIH-(G) ‡

1101.50

#89-98

(K)-VQDDFVEIHG-(K) ‡

1158.52

#92-101

(D)-DFVEIHGKHN-(E)

1194.58

#89-99

(K)-VQDDFVEIHGK-(H)

1285.63

#89-99

(K)-VQDDFVEIHGK-(H) ‡

1286.61

#91-101

(Q)-DDFVEIHGKHN-(E)

1309.61

#91-101

(Q)-DDFVEIHGKHN-(E) ‡

1310.59

#106-114

(D)-DHGYISREF-(H)

1122.51

#105-114

(Q)-DDHGYISREF-(H)

1237.54

#100-112

(K)-HNERQDDHGYISR-(E) ‡

1627.70

#136-147

(A)-DGMLTFCGPKIQ-(T)

1308.62

#135-147

(S)-ADGMLTFCGPKIQ-(T)

1379.66

#143-151

(C)-GPKIQTGLD-(A)

927.50

#143-152

(C)-GPKIQTGLDA-(T)

998.54

#146-155

(K)-IQTGLDATHA-(E)

1025.51

#143-153

(C)-GPKIQTGLDAT-(H)

1099.59

#143-154

(C)-GPKIQTGLDATH-(A)

1236.65

#146-157

(K)-IQTGLDATHAER-(A)

1310.66

#151-160

(L)-DATHAERAIP-(V)

1079.54

#150-160

(G)-LDATHAERAIP-(V)

1192.62

#148-160

(Q)-TGLDATHAERAIP-(V)

1350.69

#156-172

(A)-ERAIPVSREEKPTSAPS-(S)

1852.96

#155-172

(H)-AERAIPVSREEKPTSAPS-(S)

1924.00

#1-7

MDIAIHH-(P) ✽

877.41

#1-8

MDIAIHHP-(W) ✽

974.46

#2-9

(M)-DIAIHHPW-(I)

987.49

#1-9

MDIAIHHPW-(I) ✽

1160.54

αB

#1-11

MDIAIHHPWIR-(R) ✽

1429.73

#2-18

(M)-DIAIHHPWIRRPFFPFH-(S)

2186.20

#1-18

MDIAIHHPWIRRPFFPFH-(S) ✽

2358.20

#13-18

(R)-PFFPFH-(S)

790.38

#13-20

(R)-PFFPFHSP-(S)

974.47

#12-22

(R)-RPFFPFHSPSR-(L)

1373.70
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Table A2.1 (continued)
#13-25

(R)-PFFPFHSPSRLFD-(Q)

1592.78

#19-25

(H)-SPSRLFD-(Q)

820.41

#21-27

(P)-SRLFDQF-(F)

911.45

#21-28

(P)-SRLFDQFF-(G)

1058.52

#21-28

(P)-SRLFDQFF-(G) ‡

1059.50

#26-34

(D)-QFFGEHLLE-(S)

1118.54

#25-34

(F)-DQFFGEHLLE-(S)

1233.57

#21-30

(P)-SRLFDQFFGE-(H)

1244.58

#24-34

(L)-FDQFFGEHLLE-(S)

1380.64

#24-34

(L)-FDQFFGEHLLE-(S) ‡

1381.62

#25-39

(F)-DQFFGEHLLESDLFP-(T)

1792.83

#25-40

(F)-DQFFGEHLLESDLFPT-(S)

1893.88

#21-36

(P)-SRLFDQFFGEHLLESD-(L)

1938.91

#21-38

(P)-SRLFDQFFGEHLLESDLF-(P)

2199.06

#21-39

(P)-SRLFDQFFGEHLLESDLFP-(T)

2296.12

#21-39

(P)-SRLFDQFFGEHLLESDLFP-(T) ‡

2297.10

#21-40

(P)-SRLFDQFFGEHLLESDLFPT-(S)

2397.16

#21-40

(P)-SRLFDQFFGEHLLESDLFPT-(S) ‡

2398.15

#21-41

(P)-SRLFDQFFGEHLLESDLFPTS-(T)

2484.20

#20-40

(S)-PSRLFDQFFGEHLLESDLFPT-(S)

2494.22

#21-41

(P)-SRLFDQFFGEHLLESDLFPTS-(T) ✽ ‡

2527.19

#19-40

(H)-SPSRLFDQFFGEHLLESDLFPT-(S)

2581.25

#21-42

(P)-SRLFDQFFGEHLLESDLFPTST-(S)

2585.24

#21-42

(P)-SRLFDQFFGEHLLESDLFPTST-(S) ‡

2586.23

#20-42

(S)-PSRLFDQFFGEHLLESDLFPTST-(S)

2682.30

#21-44

(P)-SRLFDQFFGEHLLESDLFPTSTSL-(S)

2785.36

#21-44

(P)-SRLFDQFFGEHLLESDLFPTSTSL-(S) ‡

2786.34

#23-56

(R)-LFDQFFGEHLLESDLFPTSTSLSPFYLRPPSFLR-(A)

4003.02

#23-56

(R)-LFDQFFGEHLLESDLFPTSTSLSPFYLRPPSFLR-(A) ‡

4004.00

#35-44

(E)-SDLFPTSTSL-(S)

1066.52

#30-39

(G)-EHLLESDLFP-(T)

1198.59

#29-39

(F)-GEHLLESDLFP-(T)

1255.61

#29-40

(F)-GEHLLESDLFPT-(S)

1356.92

#28-39

(F)-FGEHLLESDLFP-(T)

1402.68

#29-42

(F)-GEHLLESDLFPTST-(S)

1544.74

#28-44

(F)-FGEHLLESDLFPTSTSL-(S)

1891.92

#36-57

(S)-DLFPTSTSLSPFYLRPPSFLRA-(P)

2511.32

#35-57

(E)-SDLFPTSTSLSPFYLRPPSFLRA-(P)

2598.35

#36-58

(S)-DLFPTSTSLSPFYLRPPSFLRAP-(S)

2608.37

#34-57

(L)-ESDLFPTSTSLSPFYLRPPSFLRA-(P)

2727.39

#45-52

(L)-SPFYLRPP-(S)

975.52

#45-53

(L)-SPFYLRPPS-(F)

1062.55

#45-54

(L)-SPFYLRPPSF-(L)

1209.62

#44-55

(L)-SPFYLRPPSFL-(R)

1322.70

#53-65

(P)-SFLRAPSWFDTGL-(S)

1495.75
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Table A2.1 (continued)
#43-55

(T)-SLSPFYLRPPSFL-(R)

1522.82

#45-57

(L)-SPFYLRPPSFLRA-(P)

1549.84

#45-58

(L)-SPFYLRPPSFLRAP-(S)

1646.89

#50-65

(L)-RPPSFLRAPSWFDTGL-(S)

1845.95

#47-65

(P)-FYLRPPSFLRAPSWFDTGL-(S)

2269.17

#45-65

(L)-SPFYLRPPSFLRAPSWFDTGL-(S)

2453.25

#43-65

(T)-SLSPFYLRPPSFLRAPSWFDTGL-(S)

2653.37

#58-65

(A)-PSWFDTGL-(S)

921.43

#62-70

(F)-DTGLSEMRL-(E)

1020.49

#61-70

(W)-FDTGLSEMRL-(E)

1167.56

#58-68

(A)-PSWFDTGLSEM-(R)

1268.54

#59-70

(P)-SWFDTGLSEMRL-(E)

1440.67

#58-70

(A)-PSWFDTGLSEMRL-(E)

1537.72

#75-82

(R)-FSVNLDVK-(H)

920.50

#77-84

(S)-VNLDVKHF-(S) ‡

971.51

#73-81

(K)-DRFSVNLDV-(K) ‡

1064.51

#83-90

(K)-HFSPEELK-(V)

985.49

#83-92

(K)-HFSPEELKVK-(V)

1212.65

#95-102

(L)-GDVIEVHG-(K)

824.40

#93-103

(K)-VLGDVIEVHGK-(H)

1164.65

#95-106

(L)-GDVIEVHGKHEE-(R)

1347.64

#95-108

(L)-GDVIEVHGKHEERQ-(D)

1631.80

#95-109

(L)-GDVIEVHGKHEERQD-(E)

1746.83

#109-116

(Q)-DEHGFISR-(E)

959.45

#109-118

(Q)-DEHGFISREF-(H)

1235.56

#128-135

(D)-VDPLTITS-(S)

844.45

#127-135

(A)-DVDPLTITS-(S)

959.48

#128-137

(D)-VDPLTITSSL-(S)

1044.57

#124-135

(R)-IPADVDPLTITS-(S)

1240.66

#128-140

(D)-VDPLTITSSLSSD-(G)

1333.66

#124-137

(R)-IPADVDPLTITSSL-(S)

1440.77

#122-149

(K)-YRIPADVDPLTITSSLSSDGVLTVNGPR-(K)

2942.54

#121-149

(R)-KYRIPADVDPLTITSSLSSDGVLTVNGPR-(K)

3070.63

#121-149

(R)-KYRIPADVDPLTITSSLSSDGVLTVNGPR-(K) ‡

3071.61

#138-152

(L)-SSDGVLTVNGPRKQV-(S) ‡

1556.82

#134-151

(I)-TSSLSSDGVLTVNGPRKQ-(V) ‡

1845.94

#152-159

(Q)-VSGPERTI-(P)

857.46

#152-160

(Q)-VSGPERTIP-(I)

954.53

#154-163

(S)-GPERTIPITR-(E)

1138.65

#152-162

(Q)-VSGPERTIPIT-(R)

1168.65

#160-175

(I)-PITREEKPAVTAAPKK

1735.00

#157-175

(E)-RTIPITREEKPAVTAAPKK

2105.23

#155-174

(G)-PERTIPITREEKPAVTAAPK-(K)

2203.23

#155-175

(G)-PERTIPITREEKPAVTAAPKK

2331.33

#153-174

(V)-SGPERTIPITREEKPAVTAAPK-(K)

2347.29
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Table 2.1 (continued)
#152-174

(Q)-VSGPERTIPITREEKPAVTAAPK-(K)

2446.35

#153-175

(V)-SGPERTIPITREEKPAVTAAPKK

2475.38

#152-175

(Q)-VSGPERTIPITREEKPAVTAAPKK

2574.45

#1-11

METQAEQQELE-(T) ✽

1376.58

#1-19

METQAEQQELETLPTTKMA-(Q) ✽

2220.03

#29-36

(L)-GPWKITIY-(D)

976.54

#29-37

(L)-GPWKITIYD-(Q)

1091.57

#27-36

(G)-SLGPWKITIY-(D)

1176.65

#30-40

(G)-PWKITIYDQEN-(F)

1405.69

#29-40

(L)-GPWKITIYDQEN-(F)

1462.71

#33-45

(K)-ITIYDQENFQGKR-(M)

1610.81

#54-64

(P)-NVSERSFDNVR-(S) ‡

1323.61

βA1/A3

#103-113

(S)-NAYHIERLMSF-(R) ‡

1380.65

#126-137

(K)-MTIFEKENFIGR-(Q)

1483.75

#126-137

(K)-MTIFEKENFIGR-(Q) ‡

1484.73

#126-137

(K)-MTIFEKENFIGR-(Q) #

1499.74

#142-150

(I)-SDDYPSLQA-(M)

994.42

#200-211

(G)-SHAQTSQIQSIR-(R)

1354.70

#202-215

(H)-AQTSQIQSIRRIQQ

1655.91

#201-215

(S)-HAQTSQIQSIRRIQQ

1792.97

#190-215

(G)-GDYKHWREWGSHAQTSQIQSIRRIQQ

3159.99

#189-215

(H)-GGDYKHWREWGSHAQTSQIQSIRRIQQ

3251.65

#107-118

(R)-LTIFEQENFLGK-(K)

1437.75

#123-131

(L)-SDDYPSLQA-(M)

994.42

βA4

βB1
#2-14

(M)-SQAAKASASATVA-(V) ✽

1203.61

#2-16

(M)-SQAAKASASATVAVN-(P) ✽

1416.72

#2-16

(M)-SQAAKASASATVAVN-(P) ✽ ‡

1417.71

#7-22

(K)-ASASATVAVNPGPDTK-(G)

1484.75

#38-47

(T)-TLAPTTVPIT-(S)

1012.58

#40-50

(L)-APTTVPITSAK-(A)

1084.61

#51-60

(K)-AAELPPGNYR-(L)

1086.55

#44-57

(T)-VPITSAKAAELPPG-(N)

1349.76

#61-72

(R)-LVVFELENFQGR-(R)

1449.76

#59-79

(N)-YRLVVFELENFQGRRAEFSGE-(C)

2545.27

#151-160

(K)-ISLFEGANFK-(G)

1124.59

#171-179

(D)-APSLWVYGF-(S)

1038.52

#173-184

(P)-SLWVYGFSDRVG-(S)

1384.68

#171-184

(D)-APSLWVYGFSDRVG-(S)

1552.77

#170-184

(D)-DAPSLWVYGFSDRVG-(S)

1667.79
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Table A2.1 (continued)
#203-214

(R)-GYQYLLEPGDFR-(H)

1456.70

#245-252

(P)-VLATEPPK

853.49

#244-252

(F)-PVLATEPPK

950.54

#238-246

(W)-HLEGSFPVL-(A)

997.52

#238-247

(W)-HLEGSFPVLA-(T)

1068.56

#243-252

(S)-FPVLATEPPK

1097.61

#242-252

(G)-SFPVLATEPPK

1184.64

#241-252

(E)-GSFPVLATEPPK

1241.67

#240-252

(L)-EGSFPVLATEPPK

1370.71

#240-252

(L)-EGSFPVLATEPPK ✽

1412.72

#239-252

(H)-LEGSFPVLATEPPK

1483.79

#238-252

(W)-HLEGSFPVLATEPPK

1620.85

#233-252

(L)-RDKQWHLEGSFPVLATEPPK

2334.21

βB2
#2-15

(M)-ASDHQTQAGKPQSL-(N) ✽

1508.72

#2-16

(M)-ASDHQTQAGKPQSLN-(P) ✽

1622.77

#15-21

(S)-LNPKIII-(F)

809.54

#17-23

(N)-PKIIIFE-(Q)

858.52

#14-23

(Q)-SLNPKIIIFE-(Q)

1172.68

#17-26

(N)-PKIIIFEQEN-(F)

1229.67

#17-26

(N)-PKIIIFEQEN-(F) ‡

1230.65

#17-28

(N)-PKIIIFEQENFQ-(G) ‡

1506.76

#17-30

(N)-PKIIIFEQENFQGH-(S) ‡

1699.86

#17-30

(N)-PKIIIFEQENFQGH-(S) ‡

1700.84

#17-30

(N)-PKIIIFEQENFQGH-(S) ‡

1701.83

#45-54

(T)-GVEKAGSVLV-(Q)

957.55

#44-54

(E)-TGVEKAGSVLV-(Q)

1058.60

#45-55

(T)-GVEKAGSVLVQ-(A)

1085.61

#45-56

(T)-GVEKAGSVLVQA-(G)

1156.65

#44-55

(E)-TGVEKAGSVLVQ-(A)

1186.66

#44-56

(E)-TGVEKAGSVLVQA-(G)

1257.69

#45-58

(T)-GVEKAGSVLVQAGP-(W)

1310.72

#43-55

(K)-ETGVEKAGSVLVQ-(A)

1315.70

#44-58

(E)-TGVEKAGSVLVQAGP-(W)

1411.77

#43-58

(K)-ETGVEKAGSVLVQAGP-(W)

1540.81

#92-99

(T)-DSLSSLRP-(I) ¤

953.42

#91-102

(R)-TDSLSSLRPIKV-(D)

1314.75

#91-102

(R)-TDSLSSLRPIKV-(D) ¤

1394.72

#109-120

(K)-IILYENPNFTGK-(K)

1407.74

#116-128

(P)-NFTGKKMEIIDDD-(V) ¤

1604.68

#127-134

(D)-DDVPSFHA-(H)

886.38

#126-134

(I)-DDDVPSFHA-(H)

1001.41

#135-144

(A)-HGYQEKVSSV-(R)

1132.55

#135-147

(A)-HGYQEKVSSVRVQ-(S)

1515.78
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Table A2.1 (continued)
#148-162

(Q)-SGTWVGYQYPGYRGL-(Q)

1702.81

#177-184

(D)-FGAPHPQV-(Q)

851.43

#176-185

(S)-DFGAPHPQVQ-(S)

1094.52

#174-184

(D)-SSDFGAPHPQV-(Q)

1140.52

#175-185

(S)-SDFGAPHPQVQ-(S)

1181.55

#175-185

(S)-SDFGAPHPQVQ-(S) ‡

1182.53

#169-180

(K)-GDYKDSSDFGAP-(H)

1257.50

#174-185

(D)-SSDFGAPHPQVQ-(S)

1268.58

#191-198

(I)-RDMQWHQR-(G)

1155.54

#2-10

(M)-SKTGTKITF-(Y) ✽

1023.56

#2-13

(M)-SKTGTKITFYED-(K) ✽

1430.69

#8-19

(K)-ITFYEDKNFQGR-(R)

1516.73

#2-15

(M)-SKTGTKITFYEDKN-(F) ✽

1672.83

γS

#2-15

(M)-SKTGTKITFYEDKN-(F) ✽‡

1673.82

#2-22

(M)-SKTGTKITFYEDKNFQGRRYD-(C) ✽

2595.27

#2-22

(M)-SKTGTKITFYEDKNFQGRRYD-(C) ✽ ‡

2596.79

#73-79

(R)-WMGLNDR-(L)

890.41

#85-95

(R)-AVHLPSGGQYK-(I)

1155.60

#94-114

(Q)-YKIQIFEKGDFSGQMYETTED-(C)

2528.14

#94-114

(Q)-YKIQIFEKGDFSGQMYETTED-(C) ‡

2529.13

#92-114

(G)-GQYKIQIFEKGDFSGQMYETTED-(C)

2713.22

#132-146

(K)-VLEGVWIFYELPNYR-(G)

1896.98

#159-166

(R)-KPIDWGAA-(S)

856.44

#167-178

(A)-SPAVQSFRRIVE

1387.80

#160-178

(K)-PIDWGAASPAVQSFRRIVE

2098.10

#77-89

(R)-ALGISSVFLQGLR-(S)

1359.79

#77-89

(R)-ALGISSVFLQGLR-(S) ‡

1360.77

#76-89

(R)-RALGISSVFLQGLR-(S)

1515.89

#406-415

(Y)-HALLDREESG

1125.54

BFSP2

VIME
#15-24

(M)-FGGPGTASRP-(S)

945.47

#72-80

(R)-SSVPGVRLL-(Q)

926.55

MATN2
#868-875

(I)-NIQDLLSC-(S)

904.43

#867-875

(T)-INIQDLLSC-(S)

1017.52

(G)-FTNTMRVVPVP

1259.67

KPYM
#521-531
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Table A2.1 (continued)
BHMT2
#100-111

(R)-EVAGKGDALVAG-(G)

1085.57

(M)-SSEPPPPPQPPTHQA-(S) ✽

1607.76

(A)-PAANSDQTVTVKE ‡

1359.65

CHSP1
#2-16

BASP1
#215-227

a. All crystallins (αA, αB, βA1/A3, βA4, βB1, βB2 and γS) were listed on Table A2.1 without the
word “crystallin”. Abbreviations for other lens proteins are: BFSP2 - phakinin; VIME - vimentin;
MATN2 - matrilin-2; KPYM - pyruvate kinase isozymes M1/M2; BHMT2 betaine-homocysteine S-methyltransferase 2; CHSP1 - calcium-regulated heat stable protein 1;
BASP1 - brain acid soluble protein 1.
b. Adjacent residues to the sequence of respective peptides are indicated in brackets. Peptides have
been grouped according to their position within the original proteins. Peptides with
posttranslational modifications are highlighted. Posttranslational modifications are indicated using
the following symbols: ‡ for deamidation; ✽ for acelyation; ※ for the loss of water; # for
oxidation and ¤ for phosphorylation. Modified residues are underlined. In the case where more
than one modified residues are present on one peptide, symbols are listed so that the modifications
present on residues closer to the N-terminus of the peptide are listed first.
c. Lenses aged 16, 44, 75 and 83 years.
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Fig. A2.1: Base peak chromatogram of nanoLC-ESI-MS analysis of the CWS
extracts of the (A) 44 and (B) 75 year lenses.
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Fig. A2.2: The ESI-MS/MS of peptide αA57-65 from analysis of the CWS extract of a 75 year lens. CID spectrum of the isolated
488.42+ ion (M+H 975.5), showing the major b (green), y (red) ions and the parent ion (blue). See Table A2.2 for the complete list of
matching ions.
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Table A2.2: The predicted b and y ions of peptide αA57-65. The matching ions
observed from the CID spectrum (Fig. A2.2) are indicated in bold text (highlighted
cells).

Residue

Mass

L, Leu

113.08 114.09 975.51

D, Asp

115.03 229.12 862.43

S, Ser

87.03

316.15 747.40

G, Gly

57.02

373.17 660.37

I, Ile

113.08 486.26 603.35

S, Ser

87.03

E, Glu

129.04 702.33 403.23

V, Val

99.07

R, Arg

156.10 957.50 175.12
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Fig. A2.3: The ESI-MS/MS of peptide αA66-75-H2O from analysis of the NWS extract of a 75 year lens. CID spectrum of the
isolated 611.52+ ion (M+H 1221.7 Da), showing the major a (purple), b (green), y (red) ions and the parent ion (blue). See Table A2.3
for the complete list of matching ions.

242

Appendix II

Table A2.3: The predicted b and y ions of peptide αA66-75-H2O. The matching
ions observed from the CID spectrum (Fig. A2.3) are indicated in bold text
(highlighted cells).

Residue

Mass

a

b

y

87.03

60.04

88.04

1221.67

D, Asp(-18) 115.03

157.07

185.07

1019.61

R, Arg

156.10

313.17

341.17

1037.61

D, Asp

115.03

428.20

456.19

881.51

K, Lys

128.10

556.29

584.29

766.49

F, Phe

147.07

703.36

731.36

638.39

V, Val

99.07

802.43

830.43

491.32

I, Ile

113.08

915.52

943.51

392.25

F, Phe

147.07 1062.58 1090.58

279.17

L, Leu

113.08 1175.67 1203.66

132.10

S, Ser
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Fig. A2.4: The ESI-MS/MS of peptide βB217-30 from analysis of the NWS extract of a 75 year lens. CID spectrum of the isolated
568.43+ (M+H 1702.8), showing the major b (green), y (red) ions and the parent ion (blue). See Table A2.4 for the complete list of
matching ions.
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Table A2.4: The expected b and y ions of peptide βB217-30. The matching ions
observed from the CID spectrum (Fig. A2.4) are indicated in bold text (highlighted
cells).

Residue

Mass

b

y

P, Pro

97.05

98.06

1702.88

K, Lys

128.10

226.16

1605.83

I, Ile

113.08

339.24

1477.73

I, Ile

113.08

452.32

1364.65

I, Ile

113.08

565.41

1251.56

F, Phe

147.07

712.48

1138.48

E, Glu

129.04

841.52

991.41

Q, Gln(+1)

128.06

969.58

862.37

E, Glu

129.04 1099.62

733.31

N, Asn(+1) 114.04 1213.66

604.27

F, Phe

147.07 1361.73

489.23

Q, Gln(+1)

128.06 1489.79

342.16

G, Gly

57.02

1547.81

213.10

H, His

137.06 1684.87

156.08
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Fig. A2.5: The ESI-MS/MS spectrum of peptide βB292-99 from analysis of the CWS extract of an 83 year lens. CID spectrum of
the isolated 477.72+ ion (M+H 954.4), showing the major b (green) and y (red) ions. See Table A2.5 for the complete list of matching
ions.
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Table A2.5: The predicted a, b and y ions of peptide βB292-99. The matching ions
observed from the CID spectrum (Fig. A2.5) are indicated in bold text (highlighted
cells).

Residue

Mass

a

b

b-H3PO4

y

D, Asp

115.03

88.04

116.03

18.06

954.46

S, Ser (+80)

80.00

255.07 283.07

185.09

752.40

L, Leu

113.08 368.16 396.15

298.17

672.40

S, Ser

87.03

455.19 483.18

385.21

559.32

S, Ser

87.03

542.22 570.21

472.24

472.29

L, Leu

113.08 655.30 683.30

585.32

385.26

R, Arg

156.10 811.40 839.40

741.42

272.17

P, Pro

97.05

838.48

116.07

908.46 936.45
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Fig. A2.6: The ESI-MS/MS of peptide BFSP277-89 from analysis of the CWS extract of the 75 year lens. CID spectrum of the
isolated 681.52+ ion (M+H 1361.8), showing the major b (green), y (red) ions and the parent ion (blue). See Table A2.6 for the
complete list of matching ions.
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Table A2.6: The predicted a, b and y ions of peptide BFSP277-89. The matching
ions observed from the ESI-MS/MS spectra (Fig. A2.6) are indicated in bold text
(highlighted cells).

Residue

Mass

b

y

A, Ala

71.04

72.04

1361.79

L, Leu

113.08

185.13

1290.76

G, Gly

57.02

242.15

1177.67

I, Ile

113.08

355.23

1120.65

S, Ser

87.03

442.27

1007.57

S, Ser

87.03

529.30

920.54

V, Val

99.07

628.37

833.50

F, Phe

147.07

775.43

734.44

L, Leu

113.08

888.52

587.37

Q, Gln(+1) 129.06 1017.58

474.28

G, Gly

57.02

1074.60

345.22

L, Leu

113.08 1187.68

288.20

R, Arg

156.10 1343.78

175.12
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A3.1 List of buffers, media and solvents in this thesis

Buffers
Buffer A (pH 7.4)
Tris-HCl
NaCl
EDTA

20 mM
20 mM
1 mM

Buffer B (pH 7.4)
Tris-HCl
NaCl
EDTA
Urea

20 mM
20 mM
1 mM
8M

Buffer C (pH 6.8)
Tris-HCl
SDS
Glyerol
β-mercaptoethanol
Urea

60 mM
1%
10%
1 mM
8M

Buffer D (pH 7.4)
Tris-HCl
NaCl
EDTA
D-(+)-maltose monohydrate

20 mM
20 mM
1 mM
100 mM

SSS buffer
Tris-HCl
DTT
CHAPS
Carrier ampholytes
Urea

40 mM
100 mM
4%
0.8%
8M
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Lysis buffer (pH 8.0)
Tris-HCl
NaCl

50 mM
100 mM

2-D buffer
CHAPS
Thiourea
Urea

4%
2M
7M

Phosphate buffer (pH 7.2)
Phosphate
NaCl
EDTA
DTT
NaN3

50 mM
100 mM
1 mM
0.1 mM
0.02%

AE buffer A (pH 8.5)
Tris-HCl
EDTA
NaN3

20 mM
1 mM
0.02%

AE buffer B (pH 8.5)
Tris-HCl
NaCl
EDTA
NaN3

20 mM
2M
1 mM
0.02%

Tris-membrane buffer (pH 7.4)
Tris-HCl
EDTA
β-mercaptoethanol
NaN3

50 mM
5 mM
10 mM
0.2%

Urea-membrane buffer (pH 7.4)
Tris-HCl
Urea

50 mM
7M
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Binding buffer (pH 7.3)
NaCl
KCl
Na2HPO4
MgCl2

137 mM
2.7 mM
4.3 mM
5 mM

PBS/T (pH 7.4)
NaCl
KCl
Na2HPO4
KH2PO4
Tween 20

137 mM
2.7 mM
12.5 mM
1.8 mM
0.05%

SDS-PAGE loading buffer (pH 6.8)
Tris-HCl
SDS
β-mercaptoethanol
Glycerol
Bromophenol blue

60 mM
1%
1%
10%
0.01%

Media
LB (for αA- and αB-crystallins expression)
Tryptone
Yeast extract
NaCl

1%
0.5%
1%

Rich broth (for MBP-αB expression)
Tryptone
Yeast extract
NaCl
Glucose

1%
0.5%
0.5%
0.2%
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Other solvents and solutions
Coomassie Blue destain solution (pH 7.8)
NH4HCO3
Acetonitrile

30 mM
40%

Solvent A (for nanoLC)
Formic acid

0.1%

Solvent B (for nanoLC)
Formic acid
Acetonitrile

0.1%
90%
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